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Preface
The nascent field of regenerative medicine has advanced at a rapid pace, and clinical trials
are ongoing to assess the safety and efficacy of stem cell-based therapies in indications
that range from congestive heart failure to Crohn’s disease. However, in general there is a
lack of understanding of the specific mechanisms of action, and application of these new
biologic products faces special challenges.
Four key areas in regenerative medicine are highlighted in this book: (i) cell-fate deter-
mination, (ii) regeneration, (iii) designer cells, and (iv) translation of cell-based therapies.
The utility of stem cell-based therapies relies upon efficient manipulation of cell fates,
not only to generate sufficient quantities of the desired cell type for transplantation but
also to prevent tumor formation from residual, undifferentiated cells. The biologic mecha-
nisms related to cell-fate determination will be presented in depth to provide the necessary
background. While the focus of stem cell-based therapies has traditionally been on trans-
plantation and engraftment, this is not the only paradigm. Instead, some therapies may
stimulate regeneration in the host tissue through activation of endogenous stem-cell pools.
In this volume, the use of mesenchymal stem cells (MSCs) in the context of wound healing
and regeneration will be discussed. In addition, in recognition of the revolutionary advances
in patient-derived induced pluripotent stem cells (iPSCs) and reprogramming of somatic
cells, the issue of customizing iPSCs for research and clinical applications will be dis-
cussed. A myriad of technical and conceptual issues remain to be overcome before the full
potential of iPSC technologies is realized, which will require an interdisciplinary approach.
Thus, this book pays particular attention to the use of small molecules and biomaterials in
addressing current challenges. Lastly, an overview of the practicalities related to translation
of stem-cell therapies for clinical use will be provided.
This book is intended for those with interests ranging from basic developmental biology
to stem-cell therapies. Biomedical researchers, clinicians, managers in biotechnology, and
undergraduate and graduate students interested in stem cells and cell-based therapies will
find this book useful in summarizing the most recent developments in stem-cell research.
The intrigue surrounding stem cell-based therapies lies not only in the treatment of
chronic diseases but also in the potential to cure them. Therefore, regenerative medicine is
rapidly moving to the forefront of many therapeutic areas, from cancer to heart disease. This
book aims to summarize the collective knowledge of active researchers, illustrate current
perspectives on the most pressing obstacles to clinical application, and serve as a guide to
what lies ahead.
Charles C. Hong, MD, PhD
Ada S. Ao, PhD
Jijun Hao, PhD
1
Wnt Signaling in Regulation
of Stem Cells
David T. Paik and Antonis K. Hatzopoulos
Department of Medicine, Vanderbilt University, USA
1.1 Overview of Wnt Signaling
The Wnt signaling pathway is classically divided into so-called canonical and noncanonical
branches based on the activation of specific intracellular components. Canonical Wnt sig-
naling is activated when Wnt ligands bind to the Frizzled (Fzd) family of 7-transmembrane
domain receptors and co-receptors, such as low-density lipoprotein receptor-related protein
(LRP) 5/6, Ryk, and Ror2 [1–4]. This disrupts the formation of the β-catenin destruc-
tion complex, which consists of the scaffolding protein Axin, the Adenomatous polyposis
coli (APC) protein, Dishevelled (Dsh), casein kinase Iα (CK-Iα), and glycogen synthase
kinase-3Inase (CK). The dissociation of the destruction complex leads to stabilization of
cytoplasmic iationein, which translocates to the nucleus to interact with TCF/LEF tran-
scription factors and initiate transcription of canonical Wnt signaling target genes, such as
c-Myc, Axin2, and Snail [5–7]. When canonical Wnt signaling is turned off, the destruction
complex phosphorylates β-catenin for ubiquitin-mediated proteosomal degradation [8].
Noncanonical Wnt signaling pathways are β-catenin-independent and are mediated
through other intracellular proteins [1–4, 9, 10]. In the Wnt/JNK pathway, binding of
Wnt to Fzd receptors activates small-GTPases, RhoA, and Rac through recruitment of Dsh,
which thereby activate Rho kinase and c-Jun N-terminal kinases (JNK). In the Wnt/Ca+2
pathway, binding of Wnt to Fzd receptors increases intracellular Ca2+ levels, activating
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calcium/calmodulin-dependent kinase (CaMK) II, protein kinase C (PKC), and the pro-
tein phosphatase calcineurin (CaCN) to trigger dephosphorylation of NF-AT transcription
factors. Thus activated NF-AT transcription factors translocate to the nucleus to stimulate
transcription of their target genes [11]. Intriguingly, noncanonical Wnt signaling has been
shown to inhibit canonical Wnt signaling in various mechanisms [10, 12, 13].
To date, 19 Wnt ligands and 10 Fzd receptors have been identified. The 19 Wnt genes fall
into 12 conserved Wnt subfamilies, which exist in most mammalian genomes, including
the human genome [14]. Different combinations of individual Wnt ligands, receptors, and
co-receptors allow differential activation of β-catenin-dependent/canonical Wnt signaling,
βWnt signaling, ligands, receptors, and/or Wnt signaling in a cellular context-dependent
manner.
In the past 2 decades, the connection between Wnt signaling and human disease has been
well established. Numerous components of the pathway have been implicated in cancer,
obesity, osteoporosis, diabetes, and cardiovascular diseases [15]. Interestingly, Wnt signal-
ing components are also critical regulators of stem and progenitor cells in various organs and
tissues. A thorough understanding of the Wnt signaling pathway in the regulation of stem
cells will be instrumental in translating the potential of stem cells to effective therapeutic
solutions for human degenerative diseases or to the restoration of organ function after injury.
1.2 Wnt Signaling in Embryonic Stem Cells
Wnt signaling has been implicated in the maintenance of the pluripotency and differentiation
potential of embryonic stem cells (ESCs). A number of studies have demonstrated that
individual Wnt ligands can stimulate self-renewal of ESCs [16–18]. Activation of the
canonical Wnt pathway complements the LIF/JAK-STAT pathway via upregulation of the
Stat3 gene to inhibit ESC differentiation [16]. Paracrine and autocrine Wnt signaling is
essential not only for self-renewal of mESCs but also to inhibit differentiation into epiblast
stem cells (epiSCs) [7]. Accordingly, mutations in the βn of the io destruction complex
APC protein increase β-catenin levels, diminishing the differentiation capacity of mouse
ESCs (mESCs) into the three germ layers [19].
In contrast, whether Wnt signaling promotes self-renewal or differentiation of human
ESCs (hESCs) has been rather controversial. In the presence of supportive feeder cells or a
conditioned medium (CM) rich in factors preventing differentiation, Wnt3a enhanced self-
renewing proliferation of undifferentiated hESC H1 cells. In the absence of CM, however,
activation of Wnt signaling accelerated both proliferation and differentiation of hESCs [20].
The canonical Wnt ligand Wnt1 displayed the same effects on hESCs as Wnt3a, while the
noncanonical Wnt ligand Wnt5a did not affect the proliferation of hESCs, indicating that β-
catenin-dependent canonical Wnt activation is responsible for enhanced hESC proliferation
[21,22]. Activation of the canonical Wnt pathway by 6-bromoindirubin-3′-oxime (BIO), a
specific inhibitor of glycogen synthase kinase 3 (GSK3), produced comparable results in
maintaining the undifferentiated phenotype of hESCs marked by sustained expression of the
pluripotent transcription factors OCT3/4 (POU5F1), REX1, and NANOG and by prevention
of the epithelial–mesenchymal transition (EMT) of hESCs [23, 24]. In complementary
fashion, addition of the Wnt inhibitors Sfrp-1, Sfrp-2, and Sfrp-4, singly or in combination,
promoted differentiation of hESCs [22].
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However, other studies have reported that canonical Wnt activation disrupted hESC
self-renewal and promoted differentiation. Specifically, conditional activation of stabilized
β-catenin in KhES-1 and KhES-3 lines resulted in downregulation of the pluripotent markers
NANOG, SOX2, and POU5F1 and upregulation of the mesodermal marker T Brachyury,
followed by induction of the ventral mesodermal and endothelial marker KDR (VEGFR2)
and the early cardiac marker NKX2.5 [25].
Experimental evidence also suggests that canonical Wnt signaling interacts with
Activin/Nodal and bone morphogenetic protein (BMP) signaling pathways to specify
differentiation lineages in hESCs. Canonical Wnt activation induced Activin/Nodal and
BMP signaling to promote posterior Primitive Streak (PS) and mesoderm differentiation
of hESCs. Synergistic interaction between Wnt and Activin/Nodal pathways was shown
to be required for anterior PS and endoderm specification, while BMP and MAPK signal-
ing antagonized it [25]. Recent studies have also shown that hESCs treated with the Wnt
inhibitor IWP are maintained as pluripotent, with the ability to differentiate into neural cells
[26]. Furthermore, Wnt3a-treated hESCs acquired PS-like characteristics and differentiated
into mesodermal and endodermal cells [26].
It is noteworthy that the effects of Wnt3a on hESCs and mESCs differ significantly. In
mESCs, Wnt3a prevented progression of mESCs to EpiSCs, while in hESCs Wnt3a facil-
itated their differentiation into mesodermal and endodermal lineages [7, 26]. In another
study, the pluripotent marker OCT4 in hESCs was shown to repress β-catenin during
self-renewal, whereas knockdown of OCT4 activated canonical Wnt signaling [27]. In sup-
port of these studies, Wnt1-treated hESCs displayed induced differentiation to hemogenic
endothelial cells, while treatment with the Wnt inhibitor Dkk1 reduced this differentiation
potential [28].
The apparently contradictory reports of Wnt signaling in hESC self-renewal and dif-
ferentiation may be due to the epiblast origin of the various hESC lines tested [25]. It
has also been proposed that the effects of Wnt signaling on hESCs are highly sensitive
to the level of Wnt activation [26, 27]. Therefore, it is likely that apparently contradictory
results regarding the role of Wnt signaling in human ESC pluripotency, proliferation, and
differentiation reflect the heterogeneity of the corresponding lines and their sensitivity to
canonical Wnt signaling levels.
1.3 Wnt Signaling in Cardiovascular Progenitor Cells and
Cardiomyocyte Differentiation
Wnt signaling also plays important roles in the maintenance and expansion of cardiovascu-
lar progenitor cells and in their differentiation into endothelial and cardiomyocyte lineages
[2, 10, 11]. The mammalian heart is one of the first organs to form during embryogenesis
and Wnt signaling has been implicated in all phases of cardiogenesis. Initially, canonical
Wnt signaling is necessary for the formation of mesodermal progenitor cells, but it must
then be suppressed in order for mesoderm progenitors to yield cardiac progenitor cells
(CPCs) [11]. Subsequently, noncanonical Wnt signaling is necessary for the specification
of CPCs. Wnt5a, a noncanonical Wnt activator, is upregulated by the mesoderm-specific
transcription factor Mesp-1 to promote formation of CPCs [29]. Other studies have shown
that intrinsic Wnt2 expression in mouse ES cells is essential for efficient cardiomyocyte
4 Chemical Biology in Regenerative Medicine
differentiation and that exogenous Wnt2 promotes cardiomyocyte differentiation. Inter-
estingly, Wnt2 induced cardiogenesis through activation of the noncanonical JNK/AP-1
pathway [30]. After CPC specification, canonical Wnt signaling activation stimulates pro-
liferation of Isl1+ CPCs, whereas subsequent Dkk1 inhibition of canonical Wnt signaling
and noncanonical Wnt activation by Wnt11 are required for cardiomyocyte differentiation
[31, 32].
The role of Wnt signaling and the effects of Wnt signaling manipulation during heart
development have been well documented in various animal models. In mouse embryos,
deletion of β-catenin in the definitive endoderm led to formation of multiple hearts along
the anterior–posterior (A/P) axis, as one of the earliest pieces of evidence to implicate Wnt
signaling in the endoderm in the induction of precardiac mesoderm [33]. Notably, the super-
numerary hearts followed the ectopic expression patterns of BMP2. Ectopic cardiac tissue
also formed in zebrafish embryos with overexpression of the BMP antagonist Gremlin2,
while Gremlin2 morphants exhibited a rise in the intracellular levels of β-catenin, suggest-
ing a crosstalk between Wnt and BMP signaling during cardiac development [33, 34]. In
chick embryos, Crescent, a Frizzled-related protein that inhibits Wnt8c, is expressed in the
anterior endoderm during gastrulation, while Wnt3a and Wnt8c expression is localized to
the primitive streak and posterior lateral plate. Dkk1 induces cardiac gene expression in
the posterior lateral plate mesoderm, while ectopic Wnt activation in the anterior meso-
derm inhibits cardiac formation. Therefore, inhibition of Wnt signaling in chick embryos
promoted heart formation in the anterior lateral mesoderm, supporting a model that car-
diogenesis initially requires high levels of BMP but low canonical Wnt activity [35]. In
Xenopus embryos, Wnt6 was found to be expressed in tissues close to and inside the
developing heart and to be required to restrict heart development, since the absence of
Wnt6 led to an abnormally large heart [36]. Intriguingly, Wnt6 is not required during the
gastrulation stage but rather in the later stages of organogenesis that precede the differen-
tiation of cardiogenic mesoderm into myocardium. Overexpression of Wnt6 reflected such
a phenotype through the activation of β-catenin-dependent/canonical Wnt signaling, which
repressed cardiogenic transcription factors such as Gata6 and Mlc2. Sfrp-1, an endogenous
Wnt inhibitor, is strongly induced in differentiating cardiomyocytes and participates in a
negative-feedback regulatory loop of Wnt signaling in regulating the cell fate of cardiac
mesoderm [37].
Later studies reinforced a biphasic role for canonical Wnt signaling in cardiac specifica-
tion in zebrafish and mice. For example, it appears that β-catenin-dependent Wnt signaling
before gastrulation promotes cardiac differentiation while inhibiting heart formation during
gastrulation [38]. Early treatment of mESCs with Wnt3a induced mesoderm specification,
which activated a feedback loop that subsequently repressed the Wnt pathway, which in
turn increased cardiac differentiation. Late activation of β-catenin in mESCs, on the other
hand, repressed cardiac differentiation. Overexpression of the noncanonical Wnt ligand
Wnt11, which may inhibit canonical Wnt signaling, promoted cardiac differentiation dur-
ing early stages but repressed it in later ones. Moreover, canonical Wnt signaling in the
early stages of embryoid body (EB) formation induced cardiac differentiation but sup-
pressed hematopoietic and vascular cell lineages. Activation of canonical Wnt signaling
in the later stages of EB formation, however, inhibited cardiac formation and induced
expression of hematopoietic and vascular genes through the suppression of BMP signaling
[39]. Such results highlight the strict temporal and spatial requirement of Wnt signaling
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in heart development. Current evidence suggests that β-catenin-dependent Wnt signaling
promotes proliferation of mesodermal and cardiovascular progenitors but that noncanonical
Wnt signaling promotes differentiation of mesodermal stem cells to CPCs and of CPCs to
cardiomyocytes.
Based on the finding that Wnt signaling plays a critical role in cardiomyogenesis during
development, recent studies have identified small-molecule compounds that modulate Wnt
signaling, thus regulating cardiomyogenesis. Using in vivo zebrafish embryo screening,
a small molecule that inhibits canonical Wnt signaling called cardionogen was shown to
induce cardiogenesis during and after gastrulation but to prevent heart formation before
gastrulation [40]. XAV939, a small-molecule inhibitor of canonical Wnt signaling, robustly
induced cardiomyogenesis in mESCs when administered immediately following the for-
mation of mesoderm progenitor cells [41]. Similarly, KY0211 is another example of a
small molecule that promotes differentiation of human pluripotent stem cells (hPSCs) into
cardiomyocytes by inhibiting Wnt signaling [42]. Small molecules inhibiting canonical
Wnt signaling robustly drove the expression of red fluorescent reporter protein driven
by the cardiac-specific MYH6 promoter in hESCs [43]. It was found that Wnt inhibi-
tion specifically promoted cardiomyocyte differentiation from hESC-derived mesodermal
cells, without inducing other mesodermal derivatives such as endothelial cells or smooth
muscle cells. Other known canonical Wnt inhibitors, such as IWR1, IWP3, and XAV939,
reproduced the same phenotype, supporting the connection between timely inhibition of
Wnt signaling and cardiac cell differentiation from hESCs. Such findings were reported
in human induced pluripotent stem cells (hiPSCs) as well. Early treatment of hiPSCs
with BMP4 followed by late treatment with small-molecule Wnt inhibitors such as IWR1
resulted in a marked increase in cardiomyocyte differentiation [44]. In summary, various
small-molecule canonical Wnt inhibitors were shown to promote cardiomyocyte differenti-
ation from several stem cell lines, including mouse and human ESCs and hiPSCs. It will be
interesting to test the effect of these molecular tools on adult cardiovascular progenitor cells
and cardiac tissue regeneration. So far, the canonical Wnt signaling inhibitor pyrvinium
has been shown to promote wound repair and post-myocardial infarction (MI) cardiac
remodeling [45].
1.4 Wnt Signaling in Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) have attracted considerable interest as a promising ther-
apeutic tool for various human diseases due to their plasticity and potential for tri-lineage
differentiation into osteoblasts, adipocytes, and chondrocytes [46]. Wnt signaling has a
key function in the cell fate decisions of multipotent MSCs. Specifically, the canonical
Wnt activator Wnt10b promotes osteoblastogenesis at the expense of adipogenesis [47,48].
Wnt10b enables this switch in MSC fate by inducing the osteoblastogenic transcription fac-
tors Runx2, Dlx5, and Osterix and suppressing the adipogenic transcription factors PPARγ
and C/EBPα [47, 49, 50]. As a result, FABP4-Wnt10b transgenic mice that overexpress the
Wnt10b gene in their bone marrow exhibited increased bone mass, density, and strength,
while Wnt10b−/− mice had decreased trabecular bone and serum osteocalcin [47]. At the
same time, FABP4-Wnt10b mice, which express Wnt10b in their white and brown adipose
tissue, resisted accumulation of adipose tissue when fed a high-fat diet [51]. These results
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provide compelling evidence that Wnt10b is a cell fate regulator of MSCs, influencing
the physiology of bone and adipose tissue, and serves as a potential therapeutic target for
diseases such as osteoporosis and obesity.
Similarly, canonical Wnt signaling has been shown to promote osteoblastogenesis in
human amniotic fluid mesenchymal stem cells (huAFMSCs). Specifically, canonical Wnt
signaling activation was linked to osteogenic differentiation of huAFMSCs through induc-
tion of Dishevelled-2 (Dvl-2), and increased levels of active β-catenin and phosphory-
lated GSK3β. Conversely, inhibition of Wnt signaling by Dkk-1 led to suppression of
the osteogenic transcription factor Runx2 and activation of FABP4, favoring adipocyte
differentiation [52]. Moreover, studies have identified Wnt6, Wnt10a, and Wnt10b as
inhibitors of adipogenesis. Notably, the three canonical Wnt ligands affect MSC differen-
tiation to varying degrees. While Wnt10a affects MSC differentiation to a similar extent
as Wnt10b, knockdown of endogenous Wnt6 stimulates preadipocyte differentiation and
impairs osteoblastogenesis to greater degrees than that of Wnt10a or Wnt10b, suggest-
ing that Wnt6 is a more potent endogenous regulator of MSC fate than are the other
Wnt factors [50]. The effects of Wnt6, Wnt10a, and Wnt10b on MSC differentiation are
β-catenin-dependent, as knockdown of β-catenin prevents the inhibition of adipogenesis
and stimulation of osteoblastogenesis by the three Wnt ligands [50].
Interestingly, mutations in the human WNT10B gene have been found in obesity patients
in various hereditary groups. Six single-nucleotide polymorphisms (SNPs) of WNT10B
were identified from direct sequencing of the genomic DNA of 1029 obese Korean female
subjects and four were found from 1013 obese Belgian male subjects, while a C256Y
mutation in WNT10B was found in 115 obese Italian male subjects [53–55]. Although
the exact molecular mechanisms connecting Wnt10b to familial obesity remain unknown,
AP-1 and NF-κB binding sites in the promoter areas are conserved among mammalian
WNT10B orthologs [56]. This finding could explain the upregulation of WNT10B by tumor
necrosis factor (TNF)α, as TNFα signaling via TNFR1 and TRADD/RIP/TRAF2 complex
activates JNK and NF-κB. It is likely that increased Wnt10b levels block adipogenesis in
favor of osteogenic differentiation of MSCs, whereas defective Wnt10B activity leads to
obesity [56, 57]. It is likely that defective Wnt activity impairs these negative-feedback
mechanisms, enhancing adipogenic differentiation of MSCs.
An additional connection has been described between NF-κB and Wnt signaling path-
ways in the differentiation of MSCs [58]. It was found that the proinflammatory cytokines
TNF and IL-17 activated the IKK/NF-κB pathway to inhibit osteogenic differentiation
of MSCs. Inhibition of IKK/NF-κB, on the other hand, promoted bone formation by sup-
pressing β-catenin ubiquitination and degradation. Furthermore, Wnt4, a noncanonical Wnt
ligand, also enhanced in vitro osteogenic differentiation of MSCs from human craniofacial
tissues and promoted bone formation in vivo [59]. Wnt4 did not stabilize β-catenin but
did activate p38 MAPK in an Axin-dependent manner. Intriguingly, Wnt4-overexpressing
MSCs improved the healing of craniofacial defects in a murine model, indicating that
both canonical and noncanonical Wnt signaling can promote osteogenic differentiation via
seemingly independent signaling cascades. In contrast, other investigators reported that
activation of β-catenin-dependent Wnt signaling suppressed the noncanonical Wnt/Ca+2
pathway, leading to increased proliferation but attenuated osteogenic differentiation of peri-
odontal ligament stem cells (PDLSCs), a specific subpopulation of MSCs [60]. Treatment
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with Dkk1 rescued the Wnt/Ca+2 signaling pathway, leading to osteogenic differentiation
of PDLSCs. Taken together, these studies implicate Wnt signaling in the regulation of
MSC differentiation. However, seemingly contradictory results suggest that this regulation
is complex, due to feedback regulatory loops and context-dependent cellular responses to
Wnt signaling.
Inhibition of Wnt signaling may also increase the therapeutic potential of MSCs. The Wnt
antagonist Sfrp-2 enhanced MSC engraftment and survival, where Sfrp-2-overexpressing
MSCs were shown to be more effective in wound and myocardial repair [61]. The observed
Sfrp-2 effects were due to dual inhibition of Wnt and BMP signaling pathways [62].
Similarly, Akt-overexpressing MSCs (Akt-MSCs) induced high Sfrp-2 expression and
promoted cardiomyocyte cell survival through an Sfrp-2-mediated reduction in caspase-3
activity [63,64]. The small-molecule Wnt inhibitor pyrvinium recapitulated the Sfrp2 effects
on MSCs [45]. These results indicate that activation of Wnt signaling leads to senescence of
MSCs, while inhibition of Wnt signaling promotes self-renewal and engraftment of MSCs
[62]. Therefore, manipulation of Wnt signaling in MSCs may prove beneficial in clinical
trials that transplant MSCs to injured tissues with limited regenerative capacity, such as in
ischemic myocardium after acute myocardial infarction (MI).
1.5 Wnt Signaling in Hematopoiesis and Hematopoietic Stem Cells
Wnt signaling is essential for hematopoiesis and differentiation of hematopoietic stem
cells (HSCs) [65, 66]. Various gain-of-function and loss-of-function approaches have
provided insights into the role of Wnt signaling in HSC differentiation [67]. For example,
constitutively active β-catenin in Bcl2-transgenic hematopoietic stem/progenitor cells led
to proliferation of HSCs via induction of HoxB4 and Notch1. In parallel, overexpression of
stabilized β-catenin in mice inhibited multilineage differentiation and resulted in transient
expansion of HSCs [68–70]. In agreement with these studies, deletion of βIn agnin in
HSCs reduced their self-renewing capacity [71], while the canonical Wnt activator Wnt3a
promoted reacquisition of stem cell-like characteristics in committed lymphoid progenitor
cells [72].
Although these studies underline the importance of canonical Wnt signaling in HSC
proliferation and prevention of differentiation, approaches using additional Wnt ligands
point to a more complex picture. For instance, the noncanonical Wnt ligand Wnt4 was
also shown to increase proliferation of hematopoietic progenitors and another noncanoni-
cal Wnt ligand, Wnt5a, promoted HSC renewal by antagonizing canonical Wnt signaling
in HSCs [73, 74]. In zebrafish, the noncanonical Wnt activator Wnt16 was identified as
interacting with Notch signaling in specifying hematopoietic stem cells [65]. Wnt16 is
required for somatic expression of the Notch ligands deltaC (dlc) and deltaD (dld), essen-
tial factors in definitive hematopoiesis. Through the use of a Wnt-reporter mouse, canon-
ical Wnt signaling was shown to regulate hematopoiesis in a dosage-dependent manner,
where lineage-specific Wnt dosages regulated HSCs, myeloid precursors, and T lymphoid
precursors during hematopoiesis [75]. These seemingly contradictory findings from gain-
of-function and loss-of-function experiments may be credited to different levels of Wnt
signaling expressed in individual experimental model systems. However, it is conceivable
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that controlled regulation of Wnt signaling might provide an effective solution for leukemia
treatment [76].
1.6 Wnt Signaling in Neural Stem Cells
Various neural cell types, such as neurons, astrocytes, and oligodendrocytes, are derived
from a single neural progenitor cell [77]. In adult neurogenesis, neural stem cells (NSCs)
are found in the subventricular zone of the lateral ventricles and the subgranular zone of
the hippocampal dentate gyrus, and evidence suggests that Wnt signaling is associated
with the regulation of both populations [3]. For example, Wnt3a has been shown to locally
regulate the expansion of the caudomedial cortex, the site of hippocampal development in
the mouse brain [78]. Wnt3a loss of function resulted in limited proliferation of caudomedial
cortical progenitor cells, indicating that canonical Wnt activation by Wnt3a is necessary
for the development and growth of the hippocampus. An independent study confirmed
this notion by showing that canonical Wnt signaling activation via Wnt3a overexpression
increased neurogenesis from adult hippocampal stem/progenitor cells both in vivo and
in vitro; in contrast, ablation of Wnt signaling blocked neurogenesis [79]. Furthermore,
stabilized β-catenin in neural precursors resulted in enlarged brains with an increased
cerebral cortical area in mice [80]. More recently, activation of canonical Wnt signaling
selectively stimulated proliferation within the oligodendrogliogenic lineage, but not the
neurogenic lineage, in adult NSCs in the mouse subependymal zone [74]. These findings
underscore the role of Wnt signaling in regulating cell fate decisions in NSCs, echoing
observations in other types of multipotent stem cell.
1.7 Wnt Signaling in Endothelial–Mesenchymal Transition
Aside from embryonic development, stem and progenitor cells are essential for maintaining
homeostasis in virtually all adult organs and tissues. One common feature of stem and pro-
genitor cells is their location in perivascular areas. Blood vessels, composed of endothelial
cells and mural cells, are typically associated with stem cell niches that protect and regulate
both vascular and nonvascular stem and progenitor cells [81]. Thus, blood vessels provide
a niche for organ-specific stem cells [81].
Furthermore, there is mounting evidence that endothelial cells in adult tissues can tran-
sition into mesenchymal cell types under injury or stress conditions, a phenomenon known
as endothelial–mesenchymal transition (EndMT), acting as a source of progenitor cells and
of cells involved in tissue repair [82–86]. EndMT was originally described in embryonic
heart formation, with endocardial cells in the cardiac cushions undergoing EndMT to form
the cardiac valves [11, 87]. On the other hand, in the adult heart, EndMT appears to give
rise to myofibroblasts, thereby contributing to pathological fibrosis [84, 88]. In the adult
mouse heart, following myocardial infarction (MI), approximately 30% of myofibroblasts
formed in the infarct tissue arise from endothelial cells [88].
The EndMT during cardiac fibrosis was shown to be mediated by transforming growth
factor beta-1 (TGFβ1) signaling in a Smad-dependent manner and could be repressed
by treatment with BMP7 [84]. Further studies revealed that mutations in ALK2 and
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treatment with TGFβ2 or BMP4 can also lead to EndMT, in which the endothelial-derived
mesenchymal cells exhibit the potential to differentiate into chondrocytes and osteoblasts,
much like MSCs [83]. In addition, EndMT has been shown to contribute to perivascular
mural cells, such as smooth muscle cells and pericytes [89,90], and to approximately 40%
of cancer-associated fibroblasts (CAFs) in the tumor stroma [85].
Wnt signaling has been implicated as a regulator of EndMT as well. EndMT-derived
repair cells were found to be canonical Wnt-activated, possibly by the MI-induced Wnt
ligands Wnt2 and Wnt10b [88]. In the homeostatic heart, canonical Wnt+ cells were
localized to vascular smooth muscle cells of the aorta and periepicardial blood vessels but
not to other cell types. Upon injury, however, large numbers of endothelial cells became
canonical Wnt-activated and transitioned into CD31+ /αSMA+ progenitor cells, which
gave rise to myofibroblasts. Supporting the role of canonical Wnt signaling in this process,
the Wnt activator BIO induced EndMT in bEnd-3 endothelial cells in vitro [88].
Another study showed however that Dkk1-mediated inhibition of Wnt signaling pro-
moted EndMT marked by induction of myofibroblasts and osteogenic markers and inhibited
cobblestone morphology and capillary-like tube formation of endothelial cells [91]. Dkk1
was shown to promote Alk-mediated Smad activation, which is responsible for triggering
the EndMT and osteogenic differentiation of endothelial cells. In a complementary fashion,
Wnt activation by Wnt7b maintained the endothelial phenotype and prevented EndMT [91].
Consistent with this finding, persistent expression of the Wnt receptor Leucine-rich repeat-
containing G protein-coupled receptor 5 (LGR5) inhibited EndMT in corneal endothelial
cells [92]. R-spondin-1, a LGR5 ligand, similarly inhibited EndMT and promoted endothe-
lial cell proliferation [92].
The discrepancies found in the role of Wnt signaling in EndMT are likely due to the fact
that various Wnt activators and inhibitors target different nodes of the signaling pathway.
For example, the Wnt chemical activator BIO targets GSK3β, an intercellular member of
the destruction complex of β-catenin, while Dkk1 and Wnt7b are extracellular proteins that
interact with various cell-membrane receptors such as Frizzled, LRP5/6, LGR5, and Alk
receptors [91]. It is likely that unlike chemical compounds, proteins such as Dkk1 trigger
a complex crosstalk of negative and positive feedback regulatory loops between various
Wnt signaling branches, as well as other pathways such as Alk/BMP/Smad, complicating
straightforward interpretation of experimental results.
1.8 Conclusion
Wnt signaling is an essential developmental pathway. As discussed in this chapter, studies
have identified it to be required for the maintenance, self-renewal, and differentiation of
various types of stem and progenitor cell, as a major regulator of stemness and stem-cell-
fate decisions. In addition to the cases of adult stem cells described here, Wnt signal-
ing has also been extensively studied in the biology of stem cells in gut epithelium and
hair follicles [15, 93, 94]. In general, activation of canonical Wnt signaling is typically
required for the proliferation and self-renewal of multi- or pluripotent stem and progenitor
cells, while inhibition of canonical Wnt or activation of noncanonical Wnt signaling pro-
motes differentiation of stem and progenitor cells. It is also noteworthy that Wnt signaling
effects are complex and stage-specific, requiring the development of elaborate protocols to
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stimulate and inhibit various Wnt signaling branches in a timely fashion. The significance
of controlled Wnt signaling in the stem cell maintenance is also reflected by the fact that
deregulation of the Wnt pathway is linked to many forms of cancer. Currently, a large
number of reagents are being developed to inhibit or stimulate Wnt signaling. Such tools
may revolutionize Wnt signaling regulation for the expansion and differentiation of organ-
specific stem cells in the treatment of human degenerative diseases or for the regeneration
of tissue after injury.
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2.1 Introduction
Generating cardiac tissue ex vivo to replace damaged or failing myocardium has been
a goal of researchers for decades. Recent advances in stem-cell biology allowing the
isolation and culture of pluripotent stem cells have made this aspiration a possibility. The
complexity of the processes that drive stem cells from a pluripotent state toward progenitor
and then specialized cell populations has made in vitro derivation of cardiomyocytes a
challenging pursuit. However, a better understanding of the processes involved in cardiac
tissue formation on a cellular and molecular level has unlocked the mechanisms that
transform a pool of cells in the mid-portion of the embryo into a beating tube and finally a
highly efficient, four-chambered double pump. Advances in our understanding of and ability
to culture pluripotent stem cells have provided a model system to which to apply our more
recent understanding of cardiac developmental mechanisms in vitro. This application has
further refined our understanding of the molecular mechanisms behind the cardiomyogenic
process and allowed for the creation of large numbers of functional cardiomyocytes in
culture. These cultured cardiomyocytes have applications in the fields of drug testing and
toxicology, basic research, and eventually as novel therapeutics.
In order to illustrate the complexity and exquisite delicacy of the processes whereby heart
tissue is formed, we will begin this chapter in vivo, learning from the embryo how a heart
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is made. This will include a look at the major morphological features of the developing
heart and at the timing of their appearance. We will then provide a summary of the major
cellular and molecular events involved in the formation of each important feature.
After establishing a biological context for the varied events that take place during car-
diogenesis, we will move out of the embryo and into the cell culture dish. In this section
we will review the different types of pluripotent stem cell and their basic biology, including
how they differ from other types of stem cell and what features make them important for
the modeling of cardiac development in vitro.
The third section will cover the approaches used to generate cardiomyocytes from
pluripotent stem cells. This will include strategies for using biological molecules such
as growth factors to modulate signaling pathways in an attempt to mimic key develop-
mental signaling events. This section will also cover the use of small molecules and other
approaches to modulating these same key developmental pathways.
The final section will discuss the applications for stem cell-derived cardiomyocytes.
This will include a look at the use of pluripotent stem cell-derived cardiomyocytes in basic
research, drug discovery, tissue engineering, and clinical applications.
2.2 A Brief Review of Heart Development
2.2.1 Cellular and Morphological Movements
While our understanding of the anatomical and morphological features of heart development
spans more than a century, it is only recently that we have begun to unlock the cellular and
molecular mechanisms of this amazingly complex process. In this section we will review
how a small number of progenitor cells in the early embryo are able to transform into a
four-chambered, life-giving pump.
Before any organs begin to form, the developing embryo must transition from a mass
of cells into layers of tissue that will eventually form a complete organism. The process
by which these primitive layers of tissue form is known as gastrulation. At gastrulation
the embryo transforms from a sphere of dividing cells into an organized, multilayered disk
(human) or tube (mouse) called a gastrula [1,2]. The position of each layer of tissue generally
lends itself to the eventual positioning of the various organs. The skin will form from the
topmost outer layer, the ectoderm, while the inner and bottom layers, the endoderm and
mesoderm, will form the gut, the muscles, the heart, and other organs. It is after gastrulation
that the heart begins to form from the mesodermal layer.
In the post-gastrulation embryo the heart is the first organ to form and is the first
functional organ, pumping blood and providing nutrients to diffusion-limited cells as the
embryo develops. The complete heart is made up of several cell and tissue types. Innermost
is the endocardium, a layer of endothelial cells that line the chambers and major vessels
coming into and stemming from the base of the heart. In the middle of the wall of the heart
is the largest portion by volume and mass, the myocardium. The myocardium consists of
cardiomyocytes, which are responsible for the contractile force of the heart and for the
propagation of membrane depolarization that drives regular beating. The myocardium is
composed of a combination of several types of cardiomyocyte, each of which is functionally
and structurally distinct. These distinctions are the result of the functionally distinct role of
each region of the myocardium during contraction. The atria are primarily responsible for
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regulating blood flow into and out of the ventricles, helping to maintain a proper rhythm. The
ventricles provide most of the contractile force generated during a heartbeat. Connecting
the atria and ventricles are bundles of mostly “nonworking” cardiomyocytes that initiate
and propagate the electrical signals which cause the heart to beat. These nonworking cells
are generally referred to as conduction system cells. The outermost layer of the heart is
the epicardium. This is a layer of connective tissue that serves as a covering and provides
mainly smooth muscle cells to support the coronary arteries. During development, each of
these layers must form at the right time and in the right place in order to provide a fully
formed and functionally normal heart.
While the heart is not fully grown until after birth, achieving a mostly complete heart
takes a remarkably short amount of time in lower mammals. In the well-studied mouse
embryo the progression from progenitor cells to a functional four-chambered heart takes
only about a week [3]. Arriving at this final configuration requires passage through what
may be described as four major stages: specification of early cardiac progenitors and their
coalescence into cardiogenic regions called heart fields; fusion of these cells at the midline
to form the heart tube; cardiac looping and primitive chamber formation; and finally cardiac
remodeling, including septation and valve formation.
The first of these four stages of heart development is the specification and migration of
cardiac progenitor cells from the mesoderm of the gastrula. These early cardiogenic regions
appear around embryonic day 6.5 in mice, at Hamburger Hamilton stage 3 in chicks and
about 22 days postfertilization in humans [4, 5]. At the earliest stages, cardiac progenitors
are not easily distinguished from other cells in the mesoderm. However, by day 7.5 in the
mouse these progenitors have migrated into the midline of the embryo to form the first
distinguishable cardiac structure, the cardiac crescent [3, 6]. This crescent, shaped like
a C with the open end oriented caudally, is located at the cranial portion of the embryo
just below the developing head fold and neural tube. At the cardiac crescent stage cardiac
progenitor cells reside in two distinct regions, called the primary and secondary heart fields
(PHF and SHF, respectively) [6]. The cells in these fields will eventually become most of
the heart. Cells in the PHF eventually become the left ventricle and a portion of the atria
and the right ventricle. The SHF is located lateral to the PHF and contributes to the rest of
the atria and right ventricle, as well as the entire outflow tract. In addition to their spatial
regulation, the cells of the PHF and SHF are also temporally regulated. The cells derived
from the PHF are the first to differentiate into cardiomyocytes and are known as first lineage
cells. The SHF cells remain in an undifferentiated state until after the PHF cells begin to
form the heart tube. During tube formation and throughout looping, SHF cells continue to
differentiate and make contributions to the atria, ventricles, and outflow tract [7].
The second stage of heart development is cardiac tube formation. This process starts
around embryonic day 8 in mice and is indicated morphologically as a budlike structure
emerges at the cranial portion in the PHF of the cardiac crescent [3]. This budlike structure
then enlarges as the crescent begins to fuse at the midline, gaining volume while expanding
cranially and caudally [8]. At the caudal end of the crescent PHF, cells migrate downward in
a bisymmetric fashion on the right and left sides of the emerging heart, forming an inverted
Y. At the top of this inverted Y the budding PHF cells, with contributions from the SHF,
expand downward to form the heart tube. This tube is a cylindrical structure composed
of developing myocardium on the outside and a layer of endothelium called endocardium
on the interior. While the PHF is expanding to form the anterior portions of the emerging
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heart, the SHF is also expanding cranially and posterior to the PHF. The expanding SHF
cells make some contribution to the mostly PHF-derived heart tube cells but also form
a distinct structure at the top of the inverted Y that will eventually become the outflow
tract. The cranial and caudal portions of this tube are known respectively as the arterial
and venous poles. Once the heart tube is completely fused between the correctly oriented
arterial and venous poles, it begins to act as a rudimentary pump. This pumping action is
essential for moving blood through the developing circulatory system of the embryo, which
at this point requires blood flow to provide nutrients and oxygen to diffusion-limited cellular
compartments. It is also evident that myocardial cells capable of producing contractions
are present even in this rudimentary heart.
Though the heart is beginning to fulfill its functional role as a pump to move blood through
the embryo, it must still detach itself from the mediastinum and orient itself properly for
chamber and valve formation. This reorientation process occurs during the third major
stage in heart development, cardiac looping. In mice this looping process begins around
embryonic day 9.0 and in humans around 5 weeks postfertilization. In mice it takes about
1–2 days to complete. As already described, the newly formed heart tube is at this point an
asymmetric structure consisting of a bifurcated region at the venous pole and a straight tube
with rudimentary SHF-derived outflow tract at the arterial pole. The bifurcated caudal end
contains the inflow tract and what will become the atria. During looping, this pole of the
heart moves dorsally and cranially while twisting to the right, bringing it to a cranial position
just above the developing ventricles. While the venous pole is reorienting as described, the
arterial pole containing the outflow tract is also moving, albeit caudally and ventrally in an
opposite and complementary fashion. These movements have now oriented the two poles
in an asymmetric dorsal–ventral configuration with the outflow tract on the right and a
common atrium and inflow tract on the left. These two regions are connected by a loop
of bulbous, asymmetric cardiac tissue that includes the atrioventricular (AV) canal. This
bulbous loop will eventually become the left and right ventricles. The former poles will
become the atria and major vessels located at the base of the heart. It is during this period
of development that the ventricles begin to be separated via the interventricular septum and
that the precursors to the valves, or endocardial cushions, begin to form [3, 8].
Now that the heart is positioned properly, it is ready to proceed to the final step of
development, cardiac remodeling and definitive formation of the cardiac chambers. As
indicated earlier, primitive chambers are already aligned and ready to form the two atria
and two ventricles characteristic of the adult heart. The atria form as the common atrium
expands to form two appendages. While these atrial appendages are forming, the outflow
tract is imposed upon their junction by continued spiraling of the heart tube. The outflow
tract and atria fuse, producing two distinct atrial chambers. At the same time the inflow
region insinuates itself between the bulging ventricular regions on the dorsal side of the
heart. The inflow tract then fuses with the cardiac loop, creating separate left and right
ventricles. During this stage the valves and septa that separate the chambers from one
another are also forming. The endocardial cushions in the AV canal give rise to the tricuspid
and mitral valves, while those in the outflow tract form the septum dividing the outflow
tract into the aorta and pulmonary artery [3].
These four steps give a sketch of the complexity of the heart-forming process. Indeed,
the procession through these four stages is complete by around E14 in the mouse, yet the
heart continues to grow and mature through the remaining week or so until birth, and even
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thereafter. For the purpose of this chapter, however, these four basic steps provide the proper
context for our discussion of the cell types that populate the heart during development and
the molecular mechanisms that drive them. It is this molecular understanding, gained by
careful inspection of the different stages of heart development, that has allowed us to
generate cardiomyocytes in vitro from pluripotent stem cells.
2.2.2 Molecular Events in Heart Development
In order to appreciate how our understanding of the major events in cardiogenesis has been
applied to pluripotent stem-cell differentiation in vitro, it is important to describe the major
cell types involved in each of the developmental stages of the heart in terms of their origin,
movement, and eventual fate. Coordinating the differentiation and movement of cells during
the four stages are major developmental signaling pathways. From mesoderm derivation to
remodeling and chamber formation, these signaling pathways act to sequentially regulate
cardiac transcription-factor networks. These transcription-factor networks regulate impor-
tant structural and functional genes that eventually characterize the mature cardial cells.
Thus the molecular and cellular events that drive cardiogenesis are best thought of in terms
of these signaling pathways and the transcription factors under their control. In the context
of cardiomyocyte differentiation from pluripotent stem cells, signals and factors regulating
the origin and differentiation of early cardiac progenitor cells are most relevant. We will
therefore focus most of our attention on the early events of cardiac differentiation.
2.2.2.1 Molecular Events of Mesoderm Derivation
Prior to gastrulation, stem cells from the inner cell mass (ICM) of the blastula form one of
the earliest embryonic tissue types, the epiblast. Cells of the epiblast then give rise to the
three primary germ layers. They first form the primitive streak and the earliest of the three
germ layers, the ectoderm. The cells of the primitive streak then go on to form the endoderm
and mesoderm. This transition of embryonic stem cells toward mesodermal tissue may be
classified as the first important transition in vivo that guides our understanding of how to
generate cardiomyocytes in vitro from pluripotent stem cells.
As gastrulation progresses, epiblast cells migrate through the primitive streak and expand
outward between the ectoderm and endoderm [9]. Mesodermal cells continue to expand lat-
erally into the developing space between the ectoderm and endoderm, eventually segment-
ing into four different sections [10]. Developmental pathways directing the specification,
migration, and expansion of mesoderm from epiblast through the primitive streak and into
its final position between ectoderm and endoderm include Activin/Nodal, Wnt, BMP, and
fibroblast growth factor (FGF) [9, 11]. These pathways act in concert to regulate each other –
confining proper activation to specific regions by regulating the expression of agonists and
antagonists – and to regulate the expression of mesodermal transcription factors.
Early induction of mesoderm is associated with the activity of Activin/Nodal signaling.
Nodal is expressed in the epiblast, where it activates BMP signaling, which in turn activates
Wnt. Later, Nodal and BMP act together to control the expression of Wnt antagonists
such as Dkk1 in order to restrict Wnt signaling to the primitive streak, where it directs
the formation of mesoderm. During mesoderm induction the Wnt signaling pathway acts
as a fulcrum point for the interaction of Nodal and BMP signaling. As mesodermal tissue
continues to form, Wnt signaling is detected toward the posterior end of the primitive streak
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around E6.5 and then expands into the entire primitive streak and much of the mesoderm
by E7.5 [12]. Loss of Wnt signaling components, including Wnt ligands, co-receptors, and
β-catenin (the nuclear protein mediating Wnt transcriptional control), results in a failure to
form mesodermal tissue [13–17].
Wnt signaling affects the formation of mesoderm mainly via the Wnt ligand
Wnt3A. Wnt3A regulates the activation of the essential mesodermal transcription factors
T-brachyury (T-bry) and Eomes [18]. In fact, Wnt signaling acts directly on T-bry via
translocation of β-catenin to the nucleus and activation of gene transcription [19]. These
transcription factors play a critical role in cell migration during mesoderm specification
and are used as definitive markers of mesodermal tissue [20].
FGF signaling also plays an essential role in the early formation of mesoderm. Loss of
FGF ligands such as FGF8 and receptors such as FGFR1 leads to a loss of mesoderm by
interfering with cell migration [21–23]. The effect of FGF signaling on mesoderm formation
is likely mediated via its regulation of the transcription factors Snail, T-bry, and Tbx6, three
genes required for mesoderm migration, specification, and patterning.
This gives a brief sketch of the molecular events required for mesoderm formation,
providing context for the next section, where we will examine the formation of cardiac
progenitors via the transcription factors that drive cardiac progenitors and the signaling
pathways that guide them. It is important to note that mesoderm formation and cardiac-
progenitor specification are not necessarily mutually exclusive processes. Many important
developmental events occur in concert with one another as the heart develops. Examples of
this concept will be apparent as we continue our discussion of the cellular and molecular
events involved in cardiac development.
2.2.2.2 Transcription Factors in Cardiac Development
Cardiac precursors can be detected in the anterior region of the primitive streak during
the early stages of mesoderm formation. These precursors are not yet cardiac cells but
are a collection of cardiac progenitors that give rise to the earliest cardiac cells. These
early cardiac cells are present on either side of the embryonic midline and express the
transcription factors Mesp-1 and Mesp-2. Loss of Mesp expression in these cells causes
a failure in the migration required for the movement of emerging cardiac progenitor cells
[8, 24, 25].
Expression of Mesp-1 in the cardiogenic mesoderm is a master signal that initiates the
cardiac transcription-factor signaling network [24]. Mesp-1 expression rapidly induces the
expression of a new set of transcription factors involved in cardiogenesis. These include
Nkx2-5, Hand2, Myocd, Gata4, Mef2c, Tbx20, FoxH1, Foxc1, SRF, and Foxc2, among
others [24]. The mechanism behind this activation lies in the ability of Mesp-1 to bind
directly within the regulatory regions of its target genes, including Nkx2-5, Hand2, and
Myocd. Myocd in turn activates Mef2c and SRF, which go on to activate the essential
cardiac structural genes Myh6, Myl1, Myl2, Myl7, and cardiac troponin 2 (Tnnt2) [26,27].
Each of the transcriptional events in the formation of cardiac progenitors is thereby linked
from Mesp-1 expression in the early mesoderm on through expression of cardiac-specific
structural and functional components in mature cardiomyocytes. This point is very impor-
tant to keep in mind: cardiogenesis on a cellular level occurs via the carefully orchestrated,
stepwise movement of progenitor cells toward mature cardiac subtypes, directed by cardiac
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transcription factors. As we will discuss later, it is upon this principle that most protocols
for production of de novo cardiomyocytes from pluripotent stem cells depend.
This summary illustrates the sequence of transcription-factor events kicked off by Mesp-
1 and propagated onward to drive heart formation. We will now discuss where these
transcription factors are expressed and the role they play during cardiogenesis. Some are
restricted temporally and spatially to a particular period of heart development, while others
are expressed throughout.
Nkx2-5, Hand1 and 2, Gata4, and Tbx1,5 and 20 are expressed in the PHF. These
transcription factors direct the differentiation of cells within the PHF as they populate the
heart tube and differentiate during looping morphogenesis [3, 6, 8]. Nkx2-5 is important in
atrial–ventricular chamber compartmentalization and the formation of ventricular tissue.
Hand1 and 2 play a direct role in the formation of the left and right ventricles, respectively.
Gata4 expression is essential for looping morphogenesis, septation of the valves, and
formation of ventricular myocardium. At the stage of heart-tube formation, cardiac cells
must migrate and fuse at the midline. Here, Gata4 and a companion transcription factor,
Foxp4, are essential for proper tube formation, as mutations in these genes lead to a failure
of the cells to fuse and form a proper heart tube [3].
The Tbx transcription factors are an important class that play diverse roles in cardiogen-
esis, including patterning and specification of conduction system cells and sinoatrial nodal
cells and distinguishing between atrial and ventricular myocardium. In fact, patterning via
the Tbx genes is the major driver for distinguishing between working and nonworking
myocardium during the later stages of cardiac development [28]. Tbx transcription fac-
tors are also critical to the formation of the outflow and inflow tracts and neuralization
of the atrium at later stages of heart development [29, 30]. Tbx20 plays an important role
in proliferation of myocardial progenitor cells during early myocardial expansion. Mutant
embryos lacking Tbx20 expression present a large decrease in the number of terminally
differentiated cardiomyocytes [31]. Tbx18 is expressed in the extreme posterior regions of
the SHF [6]. Cells that express Tbx18 end up in diverse cardiac locations, from smooth
muscle to myocardium and interventricular septum [6].
Isl1 is another essential cardiac transcription factor. Isl1 expression in the SHF plays a
role in many cardiac development processes. Mutations that inactivate or knockdown its
expression result in major cardiac defects. These include lack of septation in the atrial and
ventricular compartments, abnormal atria, and a lack of outflow tract [32]. Isl1, along with
Gata4, can directly control the expression of Mef2c by binding a genomic enhancer element
upstream of its coding sequence [33]. Incidentally, Isl1 expression has been detected in the
PHF as well as the SHF (where it was originally identified), although it does not seem to
be required for formation of the PHF lineages [34]. When Isl1 expression is knocked down
in transgenic mice, the PHF and its associated derivatives still form as expected [32].
The Forkhead transcription factors (known as Fox) are also important for cardiac devel-
opment. Foxh1 is expressed in the anterior region of the SHF and plays a role in formation
of the outflow tract and right ventricle [35]. Foxh transcription factors also play a role in reg-
ulating other transcription factors, such as Mef2c [36]. Mef2c is involved in the formation
of the outflow tract, inflow tract and proper development of the right ventricle [37].
Pitx transcription factors are also required for myocardial formation. Pitx2c expression is
detectable throughout the left side of the SHF during early cardiogenesis and is later detected
extensively in the ventricular and atrial myocardium. Pitx2c is essential in the formation of
22 Chemical Biology in Regenerative Medicine
left–right asymmetry in the heart and loss of Pitx2 expression leads to right atrial isomerism
and defects in ventricular maturation [38]. Pitx2c also regulates the formation of left versus
right atrial chambers by repression of right atrial identity.
Atrial and ventricular cells are being patterned at very early stages of cardiac develop-
ment. Cells in the SHF that will eventually become part of the atria require the expression
of the transcription factor NFAT in order to fully develop [39]. At later stages of heart devel-
opment the transcription factors Irx4 and Hey2 are expressed in emerging ventricles and
play a role in ventricular myocyte formation. The transcription factors Hey1 and Coup-TFII
are expressed in the atria, where they regulate atrial myocyte formation [28, 40, 41].
Transcription factors are a crucial component of cardiac development. Not only do they
regulate the proliferation, patterning, differentiation, and final maturation of cardiomy-
ocytes and their progenitors during development, they are also indispensable as markers
of distinct differentiation stages from progenitor populations and mature cardiac subtypes.
Understanding the role of transcription factors in tissue-specific compartments allows
us to track the development of cardiomyocytes in vitro, thereby allowing the successful
translation of developmental paradigms into the culture dish for efficient cardiomyocyte
differentiation.
It is interesting to note that many regions of the heart are sensitive to perturbations of
several transcription factors. In other words, no single transcription factor affects only one
part of the complete heart. For example Nkx2-5, Hand1/2, and Tbx20 are all required for
proper formation of the ventricles, yet their effects on ventricular tissue are not redundant.
Loss of each of these transcription factors affects ventricular development in different ways
[8]. This amazing interconnectedness of the transcriptional networks involved in cardiac
development underscores their complexity.
2.2.2.3 Major Developmental Signaling Pathways in Cardiac Development
In order to coordinate the timing and expression of these networks, cells rely on the
major developmental signaling pathways. Many of the same pathways already discussed as
important for mesoderm formation are critical for the proper differentiation and maturation
of cardiac progenitors. These pathways control diverse processes, including the expansion
of progenitor populations and differentiation of progenitors into myocardial cells. In this
section we will briefly discuss how the major developmental signaling pathways, Wnt, bone
morphogenetic protein (BMP), Activin/Nodal, FGF, Retinoic acid (RA), and Shh, regulate
cardiomyocyte development.
Wnt signaling is involved in almost all stages of heart development, from myocardial
specification and early cardiac morphogenesis through heart-tube formation, looping, and
chamber formation. Wnt ligands are expressed in the heart-forming fields during early
heart development. As the heart fields merge to form the heart tube, different ligands are
restricted to distinct regions of the heart, reflecting the diversity of function within even
the same signaling family during differentiation [42]. Wnt receptors are also expressed
in the heart fields. The expression of Wnt receptors in these tissues is just as diverse
as the expression of Wnt ligands [42]. Functionally, Wnt exhibits pleiotropic effects on
heart development. Canonical Wnt signaling is required for Isl1 induction and proliferation
of cardiac progenitor cells but exerts an inhibitory effect on cardiac differentiation, while
noncanonical JNK-mediated Wnt signaling promotes cardiac differentiation. Noncanonical
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Wnt signaling also regulates cell adhesion and cell polarity during cardiac morphogenesis
[43].
As is the case with Wnt, BMP ligands and receptors are expressed in cardiac progenitor
cells and the mature heart. BMP factors are secreted to cardiac progenitors by the endoderm
during gastrulation as they move toward the cardiac crescent and SHF [44]. BMP2 induces
the expression of Nkx2-5 in the cardiac crescent, which then directly interacts with the early
BMP effector Smad to autoregulate BMP2 expression in the SHF [45]. BMP expression is
also important in regulating elongation of the linear heart tube, heart-chamber formation,
and cushion formation, as well as in interacting with Nodal signaling to establish left–
right asymmetry [46]. These interactions between BMP and Nkx2-5 regulate early cardiac
expansion by first stimulating proliferation and then limiting the number of cardiomyocytes
in the heart tube to prevent overpopulation [34].
Nodal and Shh signaling regulate the activation of Pitx2c to control patterning of the
left–right axis [6]. Without proper Shh signaling, the heart remains attached to the dorsal
mesocardium, preventing proper detachment and looping [47]. Shh signals are expressed in
cardiac progenitors that migrate through the SHF to form the subpulmonary myocardium
and participate in atrial septation [48]. Shh restricts expression of Pitxc2 to the right side of
the heart. Shh also interacts with Isl1, helping to regulate proliferation of progenitor cells
and initiate differentiation [28].
FGF is another critical signaling pathway in various stages of cardiogenesis. FGF ligands
and receptors are expressed in early cardiac progenitor cells and mature cardiac tissues [28].
FGF is also expressed in adjacent tissues and plays an inductive role during cardiomyocyte
development. FGF interacts with BMP signaling to regulate the activity of Tbx transcription
factors, thereby influencing the formation of both early cardiac progenitors and myocardial
subtypes during differentiation. FGF and BMP also interact to regulate the differentiation
of cardiac mesodermal cells between the myocardial and epicardial lineages [49, 50]. FGF
is also required for proliferation of the SHF, formation of the arterial pole, and outflow-tract
development [6].
RA signaling is a critical component of anterior–posterior patterning, the formation of
the cardiac tube, and atrial–ventricular specification [51]. Expression of the RA receptor
Raldh2 is required for heart-tube growth and outflow-tract formation. RA signaling is also
important for stimulation of Mef2c expression via Gata4 [6].
The complexity of heart formation is reflected in the varied morphogenetic and cellular
movements that take place during it, as well as in the transcription factors and develop-
mental signaling pathways that drive them. While further research into the mechanisms
of myocardial subtype specification and cardiac maturation and maintenance remains to
be done, our current understanding of these processes allows their application toward the
successful generation of cardiomyocytes in vitro from pluripotent stem cells.
2.3 Introduction to Pluripotent Stem Cells
2.3.1 Unique Features of Pluripotent Stem Cells
Stem cells in general possess two unique and defining properties that distinguish them
from other cell types. The first is that they are self-renewing, able to proliferate practically
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indefinitely in their undifferentiated state to generate new pluripotent cells. The second
defining property of stem cells is their ability to differentiate and form more mature,
specialized cell types. In the case of adult stem cells, the capacity to differentiate into
other cells types is confined to the subtypes required by the compartment in which they
act (see Chapter 5 for more information). In contrast, pluripotent stem cells have a broader
differentiation potential and can perhaps give rise to most tissue-specific cell types. These
features make pluripotent stem cells an exciting source for the production of cardiomyocytes
in vitro.
2.3.2 Pluripotent Stem Cell Sources
Pluripotent stem cells generally come from two major sources. The first are the embryonic
stem cells (ESCs), which are derived from the inner-cell mass of blastocysts prior to
implantation. These cells are both self-renewing and pluripotent, able to produce all the
cell types of the body. Due to ethical issues and technical constraints, most early research
conducted on ESCs in culture was focused on those isolated from mouse embryos. As
technology has advanced and our ability to deal with the political and ethical concerns
surrounding research using human embryos has evolved, such research has become less
restricted, but it still poses many practical and ethical challenges. Research in mouse
and human ESCs has identified a large network of transcription factors that are required
for pluripotency, self-renewal, and suppression of differentiation [52, 53]. In a seminal
discovery by Yamanaka, it was shown that a forced expression of four of these factors –
Oct4, Klf4, Sox2, and c-Myc – is sufficient to reprogram somatic, terminally differentiated
cells into pluripotent, embryonic-like stem cells. These reprogrammed cells were first
derived from mouse embryonic and adult fibroblasts in 2006 using a subset of defined
factors exogenously expressed in cultured cells [54]. A year later the same technique was
shown to be effective at generating pluripotent stem cells from human adult fibroblasts
[55, 56].
The second major source of pluripotent stem cells is the induced pluripotent stem cells
(iPSCs), which have proven to be highly similar to ESCs in their ability both to self-renew
and to differentiate into a variety of mature cell types [57]. iPSC technology offers the
advantages of being both less ethically challenging and more patient-specific than the
use of ESCs. Patient-specific stem cells open the way for generating cardiac tissue from
patients suffering from genetic cardiac diseases in order to study these diseases in vitro, and
eventually for the creation of patient-matched tissue that is resistant to immune rejection.
Since the initial reprogramming protocol, various modifications have been made to
simplify and increase the efficiency of pluripotent stem-cell induction. These methods
include using small molecules and proteins to aid the reprogramming process, generating
new gene expression vectors that do not require viral integration, and modulating the
regulation of pluripotency [58–64]. These advances have made generating iPSCs practical
enough to be done in a routine fashion.
2.3.3 Maintaining Pluripotency
Prior to differentiation, stem cells are maintained in an undifferentiated, pluripotent state.
Maintenance of this pluripotent state is critical for taking advantage of the self-renewing
capacity of stem cells and for the efficient directed differentiation of cardiomyocytes in vitro
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[65]. If pluripotent stem cells begin to differentiate in culture prematurely, they rapidly lose
their capacity for self-renewal and spontaneously acquire the features of differentiated cells
in a more or less random fashion. In such a state they are ineffectual for use in directed
differentiation. The tendency of pluripotent stem cells to spontaneously differentiate in
culture must be kept in check until they are ready to be used for directed differentiation.
Both mouse and human cells have a tendency to spontaneously differentiate. Growth
of pluripotent stem cells on feeder cells such as fibroblasts, also used for derivation of
ESCs and iPSCs, helps to control this differentiation to some degree; however, use of
feeders introduces an undefined component to the culture system, without even completely
eliminating the differentiation.
The discovery that the protein LIF (leukemia inhibitory factor) was sufficient to pre-
vent differentiation of mouse ESCs when added to the culture medium presented a major
advancement to the field of ESC culture [66]. LIF is effective even in the absence of
feeder cells and is therefore an essential component for the undifferentiated culture of
mouse embryonic stem cells (mESCs) in feeder-free conditions. Culture of stem cells in the
absence of feeders eliminates the variability associated with the undefined role they play
in maintenance of pluripotency and their effect on the eventual fate of stem cells during
differentiation. Use of LIF as an added factor in pluripotent stem-cell media also serves to
illustrate the concept that the properties of pluripotent stem cells in culture can be directly
controlled via the addition of defined factors to their culture medium.
It is critical to note that LIF is not sufficient to prevent spontaneous differentiation of
cultured human pluripotent stem cells (hPSC). In order to support the feeder-independent
culture of hPSCs more complex mixtures of defined factors have been developed. These
formulations are based on our understanding of the signaling pathways that maintain
pluripotency in vivo and include a combination of ligands such as bFGF and transforming
growth factor beta-1 (TGF β1) [67,68]. These strategies also employ artificial extracellular
matrices such as matrigel or vitronectin in order to preserve pluripotency and enhance cell
survival and attachment [69]. Feeder-free culture of human pluripotent cells in defined
media allows for more precise control of pluripotency and differentiation [70].
In summary, the unlimited proliferative capacity and broad differentiation potential of
pluripotent stem cells are defining characteristics that distinguish them from other stem
cell types. These characteristics make them ideal for use as a source of cardiomyocytes in
vitro. Both embryonic and adult tissues from mice and humans have been used as a source
of pluripotent stem cells. Each of these stem cell types has its strengths and weaknesses
in terms of both cell culture and differentiation potential for use in the production of
cardiomyocytes, and it is critical that pluripotency is maintained prior to differentiation no
matter the source or type.
2.4 Cardiomyocyte Differentiation
2.4.1 Inducing Differentiation
Upon induction of differentiation, cultured pluripotent stem cells proceed through a well-
ordered progression highly similar to that observed in the early stages of embryonic devel-
opment in vivo [71]. This includes the sequential formation of cells with characteristics
26 Chemical Biology in Regenerative Medicine
of mesodermal progenitors, mesoderm, cardiac mesoderm, cardiac progenitor cells, imma-
ture cardiomyocytes, and finally mature myocytes [70]. The differentiation of pluripotent
stem cells into cardiomyocytes recapitulates the in vivo program with such fidelity it has
been used to yield valuable insight into the basic mechanisms driving cardiac development
[12, 72–74].
Tracking the expression of transcription factors characteristic of pluripotent cells, meso-
derm, cardiac progenitors, and mature myocytes is an important example of how in vivo
developmental paradigms aid in the derivation of cardiomyocytes from pluripotent stem
cells. Over the first few days of differentiation, gene expression patterns indicate that
pluripotency genes are downregulated while gastrulation gene expression is induced. Start-
ing around day 2 and peaking at day 3 in mouse and a little later in human stem cells the
mesodermal marker T-bry is expressed, indicating the formation of mesoderm [65, 75].
After day 4 in both human and mouse stem cells, early cardiac markers such as Mesp-1
and Nkx2-5 can be detected. By day 10 more mature cardiac genes, including the light and
heavy myosin chains, as well as cardiac conduction channels, are expressed. Expression
of important genes for the developmental signaling pathways involved in cardiac devel-
opment is also detected during this process. Thus pluripotent stem cells pass through the
necessary developmental stages discussed in Section 2.1, which lead to cardiomyocyte
formation [76].
In order to coax stem cells from their pluripotent state through each of these stages
to yield cardiomyocytes, differentiation strategies typically focus on mimicking the in
vivo differentiation process. The earliest of these techniques relies on the formation of
embryoid bodies (EBs): small spheres of pluripotent cells induced to form in droplets of
cell-suspension media hung on the lids of Petri dishes or forced to aggregate in microwells
[77, 78]. The strategy behind using such a system is to reconstruct the spherical nature
of the early post-implantation embryo from which pluripotent stem cells are originally
derived, in order to induce the process of gastrulation. In fact, differentiating EBs give rise
to layers of tissue representative of mesoderm, endoderm, and ectoderm and will eventually
produce cells representative of all the tissues of the body [79]. The EB method is used for
the differentiation of both human and mouse pluripotent stem cells. Its effectiveness in
both systems and its relative scalability have made it a popular format for induction of
differentiation.
Monolayer differentiation techniques have also been used to induce the differentiation
of pluripotent stem cells. These techniques, while not as scalable as EB or other suspension
differentiation systems, have the advantage of being less complex, more accessible to
proteins and other molecules used for cardiac induction, and more amenable for use in tissue
engineering and other applications where thin films are preferable to aggregates [80, 81].
Monolayer differentiation does not inherently produce embryonic germ-layer tissues as do
EBs. These protocols thus rely heavily on the directed differentiation techniques discussed
here in order to consistently generate significant numbers of cardiomyocytes.
2.4.2 Directed Cardiomyogenesis
EB formation alone is enough to induce some cardiogenesis. After induction of differenti-
ation, small beating clusters are usually observed between days 8 and 10 of differentiation
in mESCs and a little later in hPSCs [80, 82, 83]. However, only a small portion of cells
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in differentiating EBs will spontaneously become cardiomyocytes, usually around 5–10%
[84]. Noncardiomyocyte populations include other mesodermal lineages such as endothelial
cells and smooth muscle cells and those of the other germ layers, including neurons. Thus
merely forming EBs and allowing them to differentiate is not sufficient to generate large
numbers of cardiomyocytes from pluripotent stem cells in vitro. As already mentioned,
monolayers of pluripotent stem cells also form few if any cardiomyocytes when simply
allowed to spontaneously differentiate in culture.
In order to induce more abundant populations of cardiomyocytes, further cues from
embryonic development are used to drive or enhance the progression of cells to form
mesoderm, cardiac progenitors, and functional cardiomyocytes. The most effective current
methods employ a refined approach that relies on the addition of exogenous factors and
small molecules in defined media at precise times during the course of differentiation
[70]. These factors include protein and small-molecule agonists and antagonists of specific
developmental signaling pathways, including Activin/Nodal, Wnt, BMP, FGF, and TGFβ
[69, 70].
The first step in directing pluripotent stem cells toward becoming cardiomyocytes
involves the induction of mesoderm. As discussed earlier in this chapter, one of the first
events in the differentiation of cells into cardiomyocytes in vivo is the coordinated action of
Activin/Nodal, BMP, and FGF signaling pathways to induce expression of the mesodermal
transcription factors T-bry, Eomes, and SnaiI. Most successful protocols for the efficient
induction of mesoderm therefore include addition of the Nodal ligand ActivinA, the BMP
ligand BMP4, and the FGF ligand FGF2 [70]. Once mesoderm has been established, spec-
ification of cardiac progenitors can be induced using a combination of Wnt, TGFβ, and
BMP inhibitors with vascular–endothelial growth factor (VEGF). These molecules block
the negative regulatory effect of their respective pathways at this stage of differentia-
tion, allowing for the more robust transition of cardiac mesoderm to cardiac progenitor
cells [85, 86]. To drive cardiomyocyte differentiation from progenitor cells to functional,
beating myocytes, VEGFA, FGF2, and the Wnt inhibitor Dkk1 are added. As when enhanc-
ing progenitor-cell specification, these factors maintain the positive regulatory activity of
VEGF and FGF signaling while preventing the negative effects of Wnt on cardiomyocyte
differentiation.
Other molecules outside of the traditional pathway modulators have also been empirically
determined to enhance cardiomyocyte differentiation. These include vitamin C, which
enhances proliferation of cardiac progenitors, cardiogenic small molecules identified using
high-throughput screening methods, and polymers such as PVA, which modify surface
tension [87–89]. These molecules do not necessarily have developmental parallels but
instead serve to illustrate the flexibility and utility of in vitro differentiation methods.
Despite the relatively high yield of cardiomyocytes produced using these protocols,
there remains a significant amount of heterogeneity among the resultant cardiomyocytes.
This heterogeneity presents a challenge for practical use of pluripotent stem cell-derived
cardiomyocytes.
The first source of heterogeneity arises from the fact that even though cardiomyocyte
populations of over 80% can be achieved by careful optimization of growth factor concen-
tration and timing of treatment, the other 20% of cells are mainly mesoderm-derived cells
such as endothelial cells [70]. Thus cardiomyocytes do not necessarily make up the entire
population. To address this lack of homogeneity, purification strategies are employed to
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enrich the number of cardiomyocytes present in the culture by either selectively eliminating
unwanted cell types by inserting antibiotic resistant cassettes behind cardiac genes or phys-
ically removing late cardiac progenitors using markers like KDR (VEGFR2) and NKX2-5
[85,86, 89]. The advantage of using selection is that it yields the highest purity: up to 99%
cardiomyocytes. Another source of heterogeneity among pluripotent stem cell-derived car-
diomyocytes arises from the heterogeneous nature of cardiomyocytes themselves. Cells of
the atria, ventricles, nodes, and conduction system have distinct functional and structural
properties [82]. Pluripotent stem cell-derived cardiomyocyte populations contain both types
of working myocardium as well as conduction-system and nodal myocardial cells [90]. In
order to address this heterogeneity by directing differentiation toward specific cardiac sub-
types, cues from development have guided early strategies for subtype specification. These
protocols are in the early stages of research and remain to be fully exploited, but some
early attempts have shown that this specification may be possible soon. Modification of
differentiation protocols to modulate signaling pathways such as RA signaling can bias the
differentiation protocol toward specific subpopulations of cardiomyocytes [91–93]. These
protocols remain somewhat inefficient, however, and further research into the mechanisms
that regulate cardiomyocyte subtype differentiation is required.
2.5 Conclusion
Applications for the use of hPSCs extend near and far. In the short term, use of iPSCs derived
from patients with traditionally intractable cardiac illnesses will allow large numbers of
disease- and patient-specific cardiomyocytes to be generated [94]. These myocytes can
be used to study the pathology and development of these diseases in vitro, as well as to
test drugs and other therapeutics for their efficacy. Research into the mechanisms of long
QT syndrome and the effect of drugs on this phenotype, for example, has already yielded
insights into the molecular mechanisms underlying this disease.
Another near-term application for hPSC-derived cardiomyocytes is in toxicology and
drug screening. Most drugs fail in late stages of development and clinical trials, or are
recalled after release due to unacceptable cardiac toxicity as an off-target effect [95]. By
screening drugs in a human cardiomyocyte model system early in the drug development
process, these off-target cardiotoxic effects can be discovered and development efforts can
be shifted accordingly.
In the more long-term future, hPSC-derived cardiomyocytes hold promise as a source of
cells for regenerative therapies. One can envision new hearts grown using cardiomyocytes
derived from individual patient iPSCs, cardiac patches made from engineered myocytes on
biopolymer scaffolds, and injection of engineered ventricular myocytes into post-ischemic
tissues to replenish working myocardium.
Heart development is a complex process on the morphological, cellular, and molecu-
lar levels. Our understanding of these cellular and molecular mechanisms has improved
greatly as molecular-biology and biochemical techniques have been applied to elucidate
the once shadowy web of developmental signaling pathways and transcription-factor net-
works that drives cardiogenesis. This understanding has been applied to the directed cardiac
differentiation of pluripotent stem cells in vitro. Continued research into the mechanisms
behind cardiomyocyte maturation and subtype specification will combine with improved
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techniques to bring us closer to achieving the promising applications for pluripotent stem
cell-derived cardiac myocytes.
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3.1 Introduction
Myocardial infarction and ischemic heart disease are caused by an acute reduction of blood
to the myocardium, which has the direct effect of diminishing oxygen supply. This results
in a loss of large numbers of cardiomyocytes, leading to hypertrophy and heart failure. Care
of such patients places enormous burdens on the health care system, requiring 1 million
hospitalizations every year at an annual cost of $35 billion in the USA [1]. Development
of therapeutics that can facilitate new cardiomyocyte generation would be of enormous
medical and economic impact.
One option for replenishing a depleted cardiomyocyte population is transplantation of
exogenous cells. Over the past decade, many cell types have been evaluated in order to
find the best source for cardiac cell therapy. A wide variety of stem cells, including bone
marrow mononuclear cells (BMCs), mesenchymal stem cells (MSCs), cardiac stem cells
(CSCs), and embryonic stem cells (ESCs), have been examined regarding their capacity to
repair the infarcted myocardium and improve functionally the diseased heart [1, 2]. These
stem cells have been transplanted in animal models of myocardial infarction and have been
demonstrated to reduce infarct size, attenuate left-ventricle remodeling, increase vascular
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density, and improve myocardial function [1, 2]. However, a recent clinical trial to test
BMC therapy in patients with ischemic heart failure revealed no beneficial effects [3],
raising considerable concerns that BMCs and other exogenous stem cells may have low
capacities to integrate and differentiate into cardiomyocytes in the patient heart. Other trials
are underway to examine the potential clinical effects of c-Kit-positive and cardiosphere-
derived stem cells for the treatment of acute myocardial infarction. These findings highlight
the importance and urgency of developing alternative therapeutic approaches.
3.2 iPSC Generation
The advent of induced pluripotent stem cells (iPSCs) has offered a possible solution in
terms of generating functional cardiomyocytes. Somatic cells can be reprogrammed into
an embryonic-like state by transferring nuclear contents into oocytes [4] or by fusion with
embryonic stem cells (ESCs) [5,6]. In 2006, Yamanaka et al. hypothesized that factors that
play essential roles in the maintenance of ESC identity may also play pivotal roles in the
induction of pluripotency in differentiated cells [7]. They developed a clever screen in which
induction of the pluripotent cell state could be selected by the expression of a neomycin/lacZ
fusion gene (βgeo). The βgeo cassette was inserted into the Fbx15 locus in the genome
of mouse embryonic fibroblasts. Fbx15 can be specifically expressed in mouse ESCs and
is indispensable for the maintenance of ESC pluripotency and mouse development. In the
pluripotent stem cells, the Fbx15 promoter activates βgeo expression, resulting in G418
resistance. The initially selected candidate genes were pooled together and delivered to
fibroblasts by retroviral transfection to test for reprogramming. Successful combinations
of factors capable of G18 resistance were selected. This pool was then narrowed down
by reducing factors to Oct4, Klf4, Sox2, and c-Myc (OKSM). iPSCs generate various cell
types in teratoma assays and can contribute to tissues in chimeric mice after transplantation
into mouse blastocysts. Human pluripotent stem cells (hPSCs) can also be generated from
fibroblasts expressing OKSM or slightly different combinations, including Nanog, Lin28,
Sox2, and Oct4 [8, 9].
Recently, it was demonstrated that OKSM factors initially interact with the genome
during cell reprogramming in the first 48 hours [10]. These factors extensively access
distal regulatory elements and activate transcription of many genes required for reprogram-
ming. In both undifferentiated stem cells and fully differentiated cells, genes can exist in
stable states in which they are transcriptionally silent. During initial reprogramming, a
subset of transcription factors termed “pioneer factors” initially access closed chromatin
and directly make it competent to be bound by other factors [10]. Oct4, Sox2, and Klf4
together bind as pioneer factors to closed chromatin sites, while c-Myc facilitates the
binding of OSK to chromatin. Many of the genes that promote cell reprogramming reside
in the closed chromatin regions of the genome. Megabase-scale chromatin domains are
spanned by H3K9me3. Knockdown of relevant histone methyltransferases allows OSKM
binding and enhances cell reprogramming. H3K9me3-containing regions of the genome
are refractory to initial OSKM binding and thereby impede the efficiency of reprogram-
ming [10]. Investigating the initial binding of OSKM to the fibroblast genome helps
with understanding the mechanisms of reprogramming, leading to potential therapeutic
applications.
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3.3 The Chemical Genetics Approach in iPSC Generation
The iPSC technique represents a breakthrough in the stem cell field and offers new perspec-
tives on generating functional cardiomyocytes, but it comes with safety issues. For example,
use of iPSCs is hindered by the potential risks of genetic mutations caused by the integration
of exogenous genetic material into chromosomes. Although several nonintegrative methods
(e.g. episomal plasmid, protein, and mRNA transfection) have been developed to generate
iPSCs, induction efficiency is still quite low [11]. In contrast, small molecules provide sev-
eral distinct advantages in controlling protein functions (e.g. temporal control, reversibility,
tunability, modularity, and tractability). Hence they have attracted much interest in relation
to steering reprogramming toward a more efficient and safe process [11].
To date, various strategies have been developed to generate iPSCs with fewer or no
exogenous genetic manipulations. Different combinations of chemical compounds have
been identified to replace some exogenous transcription factors and enhance the effi-
ciency of reprogramming. Recent reports indicate that reprogramming efficiency can be
enhanced by the presence of small molecules, such as valproic acid (VPA, a histone deacety-
lase inhibitor), AZA (a DNA methyltransferase inhibitor), butyrate (a histone deacetylase
(HDAC) inhibitor), and vitamin C (Figure 3.1) [12–15].
Vitamin C improves iPSC generation mainly by reducing p53 levels and alleviating
cell senescence while still maintaining an intact DNA repair machinery (basal levels of
p53) [14]. It is possible that it accelerates transcriptome changes during reprogramming in
other ways as well. Vitamin C is a cofactor in reactions driven by dioxygenases, including
collagen prolyl hydroxylases, hypoxia-inducible factor, and histone demethylases. During
reprogramming, vitamin C may increase the activity of these enzymes, promote epigenetic
modifications, and enhance iPSC generation. For example, vitamin C may allow the repro-
gramming to run smoothly by activating histone demethylases, which are important for
development and modulate the expression of the ESC master transcription factor Nanog
[16]. It is tempting to speculate that vitamin C, as a compelling antioxidant, might improve
the efficiency of reprogramming by suppressing reactive oxygen species (ROS) produced
by cell metabolism [14].
VPA, an HDAC inhibitor, can increase reprogramming efficiency and enable efficient
induction of iPSCs without introducing the oncogene c-Myc, suggesting that chromatin
modification is a key step in reprogramming fibroblasts to pluripotent cells [12]. Likewise,
butyrate, a small-chain fatty acid, acts as HDAC inhibitor and promotes protein acetylation
at targets such as H3K9 [15]. Simultaneously, it also accelerates promoter DNA demethyla-
tion and expression of endogenous pluripotency-associated genes such as POU5F1/OCT4
and DPPA2. Furthermore, butyrate may possibly stimulate reprogramming by modulating
the activities of nonhistone key regulators, as it exhibits diverse cellular effects in culture,
including cell-cycle arrest and induction of protein synthesis [17]. AZA (5-aza-cytidine),
acting as an inhibitor of DNA methyltransferase (DNMT), improves the overall reprogram-
ming efficiency, indicating that epigenetic remodeling is a key step in the reprogramming
process [13].
Furthermore, the small molecules SB431542 and PD0325901, acting as inhibitors of
transforming growth factor beta (TGFβ) and MAPK/ERK pathways, respectively, signifi-
cantly enhance the reprogramming efficiency of human fibroblasts through the expression
of the four transcriptional factors (Figure 3.1) [18]. TGFβ is a prototypical cytokine for the












































Figure 3.1 During iPSC reprogramming, a variety of small-molecule compounds have been
identified as enhancing pluripotent reprogramming efficiency in the presence of four transcrip-
tional factors (OSKM) or Oct4 through cell senescence, epigenetic remodeling, metabolism
shift, and mesenchymal–epithelial transition (MET)
induction of epithelial–mesenchymal transition (EMT) and the maintenance of the mes-
enchymal state [19]. MAPK/ERK signaling facilitates EMT [20] and occurs downstream of
TGFβ [21]. The positive effects of SB431542 and PD0325901 on reprogramming indicate
that TGFβ and MAPK/ERK pathway antagonists have a direct impact on the reprogram-
ming process, mainly by promoting the mesenchymal–epithelial transition (MET).
Ding’s group was the first to report that a small-molecule combination – the G9a histone
methyltransferase inhibitor BIX-01294 (BIX) and the L-type calcium channel agonist
Bayk8644 (Bayk) – can enable mouse embryonic fibroblasts (MEFs) to reprogram into
iPSCs through the transduction of two factors (Oct4 and Klf4) [22]. BIX treatment causes
histone modification at the epigenetic level and thus enhances reprogramming activity. Bayk
works synergistically with BIX to further increase reprogramming efficiency and has no
impact on reprogramming in the absence of BIX. Bayk might influence the reprogramming
process in specific manners rather than at general epigenetic levels [22].
Both mouse and human iPSCs can be generated by ectopic expression of Oct4 plus dif-
ferent combinations of small molecules. A defined small-molecule cocktail, including the
histone deacetylase inhibitor NaB, the TGF-G receptor inhibitor A-83-01, the MAPK/ERK
inhibitor PD0325901, and PS48 (an activator of 3-phosphoinositide-dependent kinase-1),
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is sufficient to reprogram human primary somatic cells to iPSCs through the expression
of a single transcription factor, Oct4 (Figure 3.1) [23]. It is known that many types of
stem cell, including pluripotent stem cells, mainly rely on glycolysis followed by lactic
acid fermentation in the cytosol to produce energy [23]. This is in contrast to most differ-
entiated cells, in which oxidation of pyruvate in mitochondria is used to produce energy.
This might be advantageous for stem cells, as glycolytic metabolism effectively produces
various macromolecular precursors in order to meet metabolic and energy demands, while
generating fewer ROS (which induce oxidative damage). Consistent with the hypothesis
that PS48 facilitates a metabolic conversion from mitochondrial oxidation to glycolysis
during the reprogramming process, treatment with PS48 activates downstream AKT/PKB,
upregulates expression of several key glycolytic genes, and consequently enhances glycol-
ysis, as measured by increased lactate production. Notably, several known small molecules
that have been widely used to modulate mitochondrial oxidation, glycolytic metabolism,
or hypoxia-inducible factor (HIF) pathway activation also show corresponding effects
on reprogramming. For example, compounds that promote glycolytic metabolism (such
as 2,4-dinitrophenol and N-oxaloylglycine) enhance reprogramming, whereas compounds
that block glycolytic metabolism (such as oxalate) inhibit reprogramming (Figure 3.1)
[23–25].
A study from Li et al. showed that the combination of four small molecules, VPA
(an HDAC inhibitor), CHIR99021 (a glycogen synthase kinase 3β (GSK3β) inhibitor),
616452 (a TGFβ signaling inhibitor), and tranylcypromine (TAYPM, an H3K4 demethy-
lation inhibitor) (referred to collectively as VC6T), was sufficient to generate iPSCs from
mouse fibroblasts with a single transcription factor, Oct4, thus replacing Sox2, Klf4, and
c-Myc (Figure 3.1) [26]. Based on previous studies, Li et al. concluded that VC6T may
facilitate the reprogramming process by lowering four major barriers (two epigenetic barri-
ers and two signaling barriers). The effects of VPA and tranylcypromine suggest that H3K4
demethylation and histone deacetylation are two critical epigenetic barriers to reprogram-
ming that may repress the establishment of a pluripotency transcriptional network.
In embryonic stem cells, it has been revealed that Tcf3, one of the key transcriptional
regulators downstream of the Wnt pathway, occupies and regulates the promoters of Oct4,
Sox2, and Nanog [27, 28]. In MEFs, these endogenous pluripotency transcription factors
are silenced. During reprogramming, Wnt signaling can directly potentiate the effect of
exogenous Oct4, Sox2, and Klf4, as it does in ESCs [27], thereby directly promoting the
induction of pluripotency in the absence of c-Myc transduction. Inhibition of GSK3β to
activate Wnt signaling could enhance mESC self-renewal and cell reprogramming, possibly
by regulating the stability of the c-Myc protein [29,30]. As is known, the MET is a crucial
initiating event in the derivation of iPSCs from fibroblasts [31,32]. TGFβ induces EMT by
both Smad-dependent and Smad-independent signaling events. Recent studies demonstrate
that full reversal of EMT morphology and patterns of gene expression can be accomplished
by concurrently inhibiting TβRI (TGFβ type I receptor) kinase. Besides promoting MET
[32–34], TGFβ inhibition has also been reported to facilitate Nanog gene expression [35].
Together, these findings indicate that GSK3β and TGFβ signaling may be two major
signaling barriers that normally repress the reprogramming process.
Inspired by the approach to iPSC generation using multiple transcription factors (TFs),
researchers have devised an alternative method for directly reprogramming mouse fibrob-
lasts into cardiomyocytes [36]. They employ the transient overexpression of Oct4, Sox2,
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and Klf4 to activate early cardiac programming in as little as 4 days and then exposed
cells to leukemia inhibitory factor (LIF)-free medium containing 15% fetal bovine serum
(FBS) and 5% knockout serum replacer (KSR) for 6 days, before switching to 1% FBS and
14% KSR for 3 days. During the initial 9-day period, a small-molecule Janus kinase (JAK)
inhibitor, JI1, is continuously kept in the culture condition to promote cardiomyogenesis
and prevent iPSC intermediates from forming. From day 9 onwards, the cells are cultured
in chemically defined media, with bone morphogenetic protein 4 (BMP4) treatment for the
first 5 days. This process generated a large number of spontaneously contracting patches
of cardiac cells in as few as 11 days, as well as minor iPSC-like cells. Remarkably, nearly
40% of cells had become mature (cTnT+ ) cardiac populations by day18. The authors
attributed the increased efficiency to the generation of highly proliferative progenitor cells,
and further speculated that these less-mature cardiac cells may be more valuable for heart
regeneration than terminally differentiated cardiomyocytes. This method potentially offers
a faster and more efficient route for generation of desired cell types. Once the safety issue
is essentially eliminated, it will be more attractive for eventual therapeutic use.
3.4 Heart Regeneration
Developing treatments that can stimulate endogenous cardiomyocyte regeneration in areas
of infarction could be the new frontier of regenerative therapy. An ideal therapeutic option
would be to employ small molecules that have the capacity to stimulate and accelerate
endogenous cardiomyocyte regeneration after injury. In zebrafish, adult heart regenerates
after partial surgical resection [37]. Approximately 3% of cardiomyocytes in the compact
myocardium of adult zebrafish hearts incorporated the thymidine analog bromodeoxyuri-
dine (BrdU) during a 7-day pulse-labeling experiment. Two weeks after amputation of the
cardiac apex, the fraction of BrdU-positive cardiomyocytes had increased by 10-fold, and
this parameter remained as high as 20% 1 month after injury. By 60 days post-amputation,
the lost cardiomyocytes had completely regenerated. Cardiac muscle supplanted the fibrin
clot without generating scar tissue, leading to restoration of vascularized cardiac mus-
cle and normal electrical coupling with adjacent cells. Another three dissimilar injury
models – genetic ablation [38], cryocauterization [39], and hypoxia/reoxygenation [40] –
also stimulated robust myocardial regeneration in zebrafish. The injured heart had entirely
regenerated after 30, 130, and 30 days, respectively. Organ-wide heart tissue is respon-
sive to injury during zebrafish heart regeneration, not just that near the trauma. All major
cardiac tissues, including epicardium, endocardium, and myocardium, appear to employ
this strategy, in which endocardial cells show the earliest responses [41]. Over different
time courses, depending on the cell type, these injury-activated expression signatures dis-
appear globally and seem to localize to the injury site. Factors released during cardiac
inflammation may help to trigger an organ-wide injury response, which might be a key
to regenerative success. Signaling pathways that participate in zebrafish heart regeneration
have been identified, including fibroblast growth factor (FGF) [42], platelet-derived growth
factor (PDGF) [43], and retinoic acid (RA) pathways [44]. In mammals, the heart of 1-day-
old neonatal mice can regenerate after partial surgical resection or left anterior descending
artery (LAD) ligation [45, 46]. Local injury induces global cardiomyocyte morphology
changes and proliferation in the neonatal mouse heart. This regenerative capacity is lost
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7 days after birth, when resection or ligation surgery lead to the formation of a fibrotic scar.
The timeline coincides with the withdrawal of cardiomyocytes from the cell cycle through
the completion of mitosis without cytokinesis, resulting in formation of binucleated cells.
This postnatal switch in cardiomyocyte proliferation leads to the transient presence of
regenerative capacity in the neonatal mouse heart. Scar formation may also cause loss of
regeneration capacity by 7 days. In humans, over the course of an average lifetime almost
45% of cardiomyocytes slowly renew into adulthood, while 55% remain after birth [47].
This turnover is very low and decreases significantly with age. Both the integration of
radioactive 14C (generated by nuclear bomb tests during the Cold War) into DNA and the
infusion of iododeoxyuridine (IdU, a thymidine analog used as a radiosensitizer for therapy
[48]) provide evidence for this measurable ability in the adult human heart. Compared with
lower vertebrate heart, mammalian heart has more fibroblasts and less endocardial cells;
more importantly, mammalian cardiomyocytes contain more myofibrils and have a higher
DNA content (binucleated cells with diploid nucleus in rodents, mononucleated cells with
polyploid nucleus in humans). These cardiac cell properties result in poor regenerative
capacity when the mammalian heart is injured.
Inducible genetic fate-mapping analyses demonstrate that zebrafish heart regenera-
tion occurs through cardiomyocyte dedifferentiation and proliferation [49, 50]. The 4-
hydroxytamoxifen (4-HT)-inducible Cre/lox system in zebrafish has been established to
prelabel cardiomyocytes with enhanced green fluorescent protein (EGFP) prior to regen-
eration tests. After amputation of the apex, the new apical myocardium is 100% EGFP+ ,
indicating that new cardiomyocytes arise from existing cardiomyocytes rather than the
recruitment of cardiomyogenic precursors. A subpopulation of cardiomyocytes within the
ventricular wall expresses Gata4 to activate an embryonic program that facilitates dedif-
ferentiation and proliferation and contributes substantially to local muscle regeneration.
This is consistent with the results of a cardiac sarcomere study, indicating that proliferating
cardiomyocytes detach from one another and acquire a less organized sarcomeric struc-
ture during regeneration. Likewise, recent studies suggest that mammalian cardiomyocytes
regenerate through the division of preexisting cardiomyocytes [51]. By combining genetic
fate-mapping with stable isotope-labeling, the nonradioactive tracer [15N] thymidine and
DNA synthesis can be measured using multi-isotope imaging mass spectrometry (MIMS)
in the adult heart of double-transgenic MerCreMer/ZEG mice. During normal mammalian
myocardial homeostasis, mature resident cardiomyocytes are the dominant source of car-
diomyocyte replacement, at a rate of about 0.76% per year. This process is increased
fivefold during recovery from myocardial infarction. Adult cardiomyocytes retain some
capacity to re-enter the cell cycle, but after injury most DNA synthesis occurs in preex-
isting cardiomyocytes, without completion of cell division. In contrast, cardiac progenitor
cells do not make a significant contribution to myocardial homeostasis in mammals, and
their roles after injury are also limited. However, when bone marrow-derived c-Kit+ cells
are injected into the infarcted heart, the transplanted cells stimulate cardiomyocyte regen-
eration some degrees removed from endogenous progenitors or unlabeled cardiomyocytes
through paracrine effects [52]. The epicardium and endocardium also appear to play indis-
pensable signaling roles in heart regeneration. Some of the activated epicardial cells can
transdifferentiate into cardiomyocytes at a low reprogramming rate while preconditioning
with thymosin β4 injections [53]. Together, these findings provide strong evidence that
the adult human heart is capable of regenerating cardiomyocytes in order to preserve its
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function, although the cell turnover is low throughout life. An ideal therapeutic option would
be to employ small molecules that have capacity to stimulate and accelerate endogenous
cardiomyocyte regeneration after injury.
3.5 The Chemical Genetics Approach in Heart Regeneration
Although high-throughput, high-content small-molecule heart-regeneration screens present
great challenges in adult zebrafish, they can be carried out in zebrafish embryos. Compounds
identified from heart developmental screens may have capacity to induce heart regeneration,
considering similar signaling molecules and pathways are employed.
A newly developed fluorescent ubiquitylation-based cell-cycle indicator (FUCCI) screen-
ing system employs two fusion proteins (mCherry-zCdt1 and Venus-hGeminin) that are
expressed during the G1 and S/G2/M phases. The FUCCI system enables the visualiza-
tion of cell-proliferation events in live animals. After the cmlc2:FUCCI embryos have been
exposed to a panel of compounds targeting various developmental signaling pathways, small
molecules that activate or block Hedgehog (Hh), insulin-like growth factor (IGF), and TGFβ
signaling pathways can be seen to regulate cardiomyocyte proliferation [54]. Direct exami-
nation of zebrafish heart regeneration after mechanical or genetic ablation injuries indicates
that Hh, IGF, and TGFβ signaling pathways are activated in regenerating cardiomyocytes.
These pathways can be pharmacologically manipulated by molecules identified from heart-
development screens. Since the embryonic heart size primarily reflects cardiomyocyte
generation, the size of fluorescence-expressing heart can also be used as a visual screen
phenotype. Three structurally related compounds with the same pharmacophore, named
cardionogen-1 to -3, have been found to enlarge heart size via myocardial hyperplasia
[55]. The increased cardiomyocyte number in cardionogen-treated embryos is due to an
expansion of the cardiac progenitor cell population, and it may also promote cardiac cell
proliferation. Mechanistically, cardionogen functions as an inhibitor of the Wnt/β-catenin
signaling pathway and can rescue cardiomyocyte deficiency and heart-specific phenotypes
induced by Wnt8 overexpression during development. Expanding the panel of pharmaco-
logical manipulations that regulate this process will help reveal mechanisms that induce
myocardial regeneration. Compounds identified from the unbiased screens in zebrafish are
likely to represent promising tools for probing and potentially enhancing cardiomyocyte
proliferation in the injured mammalian heart.
Mammalian ESCs have also been used to screen small molecules in inducing cardiomy-
ocyte formation. Among 550 known pathway modulators, small-molecule IWR1 (inhibitor
of Wnt response) and IWP3 (inhibitor of Wnt production) were identified as inducing
cardiogenesis, demonstrating that Wnt inhibition is sufficient to drive human ESCs to
form cardiomyocytes [56]. However, treating zebrafish embryos with IWR1 results in trun-
cation of the posterior axis and disruption of the cardiac chamber formation. Notably,
cardionogen treatment induces cardiac cell formation without causing tail truncation and
atrium disruption in zebrafish, indicating that cardionogen has little toxicity compared to
IWR1. Consistent with the in vivo activities, cardionogen blocks Wnt/β-catenin-dependent
transcription in embryos and ESCs but not in HEK293 cells, while IWR1 blocks Wnt
signaling in embryos, ESCs, and HEK293 cells. These findings suggest that cardionogen
selectively reduces Wnt signaling associated with certain tissues, revealing the benefits of
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whole-embryo screens by targeting specific cell types. Whole-embryo screens offer con-
siderable advantages in drug discovery by evaluating target cell populations and organs,
as well as the relevant physiological context. The identified compounds normally have
efficacy with little toxicity, which can be further developed as medicine.
3.6 Cardiac Cell Transdifferentiation
Recent studies have revealed an advanced reprogramming technology that can directly con-
vert one somatic cell type to another, such as fibroblasts to cardiomyocytes, representing a
new approach to generating cardiomyocytes from endogenous cells. In order to accomplish
this goal, an assay system was developed in which the induction of mature cardiomyocytes
from fibroblasts could be analyzed quantitatively by reporter-based fluorescence-activated
cell sorting (FACS) [57]. In order to have sufficient cardiac fibroblasts for transdiffer-
entiation, cells which express not GFP but rather Thy1 (a marker of cardiac fibroblasts)
were obtained from neonatal aMHC-GFP hearts by explant culture [58]. Fourteen genes
were selected, using microarray analyses between cardiomyocytes and cardiac fibroblasts,
as candidate factors that induce fibroblasts into cardiomyocytes [58]. All these candidate
genes were introduced into cardiac fibroblasts by retrovirus-mediated transfection. A com-
bination of three transcription factors (Gata4, Mef2c, and Tbx5) was found to be sufficient
to convert cardiac fibroblasts into functional induced cardiac-like myocytes (iCLMs). To
exclude the possibility that iCLMs were derived from rare cardiac progenitors or contam-
ination of cardiomyocytes, the potential for mouse tail–tip dermal fibroblasts to produce
iCLMs was tested. Thy1+ /GFP− tail–tip dermal fibroblasts transduced with GMT can
also be reprogrammed into cardiac-like myocytes [57].
To determine whether fibroblasts directly convert into cardiomyocytes or whether they
undergo dedifferentiation before further differentiation, Isl1- and Mesp-1-yellow fluores-
cent protein (YFP) mice were obtained by crossing Isl1-Cre and Mesp-1-Cre mice with
R26R-EYFP mice, respectively [58]. Isl1 is a marker of cardiac progenitors that are tran-
siently expressed before cardiac differentiation. Mesp-1 is the earliest pan-cardiovascular
progenitor cell marker that is transiently expressed in nascent mesoderm before further
cardiovascular differentiation. If iCLMs generated from fibroblasts undergo a cardiac pro-
genitor cell or early cardiac mesodermal state, YFP will permanently express in their
descendants. Isl1-YFP−/Thy1+ and Mesp-1-YFP−/Thy1+ fibroblast cells are isolated
and transduced with GMT. The cardiac cells expressing cTnT do not express YFP, suggest-
ing that the transdifferentiation does not involve the cardiac progenitor or cardiac mesoderm
cell state but rather directly reprograms from fibroblasts into functional cardiomyocytes
[57].
The human heart contains 30% cardiomyocytes and 70% cardiac fibroblasts. Cardiac
fibroblasts are fully differentiated cells, providing structural support for the heart [59].
Following myocardial infarction, fibroblasts become activated, migrate to the injury site,
and proliferate. The vast pool of endogenous cardiac fibroblasts in the heart could serve as
a potential source of cardiomyocytes for regenerative therapy if it were possible to fully
reprogram the fibroblasts into functional beating cardiomyocytes in vivo. To accomplish
this, lineage-tracing experiments have been performed to track the origin of putative iCLMs.
To track the fibroblast cells, a mouse Fsp1-Cre transgenic line is used, in which Cre
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recombinase is expressed under the promoter of fibroblast maker genes, FSP1. When
intercrossed with an R26R-lacZ reporter line, only fibroblasts and their progeny are labeled
by β-galactosidase [60]. Four transcriptional factors (Gata4, Mef2C, Tbx5, Hand2), or even
three of them (Gata4, Mef2C, Tbx5), are locally delivered into dividing fibroblasts using a
retrovirus expression system following myocardial infarction [59,60]. After 4 weeks, cells
co-expressing β-galactosidase andα-actinin in the infarct zone are detected. These cells have
well-formed sarcomeres and express sarcomeric markers. In addition, the reprogrammed
iCLMs have a normal contractile potential and are electrically coupled with endogenous
cardiomyocytes and other iCLMs. Injured myocardium infected with GHMT retroviruses
relieves the worsening of the heart function after 3 weeks of myocardial infarction. Ejection
fraction, stroke volume, and cardiac output are significantly improved 8–12 weeks after
injection [59]. Co-injecting thymosin β4 and GMT further improves ejection fraction and
cardiac output 8 weeks after infarction. These results demonstrate that GMT or GMTH
can reprogram cardiac fibroblasts into iCLMs, resulting in a reduction of infarct size
and improved cardiac function. The strategy bypasses many of the obstacles associated
with cellular transplantation, providing a potential method for cardiac regeneration using
patient-derived cells.
3.7 Conclusion
The past decade has improved our knowledge of chemical biology and regenerative
medicine. A profound understanding of cardiomyogenesis will be required for the devel-
opment of advanced therapeutics to treat ischemic heart diseases. Small molecules are
not only valuable in inducing cardiomyocyte generation but also provide insight into the
signaling networks and molecular mechanisms underlying these processes. Future studies
will likely include identification of chemical regulators capable of reprogramming fibrob-
lasts into cardiomyocytes. It will be essential to discover and study small molecules that
can induce regeneration of preexisting cardiomyocytes. Further studies of heart develop-
ment and regeneration, in combination with chemical genetics, will have great potential to
advance our knowledge of and therapeutics in the treatment of cardiovascular diseases.
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4.1 Introduction
Despite remarkable advances in cardiovascular medicine, ischemic heart disease, including
myocardial infarction and subsequent heart failure, is the number one cause of morbidity
and mortality worldwide [1]. The fundamental yet unresolved problem is that the adult
heart irreversibly loses millions to billions of cardiomyocytes during myocardial infarction
due to an inability to regenerate cardiomyocytes [2]. Injured and aging cardiomyocytes are
replaced by fibrotic scar. This leads to loss of pump function and provides a substrate for
life-threatening arrhythmias, a common mode of death in heart failure. Thus, the ability to
generate new cardiomyocytes remains an imperative scientific focus.
4.2 Strategies for Heart Repair
One approach under active investigation is to transplant stem/progenitor cells, which have
the potential to differentiate into cardiomyocytes, to repair the injured heart. One obvious
potential source for this approach is human embryonic stem cells (ESCs), which can
efficiently differentiate into cardiomyocytes and have the potential to regenerate the heart
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[3]. Besides ethical issues, however, two major problems limit this strategy from clinical
application: immunological rejection (because ESCs are foreign to the body) and teratoma
formation from undifferentiated cells. An alternative approach is to identify stem/progenitor
cells that can differentiate into cardiomyocytes as the source for cell therapy. Although this
approach has been extensively tested in animal models and numerous clinical trials over
the past decade, clinical efficacy has been modest at best and is not supported by clear
mechanistic insights [4]. Furthermore, transdifferentiation of transplanted stem/progenitor
cells into cardiomyocytes has not been clearly and consistently demonstrated. Rather,
it has been a general consensus that the beneficial effect of cell-based therapy results
from paracrine effects of transplanted cells [5]. Induced pluripotent stem cells (iPSCs)
or iPSC-derived cardiomyocytes are another attractive cell source for cell-replacement
therapy and heart repair [6]. There is no doubt that iPSC reprogramming, followed by
directed differentiation, offers a powerful approach to regenerating any cell type and permits
in vitro production of personalized cell therapies. Before this strategy can be translated
into therapeutic application, however, tumor formation from undifferentiated cells and
unexpected immunogenicity must be resolved [7]. Poor survival rate of transplanted cells
is another obstacle preventing clinical use of cell replacement-based strategies. As few as
∼15% of transplanted cells remain in the heart without leaking from the injection site or
entering systemic circulation [8], with only 10% of the 15% surviving more than a week
in the heart [9]. Overall, cell transplantation-based therapy for cardiac repair will remain
inefficient unless the delivery systems and survival of transplanted cells improve. Therefore,
there is a major need to develop an entirely new therapeutic strategy that will eliminate the
obstacles facing current cell-based therapies for post-heart attack intervention.
More than half of the cells in the heart are fibroblasts. They are activated during injury and
lead to cardiac fibrosis and scar formation, thereby impeding contractility, and contribute
to adverse remodeling and conduction abnormalities. Therefore, directly targeting cardiac
fibroblasts in the heart so that they transform into new cardiac muscle tissue is a particularly
attractive strategy for heart repair after injury (Figure 4.1). In fact, this direct phenotypic
conversion from one fully differentiated cell type into another has long been described
in studies, but it was previously restricted to related cell types for which a single master
transcription factor controls cell fate. Examples include (i) fibroblasts to myofibers, (ii)
fibroblasts to smooth muscle cells, (iii) B lymphocytes to macrophages, and (iv) inner-ear
support cells to hair cells [10–13]. The discovery that a combination of transcription factors
was required to reprogram iPSCs, rather than a single master transcription factor, opened up
new avenues for specific lineage conversions. As a result, lineage reprogramming has been
extended to other medically useful cell types that require more complex transcriptional
regulation to establish their identities, including pancreatic β-cells, neurons, hepatocytes,
and cardiomyocytes [14–18].
4.3 Direct Reprogramming Approaches
A heart-repair strategy using direct reprogramming has multiple advantages over current
stem cell-based approaches. First, there is no need for ex vivo manipulation of cells and
reintroduction into the heart, since reprogramming occurs in vivo [19, 20]. This eliminates
the obstacles associated with efficient transplantation and integration of engrafted cells
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Figure 4.1 Heart repair by reprogramming of non-myocytes into cardiomyocyte-like cells
in vivo. Immediately after left anterior descending (LAD) coronary artery ligation to induce
myocardial infarction, a viral cocktail of reprogramming factors is directly injected into the
border zone adjacent to the infarcted myocardium. The forced expression of reprogramming
factors in non-myocytes in the heart after myocardial infarction induces new cardiomyocyte-
like cells and leads to the improvement of contractile function and reduction of scar formation.
LV, left ventricle. (Adapted by permission fromMacmillan Publishers Ltd: Nature Medicine [20],
copyright (2013))
into the functioning myocardium. Second, this lineage reprogramming approach does not
transverse a stem cell-like state, which reduces the likelihood of teratoma formation from
undifferentiated cells. Third, this strategy is expected to reduce cardiac fibrosis by directly
targeting cardiac fibroblasts, the principal mediators of cardiac fibrosis and scar formation
after myocardial infarction (MI [21]. Fibrotic scar formation at the site of an infarct and
interstitial fibrosis of adjacent myocardium act as additional barriers to cardiac repair
and contribute to loss of pump function, pathological remodeling, and susceptibility to
arrhythmias [22].
Fibroblasts can be induced to become skeletal and smooth muscle cells by ectopic expres-
sion of a single transcription factor, such as MyoD and Myocardin, respectively; however,
a master transcription factor has not been identified for cardiac muscle despite exhaustive
searches over the past 2 decades [10, 11]. It is clear that cardiac cell fate is determined by
a complex network of core cardiac transcription factors rather than a single transcription
factor [23]. Based on this knowledge, Srivastava’s group made an important first step toward
direct cardiac reprogramming. Ieda et al. first reported the ability of exogenous transcrip-
tion factors to direct mouse fibroblasts toward a cardiac fate [18]. First, they identified 14
candidate transcription factors that are important in heart development. Then they created
a cardiac-specific αMHC-GFP transgenic mouse to isolate neonatal cardiac fibroblasts.
Using these reagents, they identified three transcription factors – Gata4, Mef2c, and Tbx5
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(also known as GMT) – that were sufficient to induce cardiac phenotype in mouse fibrob-
lasts. However, the reprogramming efficiency remains low; 5–15% of fibroblasts express
cardiac markers, and only 0.5% of cardiac marker-expressing cells contract. The Olson
group advanced this reprogramming protocol, showing that inclusion of another cardiac
transcription factor, Hand2 (H), in the GMT cocktail significantly increases the repro-
gramming efficiency. Song et al. demonstrated in side-by-side comparisons that GHMT is
around 4-fold more effective than GMT in cardiac reprogramming in vitro. Importantly,
they focused on adult fibroblasts (cardiac and tail–tip), which are less susceptible to repro-
gramming than immature cell types and more likely to represent the substrate for in vivo
therapeutic reprogramming [20]. The use of adult fibroblasts for cardiac reprogramming
also diminishes the likelihood that residual embryonic cardiac progenitors present in neona-
tal preparations might contaminate fibroblast preparations. The enhanced reprogramming
power of GHMT is further demonstrated by its ability to induce a contractile phenotype
in adult tail–tip fibroblasts that is not achieved by GMT. A muscle-specific microRNA,
miR-1, alone or in combination with other muscle-specific microRNAs (miR-133, -208,
and -499), has also been reported to activate cardiac gene expression in fibroblasts with low
efficiency [24]. Although a microRNA-based reprogramming approach can induce global
transcriptional changes favoring a cardiac phenotype, sarcomere-like structures, calcium
transients, and spontaneous contraction of reprogrammed cells have not been reported.
Other groups showed that different combinations of transcription factors (GMT Myocardin
and GHMT Nkx2-5) are able to induce cardiac phenotype in mouse fibroblasts [25, 26].
These results indicate that multiple combinations of cardiac regulators can initiate the car-
diac differentiation program because they function within complex regulatory networks
that involve feed-forward and autoregulatory interactions.
The most important turning point for cardiac reprogramming as a potential cardiac
regenerative therapy was the unexpected success of in vivo reprogramming [19,20, 24, 27].
Srivastava and Olson’s groups independently showed that in vivo reprogramming is feasible
using the same reprogramming factor combinations identified in in vitro reprogramming
(GMT and GHMT, respectively) [19, 20]. Both groups used retroviruses to induce repro-
gramming of activated cardiac fibroblasts in the infarct zone of mouse infarct models,
because retroviruses infect only proliferating fibroblasts rather than quiescent cardiomy-
ocytes. To identify the origin of newly generated cardiomyocytes, both groups performed
lineage-tracing experiments using FSP1 Cre or Periostin Cre/Rosa26LacZ mice, in which
they could label fibroblasts with β-galactosidase following injury. There has been concern
that cardiac injury or viral transduction might unintentionally activate the promoter of these
reporters. To exclude this possibility, the Olson group generated a new inducible lineage
marker for noncardiomyocytes, in which MerCreMer was knocked into the Tcf21 locus by
homologous recombination. Tcf21 is specific for non-myocytes within the heart, with no
expression in cardiomyocytes. Using this new inducible non-myocyte lineage marker, they
substantiated their conclusion that newly generated cardiomyocytes originate from non-
myocytes. However, it is still unclear whether the new myocytes were derived only from
cardiac fibroblasts, rather than from other non-myocyte cell types, because a true fibroblast-
specific lineage marker is unavailable. Thus, these studies cannot exclude the contribution
of the other reprogrammed cell types to cardiac repair by GMT or GHMT. Interestingly, the
reprogramming efficiency in vivo seems to be higher than that in vitro. This result suggests
that the in vivo environment, which contains cardiomyocytes and other cell types, as well
Challenges and New Directions for Cardiac Reprogramming 53
as extracellular factors, is more permissive for reprogramming than plastic tissue culture
dishes. In addition, constant electrophysiological activation and mechanical contraction in
the intact heart likely have salutary effects on cardiac reprogramming. More importantly,
both studies demonstrated that introduction of reprogramming factors (GMT or GHMT)
improved contractile function and reduced scar formation after myocardial infarction in
a mouse model. This functional benefit seems to be greater than predicted based on the
number of newly generated cardiomyocytes observed in lineage-tracing experiments. This
may indicate that introduction of cardiac reprogramming factors upon injury enhances
contractile function through mechanisms beyond simple directing of fibroblasts toward a
cardiomyocyte cell fate. Potential mechanisms include (i) promoting neoangiogenesis, (ii)
preventing cardiomyocyte death, (iii) inhibiting fibroblast activation/proliferation, and (iv)
facilitating the differentiation of cardiac progenitors to cardiomyocytes following injury.
Further studies to clarify these additional mechanisms are warranted prior to potential
clinical application.
One common hurdle for the reprogramming approach is induction of desired cell types
in human fibroblasts. As every potential clinical application of reprogramming can only
be realized in human cells, reprogramming of human fibroblasts is a mandatory step to
practical usage. However, human-cell reprogramming is known to be less efficient and
requires longer time in culture, as indicated by human iPSC and neuron reprogramming
studies [28–30]. Nam et al. first reported successful induction of cardiac phenotype in
human fibroblasts with the addition of myocardin to GHMT [31]. Although this new
combination of factors is able to induce multiple cardiac markers, evidence suggests that
cardiac reprogramming is incomplete. For example, the global transcriptional changes
in reprogrammed cells are similar but not identical to human cells, and sarcomere-like
structures, calcium transients, and spontaneous contraction only occur in a very small subset
of reprogrammed cells after a prolonged culture period. These results indicate that higher
barriers to cardiac reprogramming are likely to exist in human fibroblasts. The protocol
was modified to include two muscle-specific microRNAs, miR-1 and miR-133, making
Mef2c dispensable in the reprogramming cocktail. The rationale for using these muscle-
specific microRNAs is based on previous findings that miR-1 and miR-133 are regulated by
Mef2c [32]. Subsequent studies by two other groups also showed reprogramming of human
fibroblasts toward a cardiac cell fate using a slightly different combination of transcription
factors, namely GMT-Myocardin-Mesp1 with or without the nuclear hormone receptor
ESRRG [33, 34]. In general, conversion of human fibroblasts toward a cardiac cell fate
relies on more reprogramming factors, requires a longer period of time, and is less efficient
than mouse cardiac reprogramming. The different requirements for reprogramming of
mouse and human fibroblasts likely reflect differences in the mouse and human fibroblast
populations and the susceptibility of cardiac genes to activation in these different cells.
4.4 Current Challenges
The examples provided of cardiac reprogramming suggest a potentially promising and
entirely new heart-repair strategy. However, like any other innovative therapeutic interven-
tion, this new approach faces numerous biological and technical obstacles. We will discuss
a number of current challenges here.
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The most rigorous criterion for confirming cardiac phenotype in reprogrammed cells is
contractility. Based on this criterion, reprogramming efficiency remains low despite the
development of innovative methods. Efficiency is especially important in direct reprogram-
ming because the resulting cardiomyocyte-like cell does not proliferate and cannot be
maintained indefinitely in culture. Given the fact that billions of cardiomyocytes are lost
during an infarction, optimal cardiac reprogramming efficiency will be required to con-
tribute to meaningful clinical application. Furthermore, the current cardiac-reprogramming
protocol generates a wide spectrum of heterogeneous phenotypes that can be classified in
multiple groups: (i) single cardiac marker-positive cells without sarcomeric structure, (ii)
multiple cardiac marker-positive cells without sarcomeric structure, (iii) multiple cardiac
marker-positive cells with sarcomeric structure, (iv) contractile cells with action poten-
tial upon electrical stimulation, and (v) contractile cells with spontaneous action potentials.
Reprogrammed cells that develop an organized sarcomeric structure and contractility repre-
sent all three subtypes of cardiomyocyte, including atrial, ventricular, and pacemaker cells.
This raises the concern that heterogeneity in cell-type identity and maturity may increase
the risk of conduction abnormalities in vivo as the infarct zone is already at a higher risk
for arrhythmogenesis. Thus, future efforts will need to focus on improving the efficacy
of cardiac reprogramming in terms of cell-type specificity and the maturity of individual
cardiomyocytes. Why is cardiac reprogramming a relatively inefficient and heterogeneous
process? This may reflect a specific stoichiometry of each reprogramming factor in acti-
vating the cardiac development program, which is achieved in a very small subset of the
starting cell population. Because at least three transcription factors are required for cardiac
reprogramming, this lower efficiency is not unexpected when compared to other reprogram-
ming processes dominated by a single master regulator. Another possible explanation is
that heterogeneity in the starting population of fibroblasts may contribute to reprogramming
inefficiency because only a subset of cells is susceptible to reprogramming. An additional
factor by which to explain cardiac reprogramming inefficiency and heterogeneity is that
GHMT factors play multiple roles during embryonic development and perhaps in lineage
conversions. Thus, the simultaneous action of all four factors may promote multiple alter-
native cell fates that detract from the goal of creating cardiomyocytes. Also, the role of
reprogramming repressors should be considered; their deletion may markedly enhance
reprogramming efficiency. In this regard, a recent study by Hanna’s group demonstrated
that deletion of a single repressor, Mbd3, is able to produce iPSCs with near 100% efficiency
when used in combination with Yamanaka factors [35]. The search for similar roadblocks
in cardiac reprogramming will be an important research focus in this field.
Induced cardiomyocytes are relatively immature, and only a small fraction displays the
strong contractility, well-developed sarcomeres, and binucleation associated with adult
cardiomyocytes. In addition, none of the induced cardiomyocytes from any published
studies displays rod-shaped adult cardiomyocyte morphology. This is unsurprising when
we consider how current reprogramming protocols were developed. The selection of cardiac
reprogramming factors has been based solely on embryonic heart development [18, 20].
Additional factors that can induce the adult cardiac phenotype will be required, and further
study on transcriptional regulation of postnatal cardiac muscle maturation is warranted to
achieve this goal.
The current in vivo reprogramming strategy for myocardial infarction in a mouse model
is to directly inject a viral cocktail of reprogramming factors into the infarcted myocardium
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during open-chest surgery [19, 20, 24, 27]. Given the potential for teratogenic viral inser-
tions in the genome and the potential inflammatory complications associated with viral
delivery, it will be important to develop nonintegrative and nonviral methods for safe
clinical application. Small molecules can be a powerful tool for nonviral reprogram-
ming. They have enhanced transcripton factor-mediated iPSC and neuronal reprogram-
ming [36–43]. Furthermore, iPSCs have recently been generated using a seven-molecule
cocktail, without any viral transduction, suggesting that a new chemical strategy for
reprogramming is possible [44]. A couple of small molecules – JAK inhibitor and trans-
forming growth factor beta (TGF)β – demonstrated synergistic effects with transcription
factors used in cardiac reprogramming [24, 34, 45]. Although these small molecules are
unable to replace transcription factors or microRNAs in achieving cardiac reprogram-
ming, these studies provide a starting point from which to develop a virus-free cardiac-
reprogramming protocol in the future. MicroRNAs are another alternative to transcription
factors in cardiac reprogramming. As we discussed earlier, miR-1 alone was sufficient
to induce cardiac phenotype in mouse fibroblasts [24], and a combination of miR-1 and
miR-133 is able to replace the transcription factor Mef2c in human cardiac reprogram-
ming [31]. MicroRNA-based cardiac reprogramming is particularly attractive for heart
repair because the expression of microRNAs is efficiently manipulated in muscle tissue
in vivo using miR-mimics or anti-miRs. Reprogramming fibroblasts to cardiomyocytes
using purely chemical means will be a critical step toward therapeutic application of this
strategy in the future. Replacing cardiogenic transcription factors with small molecules
or synthetic oligonucleotides with cardiogenic activity will have long-term therapeutic
possibilities.
From a clinical standpoint, direct injection of reprogramming factors into the myocardium
after a heart attack is far from realistic, and the risks associated with this procedure outweigh
the potential benefits. It is also important to develop less invasive procedures for the intro-
duction of reprogramming factors, perhaps a catheter-based delivery during percutaneous
coronary intervention (PCI) after a myocardial infarction with a virus-free reprogramming
protocol. Clinical translation of direct reprogramming will benefit from safe and effective
delivery methods previously developed for cell transplantation. As a starting point, repro-
gramming factors can be directly delivered during a coronary artery bypass graft surgery
(CABG) after a heart attack.
The heart is not just a muscle pump solely composed of force-generating muscle cells, but
a much more complex organ system made up of distinctive cell types that are highly orches-
trated for effective blood pumping. Myocytes in different regions of the heart also display
distinct phenotypes. Therefore, full restoration of cardiac function after injury will require
regeneration of the cell types that are substantially compromised upon cardiac injury. In
this regard, smooth muscle cells, endothelial cells, and angioblast-like progenitor cells have
been successfully generated using direct reprogramming strategies [11, 46, 47], and inclu-
sion of a vascular–endothelial growth factor (VEGF)-expressing virus with GMT enhances
functional recovery of the injured myocardium, possibly through neovascularization [48].
In addition, forced expression of Tbx18 or activated Notch in ventricular cardiomyocytes
or Tbx3 in atrial cells is sufficient to generate conduction system cells [49–51]. However,
direct reprogramming of fibroblasts toward specific cardiomyocyte subtypes, including
atrial, ventricular, and pacemaker myocytes, remains to be investigated. In this regard, mul-
tiple subtypes of neurons, such as excitatory, dopaminergic, and motor, have been directly
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reprogrammed from fibroblasts using distinctive combinations of transcription factors and
may inform studies in cardiomyocyte subtypes.
4.5 Conclusion
Over the past few years cardiac reprogramming has drawn enormous scientific attention,
mainly due to an unmet need for new heart-repair strategies. As we have discussed here, there
are numerous challenges in cardiac reprogramming that must be met before any potential
clinical application. We have learned from numerous cell-transplantation studies in the
past that simply introducing new cells into the heart has minimal benefits. Practical use of
cardiac reprogramming will require efforts to address the main challenges facing this field:
(i) inefficiency, (ii) heterogeneity, (iii) development of a virus-free cardiac-reprogramming
protocol, (iv) provision of a safe and effective delivery method, (v) elucidation of the
mechanical basis of cardiac reprogramming, and (vi) demonstration of the efficacy and
safety of the procedure in a large-animal model prior to human clinical trial.
Acknowledgements
We are grateful to Jose Cabrera for excellent graphical assistance and to many members of
the Olson lab for their intellectual input. YJN is supported by a K08 Award from the NHLBI
and work in the lab of NVM is funded by a K08 Award from the NHLBI, a Career Award for
Medical Scientists from the Burroughs Wellcome Fund, a Basil O’Connor Starter Scholar
Award from the March of Dimes Foundation, and a Disease Oriented Clinical Scholar
Award from UT Southwestern Medical Center.
References
(1) Go, A.S., Mozaffarian, D., Roger, V.L. et al. (2013) Heart disease and stroke statistics–2013
update: a report from the American heart association. Circulation, 127 (1), e6–e245.
(2) Murry, C.E., Reinecke, H., and Pabon, L.M. (2006) Regeneration gaps: observations on stem
cells and cardiac repair. Journal of the American College of Cardiology, 47 (9), 1777–1785.
(3) Garry, D.J. and Olson, E.N. (2006) A common progenitor at the heart of development. Cell,
127 (6), 1101–1104.
(4) Segers, V.F. and Lee, R.T. (2008) Stem-cell therapy for cardiac disease. Nature, 451 (7181),
937–942.
(5) Garbern, J.C. and Lee, R.T. (2013) Cardiac stem cell therapy and the promise of heart regener-
ation. Cell Stem Cell, 12 (6), 689–698.
(6) Takahashi, K. and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embry-
onic and adult fibroblast cultures by defined factors. Cell, 126 (4), 663–676.
(7) Zhao, T., Zhang, Z.N., Rong, Z., and Xu, Y. (2011) Immunogenicity of induced pluripotent
stem cells. Nature, 474 (7350), 212–215.
(8) Muller-Ehmsen, J., Whittaker, P., Kloner, R.A. et al. (2002) Survival and development of
neonatal rat cardiomyocytes transplanted into adult myocardium. Journal of Molecular and
Cellular Cardiology, 34 (2), 107–116.
(9) Laflamme, M.A. and Murry, C.E. (2005) Regenerating the heart. Nature Biotechnology, 23 (7),
845–856.
Challenges and New Directions for Cardiac Reprogramming 57
(10) Davis, R.L., Weintraub, H., and Lassar, A.B. (1987) Expression of a single transfected cDNA
converts fibroblasts to myoblasts. Cell, 51 (6), 987–1000.
(11) Wang, Z., Wang, D.Z., Pipes, G.C., and Olson, E.N. (2003) Myocardin is a master regulator
of smooth muscle gene expression. Proceedings of the National Academy of Sciences of the
United States of America, 100 (12), 7129–7134.
(12) Xie, H., Ye, M., Feng, R., and Graf, T. (2004) Stepwise reprogramming of B cells into
macrophages. Cell, 117 (5), 663–676.
(13) Zheng, J.L. and Gao, W.Q. (2000) Overexpression of Math1 induces robust production of extra
hair cells in postnatal rat inner ears. Nature Neuroscience, 3 (6), 580–586.
(14) Zhou, Q., Brown, J., Kanarek, A. et al. (2008) In vivo reprogramming of adult pancreatic
exocrine cells to beta-cells. Nature, 455 (7213), 627–632.
(15) Vierbuchen, T., Ostermeier, A., Pang, Z.P. et al. (2010) Direct conversion of fibroblasts to
functional neurons by defined factors. Nature, 463 (7284), 1035–1041.
(16) Sekiya, S. and Suzuki, A. (2011) Direct conversion of mouse fibroblasts to hepatocyte-like cells
by defined factors. Nature, 475 (7356), 390–393.
(17) Huang, P., He, Z., Ji, S. et al. (2011) Induction of functional hepatocyte-like cells from mouse
fibroblasts by defined factors. Nature, 475 (7356), 386–389.
(18) Ieda, M., Fu, J.D., Delgado-Olguin, P. et al. (2010) Direct reprogramming of fibroblasts
into functional cardiomyocytes by defined factors. Cell, 142 (3), 375–386. PubMed PMID:
20691899.
(19) Qian, L., Huang, Y., Spencer, C.I. et al. (2012) In vivo reprogramming of murine cardiac
fibroblasts into induced cardiomyocytes. Nature, 485 (7400), 593–598.
(20) Song, K., Nam, Y.J., Luo, X. et al. (2012) Heart repair by reprogramming non-myocytes with
cardiac transcription factors. Nature, 485 (7400), 599–604.
(21) Zeisberg, E.M. and Kalluri, R. (2010) Origins of cardiac fibroblasts. Circulation Research, 107
(11), 1304–1312. PubMed PMID: 21106947.
(22) Brown, R.D., Ambler, S.K., Mitchell, M.D., and Long, C.S. (2005) The cardiac fibroblast:
therapeutic target in myocardial remodeling and failure. Annual Review of Pharmacology and
Toxicology, 45, 657–687.
(23) Olson, E.N. (2006) Gene regulatory networks in the evolution and development of the heart.
Science, 313 (5795), 1922–1927.
(24) Jayawardena, T.M., Egemnazarov, B., Finch, E.A. et al. (2012) MicroRNA-mediated in vitro and
in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circulation Research,
110 (11), 1465–1473.
(25) Addis, R.C., Ifkovits, J.L., Pinto, F. et al. (2013) Optimization of direct fibroblast reprogram-
ming to cardiomyocytes using calcium activity as a functional measure of success. Journal of
Molecular and Cellular Cardiology, 60, 97–106.
(26) Protze, S., Khattak, S., Poulet, C. et al. (2012) A new approach to transcription factor screening
for reprogramming of fibroblasts to cardiomyocyte-like cells. Journal ofMolecular and Cellular
Cardiology, 53 (3), 323–332.
(27) Inagawa, K., Miyamoto, K., Yamakawa, H. et al. (2012) Induction of cardiomyocyte-like cells
in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. Circulation Research, 111 (9),
1147–1156.
(28) Takahashi, K., Tanabe, K., Ohnuki, M. et al. (2007) Induction of pluripotent stem cells from
adult human fibroblasts by defined factors. Cell, 131 (5), 861–872.
(29) Zhao, Y., Yin, X., Qin, H. et al. (2008) Two supporting factors greatly improve the efficiency
of human iPSC generation. Cell Stem Cell, 3 (5), 475–479.
(30) Pang, Z.P., Yang, N., Vierbuchen, T. et al. (2011) Induction of human neuronal cells by defined
transcription factors. Nature, 476 (7359), 220–223.
(31) Nam, Y.J., Song, K., Luo, X. et al. (2013) Reprogramming of human fibroblasts toward a cardiac
fate. Proceedings of the National Academy of Sciences of the United States of America, 110
(14), 5588–5593.
(32) Liu, N., Bezprozvannaya, S., Williams, A.H. et al. (2008) microRNA-133a regulates car-
diomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes &
Development, 22 (23), 3242–3254.
58 Chemical Biology in Regenerative Medicine
(33) Wada, R., Muraoka, N., Inagawa, K. et al. (2013) Induction of human cardiomyocyte-like cells
from fibroblasts by defined factors. Proceedings of the National Academy of Sciences of the
United States of America, 110 (31), 12667–12672.
(34) Fu, J.D., Stone, N.R., Liu, L. et al. (2013) Direct reprogramming of human fibroblasts toward
a cardiomyocyte-like state. Stem Cell Reports, 1 (3), 235–247
(35) Rais, Y., Zviran, A., Geula, S. et al. (2013) Deterministic direct reprogramming of somatic cells
to pluripotency. Nature, 502 (7469), 65.
(36) Huangfu, D., Maehr, R., Guo, W. et al. (2008) Induction of pluripotent stem cells by defined
factors is greatly improved by small-molecule compounds. Nature Biotechnology, 26 (7), 795–
797.
(37) Shi, Y., Desponts, C., Do, J.T. et al. (2008) Induction of pluripotent stem cells from mouse
embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell, 3 (5),
568–574.
(38) Mikkelsen, T.S., Hanna, J., Zhang, X. et al. (2008) Dissecting direct reprogramming through
integrative genomic analysis. Nature, 454 (7200), 49–55.
(39) Firestone, A.J. and Chen, J.K. (2010) Controlling destiny through chemistry: small-molecule
regulators of cell fate. ACS Chemical Biology, 5 (1), 15–34. PubMed PMID: 20000447.
(40) Tursun, B., Patel, T., Kratsios, P., and Hobert, O. (2011) Direct conversion of C. elegans germ
cells into specific neuron types. Science, 331 (6015), 304–308.
(41) Kubicek, S., O’Sullivan, R.J., August, E.M. et al. (2007) Reversal of H3K9me2 by a small-
molecule inhibitor for the G9a histone methyltransferase. Molecular Cell, 25 (3), 473–481.
(42) Zhu, S., Li, W., Zhou, H. et al. (2010) Reprogramming of human primary somatic cells by
OCT4 and chemical compounds. Cell Stem Cell, 7 (6), 651–655.
(43) Huangfu, D., Osafune, K., Maehr, R. et al. (2008) Induction of pluripotent stem cells from
primary human fibroblasts with only Oct4 and Sox2. Nature Biotechnology, 26 (11), 1269–
1275.
(44) Hou, P.P., Li, Y.Q., Zhang, X. et al. (2013) Pluripotent stem cells induced from mouse somatic
cells by small-molecule compounds. Science, 341 (6146), 651–654.
(45) Efe, J.A., Hilcove, S., Kim, J. et al. (2011) Conversion of mouse fibroblasts into cardiomyocytes
using a direct reprogramming strategy. Nature Cell Biology, 13 (3), 215–U61.
(46) Margariti, A., Winkler, B., Karamariti, E. et al. (2012) Direct reprogramming of fibroblasts into
endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels.
Proceedings of the National Academy of Sciences of the United States of America, 109 (34),
13793–13798.
(47) Kurian, L., Sancho-Martinez, I., Nivet, E. et al. (2013) Conversion of human fibroblasts to
angioblast-like progenitor cells. Nature Methods, 10 (1), 77–83.
(48) Mathison, M., Gersch, R.P., Nasser, A. et al. (2012) In vivo cardiac cellular reprogramming
efficacy is enhanced by angiogenic preconditioning of the infarcted myocardium with vascular
endothelial growth factor. Journal of the American Heart Association, 1 (6), e005652.
(49) Kapoor, N., Liang, W., Marban, E., and Cho, H.C. (2012) Direct conversion of quiescent
cardiomyocytes to pacemaker cells by expression of Tbx18. Nature Biotechnology, 31 (1),
54–62.
(50) Rentschler, S., Yen, A.H., Lu, J. et al. (2012) Myocardial Notch signaling reprograms car-
diomyocytes to a conduction-like phenotype. Circulation, 126 (9), 1058–1066.
(51) Bakker, M.L., Boink, G.J., Boukens, B.J. et al. (2012) T-box transcription factor TBX3 repro-
grammes mature cardiac myocytes into pacemaker-like cells. Cardiovascular Research, 94 (3),
439–449.
5
Comparative Analysis of Adult Stem
Cell Niches
Bryan A. Fioret and Antonis K. Hatzopoulos
Department of Medicine, Vanderbilt University, USA
5.1 Adult Stem Cells
Adult stem cells (ASCs) are unique clusters of undifferentiated cells which reside in
specialized tissue-specific niches within an adult organ. ASCs have the ability to self-
renew and to differentiate into some or all of the mature cells of the specific organ in which
they reside [1]. They are also known as somatic stem cells, or stem cells of the body, to
distinguish them from germ cells involved in reproduction.
Box 5.1 Abbreviations and Acronyms
ASC adult stem cell
BMP bone morphogenetic protein
EGF epidermal growth factor
HFSC hair follicle stem cell
HSC hematopoietic stem cell
IPC intermediate progenitor cell
ISC intestinal stem cell
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Lgr5 Leucine-rich repeat-containing GPCR5
LRC label-retaining cell
NSC neural stem cell
SGZ subgranular zone
TAC transient amplifying cell
V-SVZ ventricular–subventricular zone
ASCs primarily differ from their embryonic stem cell (ESC) counterparts in both their
origins and their lineage differentiation capabilities. ESCs, derived from the inner cell mass
(ICM) of the blastocyst, are pluripotent and capable of differentiating into the three germ
layers of the embryo (endoderm, mesoderm, and ectoderm) and generating all embryonic
and somatic cell types [2]. Unlike ESCs, whose origins are clearly defined, the origins of
various ASC populations are still unclear. The differentiation potential of ASCs is also
more limited (multipotent instead of pluripotent) and they are generally lineage-restricted
to the cell types of their host organ [3].
ASCs have been found in adolescent and adult animals, in tissues such as the hair
follicles of the skin, intestine, bone marrow, specific regions of the brain, skeletal muscle,
liver, teeth, ovaries, and testes [4]. However, ASC populations are relatively rare. Within
each of these tissues, ASCs exist in specified niches, which are local microenvironments
responsible for regulating their proliferation and differentiation [1, 3]. ASCs often remain
within their specific niche in a quiescent state until required to proliferate. ASC populations
are maintained through symmetric cell divisions, in which two identical daughter stem cells
are generated. They are also capable of generating multipotent progenitors with limited self-
renewal capacity through asymmetric division [3]. One of the primary characteristics of
ASCs is their ability to self-renew indefinitely [3]. Consequently, they play a vital role in
the maintenance of organ homeostasis by replacing dying cells lost to wear-and-tear, and
also serve as a regenerative cell source after tissue damage or disease [3].
Because of their ability to self-renew and differentiate into mature cell types, ASCs are a
potential resource for a wide variety of therapeutic applications. For example, various types
of organ-specific ASC have been administered to animals and patients in an attempt to treat
hematopoietic cancers [5], vascular disease [6], spinal cord injury [7], and cirrhosis of the
liver [8]. The versatility and therapeutic potential of ASCs, as well as their need for mainte-
nance and repair of adult tissue, warrant further study to optimize their use for treatment of
tissue-specific disease or injury. The number of organs in which ASCs have been identified
and characterized is continuously growing. However, numerous questions remain regarding
their origins and the factors regulating their proliferation and differentiation. Consequently,
significant effort has been applied toward understanding their regulatory signals and the
regions in which they reside: the stem cell niche.
5.2 Adult Stem Cell Niches
The concept of a niche for cells was first proposed in 1978 based on studies involv-
ing hematopoietic stem cells (HSCs) [9]. Contradictory data indicated apparent limitless
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renewal of stem cells but a finite lifespan for spleen colony-forming cells, which were
believed to be HSCs themselves [9]. To reconcile this discrepancy, the idea of a stem cell
niche was proposed to explain how stem cells were regulated to continuously self-renew
but also to generate differentiated progeny that do not persist indefinitely and have various
rates of turnover.
The stem cell niche is more fully defined as a unique, tissue-specific, regulatory microen-
vironment responsible for enabling and controlling stem cell self-renewal while balancing
internal and external molecular signals for the maintenance or repair of host tissue [1]. An
increasing number of studies have identified a wide variety of tissue-specific stem cells,
each with its own unique niche [3]. Studying the relationship between these stem cells
and their niche environments will provide a better understanding of maintenance of organ
homeostasis, or repair of damaged tissue in the adult.
The primary focus of this chapter is the study and comparison of four specific, well-
characterized niches in mammalian adult organs. These niches are found within (i) the hair
follicles of the skin, (ii) the crypts of the small intestine, (iii) marrow within the bone,
and (iv) distinct neural regions of the brain. The role of the niche in providing structure
and regulating resident stem-cell proliferation, maintenance, and differentiation through
coordination of support cells and molecular signaling is also reviewed.
5.3 The Hair Follicle Stem Cell (HFSC) Niche
The skin is composed of three layers: the epidermis, the dermis, and a subcutaneous fatty
layer, the hypodermis. The hair follicle, the structure which produces hair, extends through
each of these layers. It is part of the pilosebaceous unit, which also includes the hair shaft,
sebaceous gland, and arrector pili muscle. Each hair follicle contains a bulge region in the
outer root sheath, which houses quiescent follicular stem cells [10]. The hair germ (HG)
lies directly below the bulge and contains another cluster of proliferating follicular stem
cells. Signals from the dermal papilla (DP), which lies at the base of each hair follicle,
stimulate activation of HG stem cells. Hair follicle stem cells (HFSCs) reside in the bulge
region and migrate to the HG to regenerate hair and sebaceous glands [11].
HFSCs exist in a quiescent state in the bulge region and in an active state in the HG and
are capable of generating all lineages of hair [10, 12]. Studies of HFSCs have progressed
rapidly due to their location in the anatomically distinct bulge region and their ability to be
isolated and studied in transplant models [13]. Their primary role is to serve as a source of
cells for hair-follicle growth during the hair cycle.
The hair cycle is a three-phase process of anagen (growth), catagen (apoptosis-mediated
retraction), and telogen (resting). Each hair follicle contains a permanent segment (including
the bulge and sebaceous gland) and a cycling segment, which moves through the three hair-
cycle phases [10, 14]. Anagen begins when the DP is proximal to the bulge and HG, and
stimulates HFSC differentiation from the HG through Wnt/β-catenin signaling, fibroblast
growth factor 7 (FGF7), and antagonism of bone morphogenetic protein (BMP) signaling
[15]. Activated HG cells enter the hair matrix that surrounds the DP, which causes activation
and migration of quiescent HFSCs in the bulge to replenish the lost HG cells. TACs derived
from activated HG stem cells contribute to hair growth, which pushes the DP further
from the bulge HFSCs. The physical separation of these two components minimizes the
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continued activation of HFSCs, allowing for the transition to catagen. During this phase,
apoptosis of active progenitor cells then causes the hair follicle to shrink until the DP again
rests close to the bulge and HG, allowing the cycle to start anew, after the resting period of
telogen.
The hair follicle bulge serves as a niche for HFSCs. These cells were first hypothe-
sized to be stem cells based on studies which identified slow-cycling cells within this
anatomical compartment [16]. Labeling of HFSCs using either [3H]-thymidine or 5-bromo-
2′-deoxyuridine (BrdU) demonstrated their existence as label-retaining cells (LRCs), but
live cells could not be isolated. Subsequently, transgenic mice were generated with a ker-
atin 5 (K5) promoter driving expression of a doxycycline-controlled, histone H2B-GFP
fusion protein in the cells of the skin epithelium. Due to their slow cycling, bulge HFSCs
retained the H2B-GFP after a 4-month chase and could be isolated [12]. The self-renewal
and multipotency characteristics of HFSCs were further defined using keratin 14 (K14)
promoter-driven GFP transgenic mice [17]. HFSCs isolated using GFP and their stem-cell
marker CD34 generated the entire hair follicle after transplantation on to the back skins of
nude mice.
mRNA analysis of HFSCs (isolated LRCs) compared to their differentiated progeny
revealed a number of differences, which provide insight into their niche [12]. HFSCs had
greater expression (≥2× ) of transcripts encoding cell-cycle regulatory proteins, including
keratinocyte growth inhibitors, and downregulated levels of proliferation-related proteins
(Ki67 and Cdc25C) [12]. Expression of both secretory and integral membrane proteins
(β1,4,6 and α6 integrins, among others) were elevated in the HFSCs [12], including ephrin
receptors and their ligands, which are involved in cell–cell communication and the forma-
tion of tissue boundaries. In addition, β6 integrin is expressed only during the early anagen
growth phase and may stimulate stem cell proliferation and migration through interaction
with the extracellular matrix (ECM) glycoprotein tenascin C. These findings imply a level
of organization within the bulge that allows for regulation of HFSC proliferation, adhesion,
and interaction with neighboring cells.
The bulge HFSC niche is organized into upper and lower regions, each with a distinct
subset of cells [10,17]. The stem-cell markerLeucine-rich repeat-containingGPCR5 (Lgr5)
is expressed in the bulge and HG and can be used to subclassify these populations of cells.
The upper bulge contains a population of CD34+ , Lgr5− cells, while the lower bulge
contains a CD34+ , Lgr5+ cell pool. Within the HG, closer to the DP, is a population of
CD34−, Lgr5+ cells. These are activated first by the DP during anagen to generate TACs
and generate the hair shaft. The quiescent population of upper-bulge CD34+ , Lgr5− cells is
then activated to replace the HG cells. Thus, the bulge contains unique sites for maintaining
quiescent and active populations of HFSCs, restricting their growth and differentiation until
replenishment of cells is required.
The canonical Wnt and BMP signaling pathways are crucial regulators of the bulge
HFSC niche. Transgenic mice with transiently stabilized β-catenin exhibited de novo hair-
follicle morphogenesis, forming newly functioning follicles with DP, sebaceous gland,
outer and inner root sheath, and hair shaft [18]. The interaction of β-catenin and the
Wnt-dependent transcription factor Lef-1 was strongly implicated in mediating this new
growth. Furthermore, transgenic mice with enhanced β-catenin showed decreased time
spent in telogen in favor of a more rapid switch to the anagen growth phase of the
hair cycle.
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Signaling through BMP receptor 1A (BMPR-1A) is necessary for the differentiation
of HG progenitor cells within the inner root sheath and hair shaft [19]. BMPR-1A null
animals exhibit defects in their hair follicles. Additionally, mice unable to express the BMP
inhibitor Noggin lack expression of Lef-1, indicating an intrinsic link between canonical
Wnt and BMP signaling. Crosstalk between these two pathways begins with Noggin-
mediated inhibition of BMP signaling, allowing for activation of Wnt/β-catenin to stimulate
proliferation of HFSCs. Thus, activation of Wnt/β-catenin signaling leads to proliferation
of HFSCs, while BMP signaling represses their activation through inhibition of Wnt [20].
Consequently, maintenance of quiescence in the HFSC niche of the bulge involves a
“Wnt-off/BMP-on” balance of mediators, which is reversed at the DP to stimulate cell
differentiation and follicle growth.
Interestingly, in studies of individuals with androgenetic alopecia (AGA), or common
baldness, cytokeratin15 (KRT15+ ) stem cells were still present in samples of bald scalp
[21]. These quiescent KRT15+ cells were small in size and localized within the bulge.
However, a population of larger, proliferative CD200+ CD34+ progenitors located next
to the bulge was noticeably diminished. Within these bald-scalp samples, the size of the
hair follicle was also significantly smaller, perhaps due to a defect in the conversion of
HFSCs to their progenitors. The role of the HFSC niche as a factor in this situation cannot
be understated, especially when the problem with generation of follicular progenitors may
be a result of deficient signal transduction at the HFSC level. A better understanding of
the molecular cues related to this process, which may be misregulated by the bulge HFSC
niche, could directly benefit individuals with AGA.
5.4 The Intestinal Stem Cell (ISC) Niche
Digestion of food and absorption of nutrients occurs in the gastrointestinal (GI) tract,
particularly the stomach and the small and large intestines. The mix of digestive enzymes
from the stomach and pancreas and bile from the gallbladder creates an inhospitable
environment for GI epithelial mucosa, which causes these cells to have some of the most
rapid turnover rates of any organ in the body. Mature cells of the intestinal epithelium have
an average lifespan of less than 1 week, and thus require a robust pool of intestinal stem
cells (ISCs) for maintenance of intestinal homeostasis [22].
The ISC niche is located at the bottom of the intestinal Crypts of Lieberkühn (crypts),
which are small recesses within the epithelial lining of the small intestine and colon.
Both of these regions contain crypts, but only the small intestine contains villi [20, 22]:
epithelial protrusions from the intestinal wall composed of mature absorptive cells known
as enterocytes and numerous secretory cells, including enteroendocrine, goblet, and tuft
cells. Paneth cells are also secretory but remain in the crypt of the intestine to support
maintenance of ISCs. The ISC niche generates all of the cells of the small intestine. It does
so as they migrate upwards into the villi, maturing into the cell types needed to replace lost
cells. The colon also contains an ISC niche within the crypts, but progenitor cells migrate
apically into a smooth epithelium (instead of villi), which is optimized for absorbing water
[22].
Two populations of ISCs exist within the crypt niche of the small intestine, both of which
are multipotent and capable of self-renewal. The first, at the + 4 position from the crypt
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base, is a quiescent population of slow-cycling LRCs [10]. This population constitutes 2–4
of 16 cells in the circumferential ring of the crypt and is marked specifically by Bmi-1,
mTert, and Hopx [23, 24]. The second ISC population is found at the bottom of the crypt,
interspersed between supportive Paneth cells, and marked by Lgr5, CD133 (or Prom1), and
Sox9 [22,25]. This fast-cycling group is also known as crypt basal columnar cells (CBCs),
and like the first group is able to generate the entire crypt and villi.
While the full extent of the interactions between these two ISC populations (Bmi-1+
LRCs and Lgr5+ CBCs) is still being elucidated, it is known that they participate in a
bidirectional relationship. In mice, complete ablation of Lgr5+ -expressing cells did not
affect intestinal epithelial homeostasis [25]. In response to the loss of these cells, Bmi-1+
cell proliferation increased, and lineage-tracing studies indicate that they compensated by
generating Lgr5+ cells. Conversely, in vitro and in vivo studies have demonstrated that
Lgr5+ cells can generate Hopx+ cells at the + 4 position of the crypt [26]. These studies
also indicate that the quiescent Bmi-1+ ISC population interconverts into rapidly cycling
CBCs, which further differentiate to repopulate to the villi. Conversely, the quiescent Bmi-
1+ cells can be replenished from the CBCs. Thus, distinct clusters of ISCs in the crypt
niche appear to interact and renew one another.
Within the crypts, the ISC niche contains a number of support cells and structural
components. Paneth cells are specialized daughter cells, derived from and interspersed
between Lgr5+ CBCs. They secrete antimicrobial enzymes and peptides such as lysozyme
and cryptins/defensins, respectively [27]. In addition to providing defense against foreign
agents at the mucosal surface, CD24+ Paneth cells express epidermal growth factor (EGF),
transforming growth factor alpha (TGFα), Wnt3, and Dll4, which promote proliferation and
maintenance of ISCs through their respective signaling pathways [27]. Genetic removal of
Paneth cells in vivo leads to the loss of Lgr5+ CBCs, indicating their important supportive
role in the crypts of the small intestine.
Maintaining intestinal homeostasis under a wide range of digestive conditions requires
a number of signaling pathways to control cell fate and is mediated via niche support
cells throughout the crypt and villus. The canonical Wnt/β-catenin pathway is crucial for
maintenance and proliferation of undifferentiated ISCs [28, 29]. Paneth cells release Wnt
ligands, which act on the Wnt receptors Frizzled (Frz) and LRP5/6 in neighboring cells.
They also produce the Wnt agonist R-spondin, which also activates Wnt through the Lgr5
and LRP5/6 receptors.
In transgenic mice, inducible ablation of the β-catenin gene caused a loss of all intestinal
epithelial cells within 6 days of induction, as well as a decrease in number and size of
intestinal crypts [29]. Loss of β-catenin also inhibits ISC proliferation, partially through
decreased expression of the Wnt/β-catenin target gene c-myc, which induces ISC prolif-
eration, and partially through increased expression of the cell-cycle inhibitor p21 [29]. In
addition, loss of Tcf7l2, the gene encoding the Wnt transcription factor Tcf-4, causes death
in postnatal mice [30]. Analysis of the intestine in these mice revealed the absence of pro-
liferative crypts between villi, the entire intestinal epithelium consisting of differentiated,
nonproliferative villus cells. Conversely, young transgenic mice expressing a dominant
stable mutation of β-catenin revealed excessive ISC proliferation and adenomatous polyps
[31]. Furthermore, loss of adenomatous polyposis coli (APC), a critical member of the
β-catenin destruction complex, induces a progenitor-like state throughout the crypts of the
intestine and formation of colorectal adenomas [32, 33]. These studies indicate the strong
Comparative Analysis of Adult Stem Cell Niches 65
influence of canonical Wnt signaling on promoting ISC proliferation and maintenance of
self-renewal.
Much like canonical Wnt signaling, the Notch pathway enhances the pool of proliferative
ISCs in the crypt [28]. The Notch target gene Hairy, an enhancer of split (Hes1), and the
putative stem-cell marker Musashi-1 (Msi1) both mark CBCs and + 4 cells within the crypt
[34]. Through lineage-tracing studies of Notch signaling-positive cells, using the Notch1
Intramembrane Proteolysis (N1IP-Cre) mouse line, Notch signaling was found to be active
in ISCs [35]. Cell-fate studies in mice have also demonstrated that Notch1 and -2 receptors
are specifically expressed in crypt stem cells but do not mark supportive Paneth cells [36].
Transgenic mice lacking the Notch-dependent transcription factor CSL display an
expanded number of secretory goblet cells and less proliferative ISCs [22]. The same
effect is observed after antibody blockade of the Notch1 receptor [37]. Furthermore, mice
expressing a constitutively active Notch1 receptor (via the Notch intracellular domain,
NICD) contain villi populated with immature progenitor cells and lack a differentiated
epithelium [36]. These studies strongly indicate the role of Notch signaling in maintain-
ing ISC proliferation and inhibiting differentiation to secretory cells. This maintenance of
stemness via the Notch pathway is partially achieved in Lgr5+ CBCs through interaction
with the Notch ligand Dll4 from supportive Paneth cells [27].
In addition to active Wnt and Notch signaling, the BMP pathway is active in the epithe-
lium and mesenchyme of the small intestine [28]. Mouse models overexpressing the BMP
inhibitor Noggin display ectopic crypts and have intraepithelial neoplasia commonly asso-
ciated with polyposis [38]. A similar phenotype is observed in transgenic mice lacking the
BMPR-1A (Alk3), which exhibit hyperproliferation of ISCs [39]. Thus, BMP signaling
represses proliferation of ISCs, which reduces the number of aberrant crypts and polyp
formation in the intestine. Suppression of ISC self-renewal via intestinal BMP signaling
alternatively promotes ISC differentiation into secretory enteroendocrine cells.
BMP signaling also regulates the maturation of differentiated ISC progeny by counter-
acting the proliferative effects of the Wnt/β-catenin pathway. BMP signaling activates the
phosphatase PTEN, which then blocks AKT to inhibit activation of β-catenin [20]. This
BMP-mediated suppression of canonical Wnt balances ISC self-renewal with differentia-
tion, since both processes are equally necessary for intestinal homeostasis.
Isolated Lgr5+ CBCs have been successfully used to generate crypt–villus “minigut”
structures in vitro [40]. Single Lgr5+ stem cells, isolated from the intestines of Lgr5-EGFP-
ires-CreERT2 transgenic mice, were isolated based on expression of GFP and cultured in
conditions promoting growth of intestinal epithelium. These conditions involved treatment
with EGF, Noggin, and the Wnt agonist R-spondin to imitate the proliferative crypt envi-
ronment. After 2 weeks of treatment, proliferative intestinal-like organoids formed from
individual Lgr5+ GFP+ cells. These structures naturally formed crypts with supportive
Paneth cells interspersed between proliferating Lgr5+ GFP+ ISCs and contained a lumen
with a single-cell layer of villus-like epithelial cells. Amazingly, these organoid struc-
tures could be cultured for months while still maintaining crypt–villus morphology and
proliferative ability.
The ability to generate and maintain intestinal organoids in vitro indicates our increasing
knowledge of the ISC niche. A better understanding of the support cells, crypt structure, and
molecular signaling pathways which regulate ISC proliferation and differentiation will help
with the prevention and treatment of intestinal diseases, particularly cancerous growths.
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5.5 The Hematopoietic Stem Cell (HSC) Niche
In the adult human, approximately 1011–1012 blood cells are generated every day [41].
Due to their short lifespan, blood cells are replenished by a constant source of multilineage
progenitors, derived from self-renewing HSCs in the bone marrow. HSCs are responsible
for establishing and regenerating all mature blood cells, including lymphoid cells (B-
and T-lymphocytes, natural killer cells) and myeloid cells (erythrocytes, megakaryocytes,
monocytes, macrophages, neutrophils, etc.) [42].
Studies of HSCs have progressed rapidly due to the discovery of a plethora of stage-
specific surface markers that are easily identified from monoclonal antibodies, their capacity
for dye efflux, and their unique metabolic properties. Consequently, the multistep journey
of HSC development and migration has been largely mapped using animal models. During
development of the mammalian embryo, hematopoiesis occurs at specific sites in a tempo-
rally regulated manner. It first begins in the blood islands of the yolk sac, then moves to the
aorta–gonad mesonephros (AGM) region surrounding the dorsal aorta, then to the placenta,
fetal liver, spleen, and finally the bone marrow [42]. In each of these locations, the niche
develops prior to seeding by the migratory HSCs, which circulate during hematopoiesis in
the embryo [43]. Primitive HSCs gradually mature and expand into a definitive, quiescent
HSC pool as the cells home from one niche to the next after expressing the appropriate
receptors induced by the current niche [3, 44].
The events that occur during HSC development illustrate the diverse functions of their
specific niches. Each site controls the formation of unique blood cell populations and regu-
lates either expansion or differentiation of the corresponding HSCs [42]. The hemangioblast
in the yolk sac generates endothelial cells and red blood cells (RBCs), while the AGM and
placental niches induce formation of cycling HSCs from hemogenic endothelium. In the
fetal liver, long-term HSCs (LT-HSCs) cycle rapidly to generate short-term HSCs (ST-
HSCs), which give rise to all common myeloid and lymphoid progenitors. Within the adult,
populations of LT-HSCs become quiescent and cycle slower but continue to form all mature
hematopoietic lineages. By this stage, the adult HSC niche controls HSC self-renewal and
differentiation to regulate homeostasis of the blood system.
5.5.1 Endosteal Niche
Within the bone marrow, the HSC niche consists of two general sites: (i) a quiescent,
osteoblastic niche at the endosteum and a (ii) proliferative, vascular niche in the central
marrow [45]. The osteoblast (OB) is the primary HSC support cell within the osteoblastic
niche. OBs and osteoblastic lining cells reside along the endosteum, a connective tissue
lining within the medullary cavity of the bone, and interact with HSCs. The positive role of
OB support cells in regulating HSC proliferation becomes apparent when the transcriptional
regulator of OB differentiation, Runx2, is removed. Runx2 −/− transgenic mice showed
impaired bone marrow hematopoiesis due to reduced OB differentiation, resulting in a
lack of niche sites for HSCs [46]. Furthermore, expansion of the number of OBs through
activation of PTH/PTHrP receptors (PPRs) enhanced the expression of Jagged-1, which
induced HSC proliferation through activation of Notch signaling [47]. Alternatively, OBs
can release the glycoproteins osteopontin (OPN) and thrombopoietin (TPO) to block HSC
proliferation and maintain quiescence within the endosteal niche [45].
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In addition to HSC regulation by OBs, other support cells and inorganic ions serve
crucial functions in the endosteal niche. CXC chemokine ligand 12 (CXCL12) is highly
expressed in particular cells called CXCL12-abundant reticular (CAR) cells [48]. CAR
cells in the endosteum maintain the quiescent HSC pool through signaling via its receptor,
CXCR4. HSCs are also capable of sensing extracellular calcium (Ca2+ ) concentrations
through a Ca2+ -sensing G-protein-coupled receptor (GPCR). In response to Ca2+ levels,
HSCs localize next to OB support cells in the endosteal niche, which controls the location
of hematopoiesis within the bone.
Osteoclasts (OCLs) and macrophages exert structural and regulatory roles within the
endosteal niche. OCLs form cavities in the bone, in which HSCs reside. Mouse models
with defective OCLs have greater HSC mobilization and peripheral localization, suggesting
OCLs suppress HSC mobilization [49]. Similarly, a specific subset of endosteal F4/80+
macrophages (termed osteomacs) are necessary for maintaining HSCs within the endosteal
niche through their support of OBs. The addition of granulocyte colony-stimulating factor
(G-CSF) causes a loss of osteomacs, suppresses OBs, and ultimately induces mobilization
of peripheral HSCs through disruption of the CXCR4/CXCL12 pathway [50].
Maintenance of HSC quiescence within the endosteal niche is mediated by repression
of the canonical Wnt signaling pathway through its inhibitor, secreted Frizzled-related
protein 1 (sFRP-1) [10]. Inhibition of glycogen synthase kinase 3 (GSK3), a repressor
of β-catenin, also induces HSC progenitor cell activity, indicating the proliferative effect
of Wnt signaling on these cells. Alternatively, activation of BMP signaling through var-
ious pathway agonists is responsible for repressing HSC proliferation in this region of
the niche.
5.5.2 Vascular Niche
To maintain blood cell homeostasis, quiescent LT-HSCs within the endosteal niche migrate
to the sinusoids of the vascular niche in the central marrow and become rapidly cycling
ST-HSCs. Sinusoids are fenestrated, capillary-like blood vessels which form the vascular
component of the bone marrow and are the sites of entry and exit for circulating, HSC-
derived blood cells. Bone marrow sinusoidal endothelial cells (SECs) line the lumen of
these vessels and express vascular–endothelial growth factor receptor-2 (VEGFR-2) [45].
Myeloablation of bone marrow through lethal irradiation destroys marrow cells. Bone-
marrow transplantation is required for recovery. Blocking VEGFR-2, and thus SECs, during
this time impedes regeneration and engraftment of HSCs, illustrating the direct role of bone-
marrow SECs in supporting HSCs [51].
This SEC/HSC interaction is dependent, in part, on Notch signaling. Just as OBs express
the Notch ligands Jagged-1 and -2, SECs regulate HSC proliferation through the same
Notch-dependent pathway [45]. However, in vitro and in vivo studies suggest this pathway
may only be activated under stressful conditions, such as after myeloablation. In addition,
SECs regulate vascular HSCs through expression of the c-Kit receptor ligand stem-cell
factor (SCF) [52]. SCF is important in maintaining vascular HSCs, since its removal from
vascular endothelial cells causes the loss of HSCs. This type of SCF-mediated regulation
of HSCs is specific to endothelial cells, as loss of SCF in OBs or hematopoietic cells does
not affect HSC number or function.
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Further regulation in the vascular niche is achieved by a balance of canonical Wnt and
BMP signaling. Activation of canonical Wnt occurs through nuclear localization of β-
catenin, which induces proliferation of formerly quiescent HSCs. This process is balanced
by inhibition of BMP signaling, which would otherwise repress cell division.
In addition to vascular SECs, a number of perivascular cells are required for HSC
maintenance. Perivascular CAR cells, as distinct from the CAR cells of the endosteum,
provide structural support to the sinusoids at the central marrow and form a barrier between
the bone-marrow stroma and circulation [45]. These cells also provide a supportive role to
HSCs within the perivascular space and express SCF and CXCL-12 (or stromal cell-derived
factor 1).
A second type of perivascular support cell in the central marrow is the Nestin+ mes-
enchymal stem cells (MSCs). Considered to be a subgroup of CAR cells, Nestin+ MSCs
localize near HSCs and express genes involved in their maintenance, such as Cxcl-12, c-kit
ligand, interleukin-7, vascular cell adhesion molecule 1, and osteopontin [53]. Diptheria
toxin-mediated depletion of Nestin+ MSCs detrimentally affects HSC number and homing
to the bone marrow, indicating these cells’ supportive role for HSCs.
Nonmyelinating Schwann cells also have an important role in regulating HSC quiescence
and activity within the vascular niche. These glial cells ensheath autonomic nerves that
innervate the bone-marrow vasculature and modify inactive TGFβ, released by a number
of nearby cells, into an active form that initiates signaling through Smad [54]. Loss of
Schwann cells through autonomic nerve denervation and TGFβR-2 deficient HSCs both
independently caused loss of HSCs. These losses were due to defects in TGFβ/Smad
signaling and the inability to regulate HSC quiescence.
5.5.3 Progeny “Niche”
An additional level of control over the HSC niche is provided by feedback regulation via
progenitor cells. Bone-marrow CD169+ macrophages, derived from common myeloid pro-
genitors (CMPs), interact with Nestin+ vascular cells to retain HSCs within the niche [45].
Megakaryocytes, CMP progenitors that generate platelets, release TGFβ and Angiopoietin-
1 (Ang-1) to decrease HSC proliferation [45]. Finally, an abnormally high number of
platelets will deplete TPO, which stimulates a negative feedback loop involving megakary-
ocytes to ultimately induce HSC quiescence within the bone marrow [55].
5.6 The Neural Stem Cell (NSC) Niche
The adult brain was initially believed to be a postmitotic organ, unable to regenerate its
parenchymal cells, or neurons. However, while neurogenesis occurs during development of
the embryo in transient niches, it has been unexpectedly shown to persist in specific areas
of the brain after birth and throughout adult life. Adult neurogenesis has best been charac-
terized within neural stem cell (NSC) niches located in the ventricular–subventricular zone
(V-SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus [56].
Other regions of the brain such as the striatum, substantia nigra, amygdala, and neocortex
have been proposed as sites of neurogenesis but are currently debated. NSC markers com-
monly used to label these populations include the intermediate filament proteins Nestin and
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glial fibrillary acidic protein (GFAP), the RNA-binding proteins Musashi-1 and -2, and the
transcription factor Sox2 [56].
5.6.1 V-SVZ Niche
During neural development, radial glial cells give rise to a group of astroglial-like cells,
known as B1 cells, which persist in the adult brain and function as NSCs [57]. Neurogenesis
within the V-SVZ utilizes these B1 cells, located in the walls of the lateral ventricles, which
extend through this region to contact blood vessels within the SVZ [57]. B1 cells are
induced to generate a subpopulation of transient amplifying cells (TACs), also known as
intermediate progenitor cells (IPCs) or type-C cells. These TACs divide briefly and then
become neuroblasts (type-A cells), which, in rodents, migrate along the rostral migratory
stream to the olfactory bulb and mature into interneurons [58].
Understanding the structure of V-SVZ B1 cells provides insight into the role of their
support cells and regulatory factors. B1 cells have three domains (apical, intermediate, and
distal), which extend from the ventricular lumen through the ventricular zone (VZ) and
SVZ. The apical side of B1 cells contains a primary cilium, which projects through the
ventricular wall to contact the cerebrospinal fluid (CSF) within the lateral ventricles. This
cilium is surrounded in a circular manner by ependymal cells, a simple cuboidal epithelium,
with apical cilia that circulate the CSF within the ventricular lumen [59]. Ependymal cells
provide a supportive role by attaching to B1 cells at intercellular junctions and exposing
them to the CSF.
Exposure of B1 cells to the CSF introduces soluble factors and signaling molecules that
can regulate their proliferation. Insulin-like growth factor 2 (IGF2), circulating with the
CSF, binds to the IGF1 receptor (IGF1R) on the apical surface of B1 cells and promotes
proliferation [60]. B1 cell proliferation is also induced through the release of the BMP
antagonist Noggin from ependymal cells and by sequestration of the BMP4 ligand [57].
In addition, Sonic hedgehog (SHH) signaling mediators may regulate ventral specification
through the primary cilium, and a number of Wnt ligands have been shown to exist near the
surface of the ventricles [57]. Correspondingly, increased expression of the Wnt receptor
Frizzled has been observed in ventricular progenitor cells. Thus, the CSF contains numerous
secreted factors which regulate NSC survival and proliferation within the lateral ventricles.
Regulation of B1 NSC proliferation through negative-feedback mechanisms is likely to
occur within the intermediate domain. In this region, B1 cells maintain cell–cell contacts
with their progenitors (TACs and neuroblasts) and the neuronal terminals of support cells
[57]. TACs express the bHLH transcription factor ASCL1 (Mash1), which promotes the
production of Notch ligands. Activation of canonical Notch signaling then represses gen-
eration of TACs through the downstream mediator HES1, illustrating a mechanism of NSC
maintenance. Furthermore, neuroblasts release the neurotransmitter gamma-aminobutyric
acid (GABA), which represses TAC proliferation by blocking progression through the cell
cycle (via depolarization). Alternatively, release of the neurotransmitter dopamine from
neighboring neuronal terminals of the substantia nigra can stimulate TAC proliferation
through release of EGF [61].
Like the primary cilium of the apical region, which receives input from the CSF, the
distal domain of B1 cells is in contact with factors of the bloodstream. A basal extension
reaches into the SVZ and surrounds the blood vessels of its vascular plexus using a unique
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“end-foot” process [57]. Interaction with both blood-vessel endothelial cells and blood-
derived factors affects B1 cell proliferation. In summary, the structure of B1 NSCs of the
V-SVZ allows them to receive regulatory cues from several environments (CSF, progenitors,
blood-vessel endothelial cells, and blood) which regulate maintenance and proliferation
within the walls of the lateral ventricles.
5.6.2 SGZ Niche
A second NSC niche exists in the SGZ of the dentate gyrus, within the hippocampus [57].
The dentate gyrus is composed of several layers, with the SGZ located at the bottom,
directly above the hilus (a structure where blood vessels and nerves enter). The granule cell
layer (GCL) and inner molecular layer (IML) exist above the SGZ. In the SGZ, astroglial
cells, known as radial astrocytes (RAs) or type-1 progenitors, serve as the NSC. When
induced, RAs generate transient amplifying progenitors known as IPC1 and IPC2 (or type
2a and 2b, respectively). Once generated, IPC1 cells quickly develop into proliferating
IPC2 cells, characterized by expression of the early neuronal marker doublecortin [62].
IPC2 cells then develop into immature granule cells (IGCs), which become mature gran-
ule cells (GCs) and extend axons into both the hilus and inner molecular layer of the
dentate gyrus.
Like the B1 cells of the V-SVZ, the RAs of the SGZ can be segmented into three
distinct domains (proximal, intermediate, and distal), each with unique functions [57]. The
proximal domain of an RA is located within the SGZ and contains lateral processes that
extend from the soma to contact nearby vasculature and neighboring RAs. This domain
is in direct contact with the hilus and contains a primary cilium expressing smoothened
receptors for regulation of proliferation through SHH signaling. The proximity of the
RA proximal domain to the vasculature within the hilus also allows for stimulation of
neuronal proliferation via release of IGF and vascular–endothelial growth factor (VEGF)
[63]. These growth factors are crucial for RA neurogenesis and maintenance of synaptic
plasticity, illustrating the crucial role of endothelial support cells. In addition to stimulating
proliferation, supporting vascular endothelial cells release brain-derived neurotrophic factor
(BDNF) to induce differentiation of RA progenitors [64].
The intermediate domain of RAs contains the soma and main axonal shaft, which projects
through the granule cell layer, contacting IPCs and mature GCs [57]. These interactions
allow for maintenance of RAs. Specifically, canonical Notch signaling regulates expression
of SOX2, a transcription factor that prevents activation of the neuronal fate mediator
NeuroD [65]. Blocking expression of NeuroD preserves the pool of RAs, preventing their
generation of IPCs. This type of control over RA proliferation, as well as of ASCL1+ IPC1
cell proliferation, is governed by Notch signaling, equivalent to the feedback mechanisms
regulating B1 cells.
Further regulation at the intermediate domain of RAs occurs through mediation of BMP
signaling via expression of Noggin. This BMP antagonist is expressed within the hilus
and dentate gyrus, and its overexpression induces RA proliferation [66]. Thus, canoni-
cal BMP signaling may maintain the current RA population by promoting a quiescent
state. In direct contrast to the quiescent state invoked by BMP signaling, release of
Wnt3 from astrocytes stimulates differentiation of NSCs within the SGZ. In addition,
contact of the RA axonal shaft with mature GCs may lead to NSC proliferation through
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detection of neuronal activity via neurotransmitters. This type of RA stimulation is involved
with long-term potentiation (LTP), a process necessary for learning and memory in the hip-
pocampus [67].
The distal domain of RAs extends into the inner molecular layer of the dentate gyrus and
forms a terminal arbor. Here, the thin radial processes are influenced by neurotransmitters
such as GABA and Glutamate, released from interneurons and Mossy cells, to generate
IPCs from differentiated RAs [68].
Overall, precise regulation of RAs occurs through interaction of their three general
domains with progenitors, hippocampal support cells, and signaling mediators. These types
of refined interaction allow for maintenance of the RA NSC population within their SGZ
niche, as well as formation of the mature GCs involved in neuronal plasticity.
5.7 A Comparison between Tissue-Specific Adult Stem Cell Niches
Each of the ASC niches discussed here incorporates similar concepts in the regulation
of its respective stem cells. Several of these niche similarities are observed in different
organs, and they are also a broadly conserved evolutionarily theme between vertebrates and
invertebrates, such as D. melanogaster and C. elegans [1]. In general, maintenance of ASCs
occurs through regulation of quiescent (slow-cycling) and active (rapidly proliferating)
populations. Support cells within the niche control these opposing processes through release
of various mediators, which stimulate or inhibit stem-cell proliferation and differentiation.
Niche stem cells are responsive to secreted factors through various receptors and when
induced to proliferate either generate identical daughter cells or precursors destined to
become mature cells of the organ. This niche-mediated regulation of ASCs is crucial for
maintenance of the tissue and repair after damage.
The general use of stromal support cells that release various factors to influence stem
cell renewal extends throughout the mammalian niches discussed previously. Studies in
both mice and rats show that a variety of niche support cells regulate their respective stem
cells through a balance of Wnt and BMP pathway mediators. Interestingly, these signaling
pathways are highly conserved within the skin, small intestine, bone marrow, and brain
(lateral ventricle and hippocampus), and often elicit similar effects regardless of the tissue-
specific niche [3]. For example, within the small intestine, at the base of the crypts, support
cells release canonical Wnt signaling mediators to promote ISC proliferation [28,29]. HSCs
within the bone marrow directly stimulate their self-renewal through autocrine signaling
via the Wnt pathway [69]. Wnt signaling also promotes proliferation of bulge stem cells
within the hair follicle [18, 70]. However, the stimulatory effects of Wnt/β-catenin also
require inhibition of BMP signaling, which is often achieved through expression of Noggin.
Alternatively, active BMP signaling can maintain stem cells in a quiescent state in each of
these niches.
Similar structural features also exist between ASC niches. Cell–cell and cell–ECM
adhesion is necessary to retain quiescent stem cells within their niche, or to orient prolifer-
ating cells in a manner which induces symmetrical or asymmetrical division. A variety of
adherens junctions and integrins provide cell–cell contact or cell attachment to a basal lam-
ina [3]. HSCs and their OB support cells anchor to each other through N-cadherin junctions
and attach to their respective basal lamina through β1-integrins [71]. Targeted deletion of
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β1-integrin within hair-follicle keratinocyte stem cells disrupts keratinocyte proliferation,
differentiation, and hair-follicle morphogenesis [72]. Finally, lack of the ECM glycopro-
tein tenascin C in the subventricular zone of the lateral ventricles detrimentally affects the
function and number of NSCs [73]. These studies of three unique ASC niches indicate the
general requirement that stem cell adhesion support cells and structural components for
proper maintenance of the niche.
The structural architecture of individual stem cell niches also spatially separates subpop-
ulations of cells for distinct regulation. For example, the location of stem cells within the
hair follicle bulge allows for activation of specific transcriptional programs of gene expres-
sion. Depending on their state of proliferation, HFSCs upregulate unique combinations of
mRNAs for control of cell adhesion, changes to cytoskeletal structure, or induction of cell
growth [17]. Interestingly, a number of these mRNAs upregulated in bulge stem cells are
also expressed in NSCs and HSCs to induce similar structural and metabolic changes, as
well as to regulate cell growth. Within the intestine, separation of the two ISC populations
allows for regulation of cell proliferation. A similar theme is observed in the bone marrow,
in which slow-cycling endosteal niche stem cells replenish more rapidly cycling vascular
progenitors.
An additional level of stem cell regulation is provided through soluble mediators (proteins
and small molecules) released from progenitor cells. Progenitor-cell negative feedback
represses NSC proliferation in both the subventricular and subgranular zones, as well
as growth of ISCs and HSCs of the intestine and central marrow, respectively. Within
the hair follicle bulge, migration of activated HG cells into the hair matrix induces the
proliferation of quiescent HFSCs. Signaling molecules circulating in the bloodstream are
also used to regulate stem cells. The common role of vasculature within each of the niches
discussed allows for precise regulation of stem-cell activity through exposure to a variety
of molecular mediators. In the brain, the proximal domain of RAs and the distal domain of
B1 NSCs directly contact blood vessels. Consequently, bloodborne mediators regulate their
proliferation state through interaction with membrane-bound receptors on both cells. Lastly,
neuronal innervation of stem or progenitor cells can be employed to control maintenance
of stem cell populations, as observed in both RAs and B1 NSCs.
The information learned from studies of stem cell niches in the hair follicle, intestine,
bone marrow, and regions of the brain can be extrapolated to predict characteristics of
stem cell niches in other organs of the body. Historically, the adult heart was believed
to be composed of terminally differentiated, postmitotic cells, but a rising number of
studies suggest the existence of cardiac stem cell (CSC) populations [74]. However, each
putative population has a distinct expression of surface markers, unique or unknown origins,
and varied cardiogenic potential. While it is becoming increasingly evident that CSC
populations generate new cardiomyocytes in the heart, there is still considerable debate
about the actual regenerative ability of the myocardium over the lifetime of an individual.
A similar challenge also exists in the identification and confirmation of an ASC population
in the lungs. As in the adult heart, putative lung stem cell populations are believed to
contribute lung epithelial cells for maintenance of the tissue, but fail to provide adequate
regenerative ability after injury [75]. Current studies suggest that potential lung stem cell
niches harbor a variety of pulmonary progenitors. However, characterization of these cells
based on specific surface markers and demonstration of true stem-cell properties through
direct in vivo studies are still lacking. Nevertheless, studies of confirmed stem cell niches
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from other organs within the body provide a solid model for studying the origin, location,
structure, and regulation of novel, putative cardiac and pulmonary niches.
5.8 Future Challenges
While many questions about ASCs and their respective niches have been answered, several
uncertainties remain. ASC niches within the hair, intestine, and bone marrow explain the
source of replenishment for the millions of these cells that are lost every day. The discovery
of niches within the brain occurred later, and regions of neurogenesis in addition to the
V-SVZ and SGZ are currently under debate. Increasing evidence indicates that other organs,
such as the heart and lungs, may also contain resident populations of ASCs. However, these
putative cell populations must be definitively located and characterized in order to establish
consensus within the field. In each of these cases, it will be necessary to understand the
source and location of putative stem cell populations and how the integration of different
signals culminates to affect their function and turnover within the niche. Finally, studies to
address how and why ASCs and their niches change during normal aging processes, after
injury and disease, will provide insight into the provision of improved care for an aging
population.
Acknowledgements
This work was supported by an American Heart Association Fellowship to BAF and by
NIH grants U01HL100398 and R01HL083958 to AKH.
References
(1) Scadden, D.T. (2006) The stem-cell niche as an entity of action. Nature, 441 (7097), 1075–1079.
(2) Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S. et al. (1998) Embryonic stem cell lines derived
from human blastocysts. Science, 282 (5391), 1145–1147.
(3) Jones, D.L. and Wagers, A.J. (2008) No place like home: anatomy and function of the stem cell
niche. Nature Reviews Molecular Cell Biology, 9 (1), 11–21.
(4) National Institutes of Health (n.d.) What are adult stem cells? Available from: http://stemcells
.nih.gov/info/basics/pages/basics4.aspx (last accessed March 7, 2014).
(5) Slavin, S., Nagler, A., Naparstek, E. et al. (1998) Nonmyeloablative stem cell transplantation
and cell therapy as an alternative to conventional bone marrow transplantation with lethal
cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood,
91 (3), 756–763.
(6) Subrammaniyan, R., Amalorpavanathan, J., Shankar, R. et al. (2011) Application of autologous
bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as
a result of diabetes: our experience. Cytotherapy, 13 (8), 993–999.
(7) Lu, P., Jones, L., Snyder, E., and Tuszynski, M. (2003) Neural stem cells constitutively secrete
neurotrophic factors and promote extensive host axonal growth after spinal cord injury. Exper-
imental Neurology, 181 (2), 115–129.
(8) Terai, S., Ishikawa, T., Omori, K. et al. (2006) Improved liver function in patients with liver
cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells, 24 (10), 2292–2298.
(9) Schofield, R. (1978) The relationship between the spleen colony-forming cell and the haemopoi-
etic stem cell. Blood Cells, 4 (1–2), 7–25.
74 Chemical Biology in Regenerative Medicine
(10) Li, L. and Clevers, H. (2010) Coexistence of quiescent and active adult stem cells in mammals.
Science, 327 (5965), 542–545.
(11) Alonso, L. and Fuchs, E. (2003) Stem cells of the skin epithelium. Proceedings of the National
Academy of Sciences of the United States of America, 100, 11830–11835.
(12) Tumbar, T. (2004) Defining the epithelial stem cell niche in skin. Science, 303 (5656), 359–363.
(13) Kaur, P. (2006) Interfollicular epidermal stem cells: identification, challenges, potential. Journal
of Investigative Dermatology, 126 (7), 1450–1458.
(14) Niemann, C. and Watt, F.M. (2002) others. Designer skin: lineage commitment in postnatal
epidermis. Trends in Cell Biology, 12 (4), 185–192.
(15) Greco, V., Chen, T., Rendl, M. et al. (2009) A two-step mechanism for stem cell activation
during hair regeneration. Cell Stem Cell, 4 (2), 155–169.
(16) Cotsarelis, G., Sun, T.T., and Lavker, R.M. (1990) Label-retaining cells reside in the bulge area
of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis.
Cell, 61 (7), 1329–1337.
(17) Blanpain, C., Lowry, W.E., Geoghegan, A. et al. (2004) Self-renewal, multipotency, and the
existence of two cell populations within an epithelial stem cell niche. Cell, 118 (5), 635–648.
(18) Gat, U., Das Gupta, R., Degenstein, L., and Fuchs, E. (1998) De novo hair follicle morphogenesis
and hair tumors in mice expressing a truncated β-catenin in skin. Cell, 95 (5), 605–614.
(19) Kobielak, K., Pasolli, H.A., Alonso, L. et al. (2003) Defining BMP functions in the hair follicle
by conditional ablation of BMP receptor IA. The Journal of Cell Biology, 163 (3), 609–623.
(20) Moore, K.A. and Lemischka, I.R. (2006) Stem cells and their niches. Science, 311 (5769),
1880–1885.
(21) Garza, L.A., Yang, C.-C., Zhao, T. et al. (2011) Bald scalp in men with androgenetic alopecia
retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor
cells. Journal of Clinical Investigation, 121 (2), 613–622.
(22) Jiang, H. and Edgar, B.A. (2012) Intestinal stem cell function in Drosophila and mice. Current
Opinion in Genetics & Development, 22 (4), 354–360.
(23) Sangiorgi, E. and Capecchi, M.R. (2008) Bmi1 is expressed in vivo in intestinal stem cells.
Nature Genetics, 40 (7), 915–920.
(24) Potten, C.S., Booth, C., and Pritchard, D.M. (1997) The intestinal epithelial stem cell: the
mucosal governor. International Journal of Experimental Pathology, 78 (4), 219–243.
(25) Tian, H., Biehs, B., Warming, S. et al. (2011) A reserve stem cell population in small intestine
renders Lgr5-positive cells dispensable. Nature, 478 (7368), 255–259.
(26) Takeda, N., Jain, R., LeBoeuf, M.R. et al. (2011) Interconversion between intestinal stem cell
populations in distinct niches. Science, 334 (6061), 1420–1424.
(27) Sato, T., van Es, J.H., Snippert, H.J. et al. (2011) Paneth cells constitute the niche for Lgr5 stem
cells in intestinal crypts. Nature, 469 (7330), 415–418.
(28) Vanuytsel, T., Senger, S., Fasano, A., and Shea-Donohue, T. (2012) Major signaling pathways
in intestinal stem cells. Biochimica et Biophysica Acta, 1830 (2), 2410–2426.
(29) Fevr, T., Robine, S., Louvard, D., and Huelsken, J. (2007) Wnt/β-catenin is essential for intestinal
homeostasis and maintenance of intestinal stem cells. Molecular and Cellular Biology, 27 (21),
7551–7559.
(30) Korinek, V., Barker, N., Moerer, P. et al. (1998) Depletion of epithelial stem-cell compartments
in the small intestine of mice lacking Tcf-4. Nature Genetics, 19 (4), 379–383.
(31) Harada, N., Tamai, Y., Ishikawa, T. et al. (1999) Intestinal polyposis in mice with a dominant
stable mutation of the β-catenin gene. The EMBO Journal, 18 (21), 5931–5942.
(32) Sansom, O.J., Reed, K.R., Hayes, A.J. et al. (2004) Loss of Apc in vivo immediately perturbs
Wnt signaling, differentiation, and migration. Genes & Development, 18 (12), 1385–1390.
(33) Shibata, H., Toyama, K., Shioya, H. et al. (1997) Rapid colorectal adenoma formation initiated
by conditional targeting of the Apc gene. Science, 278 (5335), 120–123.
(34) Kayahara, T., Sawada, M., Takaishi, S. et al. (2003) Candidate markers for stem and early
progenitor cells, Musashi-1 and Hes1, are expressed in crypt base columnar cells of mouse
small intestine. FEBS Letters, 535 (1–3), 131–135.
(35) Vooijs, M., Ong, C.-T., Hadland, B. et al. (2007) Mapping the consequence of Notch1 proteolysis
in vivo with NIP-CRE. Development (Cambridge, England), 134 (3), 535–544.
Comparative Analysis of Adult Stem Cell Niches 75
(36) Fre, S., Huyghe, M., Mourikis, P. et al. (2005) Notch signals control the fate of immature
progenitor cells in the intestine. Nature, 435 (7044), 964–968.
(37) Wu, Y., Cain-Hom, C., Choy, L. et al. (2010) Therapeutic antibody targeting of individual Notch
receptors. Nature, 464 (7291), 1052–1057.
(38) Haramis, A.-P.G., Begthel, H., van den Born, M. et al. (2004) De novo crypt formation and
juvenile polyposis on BMP inhibition in mouse intestine. Science, 303 (5664), 1684–1686.
(39) He, X.C., Zhang, J., Tong, W.-G. et al. (2004) BMP signaling inhibits intestinal stem cell
self-renewal through suppression of Wnt-beta-catenin signaling. Nature Genetics, 36 (10),
1117–1121.
(40) Sato, T., Vries, R.G., Snippert, H.J. et al. (2009) Single Lgr5 stem cells build crypt–villus
structures in vitro without a mesenchymal niche. Nature, 459 (7244), 262–265.
(41) Cantani, A. (2008) Chapter one – immunology, in Cantani, A., Pediatric Allergy,
Asthma and Immunology, Springer; pp. 1–219. Available from: http://link.springer.com.
proxy.library.vanderbilt.edu/chapter/10.1007/978-3-540-33395-1_1 (last accessed March 7,
2014).
(42) Orkin, S.H. and Zon, L.I. (2008) Hematopoiesis: an evolving paradigm for stem cell biology.
Cell, 132 (4), 631–644.
(43) Wright, D.E. (2001) Physiological migration of hematopoietic stem and progenitor cells. Sci-
ence, 294 (5548), 1933–1936.
(44) Kyba, M., Perlingeiro, R.C.R., and Daley, G.Q. (2002) HoxB4 confers definitive lymphoid-
myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors.
Cell, 109 (1), 29–37.
(45) Nakamura-Ishizu, A. and Suda T. (2012) Hematopoietic stem cell niche: an interplay among
a repertoire of multiple functional niches. Biochimica et Biophysica Acta (BBA) – General
Subjects. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0304416512002498 (last
accessed March 7, 2014).
(46) Wang, C.Q., Jacob, B., Nah, G.S.S., and Osato, M. (2010) Runx family genes, niche, and stem
cell quiescence. Blood Cells, Molecules, and Diseases, 44 (4), 275–286.
(47) Calvi, L.M., Adams, G.B., Weibrecht, K.W. et al. (2003) Osteoblastic cells regulate the
haematopoietic stem cell niche. Nature, 425 (6960), 841–846.
(48) Sugiyama, T., Kohara, H., Noda, M., and Nagasawa, T. (2006) Maintenance of the hematopoietic
stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches.
Immunity, 25 (6), 977–988.
(49) Miyamoto, K., Yoshida, S., Kawasumi, M. et al. (2011) Osteoclasts are dispensable for
hematopoietic stem cell maintenance and mobilization. Journal of Experimental Medicine,
208 (11), 2175–2181.
(50) Winkler, I.G., Sims, N.A., Pettit, A.R. et al. (2010) Bone marrow macrophages maintain
hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood, 116 (23),
4815–4828.
(51) Hooper, A.T., Butler, J.M., Nolan, D.J. et al. (2009) Engraftment and reconstitution of
hematopoiesis is dependent on VEGFR2 mediated regeneration of sinusoidal endothelial cells.
Cell Stem Cell, 4 (3), 263–274.
(52) Ding, L., Saunders, T.L., Enikolopov, G., and Morrison, S.J. (2012) Endothelial and perivascular
cells maintain haematopoietic stem cells. Nature, 481 (7382), 457–462.
(53) Méndez-Ferrer, S., Michurina, T.V., Ferraro, F. et al. (2010) Mesenchymal and haematopoietic
stem cells form a unique bone marrow niche. Nature, 466 (7308), 829–834.
(54) Yamazaki, S., Ema, H., Karlsson, G. et al. (2011) Nonmyelinating Schwann cells maintain
hematopoietic stem cell hibernation in the bone marrow niche. Cell, 147 (5), 1146–1158.
(55) de Graaf, C.A., Kauppi, M., Baldwin, T. et al. (2010) Regulation of hematopoietic stem cells
by their mature progeny. Proceedings of the National Academy of Sciences of the United States
of America, 107 (50), 21689–21694.
(56) Decimo, I., Bifari, F., Krampera, M., and Fumagalli, G. (2012) Neural stem cell niches in health
and diseases. Current Pharmaceutical Design, 18 (13), 1755–1783.
(57) Fuentealba, L.C., Obernier, K., and Alvarez-Buylla, A. (2012) Adult neural stem cells bridge
their niche. Cell Stem Cell, 10 (6), 698–708.
76 Chemical Biology in Regenerative Medicine
(58) Kriegstein, A. and Alvarez-Buylla, A. (2009) The glial nature of embryonic and adult neural
stem cells. Annual Review of Neuroscience, 32, 149–184.
(59) Mirzadeh, Z., Merkle, F.T., Soriano-Navarro, M. et al. (2008) Neural stem cells confer unique
pinwheel architecture to the ventricular surface in neurogenic regions of the adult brain. Cell
Stem Cell, 3 (3), 265–278.
(60) Lehtinen, M.K., Zappaterra, M.W., Chen, X. et al. (2011) The cerebrospinal fluid provides a
proliferative niche for neural progenitor cells. Neuron, 69 (5), 893–905.
(61) O’Keeffe, G.C., Tyers, P., Aarsland, D. et al. (2009) Dopamine-induced proliferation of adult
neural precursor cells in the mammalian subventricular zone is mediated through EGF. Pro-
ceedings of the National Academy of Sciences of the United States of America, 106 (21),
8754–8759.
(62) Lugert, S., Vogt, M., Tchorz, J.S. et al. (2012) Homeostatic neurogenesis in the adult hippocam-
pus does not involve amplification of Ascl1(high) intermediate progenitors. Nature Communi-
cations, 3, 670.
(63) Licht, T., Goshen, I., Avital, A. et al. (2011) Reversible modulations of neuronal plasticity by
VEGF. Proceedings of the National Academy of Sciences of the United States of America, 108
(12), 5081–5086.
(64) Chen, J., Zacharek, A., Zhang, C. et al. (2005) Endothelial nitric oxide synthase regulates brain-
derived neurotrophic factor expression and neurogenesis after stroke in mice. The Journal of
Neuroscience, 25 (9), 2366–2375.
(65) Kuwabara, T., Hsieh, J., Muotri, A. et al. (2009) Wnt-mediated activation of NeuroD1 and
retro-elements during adult neurogenesis. Nature Neuroscience, 12 (9), 1097–1105.
(66) Bonaguidi, M.A., Wheeler, M.A., Shapiro, J.S. et al. (2011) In vivo clonal analysis reveals
self-renewing and multipotent adult neural stem cell characteristics. Cell, 145 (7), 1142–1155.
(67) Bruel-Jungerman, E., Davis, S., Rampon, C., and Laroche, S. (2006) Long-term potentiation
enhances neurogenesis in the adult dentate gyrus. The Journal of Neuroscience, 26 (22), 5888–
5893.
(68) Förster, E., Zhao, S., and Frotscher, M. (2006) Laminating the hippocampus. Nature Reviews
Neuroscience, 7 (4), 259–268.
(69) Reya, T., Duncan, A.W., Ailles, L. et al. (2003) A role for Wnt signalling in self-renewal of
haematopoietic stem cells. Nature, 423 (6938), 409–414.
(70) Nguyen, H., Rendl, M., and Fuchs, E. (2006) Tcf3 governs stem cell features and represses cell
fate determination in skin. Cell, 127 (1), 171–183.
(71) Wagers, A.J., Allsopp, R.C., and Weissman, I.L. (2002) Changes in integrin expression are asso-
ciated with altered homing properties of Lin(−/lo)Thy1.1(lo)Sca-1(+)c-kit(+) hematopoietic
stem cells following mobilization by cyclophosphamide/granulocyte colony-stimulating factor.
Experimental Hematology, 30 (2), 176–185.
(72) Brakebusch, C., Grose, R., Quondamatteo, F. et al. (2000) Skin and hair follicle integrity is
crucially dependent on β1 integrin expression on keratinocytes. The EMBO Journal, 19 (15),
3990–4003.
(73) Garcion, E., Halilagic, A., and Faissner, A. (2004) ffrench-constant C. Generation of an envi-
ronmental niche for neural stem cell development by the extracellular matrix molecule tenascin
C. Development (Cambridge, England), 131 (14), 3423–3432.
(74) Anversa, P., Kajstura, J., Rota, M., and Leri, A. (2013) Regenerating new heart with stem cells.
Journal of Clinical Investigation, 123 (1), 62–70.
(75) Ardhanareeswaran, K. and Mirotsou, M. (2013) Lung stem and progenitor cells. Respiration,
85 (2), 89–95.
6
Chemicals and Stem Cells in the
Promotion of Regeneration
Dikshya Bastakoty1, Sarika Saraswati2, and Pampee P. Young3
1Department of Pathology, Vanderbilt University, USA
2Department of Pathology, Microbiology and Immunology, Vanderbilt University School of
Medicine, USA
3Department of Pathology, Microbiology and Immunology, Vanderbilt University, USA
6.1 Introduction
Living beings possess an inherent ability to repair normal wear-and-tear of tissue caused
by daily activities; this attribute is known as physiological regeneration [1]. Examples of
physiological regeneration include replacement of blood cells, turnover of epithelial cells
of the gut and skin, and renewal of endometrium after menstrual cycle. On the other hand,
reparative regeneration refers to the replenishment of cells or tissues after post-traumatic
injury. Large cellular or tissue loss due to trauma leads to the activation of specific signaling
pathways aimed at repairing injury, which in some cases completely heals the injury and
preserves the functionality of the lost tissue and in others leaves a healed but nonfunctional
(fibrotic) scar tissue. The former type of healing occurs in many vertebrates, such as
zebrafish, while the latter is more common in mammals. Through a better understanding
of the process of regeneration in these diverse species, the field of regenerative medicine
works toward developing ways of maximizing repair and minimizing fibrosis or scarring
in humans.
As the world’s aging population grows, there is an increasing demand on medicine to slow
down or reverse the degeneration of organs and tissues. The US National Institutes of Health
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(NIH) reported in 2010 that the world market for replacement organ therapies is $350 billion,
and that for regenerative medicine it is $500 billion [2]. As a result of this increasing demand,
the field of regenerative medicine, which started with surgical implants and transplants
in the 1950s, has grown to encompass cell therapy, novel chemicals and biologics, and
increasingly sophisticated biomaterials for scaffold or delayed delivery of chemicals.
With the discovery of stem cells and their potential to replace various cells in the adult
organisms, stem-cell therapy has become the mainstay of modern regenerative medicine.
The potential of stem cells to regenerate lost tissue depends on several parameters, including
their delivery into the injured tissue, their differentiation into the desired cell type, their
cooperative integration in the injury site to form functional tissue and – most important of
all – their survival in the injured microenvironment. Hence the intrinsic healing potential of
stem cells is better harnessed with the use of growth factors, biologics, small molecules, and
biomaterials that aid their delivery, survival, and integration into the wound. In this review
we will outline the use of these approaches to promote regeneration both in conjunction
with stem cells and independent of cell therapy. We will particularly focus on the use of
small molecules in stem-cell therapy in modern regenerative medicine.
6.2 Biologics in Regenerative Medicine
Biologics, in the widest sense, are agents derived from proteins produced by organisms.
Growth factors, antibodies, and vaccines are some of the most common biologics that
have been used to treat or prevent illnesses of various forms. In regenerative medicine,
growth factors are used extensively and successfully for a number of indications [3, 4].
With increased understanding of the signaling pathways implicated in tissue regeneration,
antibodies or proteins that antagonize or activate certain pathways have emerged as thera-
peutic candidates. Some common biologics-based approaches in regenerative medicine are
discussed in this section.
6.2.1 Growth Factors and Pro-Angiogenic Agents
Ever since their Nobel Prize-winning discovery by Rita Levi-Montalcini and Stanley Cohen
in the 1950s [5,6], growth factors have been reported to play increasingly diverse and impor-
tant roles in cell growth and differentiation. These roles lend them importance not only
in development but also in regeneration after injury [3] (clinicaltrials.org: NCT00000842).
Epidermal growth factor (EGF) is found to enhance healing of wounds in the skin and
cornea [7]. Nerve growth factor (NGF) and brain-derived or glial cell-derived neurotropic
factors (BDNF and GDNF, respectively) have been shown in rat models of nerve damage to
enhance neuronal regeneration [8,9]. Similarly, platelet-rich plasma (PRP) has been shown
in numerous animal studies to enhance tissue regeneration after injuries [10]. The plasma
extracted from blood is enriched in the laboratory for platelets, which contain presynthe-
sized growth factors packaged in α-granules. Upon activation of clotting (after infusion
into the injured tissue) these growth factors are secreted into the tissue microenvironment.
Autologous transplant of PRP for the treatment of various degenerative diseases of tis-
sue or bone has reached clinical trials (clinicaltrials.gov: NCT00761423, NCT01355549).
Although the results from many of the trials and existing clinical reports have been
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promising (but inconsistent or ambiguous at best [11,12]), there still seems to be anticipation
that with proper standardization of the techniques for plasma isolation, enrichment, storage,
and delivery, better and more consistent outcomes can be expected. Pro-angiogenic factors
such as vascular–endothelial growth factor (VEGF), fibroblast growth factor (FGF), and
platelet-derived growth factor (PDGF) are another subclass of growth factors that have been
utilized to improve regeneration by inducing neovascularization at the site of injury [13,14].
6.2.2 Immune-Modulatory Therapies
The immune system plays an important role in the resolution of injury. Early after injury,
it clears the site of injury of debris and infectious agents, and allows repair to begin.
However, persistent and uncontrolled inflammation can be detrimental to wound repair
[15], so drugs that modulate the inflammatory response have long been utilized to enhance
it. Thrombin peptide (THP508) was reported to enhance fracture healing through activation
of tumor necrosis factor-α (TNFα) and other pro-inflammatory factors [16]. On the other
hand, attenuation of inflammatory response has also been shown to enhance regenerative
repair. Several reports have shown that administration of high doses of nonsteroidal anti-
inflammatory drugs improve regeneration of brain tissue after the ischemic injury induced
by a stroke in rodents [17, 18]. Even the ability of stem-cell therapy using mesenchymal
stromal or stem cells (MSCs) to enhance tissue regeneration is attributed in part to their
immune-modulatory properties [19].
6.2.3 Extracellular Matrix-Based Approaches
The extracellular matrix (ECM) plays a key role in each step of injury repair. Within
days after injury, a fibrous matrix is synthesized to replace lost or damaged tissue. The
matrix is remodeled over time as the repair progresses. All the steps, from inflammation
to reepithelialization to contraction, involve very close interactions with matricellular
proteins, which sequester growth factors, regulate collagen turnover, and provide scaffold
and support to allow cells to grow during tissue repair [20]. ECM components, such as
heparin, bind many signaling molecules and growth factors and enhance their signaling by
sequestering them to the microenvironment or by stabilizing them. They have been used
to enhance signaling by proteins of interest [21]. Moreover, a polymer mimetic of heparan
sulfate proteoglycan itself has demonstrated remarkable healing properties in both topical
wounds and internal injuries [22,23]. A clinically available formulation is already in use in
Europe and the Middle East to treat corneal ulcers and diabetic wounds [24]. Since heparan
sulfates are important for the signaling of growth factors and cytokines, their degradation
and cleavage in a wound microenvironment impairs healing. The heparan sulfate mimetics
are uncleavable by heparanases and glycanases and hence aid repair of the wounded
tissue [25].
6.3 Chemicals and Biomaterials for Healing
Biologics such as proteins and growth factors have the potential to significantly improve
regeneration. However, in order for the healing agent to be effective it is important to
ensure that it is delivered to the tissue of interest at a substantial concentration and that
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it is bioavailable at the site of injury. Hence, modern regenerative medicine is integrating
diverse disciplines such as chemistry, material physics, and bioengineering in order to
devise strategies for optimizing regeneration. Small molecules, bioactive scaffolds, and
drug-delivery tools are the major new outcomes of these multidisciplinary investigations.
6.3.1 Small Molecules
A small molecule is a low-molecular-weight (smaller than 500 Daltons) organic compound.
Small molecules that are investigated for use as therapeutics typically bind to a protein,
nucleic acid, or polysaccharide and alter its enzymatic activity or biological function
[26]. Small molecules are identified by cell phenotypic, reporter-based, or organism-based
screening of chemical libraries [27]. Phenotypic screening is based on the cellular pheno-
type or cell-surface markers in response to the chemical library. In order to identify the
modulators of specific pathways, promoter-driven reporters are used as readouts for the
pathways of interest. Zebrafish and xenopus are routinely used for organism-based screens
[28]. There is increasing interest in finding small molecules that can modulate signaling
pathways as they have a number of advantages over biologics such as proteins and antibod-
ies. For one thing, they are cheaper to synthesize. Due to their small size, they are often
orally bioavailable, and hence delivery may not require injection. Additionally, they are
more likely to be cell-permeable and thus to allow modification of the pathway at multiple
steps; an antibody would rely solely on the sequesterization of a ligand or the blocking
of the receptor. Hence, small molecules are very useful in blocking intracellular protein–
protein interactions, which has to date been the sole domain of antisense oligos. Small
molecules thus offer a safer, more effective, and easier alternative to traditional signaling
pathway-modulation approaches [26].
Given their superiority in modifying molecular signals, many types of small molecule
have been investigated for potential roles in regeneration. Small-molecule antioxidants
such as quercetin, allopurinol retinoids, and uric acid are reported to enhance wound
healing [29]. Ascorbic acid, another small molecule, commonly used for stem-cell
differentiation, is also known to regulate ECM by increasing collagen synthesis [30]. In
a model of combined injury (fracture/irradiation) in mice, Greenberger and colleagues
showed that the small molecule GS-Nitroxide attenuates ionizing radiation-driven delay in
fracture healing [31]. Another small molecule, Pirfenidone, has been evaluated in clinical
trials as an antifibrotic agent for idiopathic pulmonary fibrosis. Already reported to reduce
fibrosis in lung, liver, heart, and kidney through the modulation of the transforming growth
factor beta (TGFβ) pathway, the molecule has potential for therapeutic application in tissue
injury, through promoting regeneration by minimizing scarring [32]. Work by our group has
also shown that in a mouse myocardial infarct model, treatment with the small-molecule
Wnt inhibitor Pyrvinium alleviates adverse cardiac remodeling post-infarct [33]. The same
molecule, upon topical treatment on mouse-ear punch injury, caused dramatic closure of the
holes with remarkable restoration of tissue structure, including hair-follicle regeneration
[34]. However, careful and thorough screenings of these molecules need to be performed
before they can be proposed for therapeutic purposes, since some may have toxicity and
off-target effects. Nonetheless, with careful considerations of their shortcomings, the
exciting prospects for small molecules in advancing regenerative medicine cannot be
overlooked.
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6.3.2 Biomaterial Scaffold and Sustained Delivery
As the field of regenerative medicine has become more multidisciplinary, innovative
approaches to drug delivery, in vitro organ regeneration, and cell therapy have been intro-
duced. These new technologies have revolutionized the field of regenerative medicine by
increasing the efficacy and versatility of the traditional methods of enhancing regeneration
through cell- or drug-based approaches.
Tissue engineering has been an important part of the field of regenerative medicine for
many decades now. With the design and application of sophisticated biomaterials, tissue
engineering is moving even further toward improving regenerative therapy [35]. Degradable
biomaterials composed of collagen, fibronectin, chitosan, and so on have been used for the
delivery of cells and to provide ECM components for the survival or directed differentiation
of injected cells. Alginate, an algae-derived polysaccharide, has been used in the form of
sponge or gel to enhance the regeneration of peripheral nerve [36], spinal cord [37], or
excised axons [38] in rodent or feline models when used alone or in combination with
neural progenitor (neurosphere) cells [39]. In a remarkable study, Atala and colleagues
used a cell-polymer matrix composed of a Poly (Lactide-co-Glycolide)-poly(D,L-lactide-
co-glycolide) (PGA-PLGA) scaffold lined with urothelial cells on one side and muscle cells
on the other to show for the first time the reconstitution of an autonomous and functional
hollow organ using a tissue-engineering approach [40].
Another avenue in which bionics and biomaterial science are contributing to better tissue
regeneration is in the sustained delivery of stabilized growth factors or drugs. In 2003,
Hyongbum Kim et al. reported successfully using PLGA scaffolds for the slow release
over a month of ascorbate-2-phosphate (AsAP) and dexamethasone to induce osteogenesis
from MSCs [41]. Another recent study showed that an injectable polyvalent coacervate of
a polycation and heparin used as a matrix for the sustained delivery and stabilization of
FGF2 increased FGF2-mediated angiogenesis in a rodent model [21].
6.4 Stem-Cell Therapy
Stem cells were discovered by Becker et al. when they noted that bone-marrow cells
injected into irradiated mice developed clonal nodules [42]. Subsequent studies by multi-
ple groups have shown that stem cells are, by definition, self-renewing, multipotent cells.
They exist in the embryo and in specific microenvironments called stem cell niches of
tissues of the adult organism [43]. Although stem cells from different sources may vary in
their degree of multipotency, virtually all stem cells (or progenitor cells, which are stem
cells partially committed to a specific lineage) possess some degree of multipotency and
capacity for self-renewal. These fundamental properties have placed stem cells on the fore-
front of regenerative biology. Also, there is increasing evidence to support the hypothesis
that in almost all of the regenerative approaches mentioned in the preceding sections, true
regeneration is driven by stem or progenitor cells in the wound milieu [44]. Although
this statement may be partly contested, stem cells have for the past 2 decades been the
buzzword in the context of regenerative therapies. By the year 2000, multiple studies had
shown that stem cells from various tissues could give rise to unrelated cell types under
special circumstances [45]. For example, Clarke et al. observed that neural stem cells
82 Chemical Biology in Regenerative Medicine
(NSCs) transferred to a blastocyst could contribute to tissues belonging to all three germ
layers [46]. These observations pointed toward their value in the regeneration of tissues that
normally do not regenerate [45]. Ethical controversies surrounding embryonic stem cells
(ESCs) stalled progress in stem-cell research, but the identification of stem cells in tissues
of adult organisms opened up new avenues for research. Stem cells from various organs
have now been used for many diseases and multiple types of injury, from bone injury, to
degenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, to cardiac, renal,
and lung injuries [47]. In 2003, Lin et al. reported that hematopoietic stem cells (HSCs)
transplanted into kidney after ischemia/reperfusion injury contributed to the regeneration of
renal tubules [48]. MSCs from the bone marrow have perhaps been used most extensively
in regenerative medicine for their ease of isolation and characterization, their multipotency,
and most importantly their immunosuppressive properties. The latter have made allogeneic
transplantation possible, increasing the feasibility of MSC transplant therapy [49]. Multiple
studies using diverse injury models have reported improved regeneration by stem-cell trans-
plantation [50, 51]. This has led to several clinical trials aimed at improving regeneration
using stem-cell therapy (clinicaltrials.gov: NCT01763099, NCT00877903). Not all of these
studies have unambiguously shown remarkable success. However, with improved mecha-
nistic insight and technical standardization, there is potential for improvement. Moreover,
progress in tissue engineering and chemical biology is now providing excellent tools by
which we can better understand stem cell biology and enhance the efficacy of stem-cell
therapy.
6.4.1 Chemical Manipulation of Stem Cells in Regeneration
In order to be useful for clinical purposes, stem cells should maintain their self-renewal
ability and be able to differentiate into specific lineages. Several biologics and genetic
manipulations have been used to control the fate of stem cells, driving their self-renewal,
differentiation, survival, or reprogramming. However, modulation of these complex biolog-
ical events with small molecules seems to be safer and more effective in regulating stem-cell
fate. Using high-throughput screening of chemical libraries, many molecules have been
identified that target specific cellular pathways to maintain stem-cell self-renewal, direct
stem-cell differentiation, and enable or enhance stem-cell reprogramming [27, 52]. Here
we will focus on recent interventions introduced by small molecules in affecting and/or
improving the behavior of different types of stem cells commonly used in regenerative
biology.
6.4.2 Embryonic Stem Cells (ESCs)
6.4.2.1 Small Molecules for the Culture and Maintenance of ESCs
ESCs are stem cells derived from the blastocyst stage of the embryo [53, 54]. These cells
are pluripotent, clonal, and self-renewing, and can differentiate into the cells of three germ
layers. They are therefore a strong candidate for regenerative therapies [55]. However,
the use of ESCs is limited due to ethical considerations, potential rejection problems
following their allogeneic transplantation, and the formation of teratomas after in vivo
injection. Traditionally, ESCs require feeder cells (growth-inactivated fibroblasts), fetal
bovine serum, growth factors, and knockout serum replacement in order to grow in culture.
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However, there is a lack of fully defined and reproducible culture conditions that would
allow them to grow in vitro. Additionally, the need for interventions such as feeder cells
and other animal serum products imposes risk of contamination. To overcome this issue,
Chen et al. performed a high-throughput cell-based screening on a mouse ESC line. This
led to identification of a small molecule (Pluripotin) that could maintain the self-renewal
status of ESCs under serum-free, feeder cell-free, and growth factor (leukemia inhibitory
factor, LIF)-free conditions [52]. Pluripotin exerts its effect by inhibiting Ras GTPase-
activating protein (RasGAP) and extracellular signal-regulated kinase-1 (ERK1). This was
a breakthrough in the area of ESC research, since it was thought to be impossible to
culture ESCs without feeder cells or any extrinsic growth factors. Following this study,
another group used a combinatorial approach in which a mitogen-activated protein kinase
kinase (MEK) inhibitor, PD0325901, and a glycogen synthase kinase 3 (GSK3) inhibitor,
CHIR99021, were used to maintain mESC culture under cytokine-free and feeder-free
conditions [56]. One persistent hurdle in the expansion of ESCs was the induction of cell
death upon single-cell dissociation; this has been overcome by using the Rho-associated
coiled coil-containing protein kinase (ROCK) inhibitor Y-27632 [57].
6.4.2.2 Small Molecules for ESC Differentiation
Besides improving ESCs’ culture conditions, small molecules have also been successfully
utilized to drive differentiation of ESCs into different cell lineages. In order to allow
them to be utilized for regenerative and other clinical applications, culture conditions
have been developed that drive ESCs toward hematopoietic cells [58], pancreatic cells
[59], endothelial cells [60], and other cell types [61]. However, the poor efficiency of
differentiation and the lack of homogeneity in the differentiated cell population are among
the major challenges still facing this endeavor. Small molecules may also provide more
specific and vigorous differentiation while allowing mechanistic insight into the lineage
differentiation process. The PI3Kinase inhibitor LY294002 has been shown to prime human
ESCs (hESCs) toward the endoderm differentiation induced by activin-A [62]. Another
chemical, stauprimide, targeted nonmetastatic cell 2 (NME2) and cMyc to prime ESCs
toward endoderm lineage specification [63]. In an hESC differentiation screen, SB431542,
a TGFβ receptor-I inhibitor, directed ESCs toward endothelial lineage commitment. Dual-
inhibition strategies have been used to obtain more precise and focused outcomes. For
example, the inhibition of bone morphogenetic protein 4 (BMP4) by Noggin and that of
TGFβ by SB431542 leads to more directed and efficient (larger number of differentiated
cells obtained in shorter time) neural differentiation of hESCs. The idea behind this dual-
inhibition strategy was to drive ESCs toward neural differentiation while inhibiting ESC
commitment toward other fates. A high-content screen (an approach that allows the study
of several biological and morphological changes simultaneously at the single-cell level)
of a chemical library by Chen et al. identified a small molecule, (−)-indolactam V (ILV),
which through protein kinase C signaling dramatically (>45%) enhances the number of
Pdx1-expressing pancreatic progenitor cells derived from hESCs [64]. These cells express
other pancreatic markers and participate in the generation of endocrine, exocrine, and duct
cells, in vitro and in vivo. Efficient generation of specific cell types from ESCs could be
very helpful in disease conditions such as Parkinson’s and juvenile-onset diabetes mellitus
that are caused by the death or abnormality of a few specific cell types [55]. Chemical
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screening for in vitro differentiation of ESCs toward specific lineages is a promising tool
by which to identify targets for the development of drugs for use in regenerative therapies.
6.4.3 Induced Pluripotent Stem Cells (iPSCs)
6.4.3.1 Generation of iPSCs
Although ESCs have great potential in regenerative medicine, ethical considerations, the
potential to form teratomas, and the possibility of rejection following transplantation limit
their utilization for therapeutic purposes. Generation of induced pluripotent stem cells
(iPSCs) from the patient’s own somatic cells seems to bypass these problems. iPSCs are
pluripotent stem cells that are generated from an adult somatic cell via the forced expres-
sion of transcription programs affecting stemcellness. Nobel Prize-winning work by Dr
Yamanaka’s group has shown that virus-mediated overexpression of Oct4, Sox2, Klf4, and
Myc can induce the conversion of mouse fibroblasts into iPSCs [65]. The gene expression
patterns, epigenetic changes, and developmental potentials of these iPSCs closely matched
those of the mouse ESCs (mESCs). In another study, the same group was able to repro-
gram human fibroblasts toward iPSCs using a similar strategy [66]. Although this is a very
promising approach in regenerative medicine, the poor efficiency of iPSC generation and
the use of a retrovirus for the delivery of iPSC-generating factors remain among the major
hurdles. Virus integration can affect the quality of iPSCs and may cause tumorigenicity
in the resulting iPSCs. Fortunately, recent alternatives for the delivery of reprogramming
factors, such as reprogramming mRNA [67], proteins [68], microRNAs [69], excisable
expression systems [70], and episomal plasmids [71], have provided alternatives by which
to resolve the problems associated with virus-mediated delivery systems.
6.4.3.2 Small Molecules that Affect iPSC Epigenomes
Despite these advances there is still a need for more efficient ways of reprogramming
iPSCs. Phenotypic screening of chemicals has been useful in identifying small molecules
that can functionally replace the transcription factors required for iPSC reprogramming
and enhance the efficiency of reprogramming. An inhibitor of histone methyl transferase,
BIX-01294, was found to significantly enhance the Oct4-Klf4 mediated reprogramming of
neural progenitor cells [72] and of mouse embryonic fibroblasts into iPSCs in two different
studies [73]. Valproic acid and Trichostatin A, which are inhibitors of another histone-
modifying enzyme, histone deacetylase, have also improved the reprogramming efficiency
[74,75]. Valproic acid in particular is widely used to enhance the reprogramming of human
fibroblasts [76] and mouse embryonic fibroblasts [68].
6.4.3.3 Small Molecules that Affect iPSC Signaling Pathways
During the reprogramming process, dramatic changes occur in gene expression and cell sig-
naling due to a fundamental process known as mesenchymal–epithelial transition (MET).
Small molecules specifically targeting this process have been very useful in reprogram-
ming. Blocking of TGFβ signaling by the TGFβ-receptor inhibitor SB431542 and of a
downstream target MEK by its inhibitor PD0325901 both enhance MET. Simultaneously,
these molecules significantly enhance reprogramming efficiency [77]. The Wnt signaling
pathway has been shown to enhance reprogramming by acting on T-cell factor-3 [78].
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A GSK3 inhibitor, CHIR99021, facilitated reprogramming of mouse embryonic fibroblasts
into iPSCs by activating Wnt signaling. CHIR99021 and the lysine-specific demethylase1
(LSD1) inhibitor Parnate enabled the reprogramming of human primary keratinocytes in the
presence of Oct4-Klf4 [79]. As a positive further step, Dr Zhu’s group developed a cocktail
of chemicals consisting of A-83-01 (an inhibitor of the TGFβ1 receptors ALK4, ALK5,
and ALK7), sodium butyrate (a histone deacetylase (HDAC) inhibitor), and PD0325901
and PS48 (3′-phosphoinositide-dependent kinase-1 activators) that facilitated the genera-
tion of human iPSCs from multiple human somatic cell lines [80]. However, in addition to
the cocktail, the exogenous expression of Oct4 was necessary. Another interesting factor
which contributes to reprogramming and has been targeted by small molecules is cellular
metabolism. PS48, as found in this chemical cocktail, enabled a metabolic switch from mito-
chondrial oxidative phosphorylation toward glycolysis during the reprogramming process
[80]. This switch in energy metabolism by pluripotent stem cells would favor pluripotency
by stimulating proliferation with reduced generation of reactive oxygen species.
6.4.4 Mesenchymal Stem Cells (MSCs)
6.4.4.1 Properties of MSCs
MSCs are multipotent stem cells that have the ability to self-renew and the potential to
differentiate into multiple lineages, including adipogenic, chondrogenic, and osteogenic.
MSCs were first identified by Dr Friedenstein as colony-forming-unit fibroblasts (CFU-Fs)
[81] isolated from the bone marrow. Other than bone marrow, MSCs can also be isolated
from adipose tissue [82], blood [83], dermis [84], and muscle [85]. MSCs possess plastic
adherent properties and are clonogenic. Initially, they were used as feeder monolayers for
the HSC culture. MSCs have been implicated in promoting regeneration and this is largely
attributed to their immune-modulating properties and their secretome [86]. MSCs home to
the injury site to aid in the tissue-repair process [87]. The use of MSC-based therapies is
receiving significant consideration because they are easy to isolate, can be readily expanded,
and are considered immunosuppressive due to the lack of Human Leukocyte Antigen (HLA)
class II antigens. Hence, MSCs have been used in various indications either alone or in
combination with genetic manipulation, biomaterial scaffolds [49], growth factors, or small
molecules [88].
6.4.4.2 Small Molecules that affect MSC Differentiation
Although MSCs have an inherent ability to differentiate into multiple lineages in vitro,
this differentiation is aided by specific factors [89]. A synthetic agonist, purmorphamine,
promotes osteogenic differentiation of MSCs by activating hedgehog or BMP signaling
[90, 91]. A PPAR-γ activating drug, rosiglitazone, induces the generation of adipocytes
from both MSCs and ESCs [92]. Since MSCs have multilineage differentiation potential,
they are a very strong candidate for cartilage repair; specifically, for the treatment of degen-
erative diseases such as osteoarthritis (OA). According to the Centers for Disease Control
and Prevention (CDC), there are currently around 27 million people suffering from OA in
the United States alone [93]. An MSC-like population has been identified living in adult
cartilage that has the potential to differentiate into chondrocytes and repair the damaged
cartilage [94]. The identification of small molecules capable of enhancing the regenerating
potential of these endogenous stem-cell populations for cartilage repair, when delivered
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locally, could be of tremendous help. Image-based screening of chemical libraries has iden-
tified a small molecule, kartogenin (KGN), that can enhance the formation of chondrogenic
nodules in primary human MSCs [95]. The mechanism of KGN induction of chondrogen-
esis has been suggested to lie in its regulation of the RUNX family of transcription factors,
which are key players in MSC-mediated chondrogenesis. Finding ways of controlling
MSC fate using small molecules will have a major impact in the area of tissue engineering
and regeneration. High-throughput screenings have been very useful in the identification
of more potent small-molecule candidates that can enhance the osteogenic capability of
MSCs [96, 97]. Work by Park et al. has identified that an amiloride derivative, phenamil,
stimulates osteoblast differentiation and mineralization in MSCs by acting on the BMP
signaling pathway [98]. Another small molecule, 5-aminoimidazole-4-carboxamide-1-ß-
riboside (AICAR), which activates AMP-activated protein kinase (AMPK), significantly
inhibits human and rabbit MSC proliferation and competently promotes the differentiation
of human and rabbit MSCs toward osteogenic lineage [99].
A major hurdle in MSC-mediated regenerative therapy is the poor survival of cells
after transplantation in vivo. A study performed by Chen et al. identified that cholesterol
myristate suppresses apoptosis of MSCs by activating inhibitor of differentiation (ID1),
a downstream target of BMP4 signaling [100]. Furthermore, our group identified that a
small-molecule Wnt-signaling inhibitor, Pyrvinium, enhanced MSC proliferation in vitro
and MSC engraftment in vivowhile suppressing the differentiation potential of MSCs [101].
These studies are promising and are of great help in developing strategies for exploiting
small molecules in the direction of enhancing and exploiting the function of MSCs for
regenerative purposes.
6.4.4.3 Biopolymers that affect MSC Biology
The generation of a scaffold with small-molecule chemical functional groups for MSC
delivery is emerging as a novel approach for MSC-based therapies. The functional 3D
culture environment can mimic the in vivo microenvironment of a stem cell niche. The
significance of using biopolymers (consisting of small molecules) for drug delivery has
already been discussed earlier in this chapter. In a pilot study by Radice et al., a hyaluronan-
based scaffold was identified as a safe and efficient vehicle for MSC delivery in articular
cartilage defects [102]. In another study, hydrogels were made with tethered functional small
molecules and human MSCs were encased and cultured in this scaffold [103]. Interestingly,
small chemicals attached to the hydrogel induced MSCs to differentiate into osteogenic and
adipogenic lineages. Although these studies are promising, much work is needed to develop
strategies that can identify more targeted and efficient small molecules by which to enhance
MSC-mediated regeneration. Utilizing simple chemistry to manipulate complex biological
phenomena is an exciting way of improving MSC function for therapeutic utilization.
6.4.5 Hematopoietic Stem Cells (HSCs)
HSCs are bone marrow-derived progenitor cells that can regenerate all the mature blood
cells and have been implicated in the regeneration of other tissues [104]. These cells can
also be isolated from the placenta. Because they are immunologically naı̈ve, they are great
options for allogeneic transplantation. However, only a small number of HSCs are present
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in the bone marrow and placenta. Therefore, strategies are being developed to improve their
isolation and expansion for bone-marrow transplantation and other purposes. For example,
HSC growth is very sensitive to extracellular copper concentrations and the copper chelator
tetraethylenepentamine increases HSC proliferation and enhances their engraftment in mice
[105]. Tetraethylenepentamine has been found to be safe in phase I/II clinical trial when
added to umbilical-cord blood (UCB) [106]. Chemical screening has identified a small
molecule, StemReginin 1, that increases HSC number and engraftment in mice by targeting
the aryl hydrocarbon receptor, the role of which is not very well understood [107]. UCB
is widely used as an alternative source of HSC transplantation for patients lacking proper
HLA-matched adult donors [104]. Although this is a valuable source of stem cells, the
relatively small number poses a significant problem of delayed engraftment. A number
of strategies have been developed to expand progenitors in UCB in order to reduce time
to engraftment. Specifically, Notch signaling and hematopoietic growth factors have been
implicated in enhancing the proliferation of HSCs [108]. A significant increase in human
and mouse HSC number was detected when Notch ligands, Delta, and Jagged treatments
were employed [109, 110]. The safety and efficacy of Notch ligands were determined by
their successful utilization in a phase I clinical trial for myeloablative UCB transplantation
[109]. In addition, prostaglandin E2 has also been implicated in HSC proliferation [111].
Live animal chemical screening identified compounds that activate prostaglandin E2 and
enhance HSC proliferation.
6.5 Conclusion
Regenerative biology has grown from its humble beginnings more than half a century ago
into a rapidly expanding, multidisciplinary field of research with immense clinical impact.
With the discovery of stem cells, and of their potential to accelerate tissue regeneration,
stem-cell therapy has become almost synonymous with regenerative medicine. Furthermore,
the integration of chemical biology, material science, and biomedical engineering with
stem-cell biology has pushed back the frontiers of the field. Novel small molecules that
allow the chemical modification of stem cells or modulate signaling pathways implicated in
tissue regeneration are increasingly being synthesized and used for regeneration. Moreover,
use of scaffolds, ECM-mimetics, nanoparticles, and the like is making delivery of the
aforementioned stem cells and small molecules increasingly effective. A summary of the
effects on wound repair and regeneration of biologics, small molecules, and biomaterials
both alone and in conjunction with stem cells is given in Figure 6.1.
Regenerative biology is leading all other fields of biomedical research in setting new
records for rapid translation into the clinic. Such rapid transition inevitably carries risks of
limited efficacy or limited safety; encouragingly, however, safety issues have been minimal
so far. In regards to efficacy, ongoing efforts to standardize and regulate the techniques used
for the isolation, expansion, and storage of stem cells, as well as more effective chemicals
and small molecules, are likely to considerably improve the outlook of this therapeutic
approach in the clinic.
Stem cells have the potential to heal injury when injected/transplanted alone in the wound
microenvironment. Biologics (proteins, proteoglycans, and other biological factors), small
molecules, and biomaterials (scaffolds, ECM-mimetics, and nanoparticles) can also aid the









Figure 6.1 Stem cells, biologics, and chemicals aid injury repair
wound-repair process by directly affecting the injured microenvironment or enhancing the
wound-healing capabilities of stem cells.
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7.1 Searching for the “Perfect” Platform
The concept of “stem cells” first emerged in the 1960s when transplanted mouse marrow-
derived cell colonies were shown to have the ability to differentiate into three hematologic
lineages: erythrocytes, granulocytes, and megakaryocytes [1]. After this, researchers began
searching for the progenitor cells responsible for generating all other cell types during
embryonic development. It was not until the early 1980s that mouse embryonic stem cells
(mESCs) were first successfully isolated and established as in vitro cultures [2, 3]. In the
past 3 decades, newer platforms, including human embryonic stem cells (hESCs) [4],
human induced pluripotent stem cells (hiPSCs) [5], and, most recently, chemically induced
pluripotent stem cells (CiPSCs) [6], have been developed as tools for disease modeling,
drug discovery, and regenerative medicine.
Each platform provided a promising glimpse of what the revolutionizing field of stem-
cell research had to offer in terms of therapeutics and translational medicine. However,
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they all share a common set of technical challenges: how to develop a renewable and
efficient source of pluripotent cells, maintain a stable population of pluripotent cells in the
undifferentiated state without accumulating genetic abnormalities, and guide differentiation
to yield a homogenous somatic cell population. In this chapter, we will focus on a discussion
of CiPSCs, the most recent technology (reported in July 2013), and their advantages,
disadvantages, and application in regenerative medicine [6].
7.2 Defining the Advantages of Small Molecules in Reprogramming
Pluripotent stem cells can be derived through either direct harvesting of embryonic stem
cells (ESCs) or, more recently, reprogramming of somatic cells. The latter was first achieved
by Yamanaka’s group using a cocktail of four transcription factors (Oct3/4, Sox2, Klf4,
and c-Myc) [5, 7], circumventing the ethical dilemma of destroying the fertilized embryos
associated with ESCs and providing an autologous source of stem cells less prone to
immune rejection after transplant. However, hiPSCs must still overcome several limitations,
such as low cellular reprogramming efficiency, incomplete reprogramming resulting in
heterogeneous population of cells, and risk of tumorigenesis [8]. In particular, c-Myc
and Klf4 are known tumorigenic proteins, whose interactions with p53 lead to genomic
instability. Within the last year, one study has reported successful reprogramming of murine
somatic cells into CiPSCs using only small molecules [6].
This replacement of transcription factors with small molecules offers several distinct
advantages during traditional reprogramming and differentiation methods (Table 7.1). First,
small molecules are much more cost-effective than biological reagents, and exhibit consis-
tent potency and stability [9]. Second, small molecules can act as reversible modulators,
allowing for temporal regulation with high precision [10]. Genetic approaches, by contrast,
involve permanent genome modifications with attendant problems of tumorigenicity and
other irreversible, unintended consequences. Temporal regulation is also an issue with bio-
logical reagents in regards to the duration of effects in in vivo models. Even newer reagents,
such as small interfering RNAs (siRNAs), typically function as genetic switches in an all-
or-none manner, leaving little room for procedural fine-tuning. The final and most crucial
point, which is especially germane to the reprogramming efforts, is that cell-permeable
small molecules have the potential to target every class of macromolecule in the cell. By
contrast, biological reagents are best suited to targeting extracellular components. While
Table 7.1 Comparison of available stem-cell technologies
Safe,
Established Established Autologous Easy to robust, and Disease Regenerative
mouse line human line cells obtain cost-effective modeling medicine
CiPSCs ✓ × ✓ ✓ ? ? ?
iPSCs ✓ ✓ ✓ ✓ ? ✓ ?
ESCs ✓ ✓ × × × ✓ ?
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extracellular signals invariably influence pluripotency, modulation of extracellular signals
alone is insufficient to regulate reprogramming events in the nucleus.
7.3 Understanding the Disadvantages of Using Small Molecules
One of the main drawbacks to using small molecules is that our current database of bioactive
compounds and their cellular effects is far from comprehensive. We do not have a com-
plete database of validated compounds that specifically target every cellular component
and pathway. Furthermore, because many small molecules are not truly specific and may
have multiple targets, it is more difficult to define a precise mechanism of action. Another
concern is that some of the chemicals used in the reprogramming process directly impact
the cells at the epigenetic level, leading to potential chemically induced mutations [11].
For instance, BayK (a specific L-type calcium channel agonist) in the presence of BIX (a
G9a methyltransferase inhibitor) successfully replaced Sox2 and c-Myc during reprogram-
ming of mouse embryonic fibroblasts, but BIX as a key regulator of DNA methylation
and transcriptional silencing may concomitantly reactivate undesirable oncogenic genes
(Table 7.2) [12].
7.4 Breakthrough: The CiPSC Paradigm
Yamanaka’s retroviral method remains the most efficient and the most widely used, with a
transduction reprogramming efficiency of 0.01% [7]. The use of small molecules has had
a tremendous impact in the stem-cell field for two particular reasons: (i) its mimicry of
biological reagents in reprogramming, maintaining pluripotency, and guiding differentiation
of cells; and (ii) its ability to significantly increase the efficiency of these processes without
compromising genomic integrity or intrinsic cellular properties. Over the past several years
there has been a progressive trend toward replacing Yamanaka’s transcription factors with a
defined small-molecule cocktail, alone or with biological reagents, to enhance the efficiency
and kinetics of reprogramming [6, 8, 12–18].
A combination of three small molecules – SB431542 (an ALK5 inhibitor), PD0325901
(a mitogen-activated protein kinase kinase (MEK) inhibitor), and thiazovivin (a Rho-
associated kinase inhibitor) – was reported to improve hiPSC reprogramming efficiency
by an astounding 200-fold while retaining hESC characteristics (Table 7.2) [8]. In another
study, valproic acid (VPA (a histone deacetylase (HDAC) inhibitor) was shown to improve
reprogramming efficiency by more than 100-fold (Table 7.2) [13]. Another study that used
PS48 (3′-phosphoinositide-dependent kinase-1 activator) alone enhanced reprogramming
efficiency by about 15-fold, and by over 25-fold when it was combined with sodium butyrate
(NaB, an HDAC inhibitor) (Table 7.2) [19]. It can be inferred from these results that certain
small molecules not only aid in the reprogramming process but may also be essential to it.
Identifying the optimal combination will be the ultimate goal.
In a recent, potentially revolutionary study, Hou et al. demonstrated that pluripotent
stem cells could be generated from several mouse somatic cells with a core combination
of four small molecules (FSK, CHIR99021, 616452, and DZNep) (Figure 7.1). The same
group had demonstrated previously that pluripotent stem-cell induction could be achieved
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Table 7.2 Small molecules shown to have enhanced reprogramming efficiency
Small-molecule compound Chemical structure Mechanism of action
BayK8644 [12] L-type calcium
channel agonist
BIX01294 [24] G9a methytransferase
inhibitor
SB431542 [8] TGFβ inhibitor
PD0325901 [8, 19] MEK inhibitor
Thiazovivin [8] ROCK inhibitor
PS48 [19] PDK1 activator
NaB [19] HDAC inhibitor
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Figure 7.1 Schematic timeline of the CiPSC reprogramming protocol [6]
with a combination of VPA, CHIR99021, 616452, and Tranylcypromine, in addition to an
exogenous Oct4 [20]. After screening ∼10 000 small molecules from multiple libraries, the
reprogramming efficiency of mouse embryonic fibroblasts (MEFs) to CiPSCs was increased
to 0.2%, comparable to transcription factor-induced reprogramming, using a combination
of seven small molecules (VPA, CHIR99021, 616452, Tranylcypromine, FSK, TTNPB, and
DZNep) (Table 7.3) [6]. Using this combination, they were able to successfully generate
CiPSC lines from mouse neonatal fibroblasts, mouse adult fibroblasts, adipose-derived stem
cells, and MEFs.
When characterized, these CiPSCs shared many similarities with ESCs in terms of their
gene-expression profile (pluripotency markers detected by immunofluorescence and RT-
PCR), epigenetic status, and capacity to differentiate into tissues associated with all three
germ layers (endoderm, mesoderm, and ectoderm). CiPSC colonies were first isolated
44 days after induction. They maintained normal karyotype and genetic integrity for up to
13 passages [6]. Chimeric immune-deficient (severe combined immunodeficiency, SCID)
mice injected with CiPSCs were 100% viable and healthy for up to 6 months, with no signs
of teratogenicity.
A key finding of Hou’s study was the elucidation of the role of DZNep, which is a
known S-adenosyl-L-homocysteine (SAH) hydrolase inhibitor that functions to modulate
the expression of Oct4, a master switch governing pluripotency, at the epigenetic level
[6]. It is notable that small molecules proved to be crucial for tight temporal control of
the epigenetic modifications necessary for cellular reprogramming, an effort analogous
to reverse engineering the epigenetic modifications associated with cell differentiation
during embryogenesis. For instance, VPA and Tranylcypromine are two small molecules
used to modify the epigenome during the initial stage of reprogramming, but by different
mechanism (Figure 7.1). VPA, an HDAC inhibitor, effectively replaces the transcription
factor c-Myc, whereas tranylcypromine, a H3K4 demethylation inhibitor, replaces the
transcription factor Sox2 in conjunction with CHIR99021, a glycogen synthase kinase
3 (GSK3) inhibitor [13, 17]. Then, after 16 days, DZNep, another histone methylation
inhibitor, is administered to decrease chromatin methylation (Figure 7.1) [21]. DZNep
specifically reduces histone H3 lysine 9 (H3K9) methylation in the promoter region of
the Oct4 gene, which activates it [22]. By inducing endogenous Oct4 expression, DZNep
effectively overcomes the final epigenetic obstacle to cellular reprogramming. Thus, a
timely addition of selective small-molecule epigenetic modifiers is central to establishing
pluripotency without the need for exogenous transcription factors.
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Table 7.3 Small molecules used by Hou et al. [6] to replace all four of Yamanaka’s
transcription factors
Small-molecule compound Chemical structure Mechanism of action
VPA [13] HDAC inhibitor
CHIR99021 [17, 25, 26] GSK3 inhibitor
616452 [6] TGFβ inhibitor
Tranylcypromine [6] LSD1 inhibitor/H3K4
demethylation
inhibitor
FSK [6] cAMP agonist
DZNep [6] SAH hydrolase
inhibitor
TTNPB [6] RAR agonist
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A crucial issue is whether the chemicals alone can be used to generate human CiPSCs.
To date, no such publication has been reported, and replicating the success observed in
the mouse model may not be straightforward. For instance, an important point of diver-
gence is the difference in pluripotency and epigenetic states between mouse and human stem
cells [4,9]. A chemical approach incorporating the latest concepts in the difference between
“naı̈ve” pluripotent stem cells, presumably representing mESCs, and “primed” pluripotent
stem cells could lead to the highly anticipated breakthrough of being able to make human
CiPSCs efficiently and inexpensively. While both murine and human models can be utilized
for the study of the molecular pathogenesis of diseases, establishing the latter will be imper-
ative to advancing in the expanding field of “human biology”, including the development
of iPSC models of human diseases. Of course, an efficient and cost-effective approach to
deriving human CiPSCs will be invaluable to advancing the regenerative medicine field,
providing a renewable source of autologous stem cells.
7.5 Conclusion
While “regenerative medicine” is now a topic of constant media exposure and common
clinical jargon, the term did not exist until 1992, when it was introduced as follows: “a
new branch of medicine will develop that attempts to change the course of chronic disease
and in many instances will regenerate tired and failing organ systems” [23]. The cost-
effectiveness and scalability of small molecules are appealing attributes in regenerative
medicine, because they may solve the practical financial burden involved in generating
adequate quantities of tissue for autologous transplantation. Small molecules also pave the
way for in situ reprogramming and differentiation, since they are much less immunogenic
than biological reagents and can be quickly discontinued after therapeutic application.
Nonetheless, the use of small molecules to generate mouse CiPSCs is only the first step
in decreasing the reliance on biological reagents, despite being hailed as a potential “holy
grail of regenerative medicine” by some stem-cell experts and enthusiasts. Future studies
are required to determine whether this approach is feasible in human cells and, if so, to
define the optimal combinations of small molecules for efficient reprogramming of human
cells and for directed differentiation of human CiPSCs into desired tissue types.
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Since the pioneering studies on nuclear transplantation by John Gurdon [1] and the identi-
fication of bone-marrow stem cells by James Till and Ernest McCulloch [2], the last 50+
years have seen remarkable progress in stem-cell science (Figure 8.1). Adult stem cells
have been isolated and cultured from numerous tissues and pluripotent stem cells from
early embryos (embryonic stem cells, ESCs) have been successfully isolated, cultured, and
differentiated into many different cell types. These breakthroughs have allowed researchers
to delve into the molecular mechanisms and pathways unique to stem cells that control
their ability to develop into numerous cell types. Such fundamental studies have resulted
in the current wave of technical innovations that has allowed scientists to “reprogram”
adult somatic cells to a state of pluripotency similar to ESCs (induced pluripotent stem
cells, iPSCs) [3] or to convert cells from one type to another (direct lineage conversion or
transdifferentiation) [4]. These reprogramming technologies are transforming biomedical
science, from providing tools for the study of development and disease, to enabling the
creation of patient-specific cells for the treatment of a broad range of conditions.
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Figure 8.1 Stem cell research timeline
8.1 Defining Cell Potency
As an organism develops, stem cells gradually lose their differentiation capacity. The
fertilized egg (zygote) and the blastomeres of the four cell-stage morula are totipotent:
capable of developing into any embryonic or extraembryonic cell type [5]. Cells making
up the blastocyst inner cell mass (ICM) are pluripotent, with the ability to differentiate into
any of over 200 cell types found in the mature organism. Beyond this stage, fetal and adult
stem cells become more lineage-restricted (multipotent) in their differentiation capacity.
The final stem-cell stage is the development of precursor cells, which can change into a
very limited set of related terminally differentiated somatic cell types.
In addition to their capacity for differentiation, pluripotent cells are capable of unlimited
growth. These characteristics allow pluripotent cells to be expanded indefinitely and differ-
entiated to create large quantities of any cell type. This capability makes pluripotent cells
an enormously important tool. Cells can be followed through the differentiation process,
allowing researchers to investigate development, in both normal and disease states, in new
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ways. Additionally, the creation of large quantities of specific cell types has applications
ranging from drug and toxicity screening to cellular therapy and tissue engineering.
8.2 Types of Pluripotent Cell
8.2.1 Isolated Cell Types
8.2.1.1 Embryonal Carcinoma Cells
Embryonal carcinoma (EC) cells are derived from teratocarcinomas or malignant germ-cell
tumors. These tumors possess a mixture of cell types representing all three germ layers
as well as malignant undifferentiated EC cells. EC cells extracted from these tumors have
been shown to have the capacity to self-renew and differentiate into multiple cell lineages,
establishing the concept of the pluripotent cell [6]. EC cell lines were subsequently derived
from mouse [7] and human [8]. Although considered pluripotent, EC cells are malignant in
the undifferentiated state, are often karyotypically abnormal [9], and have a limited capacity
to differentiate [10]. Nonetheless, study of the characteristics of EC cells, how they are
cultured, how mouse and human EC cells differ, and how they differentiate has laid the
foundation for subsequent advances in stem-cell and developmental biology.
8.2.1.2 Embryonic Stem Cells
ESCs are derived by the isolation of cells from the ICM of a blastocyst-stage embryo
and adapting them to in vitro growth. ESCs from mouse embryos were first successfully
isolated and cultured in 1981 [11,12]. These mouse ESCs were shown to have the capacity
to differentiate into the three germ lineages in vitro by embryoid body formation and to
form teratomas when injected into mice. More importantly, pluripotency of these cells was
established by their ability to form germ-line chimeras when reintroduced into a mouse
blastocyst embryo [13]. The most definitive demonstration of pluripotency was done by
injection of mouse ESCs into tetraploid (4N) blastocysts, which are incapable of normal
development. This system allows the generation of mice derived completely from the
injected ESCs [14, 15].
It was not until 1998 that human embryonic stem cells (hESCs) were successfully derived
[16]. Although hESCs are similar to mouse embryonic stem cells (mESCs) in many respects,
they differ in colony morphology and growth conditions. hESCs differentiate into three germ
layers through embryoid body formation [17] and in teratomas [16], but ethical constraints
make chimera and tetraploid complementation studies impossible. As discussed later, the
true state of pluripotency in hESCs has been the subject of considerable study.
8.2.1.3 Embryonic Germ Cells
Embryonic germ cells (EGCs) are derived from the primordial germ cells (PGCs) found
in fetal gonads. PGCs are unipotent, in that they are progenitors of sperm and egg cells
via meiosis. These cells cannot self-renew or survive in culture under standard conditions.
However, under specific growth conditions mouse [18, 19] and human [20, 21] EGCs
have been derived from these primordial cells. Unlike PGCs, EGCs are capable of self-
renewal and of forming cell types representing the three germ layers. However, EGCs are
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difficult to maintain in an undifferentiated state in culture and spontaneously form embryoid
bodies. Unlike other pluripotent cells, they cannot form teratomas in nude mice and have
a gene-expression signature that is distinct from other pluripotent cell types [22]. EGCs
are morphologically similar to mESCs and express the stem-cell marker SSEA-1, which is
expressed in mESCs but not hESCs. Thus, it has been suggested that EGCs may exist in
some unique or intermediate state of pluripotency.
8.2.2 Reprogrammed Cell Types
8.2.2.1 Cell-Fusion Hybrids
The plasticity of differentiated cells is evident from cell-fusion studies [23]. In 1974, it
was shown that fusion of embryonic carcinoma cells and thymocytes resulted in hybrid
cells in which the pluripotent phenotype was maintained [24]. Similarly, hESCs have been
fused with human fibroblasts to derive stable tetraploid hybrids that retain the pluripotent
characteristics of the ESCs [25]. Cell-fusion hybrids are used primarily to investigate the
mechanisms of reprogramming and pluripotency.
8.2.2.2 Somatic Cell Nuclear Transfer Cells
Somatic cell nuclear transfer (SCNT) involves the transfer of a somatic cell nucleus into
an unfertilized oocyte. First demonstrated as a method for cloning animals [26], this
technique also offered the prospect of deriving patient-specific pluripotent cells by isolating
them from the embryo developed from the hybrid SCNT egg. Despite this prospect, fears
surrounding reproductive cloning and the legal and social issues around egg donation have
slowed progress in this area. Nonetheless, the reprogramming of human somatic cells to
pluripotency by nuclear transfer into an oocyte was recently reported, demonstrating that
this technique can be used to produce human pluripotent cells [27].
8.2.2.3 Induced Pluripotent Stem Cells
Groundbreaking work first done in mice by Takahashi and Yamanaka [28] established that
differentiated fibroblast cells taken from an adult mouse could be reverted to a pluripotent-
like state by introduction of specific transcription factors. In this remarkable study, by
homologous recombination β-galactosidase and neomycin resistance genes were incorpo-
rated into the Fbx16 gene, which is a nonessential gene expressed in pluripotent stem cells.
Using retroviruses, the authors introduced and expressed various combinations of a set of
24 candidate genes identified based on their roles in the maintenance of ESC pluripotency.
The result of this inquiry showed that the introduction of four specific transgenes, Oct4,
Sox2, Klf4, and c-Myc, could induce fibroblasts to convert to a state similar to ESCs.
This result was closely followed by the derivation of human induced pluripotent stem
cells (hiPSCs) [29, 30]. Since this landmark study, the methods used to reprogram cells
have expanded greatly, to include different viruses, episomal delivery, plasmids, proteins,
mRNA, miRNAs, and small molecules, as described later.
An Introduction to Cellular Reprogramming 107
8.3 Defining Pluripotency
Pluripotency is a complex, dynamic state that has proven difficult to precisely define and
measure [31]. Pluripotent cells follow a program of self-renewal while primed to begin a
differentiation program in response to specific developmental signals. As such, this state
is fairly unstable and there is significant variability in differentiation potential between
different pluripotent cell lines [32–34]. Furthermore, it has been found that the pluripotent
states of individual ESCs within a culture can vary [35, 36]. It has been suggested that
such variation in pluripotent states could be an integral mechanism of ESCs, where self-
renewal is maintained within the colony or embryo while opportunities for differentiation
are explored [37].
Recent studies have uncovered that there are at least two distinct states of pluripotency:
the naı̈ve and the primed states, which differ in their epigenetic status and differentiation
capacity [38]. Although hESC and mESC are both derived from pre-implantation blas-
tocysts, differences between the two cells in culture are evident. mESCs grow in tightly
packed, three-dimensional colonies and have a relatively short doubling time (16 hours);
hESCs grow in flatter colonies and their doubling time is more than twice as long (36
hours), and they are maintained with different growth-factor signaling conditions. Further-
more, while mESCs can be passaged as single cells, hESCs must be passaged as clumps,
making procedures that require clonal selection, such as genetic modification, much more
difficult. Finally, while female hESCs exhibit inactivation of one X chromosome, in mESCs
both X chromosomes are active. This indicates that mESCs may be at a different epigenetic
stage than hESCs.
Other studies have isolated mouse epiblast stem cells (epiSCs) from post-implantation
embryos that have characteristics much more similar to hESCs than to mESCs [39, 40].
The gold-standard in vivo functional assay for pluripotency is the development of chimeras
by reintroduction of ESCs into an embryo where the ESCs contribute to all cell types in
the resulting organism. Interestingly, while mESCs pass this functional test, epiSCs and
nonhuman primate ESCs [41] have limited capacity for chimera formation. Thus, although
all of these cell types exhibit pluripotency in vitro, it has been suggested that mESCs exist
in a more potent “naı̈ve” state, while epiSCs and hESCs are in a more “primed” pluripotent
state [38, 42]. More recent studies suggest that pluripotency is a metastable state which
can be determined by culture and derivation conditions [43, 44] and that hESCs can be
derived in conditions [45] or exposed to culture conditions post-derivation [46] that allow
them to exhibit functional and molecular characteristics similar to those of mESCs. These
differences in pluripotent state are important in that they may influence the differentiation
capacity and susceptibility to genetic modification of an ESC or iPSC line.
Demonstration of the pluripotency of ESC lines when they are derived and during con-
tinued expansion of the cultures is necessary to ensure that they retain the capacity for
differentiation while spontaneous differentiation is inhibited. Determination of pluripo-
tency in iPSCs is especially important as variability in methodologies, reagents, starting
materials, and environmental conditions can lead to the development of lines that are not
fully reprogrammed [28, 47].
There are a number of methods that are used to determine pluripotency in a cell line
(Table 8.1). Molecular methods can be used to detect expression of genes known to be
expressed in pluripotent cells or to define methylation patterns specific to pluripotent cells.
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Whole-genome expression Microarray hybridization
Epigenetic analysis Determination of the degree of
methylation of ESC-specific
gene promoters
In vitro Embryoid body formation Spontaneous differentiation of
cell clumps followed by
detection of lineage-specific
markers by ICC or qRTPCR.
Directed differentiation Differentiation of cultures toward
specific cell types
In vivo Teratoma formation Spontaneous differentiation of
cells injected into specific sites
in mice
Chimera production Introduction of cells into a mouse
blastocyst and detection of
differentiated progeny of the




Introduction of cells into a mouse
4N (tetraploid) blastocyst.
Mature mouse will develop
entirely from introduced cells
Other techniques demonstrate the cells’ capacity to differentiate into specific cell types
in vitro or in vivo. While the production of viable adult organisms by the introduction
of pluripotent cells into an embryo for chimera formation [48] or by tetraploid (4N)
complementation [14, 15] may be the most definitive test of pluripotency, this method is
clearly not ethical for studies of human pluripotent cells.
8.4 The Molecular Basis of Pluripotency
The pluripotent state/s is/are reliant upon a number of interconnected processes, including
the cellular environment, growth-factor signaling, transcription-factor networks, noncoding
RNAs, and epigenetic modifications [49, 50]. Current models propose that pluripotency is
primarily controlled by the core transcription factors Oct4, Sox2, and Nanog [51]. Oct4
is considered the master regulator of the development and maintenance of pluripotent
cells, as Oct4-deficient mouse embryos fail to produce an ICM [52] and suppression of
Oct4 in ESCs leads to differentiation along a trophectodermal lineage [53]. Oct4 often
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Figure 8.2 The pluripotency network
forms a heterodimer with Sox2 to bind to the regulatory elements of many different target
genes in ESCs [54, 55] and promotes an undifferentiated state in ESCs [56, 57]. Nanog,
Oct4, and Sox2 are reported to co-occupy many target genes in hESCs and function in an
interconnected autoregulatory loop to regulate their own expression (Figure 8.2) [51, 53].
These factors also interact with an extended network of other transcription factors to create
a regulatory web that promotes pluripotency [58, 59].
Interestingly, while these factors bind regulatory sequences to promote transcription,
each may also be involved in lineage specification and the repression of lineage-specific
genes in ESCs [49, 60]. Overexpression of each of these factors drives differentiation into
specific lineages, while knockdown of each factor blocks the same lineage differentiation.
While all three factors often co-occupy the regulatory elements of active genes in ESCs,
individual factors are frequently bound to repressed loci. Furthermore, active genes are
most often bound by multiple factors, while repressed genes are often associated with
a single transcription factor [58, 59]. Core transcription factors have been found to co-
occupy repressed loci encoding important developmental regulators with the polycomb
repressive complex 2 (PRC2) [61, 62]. PRC2 catalyzes the trimethylation of histone H3 at
lysine 27 (H3K27me3) to promote gene silencing [63]. Many of these developmental genes
exist within “bivalent domains” in the genome, where genes possess histone modifications
that promote gene silencing (HK27me3), but reside within larger domains that have histone
modifications of active chromatin (H3K4me3) [64]. Such bivalent modifications are thought
to allow the important developmental regulators to exist in a “primed” state in ESCs, where
RNA polymerase II is loaded on to the promoter but is held in check by the repressive
chromatin [65, 66]. In this state, transcription of lineage-specific regulatory genes can be
rapidly activated in response to specific developmental cues.
Another component of the pluripotency control circuitry involves noncoding RNAs.
MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by binding
to target mRNAs and facilitating their degradation. Numerous miRNAs have been identified
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as being expressed in ESCs, and the expression some of these appears to be regulated by
binding of the core transcription factors to their gene promoters [67]. Lineage-specific
miRNA genes are also bound by the core factors, but are not expressed due to the presence
of polycomb repressor complexes such as PRC2, as observed for lineage-specific, protein-
coding genes. In turn, several lineage-specific miRNAs can downregulate expression of
the core transcription factors [68], as well as components of polycomb group complexes
(Figure 8.2) [62].
The functions of large intergenic noncoding RNAs (lincRNAs) are not well understood,
but these evolutionarily conserved RNAs interact with chromatin-modifying complexes
and influence gene expression [69]. It has been suggested that the lincRNAs could func-
tion as flexible scaffolds, bringing together different protein complexes to regulate gene
expression. Numerous ESC-specific lincRNAs have been identified whose expression is
regulated by core pluripotency factors [70]. Many of these lincRNAs appear to help main-
tain the pluripotent state and repress expression of lineage-specific gene expression. Lin-
cRNAs may facilitate this repression by binding to chromatin-modifying complexes such
as PRC2.
8.5 Cellular Reprogramming: Altering the Epigenetic State
The variety of cell types in the adult are created via differentiation. Differentiation is
a highly complex and regulated process controlled by transcription-factor networks and
epigenetic modification of the genome. Epigenetic modifications to chromatin are carried
out by a number of different mechanisms, including DNA methylation, post-translational
modification of histones, incorporation of histone variants, noncoding RNAs, RNA interfer-
ence (RNAi, and ATP-dependent chromatin remodeling [71]. ESCs typically have an open
euchromatic chromatin state with little inactive heterochromatin. As these cells undergo
differentiation, the epigenetic “landscape” of the chromatin is modified [72]. Such mod-
ifications occur in very specific patterns throughout the genome, resulting in regions of
DNA that are expressed or repressed, and are unique to a particular cell type. Epigenetic
modifications are inherited by successive generations of the cells, ensuring that the cellular
specialization is maintained.
Chromatin remodeling, particularly in the bivalent domains corresponding to important
transcription-factor genes, is an essential temporal regulatory switch in the reprogramming
process [47, 64, 73–77]. The work of Yamanaka’s group highlighted an underappreciated
aspect of genomics and epigenetic control: the extraordinary plasticity of the mammalian
genome to reshape itself as part of the reprogramming process. A vital component in the
reprogramming timeline is the resetting of the epigenetic landscape. Stochastic remodel-
ing events occur as a result of transcription-factor overexpression leading to endogenous
expression of stem-cell factors required for stable cell-line progression [77, 78]. Immedi-
ately upon forced expression of the transfected reprogramming factors, some proportion
of cells starts to divide more quickly and continues down a path of directed somatic gene
expression downregulation. However, only a subset of cells continue to upregulate the
pluripotent expression profile, and this extended expression is essential in the development
of a fully reprogrammed cell line [79, 80]. Finally, continuous endogenous pluripotency
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gene expression establishes a stable ESC-like genomic profile that allows for a sustained
functional stem-cell phenotype. This stepwise and multistage process involves so many
interconnected pathways and mechanisms that it is not surprising that the path to induced
pluripotency is an inefficient one. While several reports have indicated that in most respects
human iPSCs and ESCs are globally quite similar, the true depth of the similarity is still
being debated at the molecular level. It appears that as analyses become more sophisticated
and the detail becomes more refined, the general similarities between ESCs and iPSCs
are considerably eroded [3, 76, 81–83]. As with many experimental systems, much of the
variability may be generated from differences between investigators relating to cell-culture
methods, starting cell populations, reprogramming methods, and screening or characteri-
zation techniques. Being different is not necessarily bad, but it does speak to the need for
standards and controls by which both research and therapeutic cell lines can be measured
before meaningful comparisons can be made.
Stem cells, particularly iPSCs, are widely lauded as powerful tools in the fields of regen-
erative medicine and the study of developmental biology and disease. However, reprogram-
ming of the epigenome is an inexact process and incomplete reprogramming can result in
some of the identity or “epigenetic memory” of the source cell being retained during iPSC
derivation [84–86]. This memory effect can influence the differentiation capacity of an
iPSC line. However, it has been shown that epigenetic memory can be partially erased
via extended culture and that DNA methylation inhibitors can significantly influence the
differentiation paths of iPSC lines [82, 85, 87]. Whether epigenetic memory is perceived
as a liability or an asset likely depends on the intended use of the reprogrammed cell
product. Screening for epigenetic memory through whole-genome sequencing may allow
for targeted application of specific cell lines for drug screens or in those cell therapies
most suited to the differentiative predisposition of the cell line. On the other hand, one
might envision the most completely reprogrammed cell lines being reserved for devel-
opmental biology investigations requiring unhindered plasticity. In either case, epigenetic
memory might be viewed as an advantageous attribute when developing future tools or
therapies.
8.6 Cellular Reprogramming: Primary Regulatory Pathways
The advent of cellular reprogramming has demonstrably changed the landscape of stem-
cell biology, disease modeling, and potentially even cellular therapies and personalized
medicine. Simply stated, cellular reprogramming is the forced expression of several
pathway-specific transcription factors in an adult somatic cell such that the cellular machin-
ery and epigenetic profile revert to a more primitive stem-cell state. The landmark publi-
cation in 2006 of the work of Takahashi and Yamanaka found that the genes they screened
(Oct3/4, Sox2, Klf4, and c-Myc) could be combined through retroviral transduction achiev-
ing prolonged factor expression in order to produce ESC-like cell lines from mouse somatic
cells [28]. Although the delivery of the original four transcription factors through viral trans-
duction remains the most commonly used method to date, work continues to improve the
efficiency and ultimate safety of the reprogramming process with an eye toward therapeu-
tics. A portion of this section will be devoted to the creative alternatives being explored to
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achieve this goal. However, our current review will be limited to the four major pathways
represented by the original combination of factors.
The four main established transcription factors, Oct4, Sox2, Klf4, and c-Myc (OSKM),
represent an interconnected reprogramming cocktail that, when expressed transiently, estab-
lishes an embryonic-like environment in the target cell. Once expressed, these factors acti-
vate the cell’s own endogenous pluripotency pathways, driving the cell toward a stable
pluripotent phenotype. Oct4 (Pou5f1), previously mentioned as the “master regulator”, is
well known as a transcription factor required for early embryonic development and for
the maintenance of pluripotency in ESCs. In experiments limiting the number of factors
used to generate iPSC lines, Oct4 was found to be essential to the occurrence of complete
reprogramming [88–90].
Sox2, a transcription factor in the SRY-related HMG-box family, is directly involved in the
determination of defined lineage development and the maintenance of the undifferentiated
state for embryonic and neural stem cells (NSCs). Oct4 and Sox2 can work cooperatively
using Sox-Oct motifs that are frequently found within the regulatory sequences of other
important pluripotency genes [54]. The expression of many pluripotency-associated genes,
including Lefty1 and Nanog, is regulated by enhancers containing Oct3/4 and Sox2 binding
motifs, which highlights the dominant regulatory role Oct4 and Sox2 have in maintaining
pluripotency [91,92]. Additionally, Sox2 and Oct4 have been reported to bind to a complex
of DNA repair proteins, facilitating the transactivation of Nanog [93]. It has been shown
in mouse fibroblasts that Sox1 and Sox3 can replace Sox2, although this adversely affects
reprogramming efficiency.
Kruppel-like factor 4 (Klf4) is required to establish asymmetrical embryo development,
as well as a myriad of roles from gut epithelial polarization to tumorigenesis, immune
regulation, and iPSC derivation [94–100]. Interestingly, based on studies by Nakagawa
and colleagues in murine cells, Klf2 can substitute for Klf4 in reprogramming-factor
combinations. Similarly, Klf1 and Klf5 can also substitute for Klf4, but with significantly
lower reprogramming efficiency [88]. DNA-binding studies have revealed several shared
targets for Oct4, Sox2, and Klf4 related to the control of pluripotency, including Klf4 and
Oct4 co-occupying the Nanog promoter, and in the absence of ecoptopic Klf4 expression,
endogenous Klf4 expression is required for the reprogramming of somatic cells [101]. This
provides further evidence of the connected functional overlap between Sox2 and Klf4 in
the disruption of cellular homeostasis and activation of regulatory networks that define
pluripotency.
The oncogene c-Myc, originally recognized for its role in Burkitt’s lymphoma through
chromosomal translocation, was also identified as a key regulator in the reprogramming
platform enabling iPSC derivations. c-Myc is a key regulator of both cell growth and
metabolism, playing a role in both transformation and cell-cycle entry [102, 103]. Addi-
tionally, c-Myc participates in the maintenance of ESC pluripotency via the Lif-Stat3
pathway and can induce global histone acetylation, allowing Oct4 and Sox2 to bind to their
specific target loci [104, 105]. Alternatively, it has been suggested that c-Myc amplifica-
tion of existing gene profiles due to increased c-Myc abundance and favorable epigenetic
access allows for the vast array of oncogenic effects seen when c-Myc is overexpressed,
as is the case under many reprogramming methods [106]. Also, the specific substitution of
c-Myc has been used in the successful reprogramming of human cells by replacement of
c-Myc with L-Myc or N-Myc [88]. While it is widely considered that Myc, in any form, is
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important for efficient reprogramming, it has been shown that it is not required for repro-
gramming of mouse and human fibroblasts [30, 88, 107]. However, subsequent studies have
shown that adding back c-Myc significantly augments reprogramming efficiency [108].
Numerous studies continue to explore new twists to the original four-factor combination.
For instance, reprogramming has been demonstrated using only Oct4 and Sox2 [109].
Furthermore, Scholer and his colleagues [110] have demonstrated that Oct4 alone was able
to convert human NSCs into iPSCs. This strongly suggests a role for the differentiative state
of the reprogramming target cell type in the overall ease and efficiency with which a somatic
cell converts to an iPSC. Another recent discovery has shown that although Oct4 is essential,
it can be replaced with a nuclear receptor gene, Nr5a2, in the derivation of iPSCs from
mouse somatic cells [111]. In addition, including the retinoic acid receptor (RARγ) and
Nr5a2 with the four factors has been shown to greatly increase reprogramming efficiency in
both mouse and human cells [112]. While these and other studies show several compelling
factor combinations or reductions can be employed in the reprogramming, the primary
set of factors still remains the minimally sufficient combination for efficient complete
reprogramming, whether that occurs as a result of the expression of the transcription
factors alone or in combination with compounds that substitute for one or more of them.
Of course, the process remains influenced by the endogenous expression of the core factors
or related pathways, as well as the characteristics of the target cell, such as proliferation
rate [113].
8.6.1 Temporal and Stoichiometric Considerations
The stoichiometry and timing of transcription-factor expression significantly influence the
properties of the reprogrammed cells [114] and numerous studies have investigated the
temporal and stoichiometric parameters related to one or more of the original reprogram-
ming factors, as well as the potential replacement of certain factors with proteins or small
molecules [100]. More recently, studies employing a tagging system using monoclonal anti-
bodies that could be used to analyze the expression levels of the four reprogramming factors
in sorted iPSCs found that the most effective ratio (Oct3/4-↑, Sox2-↓, Klf4-↑, c-Myc-↑)
was almost 100× more efficient at producing iPSCs than the least optimal ratio (Oct3/4-↓,
Sox2-↑, Klf4-↓, c-Myc-↓) [115]. In addition, Tiemann et al. [116] tested 16 different stoi-
chiometric ratios of the four factors and found that only seven combinations were successful
in generating any reprogrammed colonies, suggesting that appropriate sustained levels of
reprogramming factor expression are required to fully reprogram. Similarly, the length of
reprogramming-factor expression is equally important. It has been shown that sustained
expression for 12–16 days is needed for complete reprogramming of mouse fibroblasts to
pluripotency [117]. This type of information may allow viral, episomal, and protein-based
systems to be tailored to the reprogramming cell source type or for the addition of small
molecules in order to increase the efficiency of one or more factors and thus achieve the
optimal ratio.
8.6.2 Target Cell Type
Based on the transexpression of the prototypical reprogramming factors (OKSM), the
importance of the type and origin of the cell to be reprogrammed cannot be overlooked.
As with many scientific methods, there is a balance to be struck between ease of material
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procurement, target-cell reprogramming efficiency in relation to reprogramming method,
species, and intended outcome or use of the reprogrammed cell line. Keratinocytes and
peripheral blood cell types, such as T cells, are readily available and reasonably receptive
to reprogramming irrespective of reprogramming method. Fibroblasts are equally easy to
acquire, yet are as much as 100× less efficient in yielding iPSC lines than keratinocytes
using a viral OKSM methodology [118]. The availability of cord blood as a reprogramming
source material has the added advantage of potentially only requiring Oct4 and Sox2 to
reprogram to iPSC, due in part to the relatively high proportion of proliferative progenitor
phenotypes found in cord blood [119]. For some disease-specific iPSC derivation strategies,
blood samples may be the most readily available source material. However, numerous
biobanks are beginning to archive and make available samples from well-characterized
familial disease trees based on skin fibroblast lines in order to aid investigators. It is still
not entirely clear whether a strict hierarchy can be assigned to any given cell type or
reprogramming method with respect to overall efficiency. Alternatively, it may be more
helpful to categorize such potential hierarchies in the context of the methods and cell
sources available, as well as the intended use of the derived reprogramming products. The
potential use as a therapeutic will require significantly different methods than iPSC lines
derived for research use, so some situational flexibility will play a role in the final choice
of cell sourcing and reprogramming method. Balancing the availability of the cell source
with the potential efficiency of reprogramming is not insignificant. Generally speaking,
highly specialized terminally differentiated cell types like T lymphocytes and fibroblasts
are easy to obtain yet harder to reprogram, while cord blood cells and germline cells are
the reverse. While these gross generalizations may be true on the surface, new refinements
and à-la-carte strategies for reprogramming may change these beliefs to some extent.
8.7 Reprogramming Methods
Early methods have utilized viral vectors which integrate into the genome to boost the
efficiency of reprogramming to pluripotency. However, the potential for insertional muta-
genesis and aberrant expression of reprogramming genes embedded in the genome impedes
the path of reprogrammed cells to the clinic. So, recent efforts have turned to the devel-
opment of nonintegrative reprogramming methods, including nonviral episomal plasmid
systems, non-DNA methods, and nonintegrative viral systems with or without reprogram-
ming enhancers [120–124].
8.7.1 Viral-Driven
The convenience and effectiveness of viral-based reprogramming methods makes them a
valuable methodology for preparing iPSCs from numerous cell types from a number of
species. While the lack of a “footprint”-free resultant cell line is currently problematic for
downstream translational applications of these cells, the method itself, especially with the
later iterations that are now widely used, make viral delivery of reprogramming factors
for research-directed cell lines a viable and successful approach. Having said that, new
nonintegrative viral systems such as adeno-associated virus- or sendai virus-based delivery
systems are becoming more popular and replacing the traditional retroviral and lentiviral
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gene-delivery systems. However, the choice of delivery system is primarily dependent
upon the target cell type and species, as well as the intended use of the reprogrammed
products. The original retroviral-based reprogramming studies showed both success and
ample room for improvement [29]. This work has been confirmed and extended by other
groups, which showed that stable genomic integration and high expression of four factors
– Oct4/Sox2/Klf4/c-Myc or Oct4/Sox2/Nanog/Lin28 – can reprogram fibroblast cells, B
cells, and liver and stomach epithelial cells into iPSCs [30, 125]. The main drawback
to the integrative viral methods is the unpredictable and variable nature of the genomic
integration of the reprogramming genes, especially when one or more of these factors are
known oncogenes. Several genetic-engineering advances have sought to minimize these
unforeseen effects through polycistronic single-vector delivery systems and the use of
Cre-loxP-expression systems [126, 127]. While these systems allow for more controlled
integration and virtually complete excision of the reprogramming factors, respectively,
neither completely resolves the potential for unforeseen insertional or mutational affects to
the host genome.
Using nonintegrating adenovirus or sendai virus delivery systems, successful four-factor
reprogramming has been performed on human and mouse cells with a variety of cell types
[121, 122]. These transient expression systems utilize host machinery, both cytoplasmic
and nuclear, without integrating into the host genome and, like episomal transfection-based
methods, the absence of specific vector sequences can be verified in fully reprogrammed cell
lines through standard PCR methods. This is becoming an increasingly sought after quality
with respect to the iPSC derivation process as a whole. Adenovirus and adeno-associated
viral systems are relatively less efficient than integrating and sendai-based viral delivery
systems, but offer increased safety characteristics [128]. The combined bump in efficiency
and nonintegrative qualities for the sendai virus delivery system makes it an increasingly
popular alternative to standard viral methods [121]. One drawback of this methodology is
the current cost of the delivery system, putting large-panel derivations out of the reach of
most investigators.
Other viral vector systems, such as lentivirus and gamma-retrovirus, require integration
into the host genome for replication and can therefore disrupt the genomic integrity of
the cells that are reprogrammed, rendering iPSCs and their derivatives less safe for clinical
applications or altering gene-expression patterns, which can compromise compound screens
or disease pathway analyses. Overall, the classic lentiviral or retroviral systems and more
sophisticated constructs allowing selective removal of viral sequences still represent one
of the most efficient and economical methodologies for reprogramming somatic cells of
all types. Clearly, the integrating viral delivery methods can be upwards of 1000× more
efficient at generating fully reprogrammed cell lines (Table 8.2), but these and other factors
must be weighed when choosing a reprogramming methodology. It has been shown that
residual expression of reprogramming factors can affect the transcriptional machinery and
epigenetic profile of reprogrammed cells and should be factored into the overall cell-line
development strategy [140–142].
8.7.2 Nucleic Acid/Episomal-Driven
An economical and yet relatively inefficient choice for somatic cell reprogramming is
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133, 143]. This method allows for the generation of iPSC lines that are free of vector
or transgene sequences and have been used to reprogram a variety of somatic cell types.
More recently, episomal reprogramming has been used in conjunction with a cocktail of
small molecules to increase efficiencies 6–10-fold over episomal vector alone [144]. Serial
transfection of multiple or single polycistronic plasmids is required for even modestly
efficient reprogramming for most vector systems. Yu et al. [144] designed an Epstein–
Barr virus nuclear antigen EBNA-containing episome that is self-replicating, obviating the
need for multiple transfections and certainly reducing cell loss due to transfection toxicity.
However, this nonintegrative episomal delivery system does not guarantee complete lack of
plasmid integration and may require extensive dilution through cell replication to remove
all instances of plasmid sequences [145]. Several important parameters govern success
in episomal reprogramming, including but not limited to: (i) transfection method and
efficiency; (ii) rapid dilution of transfected vector due to highly proliferative target cells;
(iii) active silencing of plasmid sequences through host methylation; (iv) target cell type;
and (v) the overall size of the minicircle vector [128]. In all episomal reprogramming
methods, proper post-reprogramming screening should include molecular methods for
the detection of vector sequences. Episomal delivery offers significant advantages over
other methods, including an increased safety profile and compatibility with any number of
external factors/enhancers that enable the tailoring of the method to research or therapeutic
development requirements.
8.7.3 mRNA-Driven
A significant shift in nucleic acid-based reprogramming came in 2010 when Rossi and
colleagues published on the highly efficient use of synthetic mRNA species to orchestrate
reprogramming in multiple human cell types [123]. This method of using synthetic mRNA
species to drive exogenous expression of the four canonic Yamanaka reprogramming factors
proved to be a reliable (up to 10000× more efficient than standard episomal reprograming
systems; see Table 8.2) defined method that gives rise to footprint-free iPSC lines. One
drawback is the repeated transfections required over 12–16 days to ensure sufficiently stable
factor expression to give rise to completely reprogrammed cell lines. Some recent effort
has been devoted to qualitative changes in mRNA design, delivery, and screening methods
that can reduce this production time, but the method still requires daily transfections for
an extended period of time [146]. It is suggested that the initial investment in reagents and
effort with the mRNA method can be recouped in the high frequency of fully reprogrammed
colonies resulting from the method, thereby saving on screening time. As reprogramming
methods push toward solutions enabling clinical use of iPSC lines derived from patients
as personalized medicine, it is clear that nonintegrative methods like mRNA are setting
the pace.
8.7.4 miRNA-Driven
miRNAs could be as instrumental in reprogramming as the transcription factors or epige-
netic regulators that are so well known as drivers of somatic cell reprogramming. miRNAs
are known to be key regulators of cell fate in ESCs, the development of the blastocyst,
and various differentiation pathways [147–151]. Therefore, it can easily be envisioned that
miRNAs could be utilized to impart cell-fate decisions in somatic reprogramming through
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the activation and repression of lineage-specific genes. The use of miRNAs as adjuvants to
reprogramming through the addition of selected miRNA species to episomal or viral vector
systems may prove useful. The transcription factor OSK plus miR-291-3p, miR-294, or
miR-295 has been shown to consistently increase the number of Oct4- GFP+ colonies
as compared to controls transduced with OSK alone. The miR-294 mimic showed the
greatest effects, increasing efficiency by up to 10-fold for transduced mouse embryonic
fibroblasts (MEFs) [152]. Miyoshi et al. [138] showed that the transfection of a combina-
tion of mir-200c, mir-302s, and mir-369s could reprogram both mouse and human somatic
cells. It has recently been shown that the mechanism by which sodium butyrate enhances
hiPSC reprogramming efficiency works through the induction of the miR302/367 miRNA
cluster [153]. The blending of traditional methodologies for reprogramming and miRNAs
may prove a powerful combination and afford researchers selective and increasingly less
invasive methods by which to generate iPSCs [154].
8.7.5 Protein-Driven
Protein-based delivery of reprogramming factors has been demonstrated, but it has
extremely slow kinetics, requiring significant time investment – as much as 6 weeks [124].
Another drawback to the use of proteins as factor-delivery modules is that transmembrane
delivery can be challenging and therefore intracellular localization is very inefficient [155].
Amino acid segments from HIV-TAT and other basic peptides (CPPs) can significantly
increase membrane translocation and allow the delivery of nucleic acid or protein ele-
ments to the nucleus [156, 157]. Improvements in the targeting or stability of engineered
proteins may make these systems more effective in the future; however, current require-
ments for numerous applications of the reprogramming cocktail over many weeks hampers
mainstream usage of such systems.
8.7.6 External Factors/Enhancers
Several studies have shown that epigenetic remodeling is a rate-limiting step in repro-
gramming [109, 153, 158]. As shown in Table 8.3, many of the compounds that have a
positive effect on reprogramming efficiency are involved in DNA methylation and chro-
matin remodeling. While this list is by no means exhaustive, it gives a broad sense of
the pathways and fundamental approaches being taken to improve cellular reprogramming
methods. By using one or more combinations of small molecules at the appropriate times
during the reprogramming process, one may be able to avoid, at least partially, the perma-
nent genome modifications engendered by the application of exogenous oncogene products
for extended periods. These compounds can be roughly divided into three categories: (i)
cell-cycle and metabolic regulators; (ii) epithelial–mesenchymal transition (EMT) pheno-
typic modulators; and (iii) epigenetic modifiers. Depending on the target cell source, a
single factor or a defined cocktail can provide significant reprogramming enhancement by
altering the kinetics or aiding in the progression through transitional phenotypes [159–162].
It is unclear what effects, if any, these pathway-specific or genetic modifiers might have on
the genetic stability of the cell lines being generated, so exposure should be targeted and
should be as brief as possible. Risk should obviously be weighed based on several criteria,
not the least of which would be limiting the time of exposure to the reprogramming factors
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Figure 8.3 Cellular reprogramming
8.7.7 Direct Reprogramming
One potentially transformative advance in cellular reprogramming is the possibility of
bypassing the pluripotent stem-cell intermediate and going right to the differentiated cell
type of interest through a process termed “transdifferentiation” or lineage conversion. In the
1950s, Conrad Waddington described development by imagining an “epigenetic landscape”
in which cells developed along specific pathways and through defined developmental states
[172], similar to the branched structure seen in Figure 8.3. While this model remains an
elegant means of describing development, Waddington likely did not envision the plas-
ticity of cell states, even in terminally differentiated cells, that allows cells to be reverted
to pluripotency via reprogramming. However, processes that are even more radical have
emerged whereby differentiated cells can be directly converted from one type to another
without passing through pluripotency (Figure 8.3). This direct conversion, or transdifferen-
tiation, allows for an abundant and reproducible adult cell source to be directly converted
to the regenerative cell type of interest, whether for research or therapeutic application
[4, 173]. The first demonstration of transdifferentiation was made in 1986 when researchers
in the laboratory of Harold Weintraub showed that expression of a single transfected gene,
MyoD, could convert fibroblasts to myoblasts [174]. More recently, several groups have
made remarkable progress in this offshoot of reprogramming technology. In 2008, Zhou
et al. [175] showed that the overexpression of Ngn3, Pdx1, and Mafa in mouse pancreatic
exocrine cells induced them to convert into insulin-producing endocrine cells. Even more
remarkably, this conversion was done in vivo, providing a distinct advantage to therapeutic
applications of this technology. This was followed by demonstrations by several groups
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of transdifferentiation of fibroblasts into a variety of other somatic cell types representing
different germ layers, including neurons, hepatocytes, and cardiomyocytes [176–178], as
well as precursor cells in different lineages, such as hematopoietic progenitors [179]. In
addition, it was shown recently that direct reprogramming can be accomplished, includ-
ing the transdifferentiation of fibroblasts to myocytes and neuronal cells using nonviral
and nonintegrative methods [180–182]. The rapidity and relatively high efficiency of these
transdifferentiation protocols seems to indicate a preferred path for reprogramming tech-
nology, especially since they lack potentially oncogenic reprogramming factor-induced
intermediates, making them safer for clinical applications.
8.8 Applications and Future Trends
Reprogramming technology has the potential to significantly impact a broad spectrum of
biomedical research, from basic studies through clinical applications. As a tool for basic
research, ESCs and iPSCs are already making significant contributions, which will serve
as the foundation for the development of clinical uses. Studies using ESCs and iPSCs are
helping to elucidate the molecular and cellular mechanisms controlling development from
the early embryo to specific cell lineages [183]. As our understanding of the differentia-
tion process evolves, the complex interactions of cell signaling, transcription factors, and
epigenetic changes necessary for development are becoming clearer. To recapitulate the
differentiation process in vitro, cells must often be painstakingly guided through numerous
and precise intermediate cell types in order to form fully functional, terminally differenti-
ated cells (as exemplified by the production of pancreatic β-cells [184]). Such studies can
be hampered by variability in the differentiation capacity of different pluripotent stem-cell
lines [33, 185], which is even more pronounced in iPSCs due to epigenetic memory as
well as the genetic and epigenetic changes that occur during reprogramming and culture
[186–189].
In addition to the study of normal development, cellular reprogramming technology is
being used to create new model systems to study the pathology of many different diseases.
Currently, reprogrammed stem-cell models have been developed for over 80 different
genetic diseases (Table 8.4) [190–192]. These cell lines, coupled with ever-improving
differentiation protocols, allow researchers to derive large quantities of specific target cell
types affected in a disease and, importantly, to study progression of the disease through
development. Disease-specific stem-cell models are of great value in high-throughput drug
screening and toxicity assessment [193]. The value of these iPSC models is such that several
derivation and banking initiatives are either being discussed or are underway, including a
large-scale collaboration between academic institutions and pharmaceutical companies in
Europe [194] and an initiative in the United States funded by the California Institute for
Regenerative Medicine (CIRM).
8.8.1 Moving Toward Clinical Applications for Cellular Reprogramming
Researchers have long recognized the potential for the development of “patient-specific”
pluripotent stem cells in the treatment of disease [262]. Shortly after the development of
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Table 8.4 Reprogrammed disease models
Disorder Affected gene(s) Reference
α-1-antitrypsin deficiency SERPINA1 (α1-antitrypsin) gene
mutation (homozygous)
[195]
Alzheimer’s disease (familial) PS1 and PS2 gene mutations [196]
Alzheimer’s disease (familial) APP gene duplication [197]
Alzheimer’s disease (sporadic) ? [197]
Amyotrophic lateral sclerosis SOD1 gene mutation [198]
Amyotrophic lateral sclerosis TARDBP gene mutation [199]
Amyotrophic lateral sclerosis
(ALS8)
VAPB gene mutation [200]





PKP2 gene mutation [202]
Ataxia-telangiectasia ATM gene mutation [203]
Atypical Werner syndrome LMNA gene mutation [204]
Becker muscular dystrophy DMD gene, unidentified mutation [205]
Best disease BEST1 gene mutation [206]
β-thalassaemia HBB gene mutation [207]














NLRP3 gene mutation [211]
Cockayne syndrome ERCC6 gene mutation [212]
Crigler–Najjar syndrome Deletion in UGT1A1 gene [213]
Cystic fibrosis CFTR gene mutation,
homozygous
[195]
Diabetes, type 1 Multifactorial [214]
Diabetes, type 2 Multifactorial [215]
Dilated cardiomyopathy TNNT2 gene mutation [216]
Dilated cardiomyopathy LMNA gene mutation [204]
Down syndrome Trisomy of chromosome 21 [217]
Duchenne muscular dystrophy DMD gene (deletion of exons
45–52)
[205]
Dyskeratosis congenita Deletion in DKC1 gene [218]
Familial dysautonomia IKBKAP gene mutation [219]
Familial hypercholesterolemia LDLR gene mutation [220]
Familial hypertrophic
cardiomyopathy
MYH7 gene mutation [221]
Fanconi’s anemia FANCA and FANCD2 gene
mutations
[222]
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Table 8.4 (Continued)
Disorder Affected gene(s) Reference
Facioscapulohumeral dystrophy Deletion of 4q D4Z4
microsatellite repeats
[223]
Fragile X syndrome FMR1 gene CGG triplet repeat
expansion
[224]
Friedreich’s ataxia FXN gene GAA triplet repeat
expansion
[225]
Gaucher disease, types 1, 2, 3 GBA gene mutations [226]
Glycogen storage disease, type 1a G6PC gene mutation [220]
Glycogen storage disease, type 1b SLC37A gene mutation [213]
Herpes simplex encephalitis STAT1 or TLR3 gene mutation [208]





LMNA gene mutation [228]
LEOPARD syndrome PTPN11 mutation (heterozygous) [229]





SGCA gene mutation [231]
Long QT syndrome, type 1 KCNQ1 gene mutation [232]
Long QT syndrome, type 2 KCNH2 gene mutation [233]
Long QT syndrome, type 3
(Brugada syndrome)
SCN5A gene mutation [234]
Machado–Joseph disease
(spinocerebellar ataxia type 3)
MJD1 (ATXN3) gene CAG triplet
repeat expansion
[235]














JAK2 gene mutation [240]
Myeloproliferative disorder
(primary myelofibrosis)
JAK2 gene mutation [240]
Omenn syndrome RAG1 gene mutation [208]
Osteogenesis imperfecta COL1A2 gene mutation [241]
Parkinson’s disease Multifactorial [131]
Parkinson’s disease, autosomal
recessive, young onset
PARK2 gene mutation [242]
Parkinson’s disease, familial PINK1 and LRRK2 gene mutations [243]
(continued)
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Table 8.4 (Continued)
Disorder Affected gene(s) Reference
Pelizaeus–Merzbacher disease PLP1 gene, partial duplication [244]
Pompe disease GAA gene mutation [245]








COL7A1 gene mutation [246]
Retinitis pigmentosa Mutations in RP9, RP1, PRPH2 or
RHO genes
[247]
Rett syndrome MECP2 gene mutation [248]
Rett syndrome (Hanefeld variant) CDKL5 gene mutation [249]
Sandhoff disease (mouse model) HexB gene deletion
(homozygous)
[250]
Severe congenital neutropenia ELANE gene mutation [251]










RAG1 gene mutation [208]
Sickle-cell anemia HBB gene mutation
(homozygous)
[195]
Spinal muscular atrophy, type 1 SMN1 gene mutation
(homozygous)
[253]








Supravalvular aortic stenosis ELN gene mutation [255]
Systemic lupus erythematosus ? [256]
Timothy syndrome CACNA1C gene mutation [257]
Tyrosinemia, type 1 FAH gene mutation [213]
Williams–Beuren syndrome ELN gene microdeletion [258]
Wilson’s disease ATP7B gene mutation [259]
X-linked adrenoleukodystrophy,
adrenomyeloneuropathy (AMN)




ABCD1 gene mutation [260]
X-linked chronic granulomatous
disease
CYBB gene mutation [261]
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cellular reprogramming, the “proof of principle” for the use of this technology was ele-
gantly demonstrated by Rudolf Jaenisch and coworkers using a mouse model for sickle-cell
anemia [263]. In this study, fibroblasts for the sickle-cell mouse were reprogrammed to a
pluripotent state. These iPSCs were then modified by gene targeting to correct the mutated
hemoglobin allele, and the “corrected” iPSCs were differentiated into hematopoietic pro-
genitor cells. The mouse was then cured by transplantation of these corrected autologous
progenitors. While this established the roadmap to therapeutic application of reprogram-
ming technology, numerous obstacles remained. One of the primary issues surrounding the
use of any pluripotent stem cells in humans is the risk of tumorigenesis, since pluripotent
cells are capable of unlimited self-renewal. To mitigate this risk, cells introduced into a
patient would need to be a pure population of differentiated cells. The processing steps
required to achieve such purity specifications make clinical cell manufacturing with iPSCs
or ESCs particularly challenging. In addition, the tumorigenicity risk is likely even higher
for iPSCs than for ESCs, due in part to the accumulation of epigenetic and genetic abnor-
malities during reprogramming, which could promote tumor formation [264]. Thus, further
study of the reprogramming process and development of new reprogramming methods will
likely be required before the clinical application of iPSC technology is fully realized.
Despite the risks, the movement of pluripotent stem cells toward the clinic is proceeding.
There is currently a phase I clinical trial in the United States for the use of hESC-derived
retinal pigment epithelial cells for the treatment of macular degeneration [265, 266]. Fur-
thermore, although there are still many unknowns regarding the use of iPSCs in the clinic,
a similar trial using reprogrammed cells is underway in Japan [267].
8.8.2 The Merging of Stem Cells and New Methods of Genetic Engineering
To achieve the overall goal of using cellular reprogramming to treat genetic diseases,
methods of correcting the relevant mutations must be developed. Although homologous
recombination has been used for many years to modify the genome of mouse cells (including
ESCs) [268], the process is very inefficient in human cells, hampering its utility. However,
recent advances in the use of zinc finger nucleases (ZFNs) and, more recently, transcrip-
tion activator-like effector nucleases (TALENs) and the RNA-guided CRISPR (clustered
regularly interspaced short palindromic repeats)/Cas system, are providing new tools for
human gene modification. These technologies allow the production of nucleases that target
specific sequences in the genome and have been successfully used in gene modification of
hESCs and iPSCs [269–271]. TALENs have also been used to correct the genetic defect
in disease-specific iPSCs [272], moving one step closer to realizing stem-cell therapy in
the treatment of genetic disorders. Interestingly, TALENs have also been used to introduce
specific disease-causing mutations into normal iPSCs, providing a new way of generating
disease models with iPSCs [273].
8.8.3 Efficiency, Expense, and Safety
Although great strides have been made in the development of reprogramming-method
alternatives since the original report in 2006, there are still significant hurdles to overcome
in order to make somatic-cell reprogramming a reliable research and diagnostic tool and a
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viable therapeutic option. As has been suggested by Gonzalez and others, the current à-la-
carte reprogramming menu does and will allow purposeful innovation in the field, but it also
introduces the problem of having so many variations on the theme that method adoption and
standardization remain considerable challenges [128]. Significant progress has also been
made toward developing safer and more efficient methods of reprogramming. However, a
balance must be sought for the three-legged stool, which should include cost [121–123, 274].
As always, consideration of the intended use for the cell lines being developed is a main
driver in the choice of reprogramming method, and as standards for line safety and basic
characterization parameters are established these choices may narrow. Cost, as a function
of the reagents and the investigator time required to perform reprogramming protocols and
to fully mature and characterize the resultant cell lines, is also of interest. Many of the
safer viral systems and the numerous potential enhancing reagents are currently driving
expenditures per source derivation over $5000, including personnel effort and rudimentary
characterization screening. While the cost of other methods can be considerably less, one
can see how the development of panels of cell lines for drug screening or disease modeling
may be prohibitively expensive. For these and other reasons, it is difficult to find a one-
size-fits-all reprogramming strategy. In addition, increased safety and enhanced efficiency
do not always translate into decreased variation within the derived panel of cell lines [275].
This fact demands the preparation and at least partial characterization of multiple lines for
a single tissue source to ensure availability of cell lines with qualified genetic stability and
pluripotency, thus exacerbating the cost problem.
8.8.4 Developing Standards
Beginning from as early as 1998, when Thomson and colleagues published the derivation
of human ESCs, a significant body of work has been devoted to creating a set of standards
for the development, culture, and characterization of this powerful stem cell resource [16,
276, 277]. However, since the introduction of iPSC derivation in 2006, much of the effort of
the field has been focused on refining the various methods and investigating the boundaries
of their potential uses. As this field moves forward, it will be essential to be able to assess
the various methodological enhancements using generally, if not universally, accepted
standards of phenotype and function. Proving complete reprogramming in human cells is
not trivial, and it may not be possible to show definitively to the satisfaction of all for some
time. While several groups have begun to venture down this path, setting convention in a
time of unprecedented growth for the field is a daunting task. Clearly detailed genomic,
transcriptional, and functional evaluations make up a partial list of broad analysis groups
that can be entertained as potential characterization standards. However, in a broader
sense, the development of standards around tissue sourcing, screening mechanisms, data
reporting, confidentiality, and banking should be a companion discussion to the former
detailed individual analysis. Screening tools, robotics, and selection methods need to be
developed to aid the discrimination and selection of fully reprogrammed cells and those
that harbor potential defects that would affect their performance as research tools or as
therapeutics. The method by which this is done is still a matter of some debate and still
needs to be developed for human cell analysis [34, 278, 279]. However, previous work
with ESC characterization could serve as a rough template for the development of iPSC
standards.
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8.9 Conclusion
Our understanding of the role of stem cells in development has advanced significantly
over the past 50 years. Dissection of the complex interplay between genes, proteins, and
RNAs that maintain pluripotency and drive differentiation has spurred the development
of revolutionary new cellular reprogramming technologies. The ability to reprogram cells
to pluripotency and to “transdifferentiate” cells from one type to another emphasizes the
remarkable plasticity of our cells and has opened up tantalizing new opportunities in the
study of disease and in regenerative medicine. However, much remains to be done. We are
still uncovering the unique properties of iPSCs and new methods for their production and
differentiation using an array of viral, RNA, protein, and chemical tools that continue to
be developed. Improvements in the efficiency and safety of reprogramming and differen-
tiation protocols are critical, and considerations of an administrative nature, including the
development of policies and standards, should also be taken into account as the field moves
closer to the ultimate goal of clinical application.
These landmark studies have uncovered the potential of stem cells, demonstrated cellular
plasticity, and shown our increasing ability to manipulate cell identities.
The core pluripotency regulators Oct4, Nanog, and Sox2 control a network of protein-
coding genes, miRNAs, and lincRNAs in order to regulate pluripotency. These three fac-
tors autoregulate their expression and upregulate expression of the genes associated with
pluripotency. In turn, these pluripotency proteins and RNAs interact with the core factors
and the polycomb complexes PRC1 and PRC2 to repress expression of lineage-specific
proteins and RNAs. When activated, the lineage-specific factors repress the polycomb
complexes and downregulate expression of the core pluripotency factors.
Where most reprogramming techniques take the differentiated cell back to pluripotency,
direct conversion or transdifferentiation involves switching from one differentiated cell type
to another without conversion to a pluripotent state.
References
(1) Gurdon, J.B., Elsdale, T.R., and Fischberg, M. (1958) Sexually mature individuals of Xenopus
laevis from the transplantation of single somatic nuclei. Nature, 182 (4627), 64–65.
(2) Till, J.E. and McCulloch, E.A. (1961) A direct measurement of the radiation sensitivity of
normal mouse bone marrow cells. Radiation Research, 14, 213–222.
(3) Stadtfeld, M. and Hochedlinger, K. (2010) Induced pluripotency: history, mechanisms, and
applications. Genes & Development, 24 (20), 2239–2263.
(4) Vierbuchen, T. and Wernig, M. (2011) Direct lineage conversions: unnatural but useful?Nature
Biotechnology, 29 (10), 892–907.
(5) Van de Velde, H., Cauffman, G., Tournaye, H. et al. (2008) The four blastomeres of a 4-cell
stage human embryo are able to develop individually into blastocysts with inner cell mass and
trophectoderm. Human Reproduction, 23 (8), 1742–1747.
(6) Kleinsmith, L.J. and Pierce, G.B. (1964) Multipotentiality of single embryonal carcinoma
cells. Cancer Research, 24, 1544–1551.
(7) Kahan, B.W. and Ephrussi, B. (1970) Developmental potentialities of clonal in vitro cultures
of mouse testicular teratoma. Journal of the National Cancer Institute, 44 (5), 1015–1036.
(8) Hogan, B., Fellous, M., Avner, P., and Jacob, F. (1977) Isolation of a human teratoma cell line
which expresses F9 antigen. Nature, 270 (5637), 515–518.
128 Chemical Biology in Regenerative Medicine
(9) Fraley, E.E., Lange, P.H., Williams, R.D., and Ortlip, S.A. (1980) Staging of early nonsemi-
nomatous germ-cell testicular cancer. Cancer, 45 (Suppl. 7), 1762–1767.
(10) Przyborski, S.A., Christie, V.B., Hayman, M.W. et al. (2004) Human embryonal carcinoma
stem cells: models of embryonic development in humans. Stem Cells and Development, 13
(4), 400–408.
(11) Martin, G.R. (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in
medium conditioned by teratocarcinoma stem cells. Proceedings of the National Academy of
Sciences of the United States of America, 78 (12), 7634–7638.
(12) Evans, M.J. and Kaufman, M.H. (1981) Establishment in culture of pluripotential cells from
mouse embryos. Nature, 292 (5819), 154–156.
(13) Bradley, A., Evans, M., Kaufman, M.H., and Robertson, E. (1984) Formation of germ-line
chimaeras from embryo-derived teratocarcinoma cell lines. Nature, 309 (5965), 255–256.
(14) Nagy, A., Gocza, E., Diaz, E.M. et al. (1990) Embryonic stem cells alone are able to support
fetal development in the mouse. Development (Cambridge, England), 110 (3), 815–821.
(15) Eggan, K., Akutsu, H., Loring, J. et al. (2001) Hybrid vigor, fetal overgrowth, and viability of
mice derived by nuclear cloning and tetraploid embryo complementation. Proceedings of the
National Academy of Sciences of the United States of America, 98 (11), 6209–6214.
(16) Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S. et al. (1998) Embryonic stem cell lines derived
from human blastocysts. Science, 282 (5391), 1145–1147.
(17) Itskovitz-Eldor, J., Schuldiner, M., Karsenti, D. et al. (2000) Differentiation of human embry-
onic stem cells into embryoid bodies compromising the three embryonic germ layers. Molec-
ular Medicine, 6 (2), 88–95.
(18) Resnick, J.L., Bixler, L.S., Cheng, L., and Donovan, P.J. (1992) Long-term proliferation of
mouse primordial germ cells in culture. Nature, 359 (6395), 550–551.
(19) Matsui, Y., Zsebo, K., and Hogan, B.L. (1992) Derivation of pluripotential embryonic stem
cells from murine primordial germ cells in culture. Cell, 70 (5), 841–847.
(20) Shamblott, M.J., Axelman, J., Wang, S. et al. (1998) Derivation of pluripotent stem cells from
cultured human primordial germ cells. Proceedings of the National Academy of Sciences of
the United States of America, 95 (23), 13726–13731.
(21) Turnpenny, L., Brickwood, S., Spalluto, C.M. et al. (2003) Derivation of human embryonic
germ cells: an alternative source of pluripotent stem cells. Stem Cells, 21 (5), 598–609.
(22) Pashai, N., Hao, H., All, A. et al. (2012) Genome-wide profiling of pluripotent cells reveals a
unique molecular signature of human embryonic germ cells. PLoS One, 7 (6), e39088.
(23) Soza-Ried, J. and Fisher, A.G. (2012) Reprogramming somatic cells towards pluripotency by
cellular fusion. Current Opinion in Genetics & Development, 22 (5), 459–465.
(24) Miller, R.A. and Ruddle, F.H. (1976) Pluripotent teratocarcinoma-thymus somatic cell hybrids.
Cell, 9 (1), 45–55.
(25) Cowan, C.A., Atienza, J., Melton, D.A., and Eggan, K. (2005) Nuclear reprogramming of
somatic cells after fusion with human embryonic stem cells. Science, 309 (5739), 1369–
1373.
(26) Wilmut, I., Schnieke, A.E., McWhir, J. et al. (1997) Viable offspring derived from fetal and
adult mammalian cells. Nature, 385 (6619), 810–813.
(27) Tachibana, M., Amato, P., Sparman, M. et al. (2013) Human embryonic stem cells derived by
somatic cell nuclear transfer. Cell, 153 (6), 1228–1238.
(28) Takahashi, K. and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell, 126 (4), 663–676.
(29) Takahashi, K., Tanabe, K., Ohnuki, M. et al. (2007) Induction of pluripotent stem cells from
adult human fibroblasts by defined factors. Cell, 131 (5), 861–872.
(30) Yu, J., Vodyanik, M.A., Smuga-Otto, K. et al. (2007) Induced pluripotent stem cell lines
derived from human somatic cells. Science, 318 (5858), 1917–1920.
(31) Smith, K.P., Luong, M.X., and Stein, G.S. (2009) Pluripotency: toward a gold standard for
human ES and iPS cells. Journal of Cellular Physiology, 220 (1), 21–29.
(32) Burridge, P.W., Anderson, D., Priddle, H. et al. (2007) Improved human embryonic stem
cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate
aggregation system highlights interline variability. Stem Cells, 25 (4), 929–938.
An Introduction to Cellular Reprogramming 129
(33) Osafune, K., Caron, L., Borowiak, M. et al. (2008) Marked differences in differentiation
propensity among human embryonic stem cell lines. Nature Biotechnology, 26 (3), 313–315.
(34) Bock, C., Kiskinis, E., Verstappen, G. et al. (2011) Reference maps of human ES and iPS
cell variation enable high-throughput characterization of pluripotent cell lines. Cell, 144 (3),
439–452.
(35) Stewart, M.H., Bosse, M., Chadwick, K. et al. (2006) Clonal isolation of hESCs reveals
heterogeneity within the pluripotent stem cell compartment. Nature Methods, 3 (10), 807–815.
(36) Stewart, M.H., Bendall, S.C., Levadoux-Martin, M., and Bhatia, M. (2010) Clonal tracking of
hESCs reveals differential contribution to functional assays. Nature Methods, 7 (11), 917–922.
(37) Silva, J. and Smith, A. (2008) Capturing pluripotency. Cell, 132 (4), 532–536.
(38) Nichols, J. and Smith, A. (2009) Naive and primed pluripotent states. Cell Stem Cell, 4 (6),
487–492.
(39) Brons, I.G., Smithers, L.E., Trotter, M.W. et al. (2007) Derivation of pluripotent epiblast stem
cells from mammalian embryos. Nature, 448 (7150), 191–195.
(40) Tesar, P.J., Chenoweth, J.G., Brook, F.A. et al. (2007) New cell lines from mouse epiblast
share defining features with human embryonic stem cells. Nature, 448 (7150), 196–199.
(41) Tachibana, M., Sparman, M., Ramsey, C. et al. (2012) Generation of chimeric rhesus monkeys.
Cell 148 (1–2), 285–295.
(42) De Los Angeles, A., Loh, Y.H., Tesar, P.J., and Daley, G.Q. (2012) Accessing naive human
pluripotency. Current Opinion in Genetics & Development, 22 (3), 272–282.
(43) Najm, F.J., Chenoweth, J.G., Anderson, P.D. et al. (2011) Isolation of epiblast stem cells from
preimplantation mouse embryos. Cell Stem Cell, 8 (3), 318–325.
(44) Chou, Y.F., Chen, H.H., Eijpe, M. et al. (2008) The growth factor environment defines distinct
pluripotent ground states in novel blastocyst-derived stem cells. Cell, 135 (3), 449–461.
(45) Hanna, J., Cheng, A.W., Saha, K. et al. (2010) Human embryonic stem cells with biological
and epigenetic characteristics similar to those of mouse ESCs. Proceedings of the National
Academy of Sciences of the United States of America, 107 (20), 9222–9227.
(46) Gu, Q., Hao, J., Zhao, X.Y. et al. (2012) Rapid conversion of human ESCs into mouse ESC-like
pluripotent state by optimizing culture conditions. Protein & Cell, 3 (1), 71–79.
(47) Mikkelsen, T.S., Hanna, J., Zhang, X. et al. (2008) Dissecting direct reprogramming through
integrative genomic analysis. Nature, 454 (7200), 49–55.
(48) Polejaeva, I. and Mitalipov, S. (2013) Stem cell potency and the ability to contribute to chimeric
organisms. Reproduction (Cambridge, England), 145 (3), R81–88.
(49) Loh, Y.H., Yang, L., Yang, J.C. et al. (2011) Genomic approaches to deconstruct pluripotency.
Annual Review of Genomics and Human Genetics, 12, 165–185.
(50) Young, R.A. (2011) Control of the embryonic stem cell state. Cell, 144 (6), 940–954.
(51) Boyer, L.A., Lee, T.I., Cole, M.F. et al. (2005) Core transcriptional regulatory circuitry in
human embryonic stem cells. Cell, 122 (6), 947–956.
(52) Nichols, J., Zevnik, B., Anastassiadis, K. et al. (1998) Formation of pluripotent stem cells in
the mammalian embryo depends on the POU transcription factor Oct4. Cell, 95 (3), 379–391.
(53) Ivanova, N., Dobrin, R., Lu, R. et al. (2006) Dissecting self-renewal in stem cells with RNA
interference. Nature, 442 (7102), 533–538.
(54) Masui, S., Nakatake, Y., Toyooka, Y. et al. (2007) Pluripotency governed by Sox2 via regulation
of Oct3/4 expression in mouse embryonic stem cells. Nature Cell Biology, 9 (6), 625–635.
(55) Chew, J.L., Loh, Y.H., and Zhang, W. (2005) Reciprocal transcriptional regulation of Pou5f1
and Sox2 via the Oct4/Sox2 complex in embryonic stem cells.Molecular and Cellular Biology,
25 (14), 6031–6046.
(56) Chambers, I., Silva, J., Colby, D. et al. (2007) Nanog safeguards pluripotency and mediates
germline development. Nature, 450 (7173), 1230–1234.
(57) Mitsui, K., Tokuzawa, Y., Itoh, H. et al. (2003) The homeoprotein Nanog is required for
maintenance of pluripotency in mouse epiblast and ES cells. Cell, 113 (5), 631–642.
(58) Chen, L. and Daley, G.Q. (2008) Molecular basis of pluripotency. HumanMolecular Genetics,
17 (R1), R23–27.
(59) Kim, J., Chu, J., Shen, X. et al. (2008) An extended transcriptional network for pluripotency
of embryonic stem cells. Cell, 132 (6), 1049–1061.
130 Chemical Biology in Regenerative Medicine
(60) Wang, Z., Oron, E., Nelson, B. et al. (2012) Distinct lineage specification roles for NANOG,
OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell, 10 (4), 440–454.
(61) Lee, T.I., Jenner, R.G., Boyer, L.A. et al. (2006) Control of developmental regulators by
Polycomb in human embryonic stem cells. Cell, 125 (2), 301–313.
(62) Endoh, M., Endo, T.A., Endoh, T. et al. (2008) Polycomb group proteins Ring1A/B are
functionally linked to the core transcriptional regulatory circuitry to maintain ES cell identity.
Development (Cambridge, England), 135 (8), 1513–1524.
(63) Kirmizis, A., Bartley, S.M., Kuzmichev, A. et al. (2004) Silencing of human polycomb target
genes is associated with methylation of histone H3 Lys 27. Genes & Development, 18 (13),
1592–1605.
(64) Bernstein, B.E., Mikkelsen, T.S., Xie, X. et al. (2006) A bivalent chromatin structure marks
key developmental genes in embryonic stem cells. Cell, 125 (2), 315–326.
(65) Stock, J.K., Giadrossi, S., Casanova, M. et al. (2007) Ring1-mediated ubiquitination of H2A
restrains poised RNA polymerase II at bivalent genes in mouse ES cells. Nature Cell Biology,
9 (12), 1428–1435.
(66) Dillon, N. (2012) Factor mediated gene priming in pluripotent stem cells sets the stage for
lineage specification.BioEssays: News and Reviews inMolecular, Cellular andDevelopmental
Biology, 34 (3), 194–204.
(67) Marson, A., Levine, S.S., Cole, M.F. et al. (2008) Connecting microRNA genes to the core
transcriptional regulatory circuitry of embryonic stem cells. Cell, 134 (3), 521–533.
(68) Tay, Y.M., Tam, W.L., Ang, Y.S. et al. (2008) MicroRNA-134 modulates the differentiation
of mouse embryonic stem cells, where it causes post-transcriptional attenuation of Nanog and
LRH1. Stem Cells, 26 (1), 17–29.
(69) Khalil, A.M., Guttman, M., Huarte, M. et al. (2009) Many human large intergenic noncoding
RNAs associate with chromatin-modifying complexes and affect gene expression.Proceedings
of the National Academy of Sciences of the United States of America, 106 (28), 11667–
11672.
(70) Guttman, M., Donaghey, J., Carey, B.W. et al. (2011) lincRNAs act in the circuitry controlling
pluripotency and differentiation. Nature, 477 (7364), 295–300.
(71) Tollervey, J.R. and Lunyak, V.V. (2012) Epigenetics: judge, jury and executioner of stem cell
fate. Epigenetics: Official Journal of the DNA Methylation Society, 7 (8), 823–840.
(72) Meissner, A. (2010) Epigenetic modifications in pluripotent and differentiated cells. Nature
Biotechnology, 28 (10), 1079–1088.
(73) O’Carroll, D., Erhardt, S., Pagani, M. et al. (2001) The polycomb-group gene Ezh2 is required
for early mouse development. Molecular and Cellular Biology, 21 (13), 4330–4336.
(74) Boyer, L.A., Plath, K., Zeitlinger, J. et al. (2006) Polycomb complexes repress developmental
regulators in murine embryonic stem cells. Nature, 441 (7091), 349–353.
(75) Hochedlinger, K. and Plath, K. (2009) Epigenetic reprogramming and induced pluripotency.
Development (Cambridge, England), 136 (4), 509–523.
(76) Guenther, M.G., Frampton, G.M., Soldner, F. et al. (2010) Chromatin structure and gene
expression programs of human embryonic and induced pluripotent stem cells. Cell Stem Cell,
7 (2), 249–257.
(77) Papp, B. and Plath, K. (2011) Reprogramming to pluripotency: stepwise resetting of the
epigenetic landscape. Cell Research, 21 (3), 486–501.
(78) Vierbuchen, T. and Wernig, M. (2012) Molecular roadblocks for cellular reprogramming.
Molecular Cell, 47 (6), 827–838.
(79) Maherali, N., Sridharan, R., Xie, W. et al. (2007) Directly reprogrammed fibroblasts show
global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell, 1 (1),
55–70.
(80) Wernig, M., Meissner, A., Foreman, R. et al. (2007) In vitro reprogramming of fibroblasts into
a pluripotent ES-cell-like state. Nature, 448 (7151), 318–324.
(81) Chin, M.H., Mason, M.J., Xie, W. et al. (2009) Induced pluripotent stem cells and embry-
onic stem cells are distinguished by gene expression signatures. Cell Stem Cell, 5 (1), 111–
123.
(82) Lister, R., Pelizzola, M., Kida, Y.S. et al. (2011) Hotspots of aberrant epigenomic reprogram-
ming in human induced pluripotent stem cells. Nature, 471 (7336), 68–73.
An Introduction to Cellular Reprogramming 131
(83) Wang, A., Huang, K., Shen, Y. et al. (2011) Functional modules distinguish human induced
pluripotent stem cells from embryonic stem cells. Stem Cells and Development, 20 (11),
1937–1950.
(84) Marchetto, M.C., Yeo, G.W., Kainohana, O. et al. (2009) Transcriptional signature and memory
retention of human-induced pluripotent stem cells. PloS One, 4 (9), e7076.
(85) Kim, K., Doi, A., Wen, B. et al. (2010) Epigenetic memory in induced pluripotent stem cells.
Nature, 467 (7313), 285–290.
(86) Polo, J.M., Liu, S., Figueroa, M.E. et al. (2010) Cell type of origin influences the molecular
and functional properties of mouse induced pluripotent stem cells. Nature Biotechnology, 28
(8), 848–855.
(87) Sullivan, G.J., Bai, Y., Fletcher, J., and Wilmut, I. (2010) Induced pluripotent stem cells:
epigenetic memories and practical implications. Molecular Human Reproduction, 16 (12),
880–885.
(88) Nakagawa, M., Koyanagi, M., Tanabe, K. et al. (2008) Generation of induced pluripotent stem
cells without Myc from mouse and human fibroblasts. Nature Biotechnology, 26 (1), 101–106.
(89) Kim, J.B., Greber, B., Arauzo-Bravo, M.J. et al. (2009) Direct reprogramming of human neural
stem cells by OCT4. Nature, 461 (7264), 649–643.
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9.1 Introduction
Human embryonic stem cells (hESCs) are derived from the inner cell mass (ICM) of cultured
pre-implantation human blastocysts [1]. With their ability to proliferate indefinitely in vitro
(self-renew), while maintaining the potential to differentiate into virtually any cell type
of the human body (pluripotency), they provide an unlimited source of cells suitable for
regenerative medicine, drug discovery, and the study of human development or disease
[2]. The major limitation of hESCs for cell therapy resides in their origin. In addition to
ethical controversies, transplantation of hESC-derived cells is complicated by potential
immune responses to allogeneic tissues [3]. To ensure the histocompatibility needed for
transplantation, it would be ideal to use pluripotent stem cells derived from the patient.
To accomplish this goal, somatic-cell nuclear transfer (SCNT) represents an attractive
option. More than 3 decades separate the first tadpoles cloned by John Gurdon [4] from
Dolly the Sheep, the first cloned mammal [5]. Since then, SCNT has allowed the generation
of viable adult clones in many mammalian species [6–13] and permitted the creation of
pluripotent stem cells from mouse [14], bovine [15], and rhesus macaque [16]. These
successes suggest that the same approach could apply to humans. However, SCNT has yet
to succeed in our species, due to the limited availability of human oocytes for research
and potentially reflecting inherent barriers of the human model [17]. These problems have
prevented the success of human therapeutic cloning up to now.
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SCNT [4] and somatic-cell fusion experiments with germ cells [18] or embryonic stem
cells (ESCs) [19,20] demonstrate that the somatic genome is amenable to reprogramming,
and suggest that pluripotency can be restored in a terminally differentiated cell by factors
present in oocytes or pluripotent stem cells. This concept led to the groundbreaking exper-
iment by Yamanaka and colleagues, who managed to induce pluripotency in differentiated
mouse and human adult fibroblasts by ectopically expressing four pluripotency-associated
transcription factors: Oct4, Sox2, Klf4, and c-Myc [21, 22]. This process, referred to as
reprogramming, generates induced pluripotent stem cells (iPSC) that closely resemble
ESCs in global gene-expression profile, epigenetic signature, and developmental potential
[23–29]. Reprogramming represents a simple way of generating patient-specific human
pluripotent stem cells (hPSCs) useful for a wide range of applications, including autolo-
gous cell-transplantation therapy, modeling of both monogenic and polygenic diseases, and
provision of relevant cell types for drug toxicity, differentiation, and therapeutic screens.
These applications require efficient and reliable reprogramming methods, which are
being optimized [30]. In most cases, the generation of human induced pluripotent stem
cells (hiPSC) involves ectopic expression of a set of core pluripotency-related transcription
factors (Oct4, Sox2, Klf4, and c-Myc, or other combinations) in adult fibroblasts over a
course of∼2–4 weeks [22,27]. Reprogramming of human fibroblasts is a slow and inefficient
process: less than 0.01% of donor cells become iPSCs in initial studies [31]. Hence, recent
years have seen cohorts of publications aiming to improve the original protocol by using
alternative donor cells [32–34] or identifying novel reprogramming factors [35–37]. So far,
the most efficient protocols make use of constitutive- [22,27], or inducible- [38] integrative
viral vectors to deliver the reprogramming factors. However, these approaches generate
genetically and phenotypically heterogeneous cell lines, limiting their use for therapy due
to concerns over tumorigenicity caused by potential insertional mutagenesis or reexpression
of the reprogramming factors [25, 39].
Various approaches have been developed to avoid potentially detrimental genetic modi-
fications, using alternative methods to deliver reprogramming factors, such as integration-
defective viruses [40–42], episomes [43–46], transposons [47,48], cell-permeable recombi-
nant proteins [49,50], RNAs [51], and microRNAs [52,53], often combined with treatment
with chemical compounds that induce or facilitate reprogramming [54, 55]. Beside this
increasing number of alternative approaches, a mechanistic dissection of the process may
reveal cell-intrinsic and -extrinsic signals governing reprogramming and enable the design
of rational approaches to improve it.
In this regard, small molecules provide a powerful tool by which to address these issues.
First, their biological effects are usually rapid, reversible, and dose-dependent, allowing
a precise control of specific outcomes through modulation of their concentrations and
combinations. Second, the structural diversity provided by synthetic chemistry facilitates
functional optimization of compounds of interest. Third, compared to any genetic delivery
method, the delivery of chemicals is both convenient and efficient. Using both phenotypic
screening and hypothesis-driven approaches, many compounds have been identified that
can functionally replace reprogramming transcription factors and enhance the efficiency
and/or the kinetics of reprogramming by modulating the activity of epigenetic modifiers or
signaling pathways controlling pluripotency or cell proliferation [56]. This chapter reviews
recent findings that use chemical compounds to improve reprogramming. These chemical
compounds and their roles in reprogramming are also summarized in Table 9.1.
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Table 9.1 Chemical compounds facilitating somatic cell reprogramming to pluripotency
Chemical
Category compounds Working conditions and effects
HDAC
inhibitor
VPA, TSA, SAHA Enhance iPSC formation from four-factor-infected MEFs
[54]
VPA Improves OSK-induced reprogramming and induces
iPSC generation from OS-infected human fibroblasts
[54,64]
Dramatically increases reprogramming efficiency of
MEFs transduced with OSKM under hypoxic
condition [63]
Promotes complete reprogramming and facilitates
expansion of fully reprogrammed iPSCs by inhibiting
growth of nonreprogrammed cells; generated iPSCs
can produce adult mice [48,66]
Enables reprogramming of MEFs to iPSCs using
recombinant proteins of four or three Yamanaka
factors (OSKM or OSK) [50]
Enables generation of iPSCs from MEFs by only
expressing miR302/367 [52]
NaB Enhances efficiency of iPSC generation from human
adult and fetal fibroblasts by retroviral delivery of four
or three Yamanaka factors (OSKM, OSK, OSM) [65]
Significantly improve reprogramming from MSCs
established from a patient with sickle-cell disease
using a piggyback transposon vector that contains
five transgenes (OSKM + Lin28) [65]
G9a HMTase
inhibitor
BIX01294 Enhances reprogramming efficiency of mouse NSCs
infected with OK [55]
Increases reprogramming using OK in MEFs when
combined with a DNMT inhibitor, RG108, and
L-calcium channel agonist, BayK8644 [69]
Enables reprogramming of mouse NSCs with SKM with
a very low efficiency [55]
LSD1 inhibitor Parnate Enables reprogramming of human keratinocytes
infected by KO when combined with CHIR99021
[74]
Improves reprogramming of MEFs infected by Oct4 in
the presence of VPA, CHIR99021, and E-616452 [75]
DNMT
inhibitor
5-aza Increases the reprogramming efficiency of OSKM- or
OSK-infected MEFs [54]
Promotes partially reprogrammed MEFs to fully
reprogrammed iPSCs [24]
RG108 Enhances reprogramming efficiency of MEFs transduced
with OK when combined with BIX [69]
Increases reprogramming efficiency of human
fibroblasts transduced with OSKM [65]
(continued)
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Table 9.1 (Continued)
Chemical
Category compounds Working conditions and effects
RSC133 Enhances reprogramming efficiency and kinetics of
mouse and human fibroblasts transduced with
OSKM [79]
TGFβ inhibitor E616451 Replaces Sox2 to induce iPSCs from OKM-transduced
MEFs only in the presence of VPA [81]
E616452 (RepSox) Functionally substitutes transgenic Sox2 and alleviates
the need for c-Myc for reprogramming in MEFs [81,
82]
SB431542 Replaces Sox2 during reprogramming of MEFs [81]
Increases human fibroblast reprogramming with
OSKM when combined with PD0325901 [86]
A-83-1 Enhances human keratinocyte reprogramming when
combined with PD0325901 [106]
Improves ultimate reprogramming and maintenance of
iPSCs generated from rat-liver epithelial cells
transduced with OSK when combined with
PD0325901 and CHIR99021 [85]
Enables reprogramming of MEFs transduced with Oct4
alone when combined with a protein arginine
methyltransferase inhibitor, AMI-5; the iPSCs can
give rise to liveborn pups through tetraploid
complementation [87]
Wnt signaling Wnt3a Wnt3a-conditioned medium significantly promotes
reprogramming of MEFs transduced with OSK, but
not OSKM [94]
GSK3 inhibitor CHIR99021 Promotes “pre-iPSCs” into fully reprogrammed cells
under LIF treatment when combined with
PD0325901 [97]
Enables reprogramming of MEFs transduced with OK
[74]
Enables reprogramming of human keratinocytes
transduced with OK when combined with Parnate
[74]
Kenpaullone Induces iPSC generation from MEFs transduced with
OSM [98]
Rock inhibitor Y27632 Widely used in hiPSC generation, improving cell
survival and colony formation
Thiazovivin Promotes reprogramming when combined with
SB431542 and PD0325901 [86]
Aurora kinase
inhibitor




EI275 Enables reprogramming of MEFs transduced with
OKM when combined with VPA [81]
Dasatinib, PP1,
and iPYrazine
Sufficient to support reprogramming of MEFs in the
absence of exogenous Sox2 [104]
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Table 9.1 (Continued)
Chemical
Category compounds Working conditions and effects
MEK inhibitor PD0325901 Promotes transition to mature iPSCs [55,97]





BayK8644 Improves reprogramming of MEFs transduced with OK
when combined with BIX01294 and RG108 [69]
PKA activator 8-Br-cAMP Improves reprogramming efficiency of human
neonatal foreskin fibroblasts [105]
PDK1 activator PS48 Promotes iPSC generation from human somatic cells
transduced with only Oct4 when combined with





Enhance mouse iPSC generation [100]
Senescence
alleviator
Resveratrol Improves reprogramming efficiency [142]
Vitamin C Improves reprogramming efficiency of mouse and
human fibroblasts [76,110]
Improves quality of iPSCs reprogrammed from mouse
fibroblasts and B lymphocytes, allowing generation
of all-iPSC mice [122]
O, Oct4; K, Klf4; S, Sox2; M, c-Myc.
9.2 Chemicals Modulating Epigenetic Barriers
Reprogramming involves the genome-wide reshuffling of the transcriptome and chromatin
statuses of a somatic cell to that of a pluripotent cell. At the epigenetic level, this event is
reflected in the dynamic and opposite remodeling of histone marks and DNA methylation
patterns present in the regulatory regions of somatic- and pluripotent-specific genes [57].
Under physiological conditions, the capacity of transcription factors to bind their target
sequences is modulated by the accessibility of DNA, resulting from chromatin organization.
The nucleosome, the basic subunit of eukaryotic chromatin, is composed of two molecules
of each of the core histone proteins H2A, H2B, H3, and H4, around which DNA is wrapped.
DNA accessibility is regulated at different levels by the deposition of specific histone marks
on nucleosomes, the inclusion of different histone variants, the activity of ATP-dependent
chromatin remodeling factors, and DNA methylation status [58].
A major mechanism controlling chromatin organization is the covalent modification of
histones, the building blocks of nucleosomes. Specific enzymes such as histone acetyltrans-
ferases, histone deacetylases (HDACs), histone methyltransferases, and histone kinases can
target different residues of histones and modulate their function. At the DNA level, the
methylation of CpG islands found in the promoter regions of many genes has profound
effects on their transcriptional status. Thus, chromatin-modifying enzymes play critical
roles in both reactivating silenced loci and reinstating the closed domains of heterochromatin
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during the global epigenetic remodeling of differentiated cells to pluripotency, suggesting
that these enzymes may act as facilitators or barriers to cell-fate transitions [59]. There-
fore, by modulating these specific epigenetic barriers, one may promote reprogramming
efficiency or even reduce the number of reprogramming factors. For example, inhibition
of the H3K79 histone methyltransferase Dot1L by gene knockdown can accelerate repro-
gramming, significantly increase the yield of iPSC colonies, and substitute for Klf4 and
c-Myc [59]. In principle, small molecules specifically modulating these different aspects
of chromatin and DNA structure may also have significant effects on reprogramming.
Indeed, a number of studies have shown that inhibitors of HDACs, histone methyltrans-
ferases, and histone demethylases or inhibitors of DNA methyltransferases can increase
reprogramming efficiency and/or replace the activity of certain reprogramming factors
[54, 60].
9.2.1 Histone Deacetylase Inhibitors
Although HDAC inhibitors have shown only a modest effect on the success rate of SCNT
(two- to fivefold) [61, 62], they have proved to significantly increase the efficiency of
iPSC generation. Using mouse embryonic fibroblasts (MEFs) derived from Oct4-GFP
reporter mice, Huangfu et al. [54] first showed that three HDAC inhibitors, valproic acid
(VPA), trichostatin A (TSA), and suberoylanilide hydroxamic acid (SAHA) greatly improve
reprogramming efficiency. Of the three, VPA exerts the most significant effect.
VPA (2 mM) induced >10% Oct4-GFP+ cells in MEFs infected with four-factor (Oct4,
Sox2, Klf4, and c-Myc) in 1 week, which amounts to >100-fold improvement compared
to the control. Furthermore, VPA promoted reprogramming efficiency in a dose-dependent
manner and its EC50 was ∼1.9 mM [54]. VPA has a synergistic effect with hypoxia when
reprogramming. Yoshida et al. reported that hypoxia and VPA alone could enhance iPSC
generation in MEFs transduced with four factors by ∼40-fold and ∼50-fold respectively,
while a combination of VPA and hypoxia could increase the reprogramming efficiency
more than 200-fold [63]. Notably, VPA can also increase the percentage of Oct4-GFP+
cells by 50 times when using only three factors (Oct4, Sox2, and Klf4), which is still much
higher than the four-factor reprogramming without chemical treatment [54]. Further study
has shown that VPA can also improve both four- and three-factor reprogramming efficiency
by 10–20-fold when used in primary human fibroblasts [64,65]. Importantly, VPA enables
reprogramming of human fibroblasts with only two factors, Oct4 and Sox2, without the
need for the oncogenes Klf4 or c-Myc [64]. The two-factor reprogramming efficiency
with VPA treatment is comparable to that of three-factor reprogramming without chemical
treatment in human fibroblasts [39,64]. Microarray analysis shows that VPA preferentially
upregulates ESC-specific genes and downregulates MEF-specific genes in the uninfected
MEFs, although VPA treatment alone is not sufficient to generate iPSCs from MEFs [54].
Mechanistically, VPA promotes histone acetylation, and appears to induce in MEFs a global
transcriptional program that leans toward an ESC-like state.
Besides its enhancing role in reprogramming, VPA has also been suggested to pro-
mote complete reprogramming and facilitate expansion of fully reprogrammed iPSCs by
inhibiting the growth of nonreprogrammed cells [48, 66]. Addition of VPA in four-factor
reprogramming generates more homogeneous iPSC colonies that highly resemble ESC
colonies [66]. Furthermore, some of these iPSC lines can produce adult mice using tetraploid
Chemicals Facilitating Reprogramming 147
complementation assays, suggesting that fully pluripotent iPSCs can be generated by com-
bination of VPA with four factors [66].
In addition to reprogramming using the four Yamanaka factors, VPA also promotes repro-
gramming using cell-permeable recombinant proteins or microRNAs. Zhou et al. showed
that VPA is essential to the generation of stable iPSCs from MEFs using recombinant
proteins (Oct4-11R, Sox2-11R, Klf4-11R, and c-Myc-11R), a method that circumvents
genetic modifications associated with the classic approach, which introduces reprogram-
ming genes through retroviral infections [50]. Three GFP+ colonies per 5 × 104 MEF
cells were obtained when they were transduced with four proteins (Oct4-11R, Sox2-11R,
Klf4-11R, and c-Myc-11R) and treated with VPA, and one GFP+ colony per 5 × 104 cells
when they were transduced with only three proteins (Oct4-11R, Sox2-11R, and Klf4-11R)
and treated with VPA. However, no stable GFP+ colonies were obtained from transduction
of the three or four reprogramming proteins without VPA for the same period of time [50].
Anokye-Danso et al. showed that combination of VPA treatment and miR302/367 clus-
ter expression can generate iPSCs from MEFs without using any exogenous transcription
factors, while miR302/367 alone cannot efficiently reprogram MEFs [52]. Further exper-
iments demonstrated that VPA induced degradation of Hdac2 proteins and low levels of
Hdac2 permitted miR302/367 reprogramming. However, using human foreskin and dermal
fibroblasts, miR302/367 expression generates iPSCs without VPA, presumably due to low
levels of Hdac2 being expressed in human fibroblasts [52].
Sodium butyrate (NaB), a naturally occurring fatty acid commonly used as a nutritional
supplement and differentiation agent and an analog of VPA, has also been shown to greatly
enhance the efficiency of iPSCs from human adult or fetal fibroblasts [65]. After transient
butyrate treatment, the iPSC derivation efficiency is enhanced by 15–51-fold. Butyrate
has a stronger effect (100–200-fold) on reprogramming in the absence of either Klf4 or
c-Myc transgene. BIX01294 (see Section 9.2.2) can synergize with butyrate to further
enhance the butyrate-stimulated reprogramming by three factors in human fibroblasts or
mesenchymal stem cells (MSCs). By day 6–12 during reprogramming, butyrate treatment
enhances histone H3 acetylation, promoter DNA demethylation, and the expression of
endogenous pluripotency-associated genes [65]. Since NaB is an analog of VPA, their
reprogramming-enhancing mechanisms might be the same.
Histone acetylation and deacetylation regulate chromatin structure and transcriptional
activity. The genome-wide acetylation induced by VPA and other HDAC inhibitors could
allow fibroblasts to adopt a more open chromatin structure that facilitates the binding of
ectopically expressed reprogramming factors or downstream secondary factors [67], and
thus promotes reprogramming efficiency. Since NaB and VPA appear to have stronger
effects on reprogramming than other HDAC inhibitors, it is possible that these two com-
pounds also act through additional, yet unidentified mechanisms to regulate reprogramming.
9.2.2 Histone Methyltransferase Inhibitor and Demethylase Inhibitor
Histone methylation and demethylation also play important roles in regulating gene expres-
sion and reprogramming. BIX01294 (BIX), an inhibitor of the G9a histone methyltrans-
ferase [68], improves the reprogramming efficiency in mouse neural stem cells (NSCs)
and fibroblasts that were transduced with only two factors (OK) [55, 69]. The two-factor
(OK) reprogramming efficiency of BIX-treated NSCs is comparable to four-factor (OSKM)
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reprogramming [55]. Although the overall efficiency is improved, the reprogramming pro-
cess is not significantly shortened by the presence of BIX. Interestingly, BIX treatment
enables reprogramming of NSCs to iPSCs with KSM, without the need for Oct4, albeit
at a low frequency [55]. Because G9a promotes histone H3 methylation on Lys 9 and
inhibits Oct4 by attracting de novo DNA methylases to the Oct4 promoter [70], by inhibit-
ing G9a, BIX may release repression of endogenous Oct4 and thus reduce the need for
exogenous Oct4 during reprogramming of NSCs. It has been shown that Sox2 can maintain
ESC pluripotency by regulating the expression of Oct4 [71]. NSCs endogenously express
Sox2 and c-Myc, and expression levels of Sox2 and c-Myc are comparable to those in
ESCs [72, 73]. Generation of iPSCs from NSCs can be achieved by expressing only Oct4
and Klf4 [73]. Therefore, it is not clear whether BIX actually functionally replaced Sox2
and c-Myc in the cases of reprogramming of NSCs. In a further study using OK-infected
MEFs, Shi et al. showed that, unlike NSCs, BIX treatment did not effectively enhance
generation of iPSCs [69]. However, when combined with a DNMT inhibitor, RG108, and
an L-calcium channel agonist, BayK8644, BIX significantly increased reprogramming of
MEFs in the absence of Sox2 and c-Myc [69]. The mechanism by which BayK8644 acts
remains unclear, however, as BayK8644 alone or in combination with BIX did not alter
cell proliferation or Sox2 expression.
In a reprogramming study using human primary keratinocytes, the cells were transduced
with two-factor combinations (Oct4/Klf4, Oct4/Sox2, and Sox2/Klf4) and treated with
CHIR99021 (a glycogen synthase kinase 3 (GSK3) inhibitor) alone or combined with
epigenetic modifiers, including inhibitors of DNA methyltransferase (DNMT) (RG108),
histone methyltransferase (BIX01294), HDAC (VPA), and lysine-specific demethylase 1
(LSD 1) (Parnate). Using the human pluripotency cell-surface marker Tra-1-81, hESC-
like colonies were identified only from cells infected by Oct4 and Klf4 and treated with
CHIR99021 and parnate [74]. Parnate, also known as tranylcypromine, is a monoamine
oxidase inhibitor. It exhibits a potent inhibitory effect on LSD1 and inhibition of H3K4
demethylation, but it does not affect the acetylation of H3K9/K14. Parnate may facilitate
the reprogramming of human keratinocytes by inhibiting H3K4 demethylation. In another
study, parnate together with VPA, CHIR99021, and E-616452 (a transforming growth factor
β (TGFβ) inhibitor) was sufficient to induce reprogramming in MEFs in combination with a
single transcription factor, Oct4, without the need for Sox2, Klf4, or c-Myc [75]. However,
how histone demethylase inhibitors enhance reprogramming remains unclear.
Chemical inhibitors of histone demethlyases (the iron chelator desferrioxamine or
the α-ketoglutarate analog dimethyloxalylglycine) inhibit Sox2/Klf4/Oct4 (SKO) repro-
gramming in a dose-dependent manner [76]. The combination of the histone demethy-
lases Jhdm1a and 1b can promote reprogramming of MEFs using three-factor SKO, and
even more efficiently in the presence of vitamin C [76]. In addition, through its histone
demethylase activity, Jhdm1b enables reprogramming with only Oct4 in the presence of
vitamin C [76].
In a recent study, a new class of chemical compounds that specifically inhibit histone
demethylase LSD1 has been developed [77]. Unlike monoamine oxidase inhibitors, the new
LSD1 inhibitors specifically interact with LSD1 and inhibit its activity without forming a
covalent bond. These new inhibitors enhance H3K4 methylation and derepress epigeneti-
cally suppressed genes in vivo. Strikingly, these compounds inhibited the proliferation of
pluripotent cancer cells (including teratocarcinoma, embryonic carcinoma, and seminoma)
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and ESCs that expressed the stem-cell markers Oct4 and Sox2 while displaying minimum
growth-inhibitory effects on nonpluripotent cancer or normal somatic cells [77]. It would
be interesting to see whether these new LSD1 inhibitors have a different effect on cellular
reprogramming to pluripotency compared with parnate, and such studies might be able to
provide further mechanistic understanding of reprogramming.
9.2.3 DNA Methyltransferase Inhibitors
DNA methylation is one of the common epigenetic mechanisms regulating gene silencing.
Pluripotent stem cells have a less methylated epigenetic signature than somatic cells.
Therefore, inhibition of DNMTs can reactivate the expression of genes that have been
repressed by DNA methylation, which may facilitate cellular reprogramming.
A prototypical inhibitor of DNMT, 5-Aza-cytidine (5-aza), is a chemical analog of the
DNA and RNA nucleoside cytidine. 5-aza needs to be incorporated into DNA to covalently
trap DNMTs [78]. 5-aza has a half-life of 17 hours and is considerably cytotoxic [78]. Not
only can it enhance reprogramming efficiency, but it also improves reprogramming quality
by pushing partially reprogrammed cells forward to a complete reprogrammed state. 5-aza
treatment increases the percentage of Oct4-GFP+ cells in both four- and three-factor-
infected MEFs in a dose-dependent manner, and increases the number of ESC-like colonies
formed during reprogramming [24, 54]. Dexamethasone (1 μM), a synthetic glucocorti-
coid, improves the effect of 5-aza further, although dexamethasone alone has no effect
[54]. Furthermore, 5-aza induces a rapid and stable transition to a fully reprogrammed
iPSC state when used on partially reprogrammed MEFs [24]. Partially reprogrammed
MEFs treated with 5-aza reactivated endogenous Oct4, exhibited demethylation at the pro-
moters of pluripotency genes, and formed teratomas when injected into severe combined
immunodeficiency (SCID) mice, just like fully reprogrammed iPSCs [24]. These find-
ings suggest that DNA demethylation is a critical step in direct reprogramming, and that
inhibition of DNMT facilitates the transition to pluripotency by lowering this epigenetic
barrier [24].
RG108 is a non-nucleoside DNMT inhibitor with a mean half-life of 20 days [78].
It significantly inhibits DNA methylation in cells at 10 μM without detectable toxicity,
distinguishing it from nucleoside-based inhibitors like 5-aza. Furthermore, RG108 can
inhibit free DNMTs; the inhibition of DNMT activity is achieved by blocking the enzyme
active site [78]. RG108 enhances the reprogramming efficiency of MEFs transduced with
Oct4 and Klf4 in the presence of a histone methyltransferase inhibitor, BIX01294 [69]. It
also increases the reprogramming efficiency of human fibroblasts transduced with all four
Yamanaka factors (OSKM) by twofold [65]. Although RG108 is a more potent and non-
covalent DNMT inhibitor than 5-aza, it appears to have a lesser effect on reprogramming.
This could be due to the differences in experimental specifications in different studies. The
mechanism by which RG108 enhances reprogramming has not been further elucidated,
though it is reasonable to assume that RG108 and 5-aza both promote reprogramming by
modulating DNA methylation.
More recently, Lee et al. reported that a novel indoleacrylic acid analog, named RSC133,
promotes iPSC generation from both mouse and human fibroblasts [79]. Continuous treat-
ment with RSC133 throughout reprogramming increased the reprogramming efficiency
by up to fourfold. Under hypoxic conditions (5% O2), RSC133 synergistically increased
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the reprogramming efficiency to five- to sixfold compared to untreated controls [79]. On
treatment with RSC133, OSKM-transduced human fibroblasts displayed a rapid activation
of pluripotency genes and highly proliferative hESC-like colonies in 10 days, suggesting
that RSC133 significantly enhanced both the efficiency and kinetics of the reprogramming
process [79]. The enhanced reprogramming efficiency was most likely due to RSC133 pro-
motion of cell proliferation, ablation of pro-senescence phenotypes, inhibition of DNMT1
activity, and subsequent reduction of HDAC activity [79].
5-aza, RG108, and RSC133 are structurally very different DNMT inhibitors, and the
ways in which they modulate DNMT activities are also different. It is not clear whether
these differences have any effects in their promotion of reprogramming.
9.3 Chemicals Targeting Signaling Pathways
Although chemicals that modify epigenetic state have been shown to improve reprogram-
ming efficiency, the precise molecular mechanisms remain elusive. Presumably, they facil-
itate the shifting of epigenetic balances among different states during reprogramming and
these epigenetic modifiers have broad effects on the epigenome [80]. Studies have shown
that small molecules targeting certain signaling pathways can also promote reprogram-
ming. Many of these signaling pathways are involved in the regulation of pluripotency gene
expression, cell proliferation, and pluripotency maintenance. Therefore, these studies not
only show that chemical compounds that modulate signaling pathways can improve gener-
ation of iPSCs but also provide insights and direct clues about the molecular mechanisms
of reprogramming.
9.3.1 TGF𝛃 Signaling Inhibitors
It has been shown that TGFβ signaling plays important roles in reprogramming. In a
study by Ichida et al. through a high-content chemical screen, two inhibitors of TGFβ
receptor-1 kinase (E616451 and E616452) had been identified [81]. E616451 can replace
Sox2 to induce iPSCs from OKM-transduced MEFs in the presence of VPA. In contrast,
E616452 can functionally replace transgenic Sox2 in the absence of VPA and c-Myc,
and thus it has been named “RepSox” [81]. RepSox is not involved in direct activation
of endogenous Sox2. Similarly, TGFβ-neutralizing antibodies and a nonspecific inhibitor
of TGFβ receptor-1 kinase (SB431542) can also replace Sox2 during reprogramming.
Furthermore, inhibition of TGFβ signaling early in reprogramming also alleviates the
need for transgenic c-Myc expression [81, 82]. Maherali and Hochedlinger demonstrated
that inhibition of TGFβ signaling at early time points (days 1–3) during mouse fibroblast
reprogramming could effectively substitute for transgenic Sox2 [82]. In contrast, Ichida
et al. found that Sox2 replacement by RepSox was a late event (beginning at day 10–11).
Moreover, only a 24-hour pulse of RepSox at day 11 on OKM-transduced MEFs was
able to induce detectable reprogramming, suggesting that RepSox acts by triggering an
endogenous switch in partially reprogrammed cells [81, 83]. In OKM-transduced partially
reprogrammed MEFs, inhibition of TGFβ signaling by RepSox, SB431542, and anti-TGFβ
antibodies can induce Nanog expression, leading to full reprogramming [81]. However, the
mechanism by which RepSox activates Nanog remains elusive.
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Several TGFβ superfamily members represent important contributors to the pluripotent
state. For instance, BMP4 signaling helps maintain mouse ESCs in an undifferentiated
state [84], and use of a TGFβ inhibitor (A-83-01) in conjunction with mitogen-activated
protein kinase kinase (MEK) and GSK3 inhibitors is critical for ultimate reprogramming
and maintenance of rat iPSCs [85]. Lin et al. found that reprogramming efficiency was
significantly improved in OSKM-transduced human primary fibroblasts when treated with
a combination of the ALK5 inhibitor SB431542 (2 μM) and the MEK inhibitor PD0325901
[86]. However, Maherali and Hochedlinger did not observe enhancing effects of RepSox
in human fibroblasts transduced with OSKM [82]. The TGFβ inhibitor A-83-01, combined
with a protein arginine methyltransferase inhibitor, AMI5, enabled reprogramming of MEFs
transduced with Oct4 alone, and the derived iPSCs could give rise to liveborn pups through
tetraploid complementation [87].
Reprogramming of fibroblasts to iPSCs requires a fundamental process termed
mesenchymal–epithelial transition (MET) [88,89]. During MET, the mesenchymal fibrob-
lasts undergo dramatic morphological changes that result in iPSCs with distinct cell polar-
ities, boundaries, and cell–cell interactions, as well as high E-cadherin expression [80].
Inhibition of TGFβ signaling promotes MET during reprogramming [88, 89]. Therefore,
those TGFβ inhibitors that enhance reprogramming reported previously might also involve
enhanced MET induced by the inhibitors [81, 82, 86].
9.3.2 Wnt Signaling and GSK3 Inhibitors
The Wnt signaling and β-catenin pathways have been shown to play important roles in both
ESC self-renewal and ESC differentiation toward lineage-committed cell types [90, 91].
The Wnt signaling pathway contributes to the maintenance of self-renewal of both mouse
embryonic stem cells (mESCs) and hESCs through inhibition of GSK3 and the subsequent
nuclear accumulation of β-catenin [91, 92]. Mechanistically, when the canonical Wnt sig-
naling pathway is stimulated, β-catenin translocates into the nucleus and then interacts with
Tcf/Lef proteins to activate target genes [93]. During reprogramming, constitutively active
β-catenin may promote reprogramming of fibroblasts to pluripotency [21]. When Oct4-GFP
reporter MEFs were infected with three factors (OSK), a small population (∼0.3%) of GFP+
cells was detected until day 20 only when cultured in Wnt3a-conditioned medium (Wnt3a-
CM) [94]. The iPSC colonies induced by OSK+Wnt3a-CM morphologically appeared
homogenously ESC-like. Moreover, at 4 weeks, Wnt3a-CM promoted the reprogramming
efficiency up to 20-fold in OSK-infected MEFs based on endogenous Oct4-GFP+ colony
counting. Conditioned media from control fibroblasts also moderately improved repro-
gramming, suggesting that normal fibroblasts may secrete soluble factors beneficial to
reprogramming [94]. In contrast, Wnt3a-CM only slightly increased reprogramming effi-
ciency when using OSKM four factors (including c-Myc) [94]. These data suggest that
Wnt3a can compensate for exogenous c-Myc gene expression in terms of reprogramming
efficiency.
Besides the direct promoting effects on reprogramming, Wnt3a can also enhance somatic-
cell reprogramming mediated by cell fusion [95]. Deletion of Tcf3, which in turn derepresses
β-catenin target genes, can enhance both cell fusion-mediated and Oct4-Klf4 (OK)-induced
direct reprogramming of NSCs [96]. Interestingly, this reprogramming process appears not
to be independent of β-catenin; rather, it seems to be coupled with the activity of the Wnt
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signaling pathway [96]. Furthermore, the increased reprogramming efficiency is largely
attributable to genome-wide epigenome modifications that occur before the endogenous
stem-cell genes are reactivated in the iPSC clones.
GSK3 is an important part of the canonical β-catenin/Wnt pathway, which signals the
cell to divide and proliferate. Inhibition of GSK3 has been shown to enhance reprogram-
ming, presumably due to activation of Wnt signaling by inhibition of GSK3. Silva et al.
showed that inhibition of mitogen-activated protein kinase kinase (MEK) and GSK3 (using
PD0325901 and CHIR99021 (2i), respectively) can promote “pre-iPSCs” into fully repro-
grammed pluripotent cells (ground-state pluripotency) under leukemia inhibitory factor
(LIF) treatment [97]. Another GSK3/cyclin-dependent kinase 2 (CDK2) inhibitor, ken-
paullone, can substitute Klf4 in reprogramming of MEFs in the presence of Oct4, Sox2,
and cMyc [98]. However, as a more specific GSK3 inhibitor, CHIR99021, failed in pro-
ducing the same positive effects on inducing the reprogramming of MEF cells under the
Oct4/Sox2/c-Myc transduction [98], the effects of kenpaullone may not result from its
GSK3 inhibition, and the precise mechanism remains elusive.
The GSK3 inhibitor CHIR99021 (10 μM) can however induce the reprogramming of
MEFs transduced by only two factors, Oct4 and Klf4, but not any other two-factor com-
bination of OSKM [74]. MEFs do not express Sox2 endogenously, and RT-qPCR analysis
revealed that CHIR99021 treatment did not induce the expression of Sox2 and Oct4 in
MEFs [74]. Therefore, the mechanisms by which CHIR99021 promotes the reprogramming
of MEFs transduced by Oct4 and Klf4 are independent of direct Sox2 induction. When
combined with parnate (known as tranylcypromine, 2 μM), an inhibitor of lysine-specific
demethylase 1 (LSD1), CHIR99021 can cause the reprogramming of human primary ker-
atinocyte transduced with the two factors Oct4 and Klf4 (OK) [74]. On average, about
two Tra-1-81-positive colonies can be obtained from 1 × 105 transduced keratinocytes.
Addition of PD0325901 (0.5 μM) and SB431542 (2 μM) can further increase the repro-
gramming efficiency using CHIR99021 and parnate with OK [74]. Notably, pretreatment of
mESCs with a small-molecule GSK3β kinase inhibitor, 6-bromoindirubin-3′-oxime (BIO),
can enhance the ability of ESCs to reprogram somatic cells after fusion [95]. However, BIO
cannot enhance somatic-cell reprogramming to pluripotency via direct reprogramming
induced by OSKM [95].
9.3.3 Other Kinase Inhibitors and Activators
An inhibitor of the protein kinase ROCK, known as Y27632, which allows survival and
clonogenicity of single dissociated hESCs [99], has been widely used in hiPSC generation.
Another ROCK inhibitor, thiazovivin, whose function is to regulate E-cadherin stability
and facilitate cell–cell interactions, can also promote reprogramming when combined with
SB431542 and PD0325901 [86]. Another study shows that two small molecules, apigenin
and luteolin, can also enhance mouse induced pluripotent stem cell (miPSC) generation
through upregulation of E-cadherin [100]. A myosin inhibitor, blebbistatin, can efficiently
inhibit hiPSC apoptosis induced by ROCK-dependent hyperactivation of actomyosin during
dissociation and replating, resulting in better cell survival and colony formation [101].
However, it has not been shown whether blebbistatin can also enhance reprogramming
efficiency.
Inhibitors for other kinases such as p38 MAPK, inositol trisphosphate 3-kinase (IP3K),
and Aurora A kinase (Aurka) can also enhance iPSC generation from MEFs. Inhibition
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of Aurka can inactivate GSK3β mediated by the Akt signaling pathway, resulting in an
increased reprogramming efficiency [102]. Contradictorily, Lee et al. reported that during
reprogramming, Aurka activity increases, while depletion of Aurka leads to increased
activity of p53, resulting in a reduced reprogramming efficiency [103].
A few other small molecules that affect many other signaling pathways also facilitate
iPSC reprogramming. Pan-Src-family kinase inhibitors, including EI275, Dasatinib, PP1,
and iPYrazine, support reprogramming of MEFs in the absence of exogenous Sox2 as
efficiently as TGFβ inhibitors [81, 104]. An activator of cyclic AMP-dependent protein
kinase (PKA), 8-bromoadenosine 3′, 5′-cyclic monophosphate (8-Br-cAMP), can improve
the reprogramming efficiency of human neonatal foreskin fibroblasts [105].
These observations are consistent with the fact that the GSK3 pathway, the PKA pathway,
and Src-family kinases influence ESC self-renewal and differentiation. These data again
suggest that the inhibitors and activators of key signaling pathways in ESC self-renewal
and differentiation are more likely to be able to regulate the efficiency of reprogramming
to pluripotency. This can be used as one of the guidelines for small-scale chemical screen.
Interestingly, an activator of the 3-phosphoinositide-dependent protein kinase-1 (PDK1)-
PI3K/Akt pathway, PS48, can significantly induce expression of glycolytic genes and pro-
mote iPSC generation from human somatic cells transduced with only Oct4 when combined
with NaB and A-83-01 [106]. These data suggest that modulation of cellular metabolism
by small molecules may provide an additional way of improving reprogramming.
9.3.4 Cell Senescence Alleviators
Cell senescence represents an irreversible arrest in the G1 phase of the cell cycle induced
by replicative exhaustion or in response to a number of stresses, such as DNA dam-
age, chemotherapeutic drugs, or ectopic expression of oncogenes. This arrest is mainly
implemented through p53 activation and upregulation of the CDK inhibitors p16INK4a and
p21CIP1 [107]. The observation that early-passage MEFs reprogram with much higher effi-
ciency than late passages, in which β-galactosidase-positive senescent cells accumulate,
suggests a high replicative potential of the donor cell is critical for successful reprogram-
ming to pluripotency [108]. Moreover, ectopic expression of OKSM in human fibroblasts is
sufficient to increase the percentage of G1-arrested cells displaying senescent-associated β-
galactosidase (SA β-Gal) activity and senescence-associated heterochromatic foci (SAHF)
[109].
Several factors may contribute to the induction of senescence and/or apoptosis in repro-
gramming factor-expressing cells. For instance, the level of reactive oxygen species (ROS)
[109, 110] is significantly increased in the pool of cells expressing OSKM, correlating
with an overall upregulation of critical senescent effectors such as p16INK4a and p21CIP
[109]. Alternatively, but not exclusively, senescence and/or apoptosis can be elicited by
an increase in the DNA double-strand breaks (DSBs) observed in cells expressing OSKM
or OSK [111]. Consistently, genetic ablation or shRNA knockdown of the tumor suppres-
sors p53 [109, 112–115], p21CIP1 [109, 113], or genes belonging to the Ink4/Arf locus
[108, 109, 116] have a positive effect on the efficiency of reprogramming, suggesting the
activity of these genes acts as a barrier to reprogramming.
Therefore, transient alleviation of cell senescence using chemical compounds during
reprogramming may represent a simple way of increasing reprogramming efficiency,
particularly in the context of nonintegrative approaches, which usually show very low
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efficiencies [117]. However, because p53, p16INK4a, and p21CIP are key players in safe-
guarding chromosomal stability, their manipulation should be considered very carefully in
order to generate therapeutically relevant iPSC lines, since their activity during reprogram-
ming may be essential to eliminating cells accumulating chromosomal aberrations due to
high levels of DNA damage [111]. A more appealing alternative would therefore be to act
upstream, on the causes leading to cell senescence during reprogramming.
As we just mentioned, one of the possible triggers of cell senescence and/or apoptosis
during reprogramming is the accumulation of ROS. High ROS levels promote the modifica-
tion of individual nucleotide bases, the formation of single and double strand breaks [118],
and telomere shortening [119], all of which result in the activation of the p53 pathway.
Consistently, a recent study shows that two antioxydants, resveratrol and curcumin, sig-
nificantly improve reprogramming efficiency in MEFs [120]. Another antioxidant, vitamin
C, has also been shown to positively affect the reprogramming of MEFs using OSKM
and OSK, and of human fibroblasts using OSKM [110]. Reprogramming enhancement by
vitamin C does not however seem to result from its antioxidant activity but rather from
the decreasing level of p53 [110]. Further studies have revealed that vitamin C enhances
reprogramming by promoting histone demethylation of the Ink/Arf locus of Jhdm1a/1b
and by activating the miR302-367 microRNA cluster [76]. Vitamin C has also been shown
to influence DNA methylation patterns in hESCs [121]. Reprogramming in the presence
vitamin C reduces the hypermethylation of the Dlk1-Dio3 locus by promoting a chromatin
configuration, interfering with the binding of the de novo DNMT Dnmt3a and thus allowing
all-iPSC mice to be generated from mature B cells [122].
9.4 Chemicals Promoting Lineage Reprogramming
In addition to reprogramming to pluripotency, it has been shown that one cell type can be
directly reprogrammed into another without going through a pluripotent state by ectopically
expressing lineage-specific genes. This is termed lineage reprogramming or transdifferenti-
ation and can be achieved both in vitro and in vivo. For example, fibroblasts can be directly
converted into myoblasts by MyoD [123], functional neurons by Ascl1/Brn2/Mytl1 [124],
and cardiomyocytes by Gata4/Mef2c/Tbx5 [125], while exocrine cells in a mouse pancreas
can be converted into islet β-like cells by Pdx1/MafA/Ngn3 [126]. It seems that lineage
reprogramming may be a faster and more efficient means of generating functional cell
types and essentially eliminates the teratoma risk of using pluripotent cells. However, cell
proliferation rate may be limited during lineage reprogramming, because terminally differ-
entiated cells usually have a very low proliferation rate compared to iPSCs. Recently, it has
been shown that by transiently expressing all four Yamanaka factors or by expressing one of
the Yamanaka factors (Sox2 or Oct4) in mouse or human fibroblasts, lineage-specific cells
or precursors can be generated directly from fibroblasts without going through pluripotency
[127–130]. One of the advantages of this method is that the transcription factors are uni-
versal and may be easily replaced by safer and more convenient methods without genetic
modification [131].
As in reprogramming to pluripotency, there is a dramatic change in epigenetic state
during lineage reprogramming; therefore, it is conceivable that we can improve lineage-
reprogramming efficiency using chemical molecules as epigenetic modifiers, although this
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remains to be investigated. Furthermore, we can imagine that employing lineage-specific
chemical signals during transdifferentiation may facilitate lineage conversion.
Ladewig et al. showed that human fibroblasts can be efficiently converted into neuronal
cells by only expressing Ascl1 and Ngn2 in the neuronal medium containing a set of
small molecules (GSK3 inhibitor CHIR99021, TGFβ inhibitor SB-431542, and Noggin)
[132]. Spontaneously contracting cardiomyocytes can be generated from mouse fibroblasts
that transiently express all four Yamanaka factors for only 4–6 days with a JAK inhibitor
(JI1) and without LIF, followed by BMP4 treatment in a chemically defined medium for
an additional 5 days [127]. Similarly, mouse fibroblasts can be efficiently converted into
NSCs when the transient reprogrammed cells are exposed to neural reprogramming media
containing EGF, FGF2, and FGF4 [128]. Furthermore, mouse and human fibroblasts can
be converted into multipotent NSCs by only expressing a single factor, Sox2 [129]. During
this lineage reprogramming, the fibroblasts are cultured on gelatin-coated glass coverslips
in NSC medium supplemented with EGF and FGF2 [129]. Human fibroblasts have also
been directly converted to multipotent blood progenitors by prolonged overexpression of
Oct4 and treatment with complete F12 media containing FGF2 and IGF-II [130]. Supple-
menting with Flt3 and stem-cell factor (SCF) further increases the frequency of lineage
reprogramming [130].
In addition to the two lineage-reprogramming strategies discussed here, lineage-specific
cells can also be efficiently generated from hPSCs by expressing a set of lineage-specific
transcription factors at certain stages of differentiation and culturing them with lineage-
induction media with specific chemical signals [133–136]. For example, mature white
and brown adipocytes can be generated by expressing PPARG2 alone or in combination
with CEBPB and/or PRDM16 in mesenchymal progenitor cells derived from hPSCs under
adipogenic medium [134]; functional neurons can also be rapidly generated from hPSCs
by expressing Ascl1/Brn2/Mytl1 under N3 media [135]. The media used in these studies
are the same as the media used for directed differentiation from hPSCs, with the addition
of lineage-specific chemical signals.
Since some of the chemicals used for pluripotency reprogramming can decondense
chromatin structure and reduce epigenetic barriers for reprogramming, we would imagine
that if we select and combine the chemicals used for pluripotency reprogramming together
with lineage-specific chemicals, we might be able to further improve lineage conversion
efficiency. Chemicals used for pluripotency reprogramming may ease the transition into
other lineages, and lineage-specific chemicals may direct conversion toward a desired
lineage. This concept remains to be tested at this time.
9.5 Conclusion
Pluripotent stem cells represent powerful platforms for basic research, disease modeling,
drug screening, and regenerative medicine. The recent availability of simple approaches to
the generation of patient-specific pluripotent stem cell lines through pluripotency repro-
gramming or specific differentiated cell types through lineage reprogramming not only
brings us closer to the implementation of cell-based therapies in humans but also contributes
significantly to our understanding of the mechanisms underlying lineage commitment and
cell plasticity. Efficiently complementing the overexpressing of defined transcription factors
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with chemical manipulation represents an effective tool for directing changes in cell fate
and facilitating reprogramming or transdifferentiation, and for dissecting the mechanisms
governing these dramatic changes in cell fate.
Chemical compounds may have an effect on reprogramming at different levels by mod-
ulating epigenetic states, regulating master gene expression, controlling key signaling
pathways, or preventing cell senescence. To improve reprogramming through chemical
treatment, future work should focus on screening compounds that improve the erasure of
the somatic gene expression signature, activate master regulators of pluripotency and self-
renewal, and enhance chromatin plasticity. Sometimes, the mechanisms by which novel
small molecules identified in a chemical screen can enhance reprogramming efficiency or
quality remain unknown and need to be further investigated. For example, an Oct4-activating
compound was found to activate both Oct4 and Nanog and increase reprogramming effi-
ciency in MEFs transduced with four factors, but the underlying mechanism was unclear
[137]. In addition, it seems that most chemicals can not only promote reprogramming in
mouse cells but also enhance reprogramming in human cells. Whether these chemicals
function in the same way and result in the same quality of iPSCs in mouse and human
remains to be explored. Understanding how chemicals assist in reprogramming will allow
us to use them more effectively.
For cell-replacement therapy, high-quality, safe, and large numbers of iPSCs are desired.
We need not only to find chemicals that can significantly speed up the generation of iPSCs
from a patient’s cells but also to identify chemicals that can generate safe iPSCs. It has been
shown that iPSCs can still acquire many mutations during reprogramming even when using
a nonintegrated method for transduction [111, 138–141]. These genetic abnormalities may
originate from the oncogenic activity of the reprogramming factors and from epigenetic
remodeling during reprogramming. Using chemicals to replace one or more transcription
factors has been a step toward achieving safer iPSCs. So far, there have been no chemicals or
chemical combinations that can completely replace the four transcription factors reported.
Further studies focusing on the combination of multiple chemicals at certain reprogram-
ming stages may be helpful in completely eliminating the need for transcription factors.
In addition, most of the chemicals used to enhance reprogramming can promote global
modifications and result in genetic aberrations in iPSCs. Identifying additional chemicals
for the generation of safe iPSCs is critical to the therapeutic application of iPSCs.
To conclude, the development of chemical approaches to manipulating cell fate and the
constant synthesis of new compounds or improvement of existing ones has placed small
molecules in a central position in the design of safe patient-derived iPSC lines suitable
for cell-replacement therapy. By carefully selecting and combining the chemicals used for
pluripotency reprogramming with lineage-specific chemical signals, we should be able to
efficiently generate safe and high-quality lineage-specific functional cells for such therapy.
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10.1 Introduction
A variety of reprogramming strategies are being developed that address the safety concerns
associated with protocols dependent on genetic alterations such as virus-based reprogram-
ming. Approaches include the use of nonintegrating plasmids and mRNA [1–6], microRNA
[7], excisable transposons [8, 9], and proteins [10, 11]. An alternative method to enhance
reprogramming is the use of a small-molecule inhibitor, or a cocktail of small-molecule
inhibitors. Several chemicals have been reported to either improve reprogramming effi-
ciency or substitute for specific factors. DNA and histone methyltransferase inhibitors,
in particular, have shown tremendous promise in improving reprogramming efficiencies
and generating safer induced pluripotent stem cells (iPSCs). These enzymes play impor-
tant roles in controlling gene expression and are gaining attention in drug discovery and
medicinal chemistry due to their association with a variety of pathologies. The objective
Chemical Biology in Regenerative Medicine: Bridging Stem Cells and Future Therapies, First Edition.
Edited by Charles C. Hong, Ada S. Ao, and Jijun Hao.
© 2014 John Wiley & Sons, Ltd. Published 2014 by John Wiley & Sons, Ltd.
164 Chemical Biology in Regenerative Medicine
of our studies is to identify novel lead compounds for human DNMT1 and histone methyl-
transferase inhibition targeting the S-adenosylmethionine (SAM) binding pocket of these
enzymes, utilizing computer-based approaches.
10.2 DNA Methyltransferases, Inhibition, and Reprogramming
Reprogramming of mouse and human fibroblasts is an inefficient process. For mouse
embryonic fibroblasts (MEFs), Mikkelson and colleagues reported that only a small
percentage of cells transduced with defined transcription factors reactivated endogenous
Nanog. Moreover, the majority of infected cells appeared to be trapped in a partially
reprogrammed state [12–14]. They further demonstrated that partially reprogrammed cells
could be induced to become fully reprogrammed by treatment with the DNA methyl-
transferase inhibitor 5-aza-cytidine (5-AZA). In addition, treatment with 5-AZA improved
embryonic stem cell (ESC)-like colony formation by fourfold. We have proposed that
epigenetic modification increases somatic cell reprogramming efficiency through (i) direct
activation of pluripotent gene expression and (ii) activation of a pluripotent transcription
factor network that is unique in pluripotent stem cells, including ESCs [15]. To test this
hypothesis, we used a combination of two epigenetic modifying agents: a DNMT inhibitor
and a histone-modifying enzyme inhibitor [15]. Primary cultures from three different
origins of human dermal fibroblast (adult, neonatal, and fetal) were treated with epigenetic
modifying agents with and without ectopic expression of Oct4 and Nanog genes. As shown
in Figure 10.1, inhibition of DNMT in human dermal fibroblast cultures induced the expres-
sion of Oct4, Nanog, and Sox2 through auto- (Figure 10.1a) and reciprocal activation of the
endogenous pluripotent transcription factor network (Figure 10.1b). In addition, DNMT
inhibitor treatment, both before and after lentiviral-induced pluripotent factor expression,
increased the efficiency of colony maturation by measuring co-expression of Sox2 (an early
pluripotent marker) and TRA1-60 (a late pluripotent marker) from alkaline phosphatase
(AP)-positive colonies (Figure 10.2). These results indicate that DNA methylation is an
important epigenetic barrier that can limit the production of fully reprogrammed cells and
that reprogramming efficiency can be improved by inhibiting specific repressive epigenetic
regulatory components at the level of ESC-like colony formation and maturation. DNA
methylation in mammalian cells occurs through the transfer of a methyl group from the
universal cofactor SAM to cytosine of CpG dinucleotides [16, 17] and is catalyzed by two
types of DNA methyltransferase: a maintenance methyltransferase, DNMT1, and de novo
methyltransferases, DNMT3a and 3b [18, 19].
10.3 DNMT Inhibitors
DNMT inhibitors are categorized into two groups: (i) nucleoside analogs, which incor-
porate into DNA and/or RNA and inhibit DNA methylation by trapping DNMTs, and
(ii) nonnucleoside analogs, which directly inhibit DNMT activity by blocking the SAM
pocket of the enzyme [20,21]. Only two DNMT inhibitors derived from the nucleoside cyti-
dine, 5-azacytidine, and 5-aza-2′-deoxycytidine (decitabine) are currently in clinical trials
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cancers such as acute lymphoblastic leukemia and myelodysplastic syndrome, these drugs
have shown severe cytotoxicity in patients due to random incorporation into all deoxycyti-
dine and cytidine sites of DNA and/or RNA, followed by DNMT depletion [24–26]. Most
DNMT inhibitors were identified by serendipity. In contrast, RG108 was the first DNMT
inhibitor identified and developed by virtual screening using 3D homology modeling of the
catalytic domain of DNMT1. RG108 has shown comparatively low cytotoxicity in human
cell lines, but the inhibition rate of RG108 for the purified DNMT1 is low (<20%) com-
pared to that of S-adenosylhomocysteine (SAH) (> 70%), a demethylated form of SAM
[27, 28]. There is a need to develop next-generation DNMT inhibitors for therapeutic and
reprogramming applications. Our efforts to develop a new class of DNMT inhibitor are
centered on the use of computer-based approaches with an experimental crystal structure
(3SWR).
10.4 Histone Methyltransferases, Inhibition, and Reprogramming
Protein lysine methylation is a key signaling mechanism in eukaryotic cells. Protein lysine
methyltransferases (PKMTs) catalyze the transfer of a methyl group from SAM to the
ε-amino group of lysine residues of proteins, including histones [29]. PKMTs show sub-
stantial variations in protein substrate selectivity and the degree of methylation on lysine
from mono- to di- to trimethylation. At present few small-molecule probes exist to dissect
the functionality of PKMTs.
Histone methyltransferases can be subdivided into three classes: the SET domain-
containing lysine methyltransferases and the non-SET-domain lysine methyltransferases
and arginine methyltransferases (PRMTs). The focus of this chapter is on histone lysine
methyltransferases. All of them use SAM as a cosubstrate for the methylation reaction
and generate SAH as a byproduct. Histone methylation does not alter the charge of the
lysine residue in question. However, it does affect the basicity, hydrophobicity, and size
of the amino acid side-chain group, which affects the affinity of proteins that recognize
such side chains [30]. Although these changes are subtle, there are proteins that are able to
bind selectively to certain methylated residues based on specific structural motifs [31] (for
review see [32]). Chromodomains recognize mono-, di-, or trimethylated lysine residues;
Tudor domains bind trimethylated lysines; plant homeo domain (PHD) fingers bind di- or
trimethylated lysines; malignant brain tumor (MBT) domains bind mono- and dimethylated
lysines.
Histone lysine methylation is associated with both transcriptional activation and repres-
sion. For example, methylation of the tumor-suppressor protein p53 on K370 by Smyd2 [33]
or on K382 by SET8 [34] leads to inhibition of transcriptional activity, whereas methylation
on K372 by Set9 results in transcriptional activation [35]. The lysine methyltransferase G9a
has recently been shown to dimethylate p53 on K373. This was correlated with inactivity of
p53 [36]. Its impact on apoptotic processes and its overexpression in various cancer types
suggest that G9a is a putative oncogene.
G9a is a Histone3 Lysine9 (H3K9) methyltransferase and has been reported to be over-
expressed in a variety of cancers [36–38]. G9a has also been shown to be involved in
cocaine addiction [39], mental retardation [40], and DNA methylation in mouse ESCs.
GLP is a closely related protein which shares 80% sequence identity with G9a and forms a
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heterodimer with it. Both G9a and GLP catalyze mono- and dimethylation of H3K9. Inhi-
bition of G9a and GLP using small-molecule inhibitors has been demonstrated to facilitate
the reprogramming of mouse neural precursor cells (NPCs) into iPSCs. Specfically, the G9a
methyltransferase inhibitor BIX-01294 (BIX) was shown to improve the reprogramming
efficiencies of OK (Oct4, Klf4)-infected NPCs by nearly eightfold [41]. G9a has been
reported to mediate the repression of Oct4 [42] and Nanog [43]. Thus, it is possible that
G9a inhibition could facilitate the reactivation of silenced Oct4 and Nanog and promote
reprogramming.
The beneficial effect of BIX on reprogramming was further substantiated using MEFs
[44]. BIX treatment in combination with the DNA methyltransferase inhibitor RG108 and
L-calcium channel agonist BayK8644 (BayK) signficantly enhanced the reprogramming
of BIX-treated MEFs transduced with Oct4 and Klf4. Thus, the combination of epigenetic
inhibitors with other target inhibitors may be required to overcome resistance to repro-
gramming and induce responsiveness. The development of selective, potent, and cell-active
chemical inhibitors would be extremely valuable in furthering the efficiency and elucidating
the mechanisms of somatic cell reprogramming.
In addition, suppression of the histone methyltransferases DOT1L and SUV39H1
improved reprogramming. In particular, inhibition of the H3K79 histone methyltransferase
DOT1L by shRNA or a small-molecule inhibitor increased the number of iPSC colonies,
while substituting for KLF4 and MYC [45]. Onder et al. further reported that fibroblast-
specific genes associated with the epithelial–mesenchymal transition lost H3K79me2 and
that DOT1L inhibition facilitated the loss of the mark from genes typically repressed in the
pluripotent state. These studies further suggest that specific chromatin-modifying enzymes
can be modulated to improve the efficiency of reprogramming and that the production of
iPSCs using only small molecules may be possible.
10.5 Inhibitors of Lysine Methyltransferases
Methyltransferases can be inhibited by analogs of the methyl group donor SAM. There are
three known cosubstrate analogs that inhibit a variety of methyltransferases: (i) sinefungin,
an antibiotic compound that is structurally similar to SAM; (ii) SAH, the demethylated
cosubstrate of SAM, which serves as a feedback inhibitor; and (iii) methylthioadenosine. All
of these inhibitors lack selectivity [46]. There are only a few known drug-like inhibitors of
lysine methyltransferases, most of which were discovered by random screening approaches.
The first inhibitor was chaetocin, a fungal mycotoxin. It inhibits both the Drosophila
melanogaster enzyme Su(var)3–9 with an IC50 of 0.8 mM and G9a with an IC50 of 2.5 mM
[47]. The compound BIX-01294 was identified in a combined virtual and high-throughput
screening approach and shown to be an inhibitor of G9a with an IC50 of 3 mM. Cultured
cells treated with BIX-01294 showed a reduction of histone H3K9 dimethylation and a
decrease in cell number. In the same screening procedure, the compound BIX-01338 was
discovered as a nonselective inhibitor of methyltransferases. It did not show any selectivity
between lysine and arginine methyltransferases with an IC50 of 5 mM for G9a [48].
Recently, UNC0224 has been identified as a new inhibitor for G9a with an IC50 of
15 nM. UNC0224 (2,4-diamino-7-aminoalkoxyquinazoline) was developed by modifying
BIX-01294 in a structure-guided manner. It demonstrated a 1000-fold increase in selectivity
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for G9a compared to SET7/9 and Set8. The crystal structure of G9a in complex with BIX-
01294 reveals the interactions of the inhibitor with the protein at the molecular level [49].
BIX-01294 forms two hydrogen bonds to Asp1131 and Asp1140 at the entrance of the
substrate-binding pocket and two methoxy groups show van der Waals interactions with
the deeper part of the pocket. Interestingly, the inhibitor is not involved in direct interaction
with the residues of the catalytic site or the cofactor SAM. Based on such structural
reasoning, the dimethylaminopropoxy side chain in UNC0224 was attached in order to
obtain binding to the lysine tunnel, thereby increasing inhibitory activity.
10.6 Identification of DNMT1 Inhibitor Candidates Using
Virtual Screening
In order to identify novel compounds with a potential DNMT1 inhibition activity,
a small molecule library of ∼18 million 2D structures was downloaded from ZINC
(http://zinc.docking.org). Subsequently, an approximately 1.6 million compound library
was prepared by clustering the 18 million compounds into 1.6 million groups and then enu-
merating conformers, tautomers, protomers, and stereoisomers. Ligand-based screenings
were performed using SAM as a template for a 2D ligand similarity search and the 3D
coordinates for SFG, taken from the DNMT1 complex structure, for a 3D similarity search.
Using these two compound libraries, the top 256 and 17 000 compounds were selected
from 2D and 3D searches, respectively, based on the Tanimoto scores, which represent the
similarity between the query compound and the target compound. Next, structure-based
docking was carried out on the selected compounds using the widely distributed molec-
ular docking software Vina, an improved version of AutoDock, which is an open-source
program [50]. The human DNMT1 in complex with SFG (3SWR) were extracted from
the Protein Data Bank (RCSB PDB) and a grid map was generated around the SAM site
to cover the entire catalytic pocket using AutoDockTools. After docking, the top-scoring
binding pose from each of the top-scoring compounds was visually evaluated using PyMOL
[51]. Figure 10.3 shows the surface map of human DNMT1 with SFG (a), an entire SAM
binding pocket (b), an original SFG binding mode (c), and the predicted binding modes for
four of the top 46 “hit” compounds. From visualization of the docking results, two distinct
binding modes were predicted. Of the 46 compounds, 30% favored the standard substrate
binding mode (d–f) mimicking SFG (c). Meanwhile, 70% favored a new, alternative bind-
ing mode (g–i) in which the hydrophobic groups of inhibitors occupy the presumed site for
cytosine from CpG, the methyl group acceptor. Analysis of the two binding modes revealed
that the catalytic pocket contains one hydrophilic region and two hydrophobic regions
(d, g), of which SAM, SAH, and sinefungin occupy only two, suggesting that compounds
able to cover all three binding regions may demonstrate increased target-selectivity for
DNMT1.
10.6.1 Functional Screening Using a DNMT1 Activity Assay
The top 46 potential inhibitor candidates identified by docking were obtained and tested for
DNMT1 inhibition activity using a DNMT1 ELISA (enzyme-linked immunosorbent assay –
BPS Bioscience) (Figure 10.4a) at concentrations of 10 and 100 μM for each compound.




Figure 10.3 Binding-mode predictions of virtual docking with human DNMT1. (a) Diagram
of DNMT1 in complex with SFG. SFG is occupying the SAM site of DNMT1, which is the target
site for our screening. (b) SAM binding pocket. (c) An SFG binding pose in complex structure.
(d–i) Two types of predicted binding mode from docking and examples
The immobilized duplex DNAs containing several CpG sites were methylated by purified
DNMT1 in the presence of each test compound (10 and 100 μM). Methylated cytosines
were recognized by an anti-5-methylcytosine antibody. After adding HRP (horseradish
peroxidase)-labeled secondary antibody, the plate was measured by luminometer, which
detects chemiluminescence produced by HRP substrate reaction. The relative activity, as
a percentage for each compound, was determined via comparison with the full activity of
the enzyme. RG108 and SAH were used as reference compounds. Eight out of forty-six
compounds showed higher DNMT1 inhibition rates than RG108, a known nonnucleoside
DNMT inhibitor (Figure 10.4c). Surprisingly, one of them, NuP_0148, showed ∼77 and
∼90% inhibition rates at concentrations of 10 and 100 μM, respectively. This finding
validates our computer-based screening approach for identification of new lead molecules
for DNMT1 inhibition.















































































Figure 10.4 Functional screening of DNMT1 inhibitor candidates. Scheme (a) and standard
curve (b) of DNMT1 ELISA. (c) Relative DNMT1 activity of the inhibitor candidates
10.7 Targeting the SAM Binding Site to Identify Novel HMT Inhibitors
Prior to virtual screening approaches that targetted the SAM binding site of HMTs, the
binding modes of the cofactor, SAM or SAH, were visualized from the protein crystal
structures of HMTs using the programs AutoDockTools and PyMOL. Although these three
enzymes, G9a, GLP, and SUV39H2, mediate the same H3K9-specific methylation, the
shape of each binding pocket occupied by SAM or SAH looks different in the complex
structures. Furthermore, even in the same enzyme (GLP in complex with SAH), binding
of the different substrates (without H3K9 peptide, with H3K9 monomethyl and dimethyl
peptides) induced a change in the shape of the SAM binding pocket. In the GLP com-
plex with H3K9me1 (3HNA) or H3K9me2 (2RFI) peptides, the entrance of the SAM
binding pockets was narrower than that of the complex without H3K9 peptide (2IGQ)
(Figure 10.5). In subsequent studies, ligand similarity and subsequent virtual docking
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Figure 10.5 Surface maps of the SAM binding pocket of H3K9 methyltransferases in complex
with SAM or SAH. The PDB ID of each complex is shown in parentheses
screenings with the five protein structures of three H3K9 methyltransferases were per-
formed in the same way as the DNMT1 inhibitor screening approach. Docking results
were evaluated by a comparison of the top 100 “hit” compounds identified from each
docking to present a variability of SAM binding pockets of the structures. Surprisingly,
about 60% of the compounds were unique among the three different HMTs, and over 60%
were unique between even the same enzymes: GLPs with different types of substrate bound















Figure 10.6 Comparison of each top-100 compound derived from virtual docking. Names of
the enzyme, cofactor, and substrate are shown around the circles
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donor SAM as a cofactor, the SAM binding sites of HMTs with a high degree of conserva-
tion can be targeted for the development of specific inhibitors to each HMT. Furthermore,
it might be possible to develop inhibitors with specificity to the mono-, di-, or trimethyl
activities of each HMT. To test this possibility, over 300 compounds selected from five
virtual dockings were obtained and tested using G9a ELISA. The ELISA scheme is shown
in Figure 10.7a. Briefly, the biotinylated and unmethylated H3K9 peptides were methylated
by purified human G9a in the presence of 10 μM of each test compound. Monomethylated
H3K9 peptides were recognized by antihistone H3K9 monomethyl-specific monoclonal
antibodies and followed by HRP-labeled secondary antibody and HRP substrate reactions.
Signal intensity on the plate was measured by a luminometer. To investigate H3K9 dimethyl
and trimethyl inhibition of G9a in the presence of each test compound, we employed
(i) the biotinylated H3K9 monomethyl peptide and antidimethyl-specific antibody and
(ii) anti-H3K9 dimethyl peptide and trimethyl-specific antibody, respectively. From the
initial screening, 25 compounds were selected based on the criterion of less than 70% G9a
activity. This initial screening result shows that it is possible to develop specific inhibitors
targeting the SAM binding site of each HMT.
10.7.1 SAM Competitive Assay
To confirm direct competition of SAM by 25 hit compounds, we used a fluorescence
polarization-based SAM GLP Screener Assay (Cayman), or modified versions of the assay
developed in-house for other methyltransferases such as G9a and DNMT1. The fluorescence
polarization assay is based upon a proprietary small-molecule fluorescent probe that binds
to the SAM binding pocket. Binding of the small-molecule probe induces an increase in
fluorescence polarization. When the SAM-binding-site probe is bound, the probe displays
a dramatic increase in fluorescence polarization as compared to the free probe. Small
molecules such as the positive control compound sinefungin compete directly with the
SAM-binding-site probe for SAM binding on the enzyme. Displacement of the SAM-
binding-site probe by a small molecule causes a detectable loss of fluorescence polarization
in the assay in a concentration-dependent manner. Figure 10.8 demonstrates a loss of
fluorescence polarization for several compounds identified by targeting the SAM binding
pocket for GLP (c) and G9a (d).
10.7.2 SAM Binding Site is Unique and Selective across Multiple
Epigenetic Targets
There are over 500 kinases encoded in the human genome that utilize ATP as a substrate, and
they all share a high degree of conservation in their ATP binding sites. Despite this, highly
selective small molecules with favorable pharmaceutical properties have been developed
that selectively target the ATP binding sites of particular kinases, which has allowed
them to serve as important anticancer drugs. Similarly, all methyltransferases use SAM
as a universal methyl donor. Even though all methyltransferases share a high degree of
conservation in the SAM binding site, we believe that highly selective PMT inhibitors can
be developed by targeting the SAM binding site landscape as we have described. This
idea is supported by other evidence. Fluorescence polarization assays were performed with
G9a and GLP methyltransferases in the presence of each histone substrate (H3K9 mono-,
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change of fluorescence polarization signals (red circles), which means that the different
types of substrate binding induced a conformational change of the SAM binding site in GLP
and G9a.
10.8 Conclusion
There is experimental evidence that small-moleclue inhibitors can be developed for methyl-
transferases based on recent advances in our knowledge of their biochemistry, substrate
selectivity, and 3D structure. The generation of a sufficient supply of stem cells that can
be differentiated into specific tissues would advance the development of regenerative and
cell-based therapies. Considerable efforts are now underway to discover small-molecule
substitutes for transcription factors in order to make the reprogramming process more effi-
cient. Identification of inhibitors that are increasingly target-selective should help to realize
the production of iPSCs without the need for transgenes. In addition, there is a developing
body of evidence that methyltransferases have critical pathogenic roles in human diseases,
including cancer, and small-molecule inhibitors are likely to be effective therapuetics. Our
efforts have focused on the identification and development of methyltransferase inhibitors
using a virtual screening approach that exploits the SAM binding sites of these enzymes.
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Box 11.1 Abbreviations and Acronyms
ALP alkaline phosphatease
BMP bone morphogenic protein
EB embryoid body
ECM extracellular matrix
EPC endothelial progenitor cell
ESC embryonic stem cell
FAK focal adhesion kinase
iPSC induced pluripotent stem cell
MSC mesenchymal stem cell
NSC neural stem cell
NPC neural progenitor cell
PCL poly(ε-caprolactone)
PDGF platelet-derived growth factor
PDL poly(D-lysine)
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PDMS poly(dimethylsiloxane)
PEG poly(ethylene glycol)







SMC smooth muscle cell
VEGF vascular endothelial growth factor
TGF transforming growth factor
UC umbilical cord
11.1 Introduction
Stem cells and progenitor cells reside in a complex microenvironment consisting of multiple
types of extracellular matrix (ECM) components, including matrix proteins, proteoglycans,
hyaluronic acid, and growth factors deposited on or tethered to ECM. These ECM compo-
nents present a great variety of ligands and provide mechanical and topographical cues to
stem cells. The extracellular cues are sensed by stem cells and trigger intracellular signaling
pathways, thereby determining the self-renewal or differentiation of the stem cells. Working
closely with surrounding cells through direct cell–cell contact or via paracrine pathways,
these extracellular cues form “niches” and help to define stem-cell fate.
As an important field of regenerative medicine, tissue engineering is becoming increas-
ingly attractive with the fast-paced development of biomaterials. Stem cells are in a unique
position to satisfy the needs of regenerative medicine due to their potential to differentiate
into multiple lineages. The tremendous progress in stem-cell research provides greater
opportunities to regenerate tissues and organs than we could ever imagine. In addition to
using biomaterial scaffolds to improve the growth and proliferation of fully differentiated
somatic cells, stem cell-based regenerative medicine requires the scaffolds to support and
control the differentiation of stem cells. Therefore, understanding the interactions between
stem cells and biomaterials (“structure–function relationships”) is critical to the design and
fabrication of functional products. On the other hand, elucidating how ECM ligands and
the physical properties of substrates regulate stem-cell fate will provide insight into the
development of new biomaterials for successful tissue regeneration.
In this chapter, we introduce the roles of ECM-derived biomaterials in regulating stem-
cell differentiation, which include Matrigel, collagen, laminin, and fibrin, followed by the
applications of typical non-ECM-derived natural and synthetic biomaterials in the control
of stem-cell fate. The progress of this area within the past 10 years is discussed. We aim
to provide a comprehensive but concise review of the biomaterials being applied to direct
stem-cell differentiation for regenerative medicine.
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11.2 Natural Biomaterials
Natural biomaterials, including both ECM- and non-ECM-derived components, have been
used to produce scaffolds for tissue regeneration. Many ECM components, such as collagen,
fibronectin, hyaluronic acid, proteoglycans, and hydroxyapatite (HA), are widely applied.
Non-ECM components, such as chitosan, alginate, and silk, have also been used to fabricate
scaffolds. The advantage of using these natural materials is that they mimic the physiological
environment that stem cells encounter in vivo by providing ligands similar to those found in
the stem cell niche. However, the disadvantages of using natural materials in regenerative
medicine include: (i) the difficulty in controlling the chemical and physical properties of
the material for different applications; (ii) batch-to-batch variation; (iii) the possibility
of pathogen contamination; and (iv) in vivo immunogenicity with materials of animal
origin. In spite of these drawbacks, natural materials are still being extensively used in
tissue engineering due to their similarity to the stem cell niche and the ease with which




Matrigel is a superior substrate with which to maintain and differentiate stem cells. It
is derived from murine sarcoma cells and consists of type IV collagen, laminin, a small
amount of heparan sulfate proteoglycan, and growth factors [1]. It is commercialized by
BD Biosciences. Matrigel has been used as a feeder-free substrate for a wide selection of
stem cells, especially the pluripotent stem cells, such as embryonic stem cells (ESCs) and
induced pluripotent stem cells (iPSCs) [2–19]. It has also been used in the differentiation
of pluripotent stem cells to all three germ lines. For example, mouse embryonic stem cells
(mESCs) were grown on Matrigel and were differentiated to thyroid follicular cells [18];
pancreatic insulin-producing cells were obtained from ESC-derived endoderms on Matrigel
[3, 8]; hepatic cells were differentiated from ESCs that were encapsulated in Matrigel and
loaded into a poly(lactic-co-glycolic acid) (PLGA) scaffold [10]. Interestingly, Matrigel
and type I collagen supported the hepatic differentiation of human embryonic stem cells
(hESCs), but hESCs could not attach to laminin, even though laminin is one of the major
components of Matrigel [12]. The growth factor-reduced Matrigel efficiently supported
survival and neurite outgrowth of neural precursor cells in vitro, unlike collagen and
laminin. It also promoted the proliferation and differentiation of neural precursor cells in
vivo, resulting in an increased number of neurons through suppression of the inflammatory
response [20].
Besides supporting pluripotent stem cells to differentiate along the endoderm direction,
Matrigel also aids in the differentiation of pluripotent cells to mesodermal lineages, such
as vascular [4, 9, 14, 16], cardiac [5, 19], and mesenchymal stromal cells [21]. Matrigel
has traditionally been used as a substrate to demonstrate the vascular-tube formation of
stem cells. Moreover, Nakagami et al. have reported that sprouting blood vessels could
be differentiated from murine ESC-derived embryoid bodies (EBs) on Matrigel, but not
on collagen or gelatin [16]. Remarkably, a Matrigel sandwich method was developed to
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differentiate human induced pluripotent stem cells (hiPSCs) to cardiomyocytes. By seed-
ing iPSCs on Matrigel and subsequently overlaying another layer of Matrigel on top, this
method promoted epithelial–mesenchymal transition (EMT) and substantially increased the
differentiation of iPSCs to cardiomyocytes in vitro with high efficiency (∼98%). A pool of
mixed cardiomyocytes, including embryonic nodal, atrial, and ventricular cardiomycoytes,
was obtained after 30 days [19]. Although Matrigel is a wonderful substrate for supporting
the growth and differentiation of many types of stem cell, its complex and heterogeneous
composition makes isolating the effect of individual components very challenging, indicat-
ing that biomaterials with a simple composition are required to better predict the stem-cell
fate.
11.2.1.2 Fibrin
Fibrin gels or fibrin networks are created during the natural wound-healing process when
fibrinogen is converted to fibrin by thrombin and the fibrin strands are then crosslinked in
the presence of factor XIIIa. Thus, fibrin is considered another type of natural material that
can be applied to support stem-cell differentiation.
The effects of fibrin on endothelial progenitor cell (EPC) growth and differentiation were
studied at different fibrinogen–thrombin ratios. The viability, differentiation, and angiogenic
capabilities of EPCs were evaluated and compared to EPCs grown on fibronectin. Fibrin
formed a porous network in vitro, and the stiffness significantly influenced the growth of
EPCs. Cell viability was found to be higher on fibrin than on fibronectin. EPCs on fibrin
differentiated to vascular cells and released cytokines to recruit other cells, indicating that
fibrin could serve as a suitable matrix for EPC growth, differentiation, and angiogenesis
[22]. In another study, fibrin was mixed with fibronectin, gelatin, and growth factors, which
successfully induced the differentiation of EPCs and smooth muscle progenitor cells to
endothelial and smooth muscle cells (SMCs), respectively [23].
Fibrin gels can be used in bone regeneration. Osteogenic differentiation of human mes-
enchymal stem cells (hMSC) seeded in a fibrin sealant was analyzed by altering the fibrin
gel composition. Cell proliferation was higher with a low concentration of fibrinogen, but
when the fibrinogen concentration was increased the alkaline phosphatease (ALP) activity,
bone sialoprotein gene expression, and small nodules of mineralization were enhanced
after 3 weeks. However, there was no significant increase in osteocalcin expression after
4 weeks. These results suggest the osteogenic differentiation of hMSCs is dependent on
the fibrinogen–thrombin ratio of the fibrin sealant, but hMSCs did not fully differentiate
to mature osteoblasts [24]. Autologous platelet-rich fibrin glue containing canine bone
marrow-derived mesenchymal stem cells (BM-MSCs) was used to regenerate bone defects
with or without MEDPOR. Radiographic analysis 4 months post-transplantation showed
an average of 72.8 ± 8.02% new bone formation with MSC-containing fibrin glue guided
by MEDPOR and a 53.34 ± 6.87% new bone formation in the group with MSC-containing
fibrin glue without MEDPOR, compared to 15.14 ± 2.37% in a control group with fibrin gel
alone. Histological analysis demonstrated the defect was repaired by typical bone tissue in
MSC-containing fibrin glue both with and without MEDPOR, whereas only minimal bone
formation was observed in the control group, showing the critical role of fibrin in supporting
osteogenesis by MSCs [25]. Growth factor-loaded particles can be mixed in fibrin scaffolds
to direct osteogenic differentiation via controlled release of growth factors. For example,
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a system combining fibrin and bone morphogenic protein 2 (BMP2)-loaded nanocarriers
was applied for the osteogenic differentiation of hMSCs. The controlled release of BMP2
by nanocarriers significantly promoted the osteogenic differentiation of hMSCs embedded
in fibrin scaffolds as compared to non-BMP2 scaffold or BMP2-loaded fibrin constructs
without nanoparticles [26].
Porcine MSCs were able to differentiate into adipogenic, osteogenic, and chondrogenic
lineages when cultured on blood-derived autologous fibrin scaffolds [27]. Interestingly,
fibrin microthreads were developed to embed hMSCs, and these could be used as a suture
to enhance the efficiency and localization of stem-cell delivery. The cells were viable
and proliferative in microthreads. Moreover, the hMSCs in the microthreads retained their
multipotency and could differentiate to adipocytes and osteocytes, providing a potential
platform for the efficient delivery of stem cells in vivo [28].
Fibrin scaffolds have also been applied in neurogenesis of stem cells. A fibrin scaffold
was produced to release vascular endothelial growth factor (VEGF) in order to control the
migration of murine neural stem cells (NSCs) (C17.2) for neuroregeneration. The stem cells
embedded in collagen hydrogels were printed close to the VEGF-releasing fibrin gel. The
C17.2 cells printed within 1 mm of the border of fibrin gel changed their morphology in the
presence of VEGF and migrated toward the fibrin gel for a total distance of 102.4± 76.1 μm
over 3 days [29]. Other growth factors were also incorporated in fibrin scaffolds to direct
the differentiation of ESC-derived neural progenitor cells. Examples include neurotrophin
3 (NT3), Sonic hedgehog (SHH), and platelet-derived growth factor (PDGF). Mouse EBs
containing neural progenitors were seeded in these fibrin scaffolds. The simultaneous
delivery of NT3 and PDGF from fibrin increased the fraction of neural progenitors, neurons,
and oligodendrocytes and decreased the fraction of astrocytes compared to EBs in fibrin
scaffolds without growth factors [30].
11.2.1.3 Collagen
As the most abundant ECM protein, collagen favors stem-cell commitment toward many
lineages. Its excellent and adjustable mechanical properties make it ideal for directing
the differentiation of stem cells to myogenic lineages. The effects of collagen I and IV
on mouse BM-MSC differentiation to SMCs were evaluated [31, 32]. BM-MSCs cultured
on collagen I and IV reduced the expression of SMC markers such as smooth muscle
actin (SMA) and myosin heavy chain (MHC) compared to cells on tissue culture plastic.
Growth factors including transforming growth factor β1 (TGFβ1) and PDGF-BB enhanced
SMC differentiation on collagen. These results suggest that, unlike plastic, collagen tends
to maintain the undifferentiated state of BM-MSCs in the absence of exogenous growth
factors [31]. Human BM-MSCs seeded on collagen-coated silicon membranes underwent
myogenic differentiation with the addition of insulin-like growth factor 1 (IGF1). The
combination of mechanical loading and growth-factor treatment led to enhanced expression
of myogenic markers such as Myf5, MyoD, MyoG, and Myf6, indicating the supportive
role of collagen in myogenesis of MSCs [33]. Type I collagen was micropatterned on a
polyacrylamide gel with a stiffness of 10.2 kPa, which efficiently modulated elongated focal
adhesion complexes of hMSCs, and in turn preferentially recruited the β3 integrin cluster,
regulated RhoA downstream signaling, and induced specific myogenic differentiation at
both transcriptional and translational levels [34].
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To mimic the stem cell niche of collagen-rich tissues such as cartilage and bone, collagen
has been combined with other structural biomaterials and growth factors to direct stem-
cell fate toward chondrogenic and osteogenic lineages. Human umbilical cord-derived
MSCs (UC-MSCs) seeded in collagen hydrogels differentiated to chondrogenic cells after
exposure to chondrogenic factors, as characterized by increased expression of collagen
II, aggrecan, cartilage oligomeric matrix protein, and SOX9. Thus collagen hydrogels
provide an appropriate 3D environment for the promotion of chondrogenic differentiation
of UC-MSCs for cartilage regeneration [35]. In another study, when UC-MSCs were grown
on poly(ε-caprolactone) (PCL)/collagen nanoscaffolds for 3 weeks cell proliferation and
chondrogenesis were found to be higher than in human BM-MSCs. The authors also
demonstrated that basic fibroblast growth factor (bFGF) in culture medium played a crucial
role in chondrogenesis [36]. Other factors, such as mechanical stimulation and oxygen
tension, were revealed to be important in directing the tenogenic lineage commitment of
adipose tissue-derived stem cells on type I collagen gel [37].
Collagen-glycosaminoglycan (chondroitin sulfate or hyaluronic acid) scaffolds were
applied to assay the effects of stiffness and composition on MSC differentiation without the
addition of differentiation supplements. The scaffolds with lower stiffness (0.5 kPa) favored
the chondrogenic differentiation of MSCs, while scaffolds with higher stiffness (1.5 kPa)
directed cells to osteogenic differentiation, as revealed by the expression of SOX9 and
RUNX2, respectively. Besides scaffold stiffness, the composition also influenced MSC dif-
ferentiation. Upregulation of SOX9 and RUNX2 were observed with collagen-hyaluronic
acid and collagen-chondroitin sulfate scaffolds, respectively, indicating hyaluronic acid is
more efficient in chondrogenic differentiation and chondroitin sulfate is more potent in
inducing osteogenesis. More importantly, these results demonstrate that the differentiation
of MSCs can be controlled by intrinsic properties of the substrate in the absence of differen-
tiation supplements [38]. Other than stiffness and composition, 3D collagen hydrogels were
able to support the differentiation of MSCs to osteoblasts with osteoinductive supplements.
Osteocalcin expression and calcium deposition were significantly higher in 3D hydrogel
than in 2D culture [39]. The morphology of osteoblasts differentiated from MSCs in 3D
collagen cultures was similar to that of osteoblasts in vivo, as compared to cells in 2D
collagen cultures [40].
Matrigel has been shown to promote cardiogenesis by many groups. As one of the
major components of Matrigel, collagen IV may be able to support cardiac differentiation
of stem cells. In one study, collagen IV was applied in directing mouse ESCs to cardiac
cells. It was demonstrated the fraction of Flk+ cells was higher on collagen IV than on
fibronectin, laminin, or vitronectin in 2D culture. However, vitronectin induced the most
Flk+ cells among all these substrates when tested in 3D culture system [41]. The result
was confirmed by another study comparing cardiac differentiation of hESC-derived EBs
on different ECM-derived matrices under hypoxia. Collagen IV and gelatin increased the
overall number of beating EBs and enhanced the cardiac troponin T (cTNT) expression
compared to fibronectin. These results revealed that collagen IV could potentially serve as
a substrate for cardiogenesis [42]. In addition to collagen IV used in cardiogenesis ex vivo,
the interaction between type I collagen and β1 integrin has been suggested to be critical for
the growth and cardiac differentiation of mouse iPSC-derived EBs, indicating that collagen
I may be a potential substrate for cardiogenesis as well [43].
Human BM-MSCs can be directed to the epidermal lineage on electrospun collagen/
poly(L-lactic acid)-co-PCL (collagan/poly(L-lactic acid) (PLLA)/PCL) nanofibrous
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scaffolds by adding epidermis-inducing factors such as epidermal growth factor (EGF) and
1,25-dihydroxyvitamin D3. The coating of collagen on scaffolds significantly increased
the number of cells grown on this nanofibrous scaffold. BM-MSCs differentiated on
collagen/PLLA/PCL nanofibrous scaffold showed a round keratinocyte morphology and
expressed keratin 10, filaggrin, and involucrin protein, indicating the cell commitment to
epidermal lineage [44]. Human BM-MSCs were grown on tissue culture plate coated with
type I collagen gel. Depth-dependent differentiation of hMSCs to the epithelial lineage
was observed with the thick collagen gel (1900 μm), which generated significantly more
cytokeratin 18 (CK18)-positive cells than collagen gel of a less thickness (100 μm). The
addition of all-trans retinoic acid (ATRA) enhanced CK18 expression and induced cluster
formation in cells grown on the thick collagen gel. The authors argued the effect of gel depth
on hMSC differentiation was caused by partial cytoskeletal disruption, suggesting type I
collagen gel can be combined with ATRA to differentiate hMSCs to epithelial cells [45].
Corneal epithelial-like cells were generated from hair follicle- or skin fibroblast-derived
hiPSCs. When coupling with BMP4, collagen IV promoted the differentiation of iPSCs to
epithelial cells with a high purity [46].
Collagen substrates also support stem-cell differentiation to hepatocyte-like cells and
MSCs. Synergistically with hepatocyte growth factor (HGF), collagen I promoted the
hepatocyte generation of human adipose-derived stem cells in 2 weeks, as evidenced by
upregulation of α-fetoprotein, albumin, and α-antitrypsin [47]. A one-step method using
collagen I was reported to obtain MSC-like cells from hESCs and iPSCs, which could
provide a readily available multipotent cell source for tissue engineering. Dissociated human
H9 ESCs and HDFa-YK26 iPSCs were cultured on thin, fibrillar collagen I coatings with
ROCK inhibitor Y27632. Interestingly, collagen I reduced stem-cell attachment compared
to the culture plastic. After incubation for 10 days, colonies of spindle-shaped cells with
MSC marker expression were obtained and identified. This study demonstrates that type I
collagen can be used to guide a rapid and efficient derivation of MSC-like cells from human
pluripotent stem cells (hPSCs) [48].
11.2.1.4 Laminin
As an important ECM protein, laminin has been reported to support the adhesion and
functioning of a wide variety of stem cells [2, 49–52]. Of the different types of cell that can
be differentiated on laminin, focus has been placed on neural cells. Laminin has been shown
to promote NSC differentiation both in vitro and in vivo [50, 51, 53–55]. The migration,
expansion, and differentiation of human and mouse neural precursor cells (NPCs) into
neurons and astrocytes were enhanced on laminin compared to fibronectin and Matrigel.
The elongation of neurites from NPC-derived neurons was also observed on laminin. It was
further revealed that the laminin-binding integrins α3, α6, α7, β1, and β4 expressed on these
NPCs played a key role in laminin-dependent cell functions [51]. Again, the involvement of
α6β1 integrin in laminin-induced neural progenitor expansion and neurite outgrowth was
demonstrated [54, 56].
The direct incorporation of laminin in synthetic materials enhanced NSC attachment and
functioning. Laminin-coated electrospun polyethersulfone fibers were shown to support
the differentiation of rat NSCs to oligodendrocytes and neurons [57]. Laminin-1-coated
methylcellulose scaffold promoted the survival and maturation of primary murine neuro-
spheres with a significantly low level of apoptosis. The addition of laminin enhanced the
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expression of neuronal and oligodendrocyte precursor markers [56]. Poly-D-lysine (PDL)
can be incorporated in laminin to provide a positively charged substrate and facilitate the
differentiation of NSCs. For example, adult rat BM-MSCs were expanded on PDL- and
laminin-1-coated glass in vitro, leading to the expression of nestin, a marker associated with
neuronal progenitor cells, as compared to cells on TCPS- and PDL-coated surfaces, indi-
cating laminin is crucial to NSC differentiation [58]. Similarly, PDL-laminin and Matrigel
were reported to significantly promote the differentiation of hESC-derived EBs into neural
progenitors, as well as to enhance neurite outgrowth compared to collagen, fibronectin, and
PDL alone. Laminin was also found to stimulate the expansion and neurite outgrowth of
hESC-derived neural progenitor cells in a dose-dependent manner [54].
Laminin-derived peptides can be conjugated to synthetic substrates and direct stem-
cell differentiation. A laminin-derived IKVAV motif was conjugated to a self-assembling
peptide, RADA16, to make a peptide-based scaffold. The extended IKVAV sequence
directed the adhesion and neural differentiation of NSCs encapsulated in the scaffold.
Histological analysis following injection in rat brain revealed the RADA-IKVAV peptide
enhanced survival of encapsulated NSCs and reduced the formation of glial astrocytes
[50]. In another study, the IKVAV motif was conjugated to poly(2-hydroxyethyl methacry-
late) (PHEMA) with Ac-CGGASIKVAVS-OH peptide. Porous Ac-CGGASIKVAVS-OH-
modified PHEMA scaffolds significantly promoted the cell attachment, proliferation, and
differentiation of human fetal NSCs [53]. However, modifying an interpenetrating polymer
network (IPN) with laminin-derived IKVAV peptide (CSRARKQAASIKVAVSADR) failed
to support the adhesion and differentiation of adult NSCs, suggesting other factors such
as substrate stiffness and ligand density might jointly influence the overall performance of
laminin-derived peptide in regulating NSC function [59].
Laminin-coated surfaces are able to support cardiogenesis and osteogenesis. Compared
to collagen IV-coated scaffolds, laminin-coated 3D scaffolds promoted the development
of Flk+ cardiac progenitor cells from murine ESCs [41]. The late differentiation of car-
diomyocytes from adipose-derived stem cells was enhanced on laminin, as demonstrated
by a significant increase of sarcoendoplasmic reticulum calcium transport ATPase 2α
(SERCA-2α) and myosin light chain 2α (MLC-2α) expression, as well as the number of
desmin-positive cells after 5 weeks [60]. Laminin-modified poly(ethylene glycol) diacry-
late (PEGDA) hydrogels increased the expression of osteogenic markers that might occur
via the activation of α2, αv, and α6 integrin subunits [49]. Moreover, laminin-induced
osteogenesis was reported to be mediated by focal adhesion kinase (FAK) and extracellular
signal-regulated kinases 1 and 2 (ERK1/2) pathways triggered by the interaction between
integrins and laminin [61].
11.2.2 Non-ECM-Derived Materials
11.2.2.1 Chitosan
As a natural material obtained from chitin, a type of polysaccharide and a major component
of crustacean exoskeleton, chitosan is biocompatible, biodegradable, and easy to process
into various scaffold geometries for tissue engineering. Although chitosan has been shown
to support the growth and differentiation of both pluripotent and multipotent stem cells,
more attention has been focused on osteogenesis and chondrogenesis [62–72]. In bone
and cartilage engineering, chitosan composites with other biocompatible materials, such
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as HA, calcium phosphate, and gelatin, are important substrates for osteogenic and chon-
drogenic differentiation. For example, a bilayer scaffold was developed for osteochondral
tissue engineering. In this model, the chitosan/gelatin scaffold served as a chondrogenic
layer and the HA/chitosan/gelatin complex was the osteogenic layer. MSCs seeded in
these scaffolds exhibited enhanced proliferation and differentiation to chondrocytes and
osteoblasts [63]. 3D chitosan/alginate porous scaffolds promoted CD105+ cell differen-
tiation to chondral lineage, as evidenced by collagen II and SOX9 expression [68]. The
3D porous HA/chitosan/gelatin network was also proved to promote hMSC prolifera-
tion, retain progenicity, and improve osteogenic differentiation potential upon induction
[71]. Notably, nanofibrous HA/chitosan scaffolds promoted the osteogenic commitment of
murine MSCs in the absence of osteogenic supplementation, as demonstrated by the expres-
sion of osteoblast markers such as collagen I, Runx2, ALP, and osteocalcin [67]. Other than
HA, calcium phosphate cement (CPC) has been used as a substrate with excellent osteo-
conductivity. Arginine-glycine-aspartic acid (RGD)-modified chitosan was incorporated
with CPC to fabricate a CPC/chitosan/RGD scaffold. hESC-derived MSCs on this scaffold
underwent osteogenesis with enhanced marker expression and mineral deposition [64].
The CPC/chitosan composite also supported human UC-MSC differentiation to osteoblasts
with higher mineral synthesis than BM-MSCs [69].
The topography of chitosan-based scaffolds influences stem-cell behavior. It has been
found that less hESCs adhere to chitosan fibers than to membranes but that chitosan fibers
promote topography-mediated ESC differentiation compared to membranes. Moreover, the
fiber size is important to stem-cell fate. hESCs underwent ectoderm differentiation when
the fiber diameter was 400 nm and 1.1 μm; in contrast, the cells were directed to endodermal
and mesodermal lineages with smaller diameter fibers (200 nm) [65].
11.3 Synthetic Biomaterials
The biomimetic property of natural biomaterials, especially their capability for presenting
ligands to initiate intracellular pathways and direct subsequent stem-cell differentiation, is
unavailable to many synthetic materials. However, the advantages of synthetic materials
over natural biomaterials include the tunability of material properties such as hydrophobic-
ity, mechanical strength, porosity, and topography. More importantly, synthetic materials
are capable of delivering drugs and growth factors in a controlled manner. Synthetic bio-
materials are preferentially biodegradable and bioresorbable, with nontoxic degradation
products that can be readily removed from the body with new tissue formation. According
to this notion, this section will focus on polyesters and poly(ethylene glycol) (PEG), which
are highly biocompatible synthetic polymers with tunable properties that can be adapted
for tissue engineering and regenerative medicine. Recent studies using selected polymers
to differentiate stem cells are summarized in Table 11.1.
11.3.1 Polyesters
11.3.1.1 Poly(Lactic Acid) and Poly(Glycolic Acid) Copolymers
Polyesters have been extensively used in tissue engineering and regenerative medicine, as
their biocompatibility and biodegradability have been well demonstrated. They undergo
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good processability and can be fabricated into multiple platforms, such as thin films, porous
scaffolds, particles, and micro- and nanofibers, showing excellent versatility for stem-cell
therapy. Poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their copolymers PLLA
and PLGA are the well-known representatives that have been approved in clinical uses for
a few decades.
The PLLA and PLGA copolymers have been used in chondrogenesis and osteogenesis
due to the requirement for high material modulus in regeneration of these tissues. However,
the biological inertness of the polymer scaffolds limits cell–material interaction. Therefore,
natural materials are often incorporated to enhance cell retention and reaction in these
scaffolds. For example, fibrin gel was added to PLGA scaffolds to support the differentiation
of rat BM-MSC and human adipose-derived stem cells to chondrocytes under TGFβ1
treatment [73–75]. Stem cells can also be encapsulated in alginate before being loaded to
PLGA scaffolds. Human ESC-derived EBs were suspended in alginate and seeded into
PLGA 3D scaffolds. After implantation, embedded cells expressed chondrocyte markers
and formed cartilage-like tissue in mice [76]. The addition of calcium-deficient HA and
RGD to alginate gel enhanced the chondrogenesis of both adipose- and placenta-derived
MSCs [77]. The chondrogenic differentiation of hMSCs was promoted by HA nanoparticle-
loaded electrospun PLLA fibers [78].
Porous or fibrous PLGA and PLLA scaffolds have been used in bone generation; for
example, the electrospun PLLA/collagen nanofibers promoted osteogenic differentiation
compared to PLLA scaffolds without collagen [79]. After implantation in rat calvarial
defects, the PLLA/collagen nanofibrous scaffolds improved the migration and infiltration
of more osteocalcin- and Smad5-positive cells than an empty defect control [80]. The com-
posites of PLLA nanofibrous mats blended with nano-HA promoted osteogenic differenti-
ation of human BM-MSCs, murine MSCs, and ESCs [81]. Adipose-derived MSCs can also
be directed to osteoblasts on nano-HA-enriched PLLA/poly-benzyl-L-glutamate/collagen
nanofibrous scaffolds [82].
The fibrous PLLA and PLGA scaffolds are able to support stem-cell differentiation
to other lineages, including neural cells. It was reported that porous and fibrous PLLA
scaffolds induced neurite outgrowth from neonatal mouse cerebellum stem cells [83].
Furthermore, the NSC behavior was controlled by topographical features such as fiber size
and alignment. Aligned PLLA fibers with a diameter of 500 nm led to higher cell viability
and proliferation compared to either smaller or bigger fibers, as opposed to unaligned fibers.
Importantly, the fiber size and the alignment influenced cell differentiation as well. Cell
outgrowth was higher on 500 nm aligned fibers than on 307 nm fibers, but this was totally
opposite to unaligned fibers, indicating the importance of topographical features in NSC
differentiation [84].
11.3.1.2 Poly(𝛆-Caprolactone)
PCL is another commonly used polyester in tissue engineering. One of the advantages of
PCL over PLGA and PLLA is the generation of nonacidic degradation products; thus, it usu-
ally induces less inflammatory responses than PLGA or PLLA. PCL is more hydrophobic
and more bio-inert than PLGA and PLLA, so additional treatments or surface modifica-
tions are often required to make it biomimetic and thus support stem-cell functions. The
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capability of PCL to direct stem-cell commitment has been documented, including osteo-
genesis and chondrogenesis. PCL has been frequently used in bone engineering, with the
incorporation of other materials to enhance its strength and improve cell–material inter-
action. For example, rat MSCs were embedded in collagen hydrogels before being cast
into macro-channeled PCL scaffolds to increase cell retention and proliferation. Osteoblast
marker expression and mineralization were significantly enhanced under flow perfusion,
which induced shear stress to stem cells and upregulated c-Fos and COX-2 expression,
indicating a force-driven differentiation of stem cells in this PCL scaffold [85]. A hybrid
nanofibrous scaffold made of PCL/polyD,L-aspartic acid/collagen/nano-HA was applied
to differentiate hMSCs to osteoblasts [86]. The shape of the nano-HA in PCL scaffolds is
crucial to osteogenesis; for example, rod-shaped HA nanoparticles induce more osteogenic
marker expression in adipose-derived MSCs than do spherical HA nanoparticles [87]. Hal-
loysite nanoclay, an inorganic filler material, was used to fabricate PCL/nanoclay fibrous
scaffolds that were mechanically superior to PCL scaffolds alone. Increased ALP activ-
ity was observed in hMSCs grown on this scaffold, showing the PCL/nanoclay composite
directed MSCs to osteoblast lineage [88]. The ability to mimic ECM structures makes nano-
and microfibrous scaffolds very attractive. However, for synthetic polymers such as PLLA,
PLGA, and PCL, which degrade slowly, the small pore size of these fibrous scaffolds often
hinders cell filtration and tissue ingrowth, which is critical in tissue engineering. Thus,
in a previous study, water-soluble PEG fibers (“sacrificial fibers”) were blended to make
PCL/collagen/nano-HA fibers. The PEG fibers were then removed by soaking the hybrid
scaffold in water, leaving PCL scaffold with larger pores, which facilitated MSC infiltration
into the scaffold. This method therefore provides an easy way to fabricate porous fibrous
scaffolds that can facilitate stem-cell migration [89].
Commitment of stem cells to other lineages on PCL scaffolds has been reported. Adipose-
derived stem cells were differentiated to endothelial cells on porous PCL scaffolds, with the
supplement of endothelial differentiation medium [90]. EPCs were seeded in porous PCL
scaffolds functionalized with heparin and VEGF. Seven days after subcutaneous implan-
tation in non-obese diabetic/severe combined immunodeficiency (NOD-SCID) mice, scaf-
folds loaded with EPCs promoted angiogenesis and vasculogenesis with CD31+ vessel
formation [91]. The topography of PCL fibrous scaffolds again plays a crucial role in stem-
cell differentiation, especially in neurogenesis. Aligned or randomly oriented PCL and
PCL/collagen nanofibers were prepared to investigate the topographical effect on growth
and neural differentiation of rat BM-MSCs and adipose-derived MSCs. The differentia-
tion to oligodendrocytes was more pronounced on aligned PCL/collagen fibers than was
differentiation to other neural cell types [92]. In another study, aligned PCL nanofibers sig-
nificantly upregulated the expression of neural markers in MSCs compared to cells on tissue
culture plastic. The combination of sustained release of retinoic acid (RA) with aligned PCL
nanofibers significantly changed cell morphology and enhanced neural marker expression,
especially expression of the mature neural marker microtube-associated protein 2 (MAP2).
Positive staining of synaptophysin occurred only in cells on RA-releasing aligned scaf-
folds. These results highlight the regulatory effect of the topography of drug-eluting PCL
nanofibers on neural differentiation [93]. Biofunctionalization of PCL scaffolds provides
another way to efficiently promote the neural differentiation of stem cells. For example,
surface modification of PCL fibers with neurotrophin enhanced NSC differentiation to
oligodendrocytes [94].
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11.3.2 Polyethylene Glycol
PEG is a biocompatible, nondegradable hydrophilic polymer. It is an extremely versatile
material and has been extensively used in synthesizing polymeric biomaterials for different
purposes. PEGDA can be easily crosslinked when exposed to UV light with a photoinitiator
to form hydrogels that can encapsulate stem cells. However, since PEG is so hydrophilic,
it markedly repels the adsorption of proteins, which makes it non-cell-adhesive. Therefore,
modifications to PEG hydrogels with bioactive ligands have been performed to enhance
cell–material interactions, making PEG an ideal blank material with which to study the
functions of different ligands. For example, the cell-adhesive peptide RGD was conju-
gated to PEGDA hydrogels to encapsulate and support the differentiation of hESC-derived
MSC-like cells to chondrocytes [95]. TGFβ-supplemented, RGD-modified PEGDA hydro-
gels synergistically directed the chondrogenic differentiation of hESCs [96]. Moreover,
the RGD concentration required to promote rat MSC adhesion on PEGDA hydrogel was
reported to be within 0.107–0.143 mM [97]. In another study, a collagen mimetic peptide
containing a GFPGER sequence was conjugated to PEG hydrogels, which provided an
extracellular environment similar to collagen and promoted chondrogenic differentiation
of hMSCs [98]. Other than adhesive ligands, PEG hydrogels can be covalently modified
with growth factors or bioactive ligands to guide stem-cell differentiation. TGFβ has been
covalently tethered to PEGDA hydrogels by photoinitiated thiol-acrylate polymerization.
hMSCs were encapsulated in PEG hydrogels and the tethered TGFβ promoted chondro-
genesis after 3 weeks, with increased expression of collagen II and glycosaminoglycan
[99]. Phosphate (PO(4))-functionalized PEG hydrogels increased the adsorption of serum
proteins compared to the nonfunctionalized PEG hydrogel, which subsequently improved
attachment and spreading of hMSCs. The improvement of osteognesis by phosphate was
further demonstrated via activation of β1/β3 integrins and the FAK pathway [100].
PEG can be modified with other natural and synthetic polymers to improve its hydropho-
bicity and/or elasticity in order to support stem-cell attachment and differentiation. For
example, the hydrophobicity of PEG can be changed by adding poly(dimethylsiloxane)
(PDMS), which elevated osteogenic differentiation of mouse 10T1/2 MSCs as the PDMS :
PEG ratio increased [101]. Hybrid PEG/PLA fibrous scaffolds with interconnected pores
favored growth of MSCs and enhanced their differentiation to osteoblast-like cells [102]. A
photopolymerized PEG hydrogel with poly(L-lysine) increased the survival and differenti-
ation of NPCs. About 55% of the cells cultured in gels differentiated into a mature neural
cell type [103]. Acrylate-N-hydroxysuccinimide PEG was applied as a spacer in order to
covalently tether BMP2 to a PLGA scaffold. The PEG/BMP2/PLGA scaffold improved
de novo bone formation in animals by promoting osteogenesis of seeded MSCs [104].
Mouse 10T1/2 MSCs were encapsulated in fibrinogen, fibronectin, or laminin-1 conjugated
PEGDA hydrogels and the osteogenic differentiation in these hydrogels was studied. Cells
in fibrinogen and laminin-modified PEG hydrogels increased osteoblast marker expression
compared to cells in fibronectin-modified hydrogels, due to altered integrin profiles in the
differentiation process [49].
Instead of modifying PEG scaffolds to be more cell-friendly, the hydrophilicity of PEG
provides a useful tool by which to repel cell attachment and change substrate topographi-
cal properties, which influences the stem-cell morphological features and directs stem-cell
differentiation. For example, micropatterning PEG hydrogel on to a cell-adhesive substrate
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will isolate cell-adhesive and nonadhesive areas (e.g. forming microwells). By changing
the size and shape of the adhesive domains surrounded by PEG, stem-cell differentiation
within them can be controlled. Moreover, bioactive ligands in cell-adhesive domains can
be varied to assay stem-cell differentiation under different conditions, providing a high-
throughput method of screening hundreds of immobilized or soluble ligands simultane-
ously [105]. For example, RGD-modified microdomains were patterned on PEG hydrogels
and the differentiation of rat MSCs in RGD-modified domains was studied. It was found
that both osteogenic and adipogenic differentiation were promoted by cell–cell contact,
whereas isolated individual cells showed less differentiation than aggregated cells [106].
PEG/PLA line-patterned substrate reduced multiple extension of neurites and stimulated
the bidirectional neurite budding of PC12 cells [107]. In contrast to the concept of con-
fining cells in adhesive microwells, the protein- and cell-repellant nature of PEG can be
used to control the size, shape, and homogeneity of pluripotent stem cell-derived EBs in
nonadhesive microdomains. Micropatterning of PEGDA hydrogels on glass produced PEG
microwells with a diameter of 50 μm, which facilitated the homogeneous murine ESC-
derived EB formation on a microarray chip, enabling the high-throughput manipulation
of ESCs [108]. Sakai et al. compared the PEG-modified microwells and micropatterned
chip with gelatin spots on a PEG-modified surface in EB proliferation and differentiation.
They found EBs in the microwells were more likely to retain the pluripotency, whereas the
gelatin-micropatterned chip promoted EB growth and differentiation to both endodermal
and mesodermal lineages [109]. The size of EB played a role in directing stem-cell differ-
entiation. Size-controlled EBs were produced by microwell array and were encapsulated
in PEG-4-arm acrylate hydrogels with and without RGD conjugation. The size of EBs
increased when cultured on unmodified PEG hydrogels, and such cultured EBs showed
enhanced cardiogenic differentiation compared to RGD-PEG hydrogels. The differentia-
tion to endothelial cells was also dependent on the size of EBs, but it was accelerated
in RGD-PEG hydrogels within 3–5 days. Thus, PEG hydrogel may induce cardiogenic
differentiation and the RGD sequence could be a driving force of direct differentiation to
endothelial cells [110].
11.4 Conclusion
Biomaterials provide a unique platform from which to direct stem-cell differentiation syn-
ergistically with soluble factors. Naturally derived biomaterials are more closely mimetic
to the stem cell niche in vivo than synthetic materials as they can provide more functional
ligands to regulate stem-cell adhesion, proliferation, and differentiation. However, their
mechanical properties, degradability, and hydrophobicity are less tunable to the require-
ments of different applications than those of synthetic biomaterials; synthetic materials,
especially polymers, are capable of tuning their properties for ligand functionalization,
adjustable degradation, surface patterning, and controlled release of therapeutics. Thus, in
the development of tissue-engineering scaffolds, natural materials (or short motifs derived
from these materials) and synthetic materials are often combined to achieve optimal cell
functions. Stem cells, as a reliable cell source, emerge as a powerful tool for tissue engi-
neering and regenerative medicine. There is no doubt that the combination of stem cells
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with biomaterials will lead to huge breakthroughs in this area. Development of bioma-
terials that direct stem-cell differentiation to specific cell lineages, despite the exciting
findings reviewed in this chapter, remains immature. Thus, further in-depth studies are
required to allow us to understand the mechanisms behind the regulation of stem-cell fate
by biomaterials.
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12.1 Introduction
Stem cells have been used successfully for over 50 years in the treatment of patients in the
context of bone-marrow transplant [1]. However, over the last 15 years the use of stem cells
as potential therapies has been subject to both high levels of hype and a lack of significant
commercial success, since the first embryonic stem cells were discovered in the late 1990s
[2]. While regenerative medicine is a billion-dollar industry today, it is still quite small
given a single drug can generate many billions of dollars in revenue [3]. This apparent
lack of commercial success could be attributed to a variety of factors, including lack of
significant funding, limited success of clinical trials, uncertainty around business models
[4], and an overall misunderstanding of stem-cell biology by the public. However, there
are some key learnings that can be culled from the regenerative medicine industry over
the last 15 years. This chapter will focus on addressing some questions surrounding these,
including:
1. How does the process of commercializing stem-cell products differ from that of bio-
pharmaceutical products or medical devices?
2. Over the last 15 years, what cell-based therapies have been commercialized?
3. What are the key learnings (both good and bad) that can be gained from analyzing these
therapies?
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4. What are the special challenges to commercialization of stem-cell therapies?
5. What are the key learnings for a scientist to keep in mind as they move an asset through
from concept to the clinic to commercialization?
6. What is the right strategy for translating a new therapy into the clinic and beyond?
7. What are the key activities to consider for successful translation of a concept into a
company?
12.2 Commercialization Comparison with Small Molecules, Medical
Devices, and Biologics
A key question is: How does commercialization of cell-based products differ from commer-
cialization of other traditional medical therapies? We can evaluate three major categories
of medical therapies: small molecules, biologics (large molecules), and medical devices.
Small molecules have been commercialized for years using traditional approaches in mar-
keting, such as hiring large numbers of sales reps to detail physicians (both primary care
and specialists) in order to provide widespread information about the product [5]. The key
to success is strong marketing, competitive differentiation from other products, and low
cost of goods (COG), which can drive both revenue and profitability [6]. While biologics
have traditionally been focused on specialist markets, given their overall higher pricing, the
detailing and push to reduce COG are critical for profitability and the overall model is not
significantly different from that of small molecules. The primary difference is that most
biologic products must usually be kept cold (storage temperatures vary), which presents
important logistical considerations versus small molecules. Reimbursement for both types
of product is similar, although biologics are often more expensive than small molecules.
In addition, both biologic- and small molecule-based products can cost many hundreds of
millions of dollars and can take 10 or more years from early discovery to market launch
[7]. However, once an asset is on the market, it enjoys exclusivity for a period of time,
until patent expiry (which in some cases can be 10 or more years post-launch). While loss
of market exclusivity typically results in a small-molecule product losing 80% or more of
revenue within a year or two, biologics have yet to be significantly impacted by loss of
exclusivity. In fact, although several biologics have experienced patent expiry there are few
launched generics or biosimilars on the market, with those that have launched experiencing
minimal commercial revenue [8].
Medical devices are typically complex pieces of metal and/or plastic sold primarily to
surgeons or other specialists. Companies selling these devices utilize a different commer-
cialization model from that for small and large molecules. Medical devices typically have
higher COG than small molecules or biologics [9]. There are several reasons for this,
including the higher production costs, relatively lower selling price, and need for more
complex sales-force detailing. A typical medical-device sales rep will often be present and
assist in the training of physicians in the use of the device, which builds a strong relationship
with the physician but also results in higher costs for the selling company [10]. In addition,
while the product lifecycle for biopharmaceuticals is long, that for a medical device is quite
short, given the perpetual innovation that occurs in this space. This means companies must
rapidly develop new products without the long R&D cycles common with biopharmaceu-
ticals. Given the very different business models and COG, there are few companies that
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sell products which use both the device and the traditional drug model. Johnson & Johnson
(J&J) is the one large-company exception, as it has been successful selling both medical
devices and traditional small-molecule and biologic products [11]. Most other companies
in the space are focused on either traditional biopharmaceuticals or medical devices.
The models described here are well-established in the market, such that physicians,
sales reps, manufacturers, payers, and even patients are comfortable with them, despite
their differences. How does cell-based therapy fit into this? Such therapies can possess
elements from both the biopharmaceutical model and the medical-device model [12]. For
example, a cell-based therapy will likely require some type of cold-chain distribution,
not unlike biologics. However, it may require more complex provisioning and hence a
field force that is more akin to that for a medical device. This mix of models makes cell-
based therapies problematic for both traditional medical-device manufacturers who are not
familiar with cold-chain logistics and distribution and biopharmaceutical companies that are
not familiar with the complex sales and marketing requirements of devices, not to mention
the relatively lower gross margins. In addition, the business model will differ between an
autologous and an allogeneic therapy [13]. We will not delve into the business-model and
scientific differences between allogeneic and autologous therapies, as this has been covered
elsewhere [4, 9, 12,13]. However, J&J demonstrates that it is possible for a company to be
expert in both business models, and it is therefore likely that once commercial cell-based
products are on the market, medical-device and biopharmaceutical companies will adapt to
be successful in selling them.
12.3 Historical Review and Case Studies
There have been several cell-based products launched over the last 15 years [9, 12, 13].
Table 12.1 highlights the largest revenue-generating products that have launched. There
were three key launches in the 1990s: Carticel (sold by Genzyme, now part of Sanofi-
Aventis), Dermagraft (launched by Advanced Tissue Sciences (ATS) and now sold by
Advanced Biohealing (ABH)/Shire), and Apligraf (sold by Organogenesis). Each of these
has had a storied history that has been quite challenging at times. Today, Dermagraft and
Apligraf are both generating more than $100 million in revenue, with double-digit growth,
while Carticel has been selling <$50 million for the better part of a decade. Dendreon
recently launched Provenge, providing a more recent example that we can learn from.
We will review Dermagraft (as representative of the other two products) and Provenge to
evaluate what has gone right and what has not for these products since their launches.
12.3.1 Dermagraft
A detailed case study of Dermagraft was published in 2010 [14], covering the key aspects
of the company, ATS, that initially developed and marketed the product. ATS filed for
bankruptcy and was liquidated in 2003 after never making a profit in 14 years. This
discussion will not replay the company’s fate, given the prior published case study was
thorough and informative. The key facts from this case study are:
• ATS was founded in 1987 as Marrow Tech Inc.
• In 1988 ATS raised $6 million in an initial public offering (IPO).
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• ATS requested approval of Dermagraft TC (later called TransCyte) from the FDA.
Dermagraft which was approved for burns in 1996.
• Smith & Nephew signed an agreement worth $10 million upfront and $60 million in
downstream payments for a joint venture to market Dermagraft in 1996.
• In 1998, the FDA refused to approve Dermagraft for diabetic foot ulcers.
• Dermagraft was subsequently approved in 2001 for the treatment of diabetic foot ulcers
based on the submission of new clinical data.
• In 2002, ATS filed for Chapter 11 bankruptcy when it ran out of funds and sold the
Dermagraft JV to Smith & Nephew to continue supply of Dermagraft to patients [14].
It is clear that several key elements led to ATS’s eventual failure as a company despite
it having a launched product on the market. These include: a lack of focus on driving
revenue, with a weak internal sales/reimbursement team; difficulty in marketing a novel
and expensive product to a market used to relatively simple, inexpensive treatments such
as dressings; and a lack of strategic focus, resulting in a lot of “wasted” R&D spend.
Dermagraft was eventually sold to ABH for $7 million in 2006, and ABH relaunched
the product and grew it to more than $100 million in revenue by 2011. ABH was recently
purchased by Shire for $750 million, highlighting the success of the relaunched Dermagraft
[15]. Why was ABH so successful relative to ATS? The keys to its success are its focus on
exactly the things that ATS failed to focus on – namely sales and reimbursement, creating
a clear sales and marketing strategy to target key physicians, and making Dermagraft
successful without spending significant R&D dollars on any other pipeline products.
12.3.2 Provenge
Dendreon Corporation is a biotech company headquartered in Seattle, Washington. It was
founded in 1992. It took 18 years and $1.2 billion (aggregate losses from 1992 to 2010,
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with another $750 million from 2010 to 2012 post-launch) before its first product, Provenge
(sipuleucel-T), was approved in April 2010 for the treatment of asymptomatic or mini-
mally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer [16].
Dendreon is focused on developing treatments for cancer using active cellular immunother-
apy (ACI). ACI uses a patient’s own white blood cells to destroy the tumor. In the case of
Provenge, a patient’s white blood cells are harvested using Leukapheresis and sent to the
Dendreon manufacturing facility. The cells are then activated using a complex manufac-
turing process and returned to the infusion center to be infused back into the patient. The
time from final manufacturing to infusion must be less than 18 hours, which can present
logistical challenges for the company, patients, and physicians. Because of this short time
window, Dendreon has built three manufacturing sites such that the entire United States is
within a short flight or drive from one of them. The course of treatment is three infusions,
one every 2 weeks for 6 weeks, and it has led to 4 months of improved survival in clinical
studies [17].
When Provenge was approved, the expectations for the product were extremely high. In
fact, some analysts forecasted peak revenue at $4 billion [18]. However, 18 months later
they were predicting no more than $500 million in peak revenue from the drug [18]. What
had changed? There were several factors, including the launch of new competitor drugs
and commercialization and reimbursement challenges at Dendreon.
One of the competing drugs, Zytiga, was launched by J&J in April 2011 for patients with
late-stage (metastatic) castration-resistant prostate cancer in combination with prednisone
(a steroid) who have received prior docetaxel (chemotherapy) [19]. Zytiga extends life
expectancy 4–5 months and is estimated to generate $1.7 billion in peak revenue [20].
In addition, Medivation and Astellas had Xtandi approved in September 2012. Zytiga is a
small molecule and prices at $5500 a month ($66 000 annual), as versus Provenge’s price of
$93 000 for a course of treatment and Xtandi’s $85 000 annually. Xtandi has peak forecasts
at $2.2 billion [21]. In effect, the market has moved quickly to small-molecule products
that offer similar or better efficacy in a much simpler treatment procedure for both patients
and providers.
Dendreon had a full year’s lead on the competition but was not able to capitalize on
this advantage. This was due to the commercialization and reimbursement challenges the
company faced. Given the drug used a new business model, the company struggled to
determine the optimal way to commercialize it. Physicians had to treat the patients and
then be at risk of having to pay Dendreon the $93 000 cost of the drug if the insurance
company did not reimburse them. This made them very nervous. Meanwhile, a patient who
needed small-molecule therapy could get that from the pharmacy, with no financial risk
for the physician. Medicare was willing to reimburse physicians for Provenge, but many
physicians, particularly those in community practices, were wary. It has taken several years
to educate these physicians about the reimbursement on offer [22]. In fact, the company had
just begun to see an increase in the number of community physicians who use Provenge in
the fourth quarter of 2012 [23]. This business-model challenge became an acute issue when
the company warned in mid-2011 that it would not reach its guidance for 2011 revenue,
resulting in a 60% drop in its stock price [24].
Another challenge for Dendreon involved manufacturing. As already mentioned, the
company had built three manufacturing plants (New Jersey, Georgia, and California) to
enable it to ship anywhere in the United States within the 18-hour product life. However,
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Table 12.2 Provenge gross margins
Item 2010 2011 2012
Provenge Revenue $47,957.00 $213,511.00 $325,333.00
Cost of Goods $28,520.00 $159,090.00 $227,892.00
Gross Profit $19,437.00 $ 54,421.00 $ 97,441.00





















Source: Dendreon 10K filings – www.sec.gov
there was too much capacity, resulting in massive cash burn [25]. One plant was sold in an
effort to improve gross margins as Dendreon attempted to reach profitability.
If we analyze the revenue achieved by year for Provenge, as compared against COG, we
can see that the COG is not decreasing as one would hope (Table 12.2) [26]. This means
that the company will struggle to be profitable in the near future. In fact, the gross margin
only increased from 25 to 30%, while the revenue was up nearly 50% [26]. At this pace,
the revenue would need to be over $1 billion a year to obtain the margins necessary for
profitability. However, Dendreon has announced that the recent restructurings should result
in COG >50% by Q3 2013 and that they can achieve a positive cash flow at $400 million
in revenue [23].
These struggles have meant a significant amount of restructuring to drive costs down.
In 2011, Dendreon laid off 500 employees, and another 600 were laid off in 2012. These
efforts have decreased the number of employees from a high of 2000 in 2010 to 1100 in
2012. In addition, as already mentioned, in December 2012 Dendreon sold its New Jersey
manufacturing facility to Novartis for $43 million, transferring 100 employees to Novartis
in the process [27]. These struggles have also had a tremendous impact on the company’s
share price (Table 12.3).
Where does that leave us at the date of writing, in early 2013? As already mentioned,
the company has seen an increase in the use of Provenge by community physicians, which
is a positive trend. Dendreon is also expecting regulatory decisions in Europe in 2013,
which could also increase revenue, although not necessarily profitability [23]. In addition,
the massive restructuring to drive down costs should begin to pay off later in 2013, as the
company is much leaner now and expenses are much lower than they were over the last few
years. Time will tell how successful Dendreon will be, but the company has struggled to date.
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Table 12.3 Dendreon share price and market capitalization
Annual Share Market Cap on Market Cap on
Price Year High Year Low Average High ($USM) Low ($USM)
2012 $17.04 $ 3.69 $10.37 $2,556 $ 554
2011 $43.96 $ 6.46 $25.21 $6,594 $ 969
2010 $57.67 $26.25 $41.96 $8,651 $3,938
2009 $30.46 $ 4.02 $17.24 $4,569 $ 603
$60
$70 Provenge





























2009 2010 2011 2012
Source: Dendreon 10K filings – www.sec.gov
12.4 Commercialization Challenges and How to Overcome Them
From these case studies, some key themes emerge that are important to keep in mind for
products in development:
• Strong, focused strategy: Focus on achieving commercial success with the lead asset or
on getting the lead asset through clinical studies. Diluting the company’s scarce capital
on other noncritical studies of the lead asset or the development of other assets is poor
allocation of capital.
• Strong financial oversight and strategy: Manage costs to ensure that spending is focused
on activities that will most rapidly lead to clinical studies. While there may be nice-to-
haves, focus resources on the must-haves.
• Focused manufacturing strategy: Ensure that spending on manufacturing and capacity
matches the real expectations of the commercial organization. Bringing new capacity
on-line “just in time” is critical to maximizing profitability.
• Strong sales strategy: For commercial assets, focus on increasing revenue via creation of
a strong sales/reimbursement team, building relationships with payers, and understanding
how to “sell” the product.
12.5 Translation from the Bench to the Clinic: Key Considerations
Let’s take a step back from the commercialization considerations and focus on how to
develop a product from idea to the clinic. A key question is what else we should keep in
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mind when translating a potential product from preclinical to clinical development. Other
questions include:
• What indication should I pursue?
• What is my product?
• Should I worry about the competition?
• What is my partnering strategy?
• How/where do I manufacture GMP material?
• What is the regulatory environment like?
• How do I fund the product development?
• When do I start my company?
While all of these questions do not need to be answered in detail, knowing the rough answers
to each is critical for raising funds from investors and creating a successful product. In effect,
the answers to these questions become the core of the business plan and business strategy
for the new company. Ensuring a company has a robust strategy is critical to success. Each
of these key questions is discussed in detail in the remainder of the chapter.
What indication should I pursue?
Selection of a lead indication for the cell-based therapy is one of the most important con-
siderations for moving into the clinic. The current crop of cell-based therapies is spread
across multiple indications, with the majority focused in ischemic and autoimmune indi-
cations [28]. Are these the best indications to be pursuing, or is this merely the result of all
companies chasing the same indications (i.e. a lemming effect)? Key considerations when
selecting an indication are: Is there a scientific rationale for this indication? Is there preclin-
ical efficacy in an animal model (or multiple animal models)? Is there clinical efficacy with
similar products? Is this an indication for which a relatively expensive cell-based treatment
could be used and reimbursed? While the first three questions are relatively straightforward
and driven by available scientific data, the last one bears further discussion. First, expensive
treatments have historically been reserved for diseases with significant morbidity and/or
mortality, such as cancer and rheumatoid arthritis. In these diseases, expensive biologic
therapies (costing in the $20 000+ /year range) are now well established in standard treat-
ment regimens [29]. In fact, Dendreon’s cell-based therapy Provenge is priced at $93 000
for a treatment regimen in cancer [30]. In addition, orphan diseases have emerged as an area
where extremely highly priced therapies have now emerged, some costing more than $100
000 a year [31]. Why can these therapies command this type of pricing? Because of the
serious morbidity and mortality associated with these diseases and the significant positive
impact these therapies can have on patients.
This suggests that cell-based therapies are likely best placed in diseases with high unmet
need and significant mortality, such as heart attack/heart failure, cancer, neurodegenerative
diseases such as amyotrophic lateral sclerosis (ALS), and orphan diseases. These disease
states are much better starting points for a cell-based therapy than diseases that either impact
a large number of patients (e.g. diabetes) or have relatively low unmet need (e.g. allergic
rhinitis), where a relatively highly priced therapy would be likely to fail. In addition, once a
target indication is decided on, the end customer for the product (i.e. the treating physician)
Practicalities to Translation from the Clinic to the Market 211
is clear. Having discussions with these treating physicians is critical to ensuring that the
cell-based therapy meets their patients’ needs. This work can be used to create what is
called a target product profile in the biopharma industry. A target product profile spells out
who the target patient is, who the treating physician is, what the current treatment standard
is, the current standard’s efficacy and safety profiles, and the target safety and efficacy
profile of the new cell-based therapy – all of which can be communicated on a single slide.
Finally, one pitfall that many companies fall into is the temptation to target multiple
disease areas at once. Often, as we saw in our case studies, this will lead to a lack of focus
and an inability to deliver on the lead program while burning through capital, often the
scarcest resource for a small company. As seductive as it may seem to show a full pipeline
of indications, multiple simultaneous programs should be avoided until significant funding
is achieved.
What is the product?
This may seem like a simple question, but it is key to success. The product could be
the cells, the process, the manufacturing process, a device to isolate cells, among other
things. Defining what the product is can enable IP and competitive differentiation. Some
key elements to keep in mind include:
• Keep the product simple to use for the physician: it should not require significant
work-up before being given to the patient, have relatively off-the-shelf usage, include a
simple-to-use device if needed, and so on.
• Ensure that even if IP is difficult to achieve, there is significant proprietary know-how to
keep competitors at bay.
• Have some competitive advantage over other cell-based therapies or treatments in the
same disease. If efficacy is equal, is there a differentiation in safety, ease-of-use, time to
onset, or need for redosing that can provide some differentiation in the market?
• Be sure that the product can match an existing business model. As discussed earlier,
creating a new business model de novo is high-risk and often ends in product failure
[32]. Keeping the product based on an existing successful business model will make the
commercialization and partnering path much simpler [33].
• If a novel business model is required, make sure the product is clearly able to deliver
transformational efficacy in the lead indication. Transformational efficacy means that the
product provides substantial benefits over existing therapies (e.g. it is curative or greatly
extends life).
• Understand the regulatory challenges that the product might encounter. For example, is
it a device, cells only, or a combination of both? How do regulators in the United States
versus the European Union versus Japan view your product? Is there a precedent for the
regulatory path?
Answers to these questions may require discussions with treating physicians of the targeted
disease, regulatory experts, and experts in product commercialization to ensure that the
best product and optimal parameters are selected [34]. These discussions do not need to be
expensive or extensive, but some investment is required to ensure success.
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Should I worry about the competition?
Understanding the competition is critical to a successful business plan and product. This
extends beyond the cell-based competition to any therapy or device that is targeting the lead
indication. The current treatment regimen, current products in the pipeline, current/future
generic treatments, and so on should all be assessed across all therapeutic classes. Building
this competitive map can enable one to successfully place the new cell-based therapy
relative to the competition in the future treatment paradigm. For example, if the current
treatment regimen is a generic small molecule followed by an antibody product then the
new cell-based therapy is likely to be used after these two lines of therapy even if it is more
efficacious, because most new therapies are applied in the last line of the treatment regimen
and work their way toward firstline once efficacy and safety benefits relative to the other
therapies are proven.
What is my partnering strategy?
The goal of most academics and newly formed companies is to obtain support from larger
companies interested in licensing or providing funding to their idea/asset. While this is a
worthy goal, it is critical to know what larger companies are interested in and whether the
idea/asset is a good fit with their portfolio and strategy. As highlighted in a 2010 publication
[35], large companies have made some plays in the regenerative medicine space, but these
are primarily limited to the use of stem cells as tools and cell-based products that are already
in the clinic or commercialized. This suggests that many efforts to attract a partner early in
development will be unsuccessful, although making a large company aware of an asset and
meeting the right business development people are worthy goals at the early stages and can
develop a foundation for a successful partnership in the future.
How/where do I manufacture GMP material?
Manufacturing and subsequent impacts on COG cannot be overemphasized, as these can
result in product failure. Finding a good manufacturing partner early is important. This
partner could be a company, academic institution, or government-funded entity like the UK
Cell Therapy Catapult [36]. The key is to find the right partner who can help in process
development, lowering of COG, and the provision of a robust GMP facility to support the
clinical trials. Saving a few dollars on manufacturing may seem like a good idea, but it might
be a poor decision in the long-term. In addition, doing all manufacturing in-house might
be a good idea, but often finding a partner to help is simpler, less expensive, and results in
fewer problems as the therapy enters clinical trials. However, many companies have chosen
to manufacture their own products, which can work if they have the financial resources.
What is the regulatory environment like?
There are many questions that must be addressed in the regulatory environment, including:
• Is there precedent for your therapy?
• Have similar therapies entered clinical trials?
• For approved therapies in the lead indication, what was the regulatory path taken?
• How large and how long must clinical trials must be?
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• What are the key monitoring requirements from the regulatory authorities?
• How does the regulatory environment differ by geography?
• In which geographic area do you want to start clinical trials?
• In which geographic area do you want to achieve first approval?
• What are the regulatory requirements related to manufacturing, product release, ongoing
monitoring, and so on?
While the answers to some of these questions may not be known, creating a strong
regulatory strategy is important for success. This may require hiring a regulatory expert as
a consultant to ensure success.
How do I fund product development?
Product development from preclinical work to clinical trials is an expensive process and
requires significant funding. It is important to know how much funding is required for each
step and where it can be achieved. The funding plan should allocate appropriate resources
for each milestone (e.g. up to preclinical, preclinical to FIH, FIH-Phase II, etc.). It should
include all of the relevant experimental, manufacturing, regulatory, and clinical activities
and spend required to reach each milestone. This will determine how much money needs to
be raised as each stage. Funders, such as venture capitalists, will typically fund a company
to the next milestone. If the milestone is hit then more funding can be released, whereas if
it is not hit the company usually disappears. Funding can be generated from a variety of
sources. Early on, grants from nonprofit or government institutions make up the bulk of
funding. Once a technology or asset is more mature, angel funding or venture funding can be
attained. Once clinical data is achieved, large companies (e.g. pharmaceutical or medical-
device) might provide funding or an IPO could occur. An IPO results in the sale of a portion
of the company to the public capital markets, where the shares are then traded. However, the
IPO route has been severely curtailed during the recent financial crisis. Small companies
have had more recent success with either selling the company or forming a partnership to
garner new funding rather than attempting an IPO, particularly in the regenerative medicine
space [37].
When do I start my company?
Timing is everything in the formation of a company. If we assume the regenerative medicine
technology is emerging from an academic institution, many make the mistake of starting a
company too early, when the technology is quite immature. This changes the entire dynamic
regarding ability to get nonprofit or government funding, and investment is required to set up
the infrastructure for the company that would be better spent on developing the technology.
When the technology is nearing clinical trial, this is a good time to consider starting a com-
pany. Funding is usually easier to achieve at this stage, given the technology is more mature.
12.6 Conclusion
In this chapter we have reviewed the key considerations for starting a new regenerative
medicine company and for translating products from idea to the clinic, and subsequently to
commercial success. The final key to success is obvious: a therapy must provide significant
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benefit to patients. This is what companies in the drug-discovery and regenerative-medicine
industry are trying to develop. The next 10 years will be exciting as we watch new regen-
erative therapies launch to the market, providing lifesaving benefits to patients.
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